# PeptideScanner evidence objects: Semaglutide

Every published version of the records placed with Semaglutide, one section per evidence object. The section anchor is the object's path id; the JSON twin is https://peptidescanner.com/evidence/v1/peptides/semaglutide.json. Selected public evidence only; not medical advice.

- Objects: 288
- Manifest: https://peptidescanner.com/evidence/v1/manifest.json

---

<a id="clinicaltrials-gov-nct02022254-semaglutide-v1"></a>

## ClinicalTrials.gov record NCT02022254

> PeptideScanner retained ClinicalTrials.gov record NCT02022254 at 2026-07-30T21:24:24.232Z. Its registry update date was 2017-04-04, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct02022254-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2017-04-04
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02022254-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct02022254-semaglutide-v1
- Content SHA-256: `0682d621b709a586d151f993e1dec7faeda9112c74e5e4d749a47d5dda4225fa`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02022254 ([`ctg-observation-nct02022254-2017-04-04-7fd866c466e4`](#source-ctg-observation-nct02022254-2017-04-04-7fd866c466e4))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02022254 at 2026-07-30T21:24:24.232Z. Its registry update date was 2017-04-04, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct02022254-2017-04-04-7fd866c466e4`](#source-ctg-observation-nct02022254-2017-04-04-7fd866c466e4))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02022254 at 2026-07-30T21:24:24.232Z. Its registry update date was 2017-04-04, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct02022254-2017-04-04-7fd866c466e4`](#source-ctg-observation-nct02022254-2017-04-04-7fd866c466e4))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02022254-2017-04-04-7fd866c466e4`](#source-ctg-observation-nct02022254-2017-04-04-7fd866c466e4))

### Sources

<a id="source-ctg-observation-nct02022254-2017-04-04-7fd866c466e4"></a>
- **ClinicalTrials.gov record NCT02022254 · retained source version 2017-04-04:7fd866c466e4850489f4364cb3bf2262fbc26713007f4c0986c79410ae9f0cf0** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02022254) (`ctg-observation-nct02022254-2017-04-04-7fd866c466e4`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02022254." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct02022254-semaglutide-v1 SHA-256: 0682d621b709a586d151f993e1dec7faeda9112c74e5e4d749a47d5dda4225fa.

---

<a id="clinicaltrials-gov-nct02064348-semaglutide-v1"></a>

## ClinicalTrials.gov record NCT02064348

> PeptideScanner retained ClinicalTrials.gov record NCT02064348 at 2026-07-30T21:11:31.040Z. Its registry update date was 2018-06-13, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct02064348-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2018-06-13
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02064348-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct02064348-semaglutide-v1
- Content SHA-256: `820c64b966ad7df807f59d3248a1b79f3bbfa171b2685c113d4338e9708df6ee`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02064348 ([`ctg-observation-nct02064348-2018-06-13-922fd3e223f0`](#source-ctg-observation-nct02064348-2018-06-13-922fd3e223f0))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02064348 at 2026-07-30T21:11:31.040Z. Its registry update date was 2018-06-13, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct02064348-2018-06-13-922fd3e223f0`](#source-ctg-observation-nct02064348-2018-06-13-922fd3e223f0))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02064348 at 2026-07-30T21:11:31.040Z. Its registry update date was 2018-06-13, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct02064348-2018-06-13-922fd3e223f0`](#source-ctg-observation-nct02064348-2018-06-13-922fd3e223f0))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02064348-2018-06-13-922fd3e223f0`](#source-ctg-observation-nct02064348-2018-06-13-922fd3e223f0))

### Sources

<a id="source-ctg-observation-nct02064348-2018-06-13-922fd3e223f0"></a>
- **ClinicalTrials.gov record NCT02064348 · retained source version 2018-06-13:922fd3e223f0aa35801087a410d8f392da467634bbcb5bb9fb2f9186497e8c0e** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02064348) (`ctg-observation-nct02064348-2018-06-13-922fd3e223f0`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02064348." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct02064348-semaglutide-v1 SHA-256: 820c64b966ad7df807f59d3248a1b79f3bbfa171b2685c113d4338e9708df6ee.

---

<a id="clinicaltrials-gov-nct02079870-semaglutide-v1"></a>

## ClinicalTrials.gov record NCT02079870

> PeptideScanner retained ClinicalTrials.gov record NCT02079870 at 2026-07-30T21:22:00.245Z. Its registry update date was 2017-12-02, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct02079870-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2017-12-02
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02079870-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct02079870-semaglutide-v1
- Content SHA-256: `af54a12ef4443c565ba78844324ecd62b079bc928f4cee659f4dc026597d74be`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02079870 ([`ctg-observation-nct02079870-2017-12-02-8baacc24f9f5`](#source-ctg-observation-nct02079870-2017-12-02-8baacc24f9f5))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02079870 at 2026-07-30T21:22:00.245Z. Its registry update date was 2017-12-02, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct02079870-2017-12-02-8baacc24f9f5`](#source-ctg-observation-nct02079870-2017-12-02-8baacc24f9f5))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02079870 at 2026-07-30T21:22:00.245Z. Its registry update date was 2017-12-02, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct02079870-2017-12-02-8baacc24f9f5`](#source-ctg-observation-nct02079870-2017-12-02-8baacc24f9f5))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02079870-2017-12-02-8baacc24f9f5`](#source-ctg-observation-nct02079870-2017-12-02-8baacc24f9f5))

### Sources

<a id="source-ctg-observation-nct02079870-2017-12-02-8baacc24f9f5"></a>
- **ClinicalTrials.gov record NCT02079870 · retained source version 2017-12-02:8baacc24f9f5e0a5b7ab870f89875193c65afd03f23b66d1dc7ddddbda009e3b** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02079870) (`ctg-observation-nct02079870-2017-12-02-8baacc24f9f5`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02079870." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct02079870-semaglutide-v1 SHA-256: af54a12ef4443c565ba78844324ecd62b079bc928f4cee659f4dc026597d74be.

---

<a id="clinicaltrials-gov-nct02146079-semaglutide-v1"></a>

## ClinicalTrials.gov record NCT02146079

> PeptideScanner retained ClinicalTrials.gov record NCT02146079 at 2026-07-30T21:11:31.042Z. Its registry update date was 2018-04-18, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct02146079-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2018-04-18
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02146079-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct02146079-semaglutide-v1
- Content SHA-256: `5db423b3f79661f69c91e5587a2bb3e87915e1ae4c9b645989ca8399704a225c`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02146079 ([`ctg-observation-nct02146079-2018-04-18-169bfd91cc0e`](#source-ctg-observation-nct02146079-2018-04-18-169bfd91cc0e))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02146079 at 2026-07-30T21:11:31.042Z. Its registry update date was 2018-04-18, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct02146079-2018-04-18-169bfd91cc0e`](#source-ctg-observation-nct02146079-2018-04-18-169bfd91cc0e))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02146079 at 2026-07-30T21:11:31.042Z. Its registry update date was 2018-04-18, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct02146079-2018-04-18-169bfd91cc0e`](#source-ctg-observation-nct02146079-2018-04-18-169bfd91cc0e))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02146079-2018-04-18-169bfd91cc0e`](#source-ctg-observation-nct02146079-2018-04-18-169bfd91cc0e))

### Sources

<a id="source-ctg-observation-nct02146079-2018-04-18-169bfd91cc0e"></a>
- **ClinicalTrials.gov record NCT02146079 · retained source version 2018-04-18:169bfd91cc0e8b337d89fae36fec19ae6ab167c393a9db011aca39bfb2d2eb6e** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02146079) (`ctg-observation-nct02146079-2018-04-18-169bfd91cc0e`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02146079." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct02146079-semaglutide-v1 SHA-256: 5db423b3f79661f69c91e5587a2bb3e87915e1ae4c9b645989ca8399704a225c.

---

<a id="clinicaltrials-gov-nct03357380-semaglutide-v1"></a>

## ClinicalTrials.gov record NCT03357380

> PeptideScanner retained ClinicalTrials.gov record NCT03357380 at 2026-07-30T19:56:31.568Z. Its registry update date was 2021-11-22, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct03357380-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2021-11-22
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03357380-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct03357380-semaglutide-v1
- Content SHA-256: `1e7ab0ad16eda2a3467445fa443550b566b96800a0f3d0be2b718400dc3286a3`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03357380 ([`ctg-observation-nct03357380-2021-11-22-7128f5942564`](#source-ctg-observation-nct03357380-2021-11-22-7128f5942564))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03357380 at 2026-07-30T19:56:31.568Z. Its registry update date was 2021-11-22, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct03357380-2021-11-22-7128f5942564`](#source-ctg-observation-nct03357380-2021-11-22-7128f5942564))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03357380 at 2026-07-30T19:56:31.568Z. Its registry update date was 2021-11-22, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct03357380-2021-11-22-7128f5942564`](#source-ctg-observation-nct03357380-2021-11-22-7128f5942564))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03357380-2021-11-22-7128f5942564`](#source-ctg-observation-nct03357380-2021-11-22-7128f5942564))

### Sources

<a id="source-ctg-observation-nct03357380-2021-11-22-7128f5942564"></a>
- **ClinicalTrials.gov record NCT03357380 · retained source version 2021-11-22:7128f594256419eacfa28bf60ab93eb1f4807fe1ced6ed67660fb2eff39dad1e** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03357380) (`ctg-observation-nct03357380-2021-11-22-7128f5942564`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03357380." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct03357380-semaglutide-v1 SHA-256: 1e7ab0ad16eda2a3467445fa443550b566b96800a0f3d0be2b718400dc3286a3.

---

<a id="clinicaltrials-gov-nct03466567-semaglutide-v1"></a>

## ClinicalTrials.gov record NCT03466567

> PeptideScanner retained ClinicalTrials.gov record NCT03466567 at 2026-07-30T20:50:35.918Z. Its registry update date was 2019-06-19, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct03466567-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2019-06-19
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03466567-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct03466567-semaglutide-v1
- Content SHA-256: `68ea0624b08a120449f9c1e776058875631f438b8301881510850e294ea1952a`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03466567 ([`ctg-observation-nct03466567-2019-06-19-8f164b9fe435`](#source-ctg-observation-nct03466567-2019-06-19-8f164b9fe435))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03466567 at 2026-07-30T20:50:35.918Z. Its registry update date was 2019-06-19, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct03466567-2019-06-19-8f164b9fe435`](#source-ctg-observation-nct03466567-2019-06-19-8f164b9fe435))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03466567 at 2026-07-30T20:50:35.918Z. Its registry update date was 2019-06-19, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct03466567-2019-06-19-8f164b9fe435`](#source-ctg-observation-nct03466567-2019-06-19-8f164b9fe435))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03466567-2019-06-19-8f164b9fe435`](#source-ctg-observation-nct03466567-2019-06-19-8f164b9fe435))

### Sources

<a id="source-ctg-observation-nct03466567-2019-06-19-8f164b9fe435"></a>
- **ClinicalTrials.gov record NCT03466567 · retained source version 2019-06-19:8f164b9fe435e77aaa50d4cf9ccc1f2f45c6a9f34fed1d66b696c1f00b5ba61d** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03466567) (`ctg-observation-nct03466567-2019-06-19-8f164b9fe435`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03466567." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct03466567-semaglutide-v1 SHA-256: 68ea0624b08a120449f9c1e776058875631f438b8301881510850e294ea1952a.

---

<a id="clinicaltrials-gov-nct03548987-semaglutide-v1"></a>

## ClinicalTrials.gov record NCT03548987

> PeptideScanner retained ClinicalTrials.gov record NCT03548987 at 2026-07-30T19:44:52.954Z. Its registry update date was 2022-01-19, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct03548987-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2022-01-19
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03548987-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct03548987-semaglutide-v1
- Content SHA-256: `58f60fac2445ab841164d5fc5cba23180092f34f6e3832e0808c92214e80697f`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03548987 ([`ctg-observation-nct03548987-2022-01-19-39de46e416d0`](#source-ctg-observation-nct03548987-2022-01-19-39de46e416d0))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03548987 at 2026-07-30T19:44:52.954Z. Its registry update date was 2022-01-19, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct03548987-2022-01-19-39de46e416d0`](#source-ctg-observation-nct03548987-2022-01-19-39de46e416d0))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03548987 at 2026-07-30T19:44:52.954Z. Its registry update date was 2022-01-19, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct03548987-2022-01-19-39de46e416d0`](#source-ctg-observation-nct03548987-2022-01-19-39de46e416d0))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03548987-2022-01-19-39de46e416d0`](#source-ctg-observation-nct03548987-2022-01-19-39de46e416d0))

### Sources

<a id="source-ctg-observation-nct03548987-2022-01-19-39de46e416d0"></a>
- **ClinicalTrials.gov record NCT03548987 · retained source version 2022-01-19:39de46e416d0f24290e4628f67a36810b326ca7bc024dc15a5705017f17862d7** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03548987) (`ctg-observation-nct03548987-2022-01-19-39de46e416d0`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03548987." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct03548987-semaglutide-v1 SHA-256: 58f60fac2445ab841164d5fc5cba23180092f34f6e3832e0808c92214e80697f.

---

<a id="clinicaltrials-gov-nct03574597-semaglutide-v1"></a>

## ClinicalTrials.gov record NCT03574597

> PeptideScanner retained ClinicalTrials.gov record NCT03574597 at 2026-07-30T18:41:37.951Z. Its registry update date was 2024-08-30, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct03574597-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2024-08-30
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03574597-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct03574597-semaglutide-v1
- Content SHA-256: `d0ceb8896048701c6a8c019ddfe1b73591e7ce00af06ad4e00d927ad2db3697f`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03574597 ([`ctg-observation-nct03574597-2024-08-30-ea4738ed0d35`](#source-ctg-observation-nct03574597-2024-08-30-ea4738ed0d35))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03574597 at 2026-07-30T18:41:37.951Z. Its registry update date was 2024-08-30, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct03574597-2024-08-30-ea4738ed0d35`](#source-ctg-observation-nct03574597-2024-08-30-ea4738ed0d35))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03574597 at 2026-07-30T18:41:37.951Z. Its registry update date was 2024-08-30, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct03574597-2024-08-30-ea4738ed0d35`](#source-ctg-observation-nct03574597-2024-08-30-ea4738ed0d35))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03574597-2024-08-30-ea4738ed0d35`](#source-ctg-observation-nct03574597-2024-08-30-ea4738ed0d35))

### Sources

<a id="source-ctg-observation-nct03574597-2024-08-30-ea4738ed0d35"></a>
- **ClinicalTrials.gov record NCT03574597 · retained source version 2024-08-30:ea4738ed0d355d47769d8430d76fc9b77fff7831394c1ab9a761cde3164b96b2** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03574597) (`ctg-observation-nct03574597-2024-08-30-ea4738ed0d35`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03574597." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct03574597-semaglutide-v1 SHA-256: d0ceb8896048701c6a8c019ddfe1b73591e7ce00af06ad4e00d927ad2db3697f.

---

<a id="clinicaltrials-gov-nct03596450-semaglutide-v1"></a>

## ClinicalTrials.gov record NCT03596450

> PeptideScanner retained ClinicalTrials.gov record NCT03596450 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-30, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct03596450-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-09-30
- Source checked: 2026-11-14
- Published by PeptideScanner: 2026-11-14
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03596450-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct03596450-semaglutide-v1
- Content SHA-256: `1f4000d626380b10da66d17b08f2a9b1cfc48aa9543dd08d1a5e266f1bea8230`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03596450 ([`ctg-observation-nct03596450-2026-09-30-94438ec127a3`](#source-ctg-observation-nct03596450-2026-09-30-94438ec127a3))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03596450 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-30, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct03596450-2026-09-30-94438ec127a3`](#source-ctg-observation-nct03596450-2026-09-30-94438ec127a3))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03596450 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-30, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct03596450-2026-09-30-94438ec127a3`](#source-ctg-observation-nct03596450-2026-09-30-94438ec127a3))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03596450-2026-09-30-94438ec127a3`](#source-ctg-observation-nct03596450-2026-09-30-94438ec127a3))

### Sources

<a id="source-ctg-observation-nct03596450-2026-09-30-94438ec127a3"></a>
- **ClinicalTrials.gov record NCT03596450 · retained source version 2026-09-30:94438ec127a309b28198ede02e4d08f0038f874f20f85dfef638fb10e9959ee0** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03596450) (`ctg-observation-nct03596450-2026-09-30-94438ec127a3`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03596450." Version 1, published 2026-11-14. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct03596450-semaglutide-v1 SHA-256: 1f4000d626380b10da66d17b08f2a9b1cfc48aa9543dd08d1a5e266f1bea8230.

---

<a id="clinicaltrials-gov-nct03611582-semaglutide-v1"></a>

## ClinicalTrials.gov record NCT03611582

> PeptideScanner retained ClinicalTrials.gov record NCT03611582 at 2026-07-30T19:56:31.576Z. Its registry update date was 2021-11-11, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct03611582-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2021-11-11
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03611582-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct03611582-semaglutide-v1
- Content SHA-256: `4db1f80baaca805e89db4d32afee89468492c88bbb06cd877636e366cca76731`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03611582 ([`ctg-observation-nct03611582-2021-11-11-3bfb8a96c789`](#source-ctg-observation-nct03611582-2021-11-11-3bfb8a96c789))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03611582 at 2026-07-30T19:56:31.576Z. Its registry update date was 2021-11-11, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct03611582-2021-11-11-3bfb8a96c789`](#source-ctg-observation-nct03611582-2021-11-11-3bfb8a96c789))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03611582 at 2026-07-30T19:56:31.576Z. Its registry update date was 2021-11-11, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct03611582-2021-11-11-3bfb8a96c789`](#source-ctg-observation-nct03611582-2021-11-11-3bfb8a96c789))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03611582-2021-11-11-3bfb8a96c789`](#source-ctg-observation-nct03611582-2021-11-11-3bfb8a96c789))

### Sources

<a id="source-ctg-observation-nct03611582-2021-11-11-3bfb8a96c789"></a>
- **ClinicalTrials.gov record NCT03611582 · retained source version 2021-11-11:3bfb8a96c7895377c7f99569f7543d5653937dcdd2d2cf8dd0b73a717faa0c6b** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03611582) (`ctg-observation-nct03611582-2021-11-11-3bfb8a96c789`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03611582." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct03611582-semaglutide-v1 SHA-256: 4db1f80baaca805e89db4d32afee89468492c88bbb06cd877636e366cca76731.

---

<a id="clinicaltrials-gov-nct03811561-semaglutide-v1"></a>

## ClinicalTrials.gov record NCT03811561

> PeptideScanner retained ClinicalTrials.gov record NCT03811561 at 2026-09-09T19:17:17.089Z. Its registry update date was 2026-09-09, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct03811561-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-09-09
- Source checked: 2026-09-09
- Published by PeptideScanner: 2026-09-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03811561-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct03811561-semaglutide-v1
- Content SHA-256: `e098d14c4ec5abd4928b39cd17455618cebc116f68ed1b878bd030e88dd7293a`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03811561 ([`ctg-observation-nct03811561-2026-09-09-b1e4168bc41c`](#source-ctg-observation-nct03811561-2026-09-09-b1e4168bc41c))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03811561 at 2026-09-09T19:17:17.089Z. Its registry update date was 2026-09-09, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct03811561-2026-09-09-b1e4168bc41c`](#source-ctg-observation-nct03811561-2026-09-09-b1e4168bc41c))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03811561 at 2026-09-09T19:17:17.089Z. Its registry update date was 2026-09-09, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct03811561-2026-09-09-b1e4168bc41c`](#source-ctg-observation-nct03811561-2026-09-09-b1e4168bc41c))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03811561-2026-09-09-b1e4168bc41c`](#source-ctg-observation-nct03811561-2026-09-09-b1e4168bc41c))

### Sources

<a id="source-ctg-observation-nct03811561-2026-09-09-b1e4168bc41c"></a>
- **ClinicalTrials.gov record NCT03811561 · retained source version 2026-09-09:b1e4168bc41c32e816583645fa93a132c023ec1568b104a185ddb801bf1fc8d1** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03811561) (`ctg-observation-nct03811561-2026-09-09-b1e4168bc41c`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03811561." Version 1, published 2026-09-09. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct03811561-semaglutide-v1 SHA-256: e098d14c4ec5abd4928b39cd17455618cebc116f68ed1b878bd030e88dd7293a.

---

<a id="clinicaltrials-gov-nct03842202-semaglutide-v1"></a>

## ClinicalTrials.gov record NCT03842202

> PeptideScanner retained ClinicalTrials.gov record NCT03842202 at 2026-07-30T20:18:37.981Z. Its registry update date was 2020-12-24, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct03842202-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2020-12-24
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03842202-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct03842202-semaglutide-v1
- Content SHA-256: `e5fbb08b86771a4f06d4db052f5a064698ccfa7594a8a21669b10af7dbf96f09`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03842202 ([`ctg-observation-nct03842202-2020-12-24-ca1c40a593f3`](#source-ctg-observation-nct03842202-2020-12-24-ca1c40a593f3))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03842202 at 2026-07-30T20:18:37.981Z. Its registry update date was 2020-12-24, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct03842202-2020-12-24-ca1c40a593f3`](#source-ctg-observation-nct03842202-2020-12-24-ca1c40a593f3))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03842202 at 2026-07-30T20:18:37.981Z. Its registry update date was 2020-12-24, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct03842202-2020-12-24-ca1c40a593f3`](#source-ctg-observation-nct03842202-2020-12-24-ca1c40a593f3))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03842202-2020-12-24-ca1c40a593f3`](#source-ctg-observation-nct03842202-2020-12-24-ca1c40a593f3))

### Sources

<a id="source-ctg-observation-nct03842202-2020-12-24-ca1c40a593f3"></a>
- **ClinicalTrials.gov record NCT03842202 · retained source version 2020-12-24:ca1c40a593f355eb6e40be571996582b961ef827e005f9138706b12662556dbc** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03842202) (`ctg-observation-nct03842202-2020-12-24-ca1c40a593f3`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03842202." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct03842202-semaglutide-v1 SHA-256: e5fbb08b86771a4f06d4db052f5a064698ccfa7594a8a21669b10af7dbf96f09.

---

<a id="clinicaltrials-gov-nct03884075-semaglutide-v1"></a>

## ClinicalTrials.gov record NCT03884075

> PeptideScanner retained ClinicalTrials.gov record NCT03884075 at 2026-08-13T05:52:27.026Z. Its registry update date was 2026-08-10, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct03884075-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-08-10
- Source checked: 2026-08-13
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03884075-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct03884075-semaglutide-v1
- Content SHA-256: `5fa357dddf5450b4e63e0a04fa74c9f67554f3d60c66811eadf199c783ec803d`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03884075 ([`ctg-observation-nct03884075-2026-08-10-96efb931ce5b`](#source-ctg-observation-nct03884075-2026-08-10-96efb931ce5b))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03884075 at 2026-08-13T05:52:27.026Z. Its registry update date was 2026-08-10, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct03884075-2026-08-10-96efb931ce5b`](#source-ctg-observation-nct03884075-2026-08-10-96efb931ce5b))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03884075 at 2026-08-13T05:52:27.026Z. Its registry update date was 2026-08-10, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct03884075-2026-08-10-96efb931ce5b`](#source-ctg-observation-nct03884075-2026-08-10-96efb931ce5b))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03884075-2026-08-10-96efb931ce5b`](#source-ctg-observation-nct03884075-2026-08-10-96efb931ce5b))

### Sources

<a id="source-ctg-observation-nct03884075-2026-08-10-96efb931ce5b"></a>
- **ClinicalTrials.gov record NCT03884075 · retained source version 2026-08-10:96efb931ce5b056903aeedaabc69b04f7b6dd18707021615d0c48d10797bedae** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03884075) (`ctg-observation-nct03884075-2026-08-10-96efb931ce5b`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03884075." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct03884075-semaglutide-v1 SHA-256: 5fa357dddf5450b4e63e0a04fa74c9f67554f3d60c66811eadf199c783ec803d.

---

<a id="clinicaltrials-gov-nct03987451-semaglutide-v1"></a>

## ClinicalTrials.gov record NCT03987451

> PeptideScanner retained ClinicalTrials.gov record NCT03987451 at 2026-07-30T18:45:10.889Z. Its registry update date was 2024-05-29, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct03987451-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2024-05-29
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03987451-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct03987451-semaglutide-v1
- Content SHA-256: `8ac946f73edc84178bb26ece33deb33055e0bcb4d7c4de02a03d1c220fcb0a9e`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03987451 ([`ctg-observation-nct03987451-2024-05-29-d3dc7529060c`](#source-ctg-observation-nct03987451-2024-05-29-d3dc7529060c))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03987451 at 2026-07-30T18:45:10.889Z. Its registry update date was 2024-05-29, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct03987451-2024-05-29-d3dc7529060c`](#source-ctg-observation-nct03987451-2024-05-29-d3dc7529060c))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03987451 at 2026-07-30T18:45:10.889Z. Its registry update date was 2024-05-29, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct03987451-2024-05-29-d3dc7529060c`](#source-ctg-observation-nct03987451-2024-05-29-d3dc7529060c))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03987451-2024-05-29-d3dc7529060c`](#source-ctg-observation-nct03987451-2024-05-29-d3dc7529060c))

### Sources

<a id="source-ctg-observation-nct03987451-2024-05-29-d3dc7529060c"></a>
- **ClinicalTrials.gov record NCT03987451 · retained source version 2024-05-29:d3dc7529060cca36d7e96a0c50c6487ef3face28260c413737d632df4e2d0269** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03987451) (`ctg-observation-nct03987451-2024-05-29-d3dc7529060c`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03987451." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct03987451-semaglutide-v1 SHA-256: 8ac946f73edc84178bb26ece33deb33055e0bcb4d7c4de02a03d1c220fcb0a9e.

---

<a id="clinicaltrials-gov-nct04019197-semaglutide-v1"></a>

## ClinicalTrials.gov record NCT04019197

> PeptideScanner retained ClinicalTrials.gov record NCT04019197 at 2026-07-30T16:19:36.918Z. Its registry update date was 2026-05-04, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct04019197-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-05-04
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct04019197-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct04019197-semaglutide-v1
- Content SHA-256: `97f4d904579951316c24eed4f6489d62feeb22806d0a30d006aa109f430c7b6f`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT04019197 ([`ctg-observation-nct04019197-2026-05-04-583a5f7391b1`](#source-ctg-observation-nct04019197-2026-05-04-583a5f7391b1))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT04019197 at 2026-07-30T16:19:36.918Z. Its registry update date was 2026-05-04, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct04019197-2026-05-04-583a5f7391b1`](#source-ctg-observation-nct04019197-2026-05-04-583a5f7391b1))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT04019197 at 2026-07-30T16:19:36.918Z. Its registry update date was 2026-05-04, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct04019197-2026-05-04-583a5f7391b1`](#source-ctg-observation-nct04019197-2026-05-04-583a5f7391b1))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct04019197-2026-05-04-583a5f7391b1`](#source-ctg-observation-nct04019197-2026-05-04-583a5f7391b1))

### Sources

<a id="source-ctg-observation-nct04019197-2026-05-04-583a5f7391b1"></a>
- **ClinicalTrials.gov record NCT04019197 · retained source version 2026-05-04:583a5f7391b18aaf474becc838dcd7fdeddc9a80f89db35995262e9761c9adc1** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT04019197) (`ctg-observation-nct04019197-2026-05-04-583a5f7391b1`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT04019197." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct04019197-semaglutide-v1 SHA-256: 97f4d904579951316c24eed4f6489d62feeb22806d0a30d006aa109f430c7b6f.

---

<a id="clinicaltrials-gov-nct04102189-semaglutide-v1"></a>

## ClinicalTrials.gov record NCT04102189

> PeptideScanner retained ClinicalTrials.gov record NCT04102189 at 2026-07-30T18:18:33.504Z. Its registry update date was 2025-12-11, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct04102189-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2025-12-11
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct04102189-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct04102189-semaglutide-v1
- Content SHA-256: `87988acce94abf4509381a312283912cca54fcdc150a8b12f2c053b64af27ccd`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT04102189 ([`ctg-observation-nct04102189-2025-12-11-d39e5a7d08aa`](#source-ctg-observation-nct04102189-2025-12-11-d39e5a7d08aa))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT04102189 at 2026-07-30T18:18:33.504Z. Its registry update date was 2025-12-11, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct04102189-2025-12-11-d39e5a7d08aa`](#source-ctg-observation-nct04102189-2025-12-11-d39e5a7d08aa))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT04102189 at 2026-07-30T18:18:33.504Z. Its registry update date was 2025-12-11, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct04102189-2025-12-11-d39e5a7d08aa`](#source-ctg-observation-nct04102189-2025-12-11-d39e5a7d08aa))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct04102189-2025-12-11-d39e5a7d08aa`](#source-ctg-observation-nct04102189-2025-12-11-d39e5a7d08aa))

### Sources

<a id="source-ctg-observation-nct04102189-2025-12-11-d39e5a7d08aa"></a>
- **ClinicalTrials.gov record NCT04102189 · retained source version 2025-12-11:d39e5a7d08aa1073a85b0881f7c58e349e085d207dadb1c7000946e87b8d2ec3** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT04102189) (`ctg-observation-nct04102189-2025-12-11-d39e5a7d08aa`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT04102189." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct04102189-semaglutide-v1 SHA-256: 87988acce94abf4509381a312283912cca54fcdc150a8b12f2c053b64af27ccd.

---

<a id="clinicaltrials-gov-nct04174755-semaglutide-v1"></a>

## ClinicalTrials.gov record NCT04174755

> PeptideScanner retained ClinicalTrials.gov record NCT04174755 at 2026-07-30T16:20:49.311Z. Its registry update date was 2026-04-29, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct04174755-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-04-29
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct04174755-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct04174755-semaglutide-v1
- Content SHA-256: `ea08da8c845435bdbcf21b68e686b986a6d5c23afa2b6b331970e6ef8dff9be0`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT04174755 ([`ctg-observation-nct04174755-2026-04-29-9189f52797c7`](#source-ctg-observation-nct04174755-2026-04-29-9189f52797c7))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT04174755 at 2026-07-30T16:20:49.311Z. Its registry update date was 2026-04-29, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct04174755-2026-04-29-9189f52797c7`](#source-ctg-observation-nct04174755-2026-04-29-9189f52797c7))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT04174755 at 2026-07-30T16:20:49.311Z. Its registry update date was 2026-04-29, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct04174755-2026-04-29-9189f52797c7`](#source-ctg-observation-nct04174755-2026-04-29-9189f52797c7))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct04174755-2026-04-29-9189f52797c7`](#source-ctg-observation-nct04174755-2026-04-29-9189f52797c7))

### Sources

<a id="source-ctg-observation-nct04174755-2026-04-29-9189f52797c7"></a>
- **ClinicalTrials.gov record NCT04174755 · retained source version 2026-04-29:9189f52797c7274cf9ce7e018ce5982b19af64ddde26ef157e26af487e612fc8** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT04174755) (`ctg-observation-nct04174755-2026-04-29-9189f52797c7`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT04174755." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct04174755-semaglutide-v1 SHA-256: ea08da8c845435bdbcf21b68e686b986a6d5c23afa2b6b331970e6ef8dff9be0.

---

<a id="clinicaltrials-gov-nct04175665-semaglutide-v1"></a>

## ClinicalTrials.gov record NCT04175665

> PeptideScanner retained ClinicalTrials.gov record NCT04175665 at 2026-07-30T20:32:04.760Z. Its registry update date was 2020-02-21, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct04175665-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2020-02-21
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct04175665-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct04175665-semaglutide-v1
- Content SHA-256: `3051e7d9217e96dfb5e168faad53f2b5b6c1d06c2571ab667b7c833a90ae5e56`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT04175665 ([`ctg-observation-nct04175665-2020-02-21-8d0c7b4cf7a8`](#source-ctg-observation-nct04175665-2020-02-21-8d0c7b4cf7a8))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT04175665 at 2026-07-30T20:32:04.760Z. Its registry update date was 2020-02-21, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct04175665-2020-02-21-8d0c7b4cf7a8`](#source-ctg-observation-nct04175665-2020-02-21-8d0c7b4cf7a8))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT04175665 at 2026-07-30T20:32:04.760Z. Its registry update date was 2020-02-21, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct04175665-2020-02-21-8d0c7b4cf7a8`](#source-ctg-observation-nct04175665-2020-02-21-8d0c7b4cf7a8))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct04175665-2020-02-21-8d0c7b4cf7a8`](#source-ctg-observation-nct04175665-2020-02-21-8d0c7b4cf7a8))

### Sources

<a id="source-ctg-observation-nct04175665-2020-02-21-8d0c7b4cf7a8"></a>
- **ClinicalTrials.gov record NCT04175665 · retained source version 2020-02-21:8d0c7b4cf7a8cd3f3c70e2434cd6d2f2f923c8ddcac424123e0be9d4937e3707** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT04175665) (`ctg-observation-nct04175665-2020-02-21-8d0c7b4cf7a8`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT04175665." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct04175665-semaglutide-v1 SHA-256: 3051e7d9217e96dfb5e168faad53f2b5b6c1d06c2571ab667b7c833a90ae5e56.

---

<a id="clinicaltrials-gov-nct04216589-semaglutide-v1"></a>

## ClinicalTrials.gov record NCT04216589

> PeptideScanner retained ClinicalTrials.gov record NCT04216589 at 2026-07-30T18:39:33.783Z. Its registry update date was 2024-10-01, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct04216589-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2024-10-01
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct04216589-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct04216589-semaglutide-v1
- Content SHA-256: `16994e0eed09cdc2c28735a638518fa53585c5ad7a307a72948da3e5b551125e`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT04216589 ([`ctg-observation-nct04216589-2024-10-01-cbaff7e9d6c3`](#source-ctg-observation-nct04216589-2024-10-01-cbaff7e9d6c3))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT04216589 at 2026-07-30T18:39:33.783Z. Its registry update date was 2024-10-01, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct04216589-2024-10-01-cbaff7e9d6c3`](#source-ctg-observation-nct04216589-2024-10-01-cbaff7e9d6c3))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT04216589 at 2026-07-30T18:39:33.783Z. Its registry update date was 2024-10-01, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct04216589-2024-10-01-cbaff7e9d6c3`](#source-ctg-observation-nct04216589-2024-10-01-cbaff7e9d6c3))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct04216589-2024-10-01-cbaff7e9d6c3`](#source-ctg-observation-nct04216589-2024-10-01-cbaff7e9d6c3))

### Sources

<a id="source-ctg-observation-nct04216589-2024-10-01-cbaff7e9d6c3"></a>
- **ClinicalTrials.gov record NCT04216589 · retained source version 2024-10-01:cbaff7e9d6c34374f6615c3d3b0696eed99cda539093adc10ceec9f69d23034f** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT04216589) (`ctg-observation-nct04216589-2024-10-01-cbaff7e9d6c3`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT04216589." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct04216589-semaglutide-v1 SHA-256: 16994e0eed09cdc2c28735a638518fa53585c5ad7a307a72948da3e5b551125e.

---

<a id="clinicaltrials-gov-nct04251156-semaglutide-v1"></a>

## ClinicalTrials.gov record NCT04251156

> PeptideScanner retained ClinicalTrials.gov record NCT04251156 at 2026-07-30T16:25:18.009Z. Its registry update date was 2026-01-29, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct04251156-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-01-29
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct04251156-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct04251156-semaglutide-v1
- Content SHA-256: `ffebd26a456543e2c7806bdad64dea330e30c15cf6098be674ee516de42ebd89`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT04251156 ([`ctg-observation-nct04251156-2026-01-29-a4795392bb38`](#source-ctg-observation-nct04251156-2026-01-29-a4795392bb38))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT04251156 at 2026-07-30T16:25:18.009Z. Its registry update date was 2026-01-29, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct04251156-2026-01-29-a4795392bb38`](#source-ctg-observation-nct04251156-2026-01-29-a4795392bb38))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT04251156 at 2026-07-30T16:25:18.009Z. Its registry update date was 2026-01-29, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct04251156-2026-01-29-a4795392bb38`](#source-ctg-observation-nct04251156-2026-01-29-a4795392bb38))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct04251156-2026-01-29-a4795392bb38`](#source-ctg-observation-nct04251156-2026-01-29-a4795392bb38))

### Sources

<a id="source-ctg-observation-nct04251156-2026-01-29-a4795392bb38"></a>
- **ClinicalTrials.gov record NCT04251156 · retained source version 2026-01-29:a4795392bb38b2bc293a11e4a78388867e94cdaed3a9e0ad0942f7585c8a5c09** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT04251156) (`ctg-observation-nct04251156-2026-01-29-a4795392bb38`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT04251156." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct04251156-semaglutide-v1 SHA-256: ffebd26a456543e2c7806bdad64dea330e30c15cf6098be674ee516de42ebd89.

---

<a id="clinicaltrials-gov-nct04263415-semaglutide-v1"></a>

## ClinicalTrials.gov record NCT04263415

> PeptideScanner retained ClinicalTrials.gov record NCT04263415 at 2026-07-30T19:08:50.175Z. Its registry update date was 2023-09-08, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct04263415-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2023-09-08
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct04263415-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct04263415-semaglutide-v1
- Content SHA-256: `2c107258d29c7f4cea89b891ac76f15ff902758d6881499b8ed2456eda3b1122`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT04263415 ([`ctg-observation-nct04263415-2023-09-08-3fa8d01bf7c0`](#source-ctg-observation-nct04263415-2023-09-08-3fa8d01bf7c0))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT04263415 at 2026-07-30T19:08:50.175Z. Its registry update date was 2023-09-08, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct04263415-2023-09-08-3fa8d01bf7c0`](#source-ctg-observation-nct04263415-2023-09-08-3fa8d01bf7c0))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT04263415 at 2026-07-30T19:08:50.175Z. Its registry update date was 2023-09-08, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct04263415-2023-09-08-3fa8d01bf7c0`](#source-ctg-observation-nct04263415-2023-09-08-3fa8d01bf7c0))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct04263415-2023-09-08-3fa8d01bf7c0`](#source-ctg-observation-nct04263415-2023-09-08-3fa8d01bf7c0))

### Sources

<a id="source-ctg-observation-nct04263415-2023-09-08-3fa8d01bf7c0"></a>
- **ClinicalTrials.gov record NCT04263415 · retained source version 2023-09-08:3fa8d01bf7c0f53b7678f33bdd217ff76b881e295eb0dceb2ee20b7cb0f6f977** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT04263415) (`ctg-observation-nct04263415-2023-09-08-3fa8d01bf7c0`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT04263415." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct04263415-semaglutide-v1 SHA-256: 2c107258d29c7f4cea89b891ac76f15ff902758d6881499b8ed2456eda3b1122.

---

<a id="clinicaltrials-gov-nct04451837-semaglutide-v1"></a>

## ClinicalTrials.gov record NCT04451837

> PeptideScanner retained ClinicalTrials.gov record NCT04451837 at 2026-07-30T18:24:37.186Z. Its registry update date was 2025-07-16, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct04451837-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2025-07-16
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct04451837-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct04451837-semaglutide-v1
- Content SHA-256: `caef5afd16c1480d1e856868ec0cd48a854d74bc27b8624ddd0233815ae0f644`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT04451837 ([`ctg-observation-nct04451837-2025-07-16-10dde460061e`](#source-ctg-observation-nct04451837-2025-07-16-10dde460061e))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT04451837 at 2026-07-30T18:24:37.186Z. Its registry update date was 2025-07-16, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct04451837-2025-07-16-10dde460061e`](#source-ctg-observation-nct04451837-2025-07-16-10dde460061e))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT04451837 at 2026-07-30T18:24:37.186Z. Its registry update date was 2025-07-16, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct04451837-2025-07-16-10dde460061e`](#source-ctg-observation-nct04451837-2025-07-16-10dde460061e))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct04451837-2025-07-16-10dde460061e`](#source-ctg-observation-nct04451837-2025-07-16-10dde460061e))

### Sources

<a id="source-ctg-observation-nct04451837-2025-07-16-10dde460061e"></a>
- **ClinicalTrials.gov record NCT04451837 · retained source version 2025-07-16:10dde460061e9174d0819801109bb8f7a5b879d66182ee005badda8c69b00248** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT04451837) (`ctg-observation-nct04451837-2025-07-16-10dde460061e`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT04451837." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct04451837-semaglutide-v1 SHA-256: caef5afd16c1480d1e856868ec0cd48a854d74bc27b8624ddd0233815ae0f644.

---

<a id="clinicaltrials-gov-nct04466345-semaglutide-v1"></a>

## ClinicalTrials.gov record NCT04466345

> PeptideScanner retained ClinicalTrials.gov record NCT04466345 at 2026-07-30T18:20:54.428Z. Its registry update date was 2025-10-02, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct04466345-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2025-10-02
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct04466345-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct04466345-semaglutide-v1
- Content SHA-256: `56501e1f447cf9a13493b6b72e168d7165a1192be7abfeef2b5159582541c256`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT04466345 ([`ctg-observation-nct04466345-2025-10-02-856ded4dee46`](#source-ctg-observation-nct04466345-2025-10-02-856ded4dee46))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT04466345 at 2026-07-30T18:20:54.428Z. Its registry update date was 2025-10-02, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct04466345-2025-10-02-856ded4dee46`](#source-ctg-observation-nct04466345-2025-10-02-856ded4dee46))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT04466345 at 2026-07-30T18:20:54.428Z. Its registry update date was 2025-10-02, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct04466345-2025-10-02-856ded4dee46`](#source-ctg-observation-nct04466345-2025-10-02-856ded4dee46))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct04466345-2025-10-02-856ded4dee46`](#source-ctg-observation-nct04466345-2025-10-02-856ded4dee46))

### Sources

<a id="source-ctg-observation-nct04466345-2025-10-02-856ded4dee46"></a>
- **ClinicalTrials.gov record NCT04466345 · retained source version 2025-10-02:856ded4dee466792bc41747c95bf5eaaf7a719e3dcf45545d328287fc6133a90** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT04466345) (`ctg-observation-nct04466345-2025-10-02-856ded4dee46`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT04466345." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct04466345-semaglutide-v1 SHA-256: 56501e1f447cf9a13493b6b72e168d7165a1192be7abfeef2b5159582541c256.

---

<a id="clinicaltrials-gov-nct04469855-semaglutide-v1"></a>

## ClinicalTrials.gov record NCT04469855

> PeptideScanner retained ClinicalTrials.gov record NCT04469855 at 2026-07-30T16:19:36.922Z. Its registry update date was 2026-05-19, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct04469855-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-05-19
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct04469855-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct04469855-semaglutide-v1
- Content SHA-256: `95679c606d0e338ccb7eea859c9f2e19151f5ec519dfed38d4fe0b1cd2e45768`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT04469855 ([`ctg-observation-nct04469855-2026-05-19-5ae09bb317e7`](#source-ctg-observation-nct04469855-2026-05-19-5ae09bb317e7))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT04469855 at 2026-07-30T16:19:36.922Z. Its registry update date was 2026-05-19, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct04469855-2026-05-19-5ae09bb317e7`](#source-ctg-observation-nct04469855-2026-05-19-5ae09bb317e7))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT04469855 at 2026-07-30T16:19:36.922Z. Its registry update date was 2026-05-19, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct04469855-2026-05-19-5ae09bb317e7`](#source-ctg-observation-nct04469855-2026-05-19-5ae09bb317e7))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct04469855-2026-05-19-5ae09bb317e7`](#source-ctg-observation-nct04469855-2026-05-19-5ae09bb317e7))

### Sources

<a id="source-ctg-observation-nct04469855-2026-05-19-5ae09bb317e7"></a>
- **ClinicalTrials.gov record NCT04469855 · retained source version 2026-05-19:5ae09bb317e743c6b4d70e8915eb1e3ca74fe37f4505986510c2226d69e16b3f** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT04469855) (`ctg-observation-nct04469855-2026-05-19-5ae09bb317e7`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT04469855." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct04469855-semaglutide-v1 SHA-256: 95679c606d0e338ccb7eea859c9f2e19151f5ec519dfed38d4fe0b1cd2e45768.

---

<a id="clinicaltrials-gov-nct04777409-semaglutide-v1"></a>

## ClinicalTrials.gov record NCT04777409

> PeptideScanner retained ClinicalTrials.gov record NCT04777409 at 2026-07-30T16:19:03.047Z. Its registry update date was 2026-06-26, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct04777409-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-06-26
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-08
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct04777409-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct04777409-semaglutide-v1
- Content SHA-256: `90b591a7b69407e7e15d935849e296c246f5751ef9aee89d203ee01befac8e5a`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT04777409 ([`ctg-observation-nct04777409-2026-06-26-2235943a2082`](#source-ctg-observation-nct04777409-2026-06-26-2235943a2082))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT04777409 at 2026-07-30T16:19:03.047Z. Its registry update date was 2026-06-26, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct04777409-2026-06-26-2235943a2082`](#source-ctg-observation-nct04777409-2026-06-26-2235943a2082))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT04777409 at 2026-07-30T16:19:03.047Z. Its registry update date was 2026-06-26, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct04777409-2026-06-26-2235943a2082`](#source-ctg-observation-nct04777409-2026-06-26-2235943a2082))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct04777409-2026-06-26-2235943a2082`](#source-ctg-observation-nct04777409-2026-06-26-2235943a2082))

### Sources

<a id="source-ctg-observation-nct04777409-2026-06-26-2235943a2082"></a>
- **ClinicalTrials.gov record NCT04777409 · retained source version 2026-06-26:2235943a2082ba89590fb7f8ab0c45442c1bbee74312a4f8eaa2188c12ee8551** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT04777409) (`ctg-observation-nct04777409-2026-06-26-2235943a2082`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT04777409." Version 1, published 2026-08-08. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct04777409-semaglutide-v1 SHA-256: 90b591a7b69407e7e15d935849e296c246f5751ef9aee89d203ee01befac8e5a.

---

<a id="clinicaltrials-gov-nct04788511-semaglutide-v1"></a>

## ClinicalTrials.gov record NCT04788511

> PeptideScanner retained ClinicalTrials.gov record NCT04788511 at 2026-07-30T18:18:33.488Z. Its registry update date was 2025-12-05, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct04788511-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2025-12-05
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct04788511-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct04788511-semaglutide-v1
- Content SHA-256: `5c632a807ccc8f085a3b133cdbe2d13dcd0168497d0dc02a30b6b08900c3221c`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT04788511 ([`ctg-observation-nct04788511-2025-12-05-d5dca5938bec`](#source-ctg-observation-nct04788511-2025-12-05-d5dca5938bec))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT04788511 at 2026-07-30T18:18:33.488Z. Its registry update date was 2025-12-05, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct04788511-2025-12-05-d5dca5938bec`](#source-ctg-observation-nct04788511-2025-12-05-d5dca5938bec))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT04788511 at 2026-07-30T18:18:33.488Z. Its registry update date was 2025-12-05, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct04788511-2025-12-05-d5dca5938bec`](#source-ctg-observation-nct04788511-2025-12-05-d5dca5938bec))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct04788511-2025-12-05-d5dca5938bec`](#source-ctg-observation-nct04788511-2025-12-05-d5dca5938bec))

### Sources

<a id="source-ctg-observation-nct04788511-2025-12-05-d5dca5938bec"></a>
- **ClinicalTrials.gov record NCT04788511 · retained source version 2025-12-05:d5dca5938bec5ffaef229913a72f6e62fe69be368b487b14ab52e0661d2bf638** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT04788511) (`ctg-observation-nct04788511-2025-12-05-d5dca5938bec`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT04788511." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct04788511-semaglutide-v1 SHA-256: 5c632a807ccc8f085a3b133cdbe2d13dcd0168497d0dc02a30b6b08900c3221c.

---

<a id="clinicaltrials-gov-nct04822181-semaglutide-v1"></a>

## ClinicalTrials.gov record NCT04822181

> PeptideScanner retained ClinicalTrials.gov record NCT04822181 at 2026-07-30T16:19:03.054Z. Its registry update date was 2026-06-29, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct04822181-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-06-29
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-07-31
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct04822181-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct04822181-semaglutide-v1
- Content SHA-256: `137bf7ed406cbf188966e4309b685c9d27bd69b33a2ac35e0e561d12ddfe761e`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT04822181 ([`ctg-observation-nct04822181-2026-06-29-977c9e099af0`](#source-ctg-observation-nct04822181-2026-06-29-977c9e099af0))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT04822181 at 2026-07-30T16:19:03.054Z. Its registry update date was 2026-06-29, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct04822181-2026-06-29-977c9e099af0`](#source-ctg-observation-nct04822181-2026-06-29-977c9e099af0))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT04822181 at 2026-07-30T16:19:03.054Z. Its registry update date was 2026-06-29, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct04822181-2026-06-29-977c9e099af0`](#source-ctg-observation-nct04822181-2026-06-29-977c9e099af0))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct04822181-2026-06-29-977c9e099af0`](#source-ctg-observation-nct04822181-2026-06-29-977c9e099af0))

### Sources

<a id="source-ctg-observation-nct04822181-2026-06-29-977c9e099af0"></a>
- **ClinicalTrials.gov record NCT04822181 · retained source version 2026-06-29:977c9e099af0f79d521f9e2bdccbdca3b23c40e3c70adcca7dd056dc358ccb82** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT04822181) (`ctg-observation-nct04822181-2026-06-29-977c9e099af0`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT04822181." Version 1, published 2026-07-31. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct04822181-semaglutide-v1 SHA-256: 137bf7ed406cbf188966e4309b685c9d27bd69b33a2ac35e0e561d12ddfe761e.

---

<a id="clinicaltrials-gov-nct04873050-semaglutide-v1"></a>

## ClinicalTrials.gov record NCT04873050

> PeptideScanner retained ClinicalTrials.gov record NCT04873050 at 2026-07-30T18:30:10.991Z. Its registry update date was 2025-03-13, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct04873050-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2025-03-13
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct04873050-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct04873050-semaglutide-v1
- Content SHA-256: `052483eaa80c0798a2155905474c9231a9755f0bc10693aebca88942192fb71c`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT04873050 ([`ctg-observation-nct04873050-2025-03-13-63f15295109c`](#source-ctg-observation-nct04873050-2025-03-13-63f15295109c))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT04873050 at 2026-07-30T18:30:10.991Z. Its registry update date was 2025-03-13, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct04873050-2025-03-13-63f15295109c`](#source-ctg-observation-nct04873050-2025-03-13-63f15295109c))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT04873050 at 2026-07-30T18:30:10.991Z. Its registry update date was 2025-03-13, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct04873050-2025-03-13-63f15295109c`](#source-ctg-observation-nct04873050-2025-03-13-63f15295109c))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct04873050-2025-03-13-63f15295109c`](#source-ctg-observation-nct04873050-2025-03-13-63f15295109c))

### Sources

<a id="source-ctg-observation-nct04873050-2025-03-13-63f15295109c"></a>
- **ClinicalTrials.gov record NCT04873050 · retained source version 2025-03-13:63f15295109c150a78aa4514b9bcc8144f1dd153eca4a47b57f48bbf959bc665** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT04873050) (`ctg-observation-nct04873050-2025-03-13-63f15295109c`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT04873050." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct04873050-semaglutide-v1 SHA-256: 052483eaa80c0798a2155905474c9231a9755f0bc10693aebca88942192fb71c.

---

<a id="clinicaltrials-gov-nct04889183-semaglutide-v1"></a>

## ClinicalTrials.gov record NCT04889183

> PeptideScanner retained ClinicalTrials.gov record NCT04889183 at 2026-07-30T18:29:04.229Z. Its registry update date was 2025-04-22, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct04889183-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2025-04-22
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct04889183-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct04889183-semaglutide-v1
- Content SHA-256: `a40c43ab52d0d2bceba65be40e888c5ed7b30e40f0f9d711c5059d6bbcbe5cdb`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT04889183 ([`ctg-observation-nct04889183-2025-04-22-c924d2494b27`](#source-ctg-observation-nct04889183-2025-04-22-c924d2494b27))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT04889183 at 2026-07-30T18:29:04.229Z. Its registry update date was 2025-04-22, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct04889183-2025-04-22-c924d2494b27`](#source-ctg-observation-nct04889183-2025-04-22-c924d2494b27))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT04889183 at 2026-07-30T18:29:04.229Z. Its registry update date was 2025-04-22, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct04889183-2025-04-22-c924d2494b27`](#source-ctg-observation-nct04889183-2025-04-22-c924d2494b27))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct04889183-2025-04-22-c924d2494b27`](#source-ctg-observation-nct04889183-2025-04-22-c924d2494b27))

### Sources

<a id="source-ctg-observation-nct04889183-2025-04-22-c924d2494b27"></a>
- **ClinicalTrials.gov record NCT04889183 · retained source version 2025-04-22:c924d2494b274321372aa41fb22ffa79a7c198ae83c826ce73b0aa59c6acfcc1** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT04889183) (`ctg-observation-nct04889183-2025-04-22-c924d2494b27`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT04889183." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct04889183-semaglutide-v1 SHA-256: a40c43ab52d0d2bceba65be40e888c5ed7b30e40f0f9d711c5059d6bbcbe5cdb.

---

<a id="clinicaltrials-gov-nct04916470-semaglutide-v1"></a>

## ClinicalTrials.gov record NCT04916470

> PeptideScanner retained ClinicalTrials.gov record NCT04916470 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-02, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct04916470-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-11-02
- Source checked: 2026-11-14
- Published by PeptideScanner: 2026-11-14
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct04916470-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct04916470-semaglutide-v1
- Content SHA-256: `6107ae1db37ef55432aed73a9a253df0437e10ca88e4ceecc5c1e8eadacea145`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT04916470 ([`ctg-observation-nct04916470-2026-11-02-3ea49b42a25e`](#source-ctg-observation-nct04916470-2026-11-02-3ea49b42a25e))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT04916470 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-02, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct04916470-2026-11-02-3ea49b42a25e`](#source-ctg-observation-nct04916470-2026-11-02-3ea49b42a25e))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT04916470 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-02, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct04916470-2026-11-02-3ea49b42a25e`](#source-ctg-observation-nct04916470-2026-11-02-3ea49b42a25e))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct04916470-2026-11-02-3ea49b42a25e`](#source-ctg-observation-nct04916470-2026-11-02-3ea49b42a25e))

### Sources

<a id="source-ctg-observation-nct04916470-2026-11-02-3ea49b42a25e"></a>
- **ClinicalTrials.gov record NCT04916470 · retained source version 2026-11-02:3ea49b42a25e0030a0d9f1fdaace6ccf8c49251d2b1d087b7aeccbc4f0cfa568** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT04916470) (`ctg-observation-nct04916470-2026-11-02-3ea49b42a25e`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT04916470." Version 1, published 2026-11-14. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct04916470-semaglutide-v1 SHA-256: 6107ae1db37ef55432aed73a9a253df0437e10ca88e4ceecc5c1e8eadacea145.

---

<a id="clinicaltrials-gov-nct05254314-semaglutide-v1"></a>

## ClinicalTrials.gov record NCT05254314

> PeptideScanner retained ClinicalTrials.gov record NCT05254314 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-01, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct05254314-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-10-01
- Source checked: 2026-11-14
- Published by PeptideScanner: 2026-11-14
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct05254314-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct05254314-semaglutide-v1
- Content SHA-256: `8446b5130f67ebf9818a6d3ad0f9b96493bc2ef5de45c48df41739bd66c2f688`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT05254314 ([`ctg-observation-nct05254314-2026-10-01-3bd19ce4af54`](#source-ctg-observation-nct05254314-2026-10-01-3bd19ce4af54))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT05254314 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-01, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct05254314-2026-10-01-3bd19ce4af54`](#source-ctg-observation-nct05254314-2026-10-01-3bd19ce4af54))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT05254314 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-01, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct05254314-2026-10-01-3bd19ce4af54`](#source-ctg-observation-nct05254314-2026-10-01-3bd19ce4af54))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct05254314-2026-10-01-3bd19ce4af54`](#source-ctg-observation-nct05254314-2026-10-01-3bd19ce4af54))

### Sources

<a id="source-ctg-observation-nct05254314-2026-10-01-3bd19ce4af54"></a>
- **ClinicalTrials.gov record NCT05254314 · retained source version 2026-10-01:3bd19ce4af54f148583c69d5a42f5a8e19bcff267e276dc28fa822021b624805** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT05254314) (`ctg-observation-nct05254314-2026-10-01-3bd19ce4af54`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT05254314." Version 1, published 2026-11-14. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct05254314-semaglutide-v1 SHA-256: 8446b5130f67ebf9818a6d3ad0f9b96493bc2ef5de45c48df41739bd66c2f688.

---

<a id="clinicaltrials-gov-nct05302596-semaglutide-v1"></a>

## ClinicalTrials.gov record NCT05302596

> PeptideScanner retained ClinicalTrials.gov record NCT05302596 at 2026-07-30T18:29:04.234Z. Its registry update date was 2025-04-17, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct05302596-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2025-04-17
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct05302596-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct05302596-semaglutide-v1
- Content SHA-256: `b856cc0b4b7b09e00445578ba6631a68bce1f6d7abfd088d428cd8d4e71c728f`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT05302596 ([`ctg-observation-nct05302596-2025-04-17-bc6c3380b7c9`](#source-ctg-observation-nct05302596-2025-04-17-bc6c3380b7c9))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT05302596 at 2026-07-30T18:29:04.234Z. Its registry update date was 2025-04-17, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct05302596-2025-04-17-bc6c3380b7c9`](#source-ctg-observation-nct05302596-2025-04-17-bc6c3380b7c9))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT05302596 at 2026-07-30T18:29:04.234Z. Its registry update date was 2025-04-17, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct05302596-2025-04-17-bc6c3380b7c9`](#source-ctg-observation-nct05302596-2025-04-17-bc6c3380b7c9))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct05302596-2025-04-17-bc6c3380b7c9`](#source-ctg-observation-nct05302596-2025-04-17-bc6c3380b7c9))

### Sources

<a id="source-ctg-observation-nct05302596-2025-04-17-bc6c3380b7c9"></a>
- **ClinicalTrials.gov record NCT05302596 · retained source version 2025-04-17:bc6c3380b7c94f733f833433447c96a73cb7ffc862c99491a1ef6c86b35e8a71** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT05302596) (`ctg-observation-nct05302596-2025-04-17-bc6c3380b7c9`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT05302596." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct05302596-semaglutide-v1 SHA-256: b856cc0b4b7b09e00445578ba6631a68bce1f6d7abfd088d428cd8d4e71c728f.

---

<a id="clinicaltrials-gov-nct05333003-semaglutide-v1"></a>

## ClinicalTrials.gov record NCT05333003

> PeptideScanner retained ClinicalTrials.gov record NCT05333003 at 2026-07-30T16:19:36.906Z. Its registry update date was 2026-05-27, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct05333003-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-05-27
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct05333003-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct05333003-semaglutide-v1
- Content SHA-256: `3def3e5143b0b587ada1c4f9df2db90e9d17c5b65b25f7c9dbd87da50a83d7ce`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT05333003 ([`ctg-observation-nct05333003-2026-05-27-8b9552bd2b37`](#source-ctg-observation-nct05333003-2026-05-27-8b9552bd2b37))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT05333003 at 2026-07-30T16:19:36.906Z. Its registry update date was 2026-05-27, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct05333003-2026-05-27-8b9552bd2b37`](#source-ctg-observation-nct05333003-2026-05-27-8b9552bd2b37))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT05333003 at 2026-07-30T16:19:36.906Z. Its registry update date was 2026-05-27, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct05333003-2026-05-27-8b9552bd2b37`](#source-ctg-observation-nct05333003-2026-05-27-8b9552bd2b37))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct05333003-2026-05-27-8b9552bd2b37`](#source-ctg-observation-nct05333003-2026-05-27-8b9552bd2b37))

### Sources

<a id="source-ctg-observation-nct05333003-2026-05-27-8b9552bd2b37"></a>
- **ClinicalTrials.gov record NCT05333003 · retained source version 2026-05-27:8b9552bd2b378855e43973242ceb2cfdbffce18b60ec4dff41f7101b5dec04f4** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT05333003) (`ctg-observation-nct05333003-2026-05-27-8b9552bd2b37`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT05333003." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct05333003-semaglutide-v1 SHA-256: 3def3e5143b0b587ada1c4f9df2db90e9d17c5b65b25f7c9dbd87da50a83d7ce.

---

<a id="clinicaltrials-gov-nct05371496-semaglutide-v1"></a>

## ClinicalTrials.gov record NCT05371496

> PeptideScanner retained ClinicalTrials.gov record NCT05371496 at 2026-08-10T18:10:03.928Z. Its registry update date was 2026-07-02, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct05371496-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-07-02
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct05371496-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct05371496-semaglutide-v1
- Content SHA-256: `afe1c0eea6019c2edcaefc23be6348a8a0bb0acb3d88d0836dc9bdf8096067c2`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT05371496 ([`ctg-observation-nct05371496-2026-07-02-06a9a94c923b`](#source-ctg-observation-nct05371496-2026-07-02-06a9a94c923b))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT05371496 at 2026-08-10T18:10:03.928Z. Its registry update date was 2026-07-02, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct05371496-2026-07-02-06a9a94c923b`](#source-ctg-observation-nct05371496-2026-07-02-06a9a94c923b))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT05371496 at 2026-08-10T18:10:03.928Z. Its registry update date was 2026-07-02, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct05371496-2026-07-02-06a9a94c923b`](#source-ctg-observation-nct05371496-2026-07-02-06a9a94c923b))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct05371496-2026-07-02-06a9a94c923b`](#source-ctg-observation-nct05371496-2026-07-02-06a9a94c923b))

### Sources

<a id="source-ctg-observation-nct05371496-2026-07-02-06a9a94c923b"></a>
- **ClinicalTrials.gov record NCT05371496 · retained source version 2026-07-02:06a9a94c923b5d86eff686ad44306fd49719699b21f8d310ed07ea1cb5c1c2c0** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT05371496) (`ctg-observation-nct05371496-2026-07-02-06a9a94c923b`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT05371496." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct05371496-semaglutide-v1 SHA-256: afe1c0eea6019c2edcaefc23be6348a8a0bb0acb3d88d0836dc9bdf8096067c2.

---

<a id="clinicaltrials-gov-nct05424003-semaglutide-v1"></a>

## ClinicalTrials.gov record NCT05424003

> PeptideScanner retained ClinicalTrials.gov record NCT05424003 at 2026-07-30T16:19:03.066Z. Its registry update date was 2026-06-04, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct05424003-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-06-04
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct05424003-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct05424003-semaglutide-v1
- Content SHA-256: `e72f7c0aa172550e8ed949ce02b2ce6a8767f2a48c35e3bf1c69e01b150524c0`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT05424003 ([`ctg-observation-nct05424003-2026-06-04-f8207cbc7145`](#source-ctg-observation-nct05424003-2026-06-04-f8207cbc7145))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT05424003 at 2026-07-30T16:19:03.066Z. Its registry update date was 2026-06-04, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct05424003-2026-06-04-f8207cbc7145`](#source-ctg-observation-nct05424003-2026-06-04-f8207cbc7145))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT05424003 at 2026-07-30T16:19:03.066Z. Its registry update date was 2026-06-04, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct05424003-2026-06-04-f8207cbc7145`](#source-ctg-observation-nct05424003-2026-06-04-f8207cbc7145))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct05424003-2026-06-04-f8207cbc7145`](#source-ctg-observation-nct05424003-2026-06-04-f8207cbc7145))

### Sources

<a id="source-ctg-observation-nct05424003-2026-06-04-f8207cbc7145"></a>
- **ClinicalTrials.gov record NCT05424003 · retained source version 2026-06-04:f8207cbc714524d200f3dc16fc27313803b025050aa54324e69c8daf60a5f714** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT05424003) (`ctg-observation-nct05424003-2026-06-04-f8207cbc7145`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT05424003." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct05424003-semaglutide-v1 SHA-256: e72f7c0aa172550e8ed949ce02b2ce6a8767f2a48c35e3bf1c69e01b150524c0.

---

<a id="clinicaltrials-gov-nct05520775-semaglutide-v1"></a>

## ClinicalTrials.gov record NCT05520775

> PeptideScanner retained ClinicalTrials.gov record NCT05520775 at 2026-07-30T18:29:04.228Z. Its registry update date was 2025-04-02, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct05520775-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2025-04-02
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct05520775-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct05520775-semaglutide-v1
- Content SHA-256: `215d336c67d1b4981f3bf0f4ddad5bd6f08d7d8ffd0655f0ce6ca81db99e4198`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT05520775 ([`ctg-observation-nct05520775-2025-04-02-a0a30c1c7fb7`](#source-ctg-observation-nct05520775-2025-04-02-a0a30c1c7fb7))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT05520775 at 2026-07-30T18:29:04.228Z. Its registry update date was 2025-04-02, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct05520775-2025-04-02-a0a30c1c7fb7`](#source-ctg-observation-nct05520775-2025-04-02-a0a30c1c7fb7))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT05520775 at 2026-07-30T18:29:04.228Z. Its registry update date was 2025-04-02, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct05520775-2025-04-02-a0a30c1c7fb7`](#source-ctg-observation-nct05520775-2025-04-02-a0a30c1c7fb7))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct05520775-2025-04-02-a0a30c1c7fb7`](#source-ctg-observation-nct05520775-2025-04-02-a0a30c1c7fb7))

### Sources

<a id="source-ctg-observation-nct05520775-2025-04-02-a0a30c1c7fb7"></a>
- **ClinicalTrials.gov record NCT05520775 · retained source version 2025-04-02:a0a30c1c7fb71afe6f3636ebcfe1a504fcf2ce0cae29beea73e56054bc4d0611** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT05520775) (`ctg-observation-nct05520775-2025-04-02-a0a30c1c7fb7`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT05520775." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct05520775-semaglutide-v1 SHA-256: 215d336c67d1b4981f3bf0f4ddad5bd6f08d7d8ffd0655f0ce6ca81db99e4198.

---

<a id="clinicaltrials-gov-nct05530577-semaglutide-v1"></a>

## ClinicalTrials.gov record NCT05530577

> PeptideScanner retained ClinicalTrials.gov record NCT05530577 at 2026-07-30T18:23:09.828Z. Its registry update date was 2025-08-22, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct05530577-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2025-08-22
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct05530577-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct05530577-semaglutide-v1
- Content SHA-256: `7d9ce361517ab6ad47c8f41c97450e11be3480b471b1894d0371565e622942aa`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT05530577 ([`ctg-observation-nct05530577-2025-08-22-df642c5c9e22`](#source-ctg-observation-nct05530577-2025-08-22-df642c5c9e22))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT05530577 at 2026-07-30T18:23:09.828Z. Its registry update date was 2025-08-22, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct05530577-2025-08-22-df642c5c9e22`](#source-ctg-observation-nct05530577-2025-08-22-df642c5c9e22))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT05530577 at 2026-07-30T18:23:09.828Z. Its registry update date was 2025-08-22, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct05530577-2025-08-22-df642c5c9e22`](#source-ctg-observation-nct05530577-2025-08-22-df642c5c9e22))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct05530577-2025-08-22-df642c5c9e22`](#source-ctg-observation-nct05530577-2025-08-22-df642c5c9e22))

### Sources

<a id="source-ctg-observation-nct05530577-2025-08-22-df642c5c9e22"></a>
- **ClinicalTrials.gov record NCT05530577 · retained source version 2025-08-22:df642c5c9e22b5d594a66a319d237ca8ff07182ce371f0fe035b85385b184787** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT05530577) (`ctg-observation-nct05530577-2025-08-22-df642c5c9e22`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT05530577." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct05530577-semaglutide-v1 SHA-256: 7d9ce361517ab6ad47c8f41c97450e11be3480b471b1894d0371565e622942aa.

---

<a id="clinicaltrials-gov-nct05548647-semaglutide-v1"></a>

## ClinicalTrials.gov record NCT05548647

> PeptideScanner retained ClinicalTrials.gov record NCT05548647 at 2026-07-30T18:22:04.915Z. Its registry update date was 2025-09-08, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct05548647-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2025-09-08
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct05548647-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct05548647-semaglutide-v1
- Content SHA-256: `948fe4453f86929417e058336b8a530e559fba3f11a1fc9e6487a1d01bb5bf30`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT05548647 ([`ctg-observation-nct05548647-2025-09-08-45c5eb67398d`](#source-ctg-observation-nct05548647-2025-09-08-45c5eb67398d))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT05548647 at 2026-07-30T18:22:04.915Z. Its registry update date was 2025-09-08, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct05548647-2025-09-08-45c5eb67398d`](#source-ctg-observation-nct05548647-2025-09-08-45c5eb67398d))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT05548647 at 2026-07-30T18:22:04.915Z. Its registry update date was 2025-09-08, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct05548647-2025-09-08-45c5eb67398d`](#source-ctg-observation-nct05548647-2025-09-08-45c5eb67398d))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct05548647-2025-09-08-45c5eb67398d`](#source-ctg-observation-nct05548647-2025-09-08-45c5eb67398d))

### Sources

<a id="source-ctg-observation-nct05548647-2025-09-08-45c5eb67398d"></a>
- **ClinicalTrials.gov record NCT05548647 · retained source version 2025-09-08:45c5eb67398d7d60338bad1edf11b5d35beeb7705b1558e79f4ad0e33eb623aa** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT05548647) (`ctg-observation-nct05548647-2025-09-08-45c5eb67398d`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT05548647." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct05548647-semaglutide-v1 SHA-256: 948fe4453f86929417e058336b8a530e559fba3f11a1fc9e6487a1d01bb5bf30.

---

<a id="clinicaltrials-gov-nct05569772-semaglutide-v1"></a>

## ClinicalTrials.gov record NCT05569772

> PeptideScanner retained ClinicalTrials.gov record NCT05569772 at 2026-08-10T18:10:03.935Z. Its registry update date was 2026-07-07, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct05569772-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-07-07
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct05569772-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct05569772-semaglutide-v1
- Content SHA-256: `26e4cb4c611a413efd35824d796bb891f5a862fb18be7a29baf97bbb5d477c1d`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT05569772 ([`ctg-observation-nct05569772-2026-07-07-b0409466b5e2`](#source-ctg-observation-nct05569772-2026-07-07-b0409466b5e2))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT05569772 at 2026-08-10T18:10:03.935Z. Its registry update date was 2026-07-07, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct05569772-2026-07-07-b0409466b5e2`](#source-ctg-observation-nct05569772-2026-07-07-b0409466b5e2))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT05569772 at 2026-08-10T18:10:03.935Z. Its registry update date was 2026-07-07, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct05569772-2026-07-07-b0409466b5e2`](#source-ctg-observation-nct05569772-2026-07-07-b0409466b5e2))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct05569772-2026-07-07-b0409466b5e2`](#source-ctg-observation-nct05569772-2026-07-07-b0409466b5e2))

### Sources

<a id="source-ctg-observation-nct05569772-2026-07-07-b0409466b5e2"></a>
- **ClinicalTrials.gov record NCT05569772 · retained source version 2026-07-07:b0409466b5e2ec079c16d26602f8945ff03cbc2af3ac9c1e205974cc8fb41e2a** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT05569772) (`ctg-observation-nct05569772-2026-07-07-b0409466b5e2`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT05569772." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct05569772-semaglutide-v1 SHA-256: 26e4cb4c611a413efd35824d796bb891f5a862fb18be7a29baf97bbb5d477c1d.

---

<a id="clinicaltrials-gov-nct05586802-semaglutide-v1"></a>

## ClinicalTrials.gov record NCT05586802

> PeptideScanner retained ClinicalTrials.gov record NCT05586802 at 2026-07-30T16:19:36.909Z. Its registry update date was 2026-05-11, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct05586802-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-05-11
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct05586802-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct05586802-semaglutide-v1
- Content SHA-256: `c31076dca14e39b4103e29b2b2f2f97b58493dcad195878cf001ece3ea8ae695`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT05586802 ([`ctg-observation-nct05586802-2026-05-11-e0647ba026c4`](#source-ctg-observation-nct05586802-2026-05-11-e0647ba026c4))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT05586802 at 2026-07-30T16:19:36.909Z. Its registry update date was 2026-05-11, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct05586802-2026-05-11-e0647ba026c4`](#source-ctg-observation-nct05586802-2026-05-11-e0647ba026c4))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT05586802 at 2026-07-30T16:19:36.909Z. Its registry update date was 2026-05-11, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct05586802-2026-05-11-e0647ba026c4`](#source-ctg-observation-nct05586802-2026-05-11-e0647ba026c4))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct05586802-2026-05-11-e0647ba026c4`](#source-ctg-observation-nct05586802-2026-05-11-e0647ba026c4))

### Sources

<a id="source-ctg-observation-nct05586802-2026-05-11-e0647ba026c4"></a>
- **ClinicalTrials.gov record NCT05586802 · retained source version 2026-05-11:e0647ba026c4afbd817d051c9cc4125264c54dead9d6240daa29df9e32a4004d** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT05586802) (`ctg-observation-nct05586802-2026-05-11-e0647ba026c4`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT05586802." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct05586802-semaglutide-v1 SHA-256: c31076dca14e39b4103e29b2b2f2f97b58493dcad195878cf001ece3ea8ae695.

---

<a id="clinicaltrials-gov-nct05616013-semaglutide-v1"></a>

## ClinicalTrials.gov record NCT05616013

> PeptideScanner retained ClinicalTrials.gov record NCT05616013 at 2026-08-10T18:10:03.915Z. Its registry update date was 2026-07-08, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct05616013-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-07-08
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct05616013-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct05616013-semaglutide-v1
- Content SHA-256: `330d92b3788fe924ea3f9e18eb5eb7952bf56c3fe3c4b2d69d04dd113260aaa2`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT05616013 ([`ctg-observation-nct05616013-2026-07-08-d9478eaca1f6`](#source-ctg-observation-nct05616013-2026-07-08-d9478eaca1f6))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT05616013 at 2026-08-10T18:10:03.915Z. Its registry update date was 2026-07-08, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct05616013-2026-07-08-d9478eaca1f6`](#source-ctg-observation-nct05616013-2026-07-08-d9478eaca1f6))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT05616013 at 2026-08-10T18:10:03.915Z. Its registry update date was 2026-07-08, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct05616013-2026-07-08-d9478eaca1f6`](#source-ctg-observation-nct05616013-2026-07-08-d9478eaca1f6))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct05616013-2026-07-08-d9478eaca1f6`](#source-ctg-observation-nct05616013-2026-07-08-d9478eaca1f6))

### Sources

<a id="source-ctg-observation-nct05616013-2026-07-08-d9478eaca1f6"></a>
- **ClinicalTrials.gov record NCT05616013 · retained source version 2026-07-08:d9478eaca1f6c61ed090c1e67a95b9b91626e423f9f5125319e069d2bea6bd1a** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT05616013) (`ctg-observation-nct05616013-2026-07-08-d9478eaca1f6`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT05616013." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct05616013-semaglutide-v1 SHA-256: 330d92b3788fe924ea3f9e18eb5eb7952bf56c3fe3c4b2d69d04dd113260aaa2.

---

<a id="clinicaltrials-gov-nct05646706-semaglutide-v1"></a>

## ClinicalTrials.gov record NCT05646706

> PeptideScanner retained ClinicalTrials.gov record NCT05646706 at 2026-07-30T16:20:49.307Z. Its registry update date was 2026-04-23, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct05646706-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-04-23
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct05646706-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct05646706-semaglutide-v1
- Content SHA-256: `2b478f686ef2cab9909145a34b3c3636fec283f7cf7f2059da6badccc7fa2333`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT05646706 ([`ctg-observation-nct05646706-2026-04-23-229db4f2c6e8`](#source-ctg-observation-nct05646706-2026-04-23-229db4f2c6e8))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT05646706 at 2026-07-30T16:20:49.307Z. Its registry update date was 2026-04-23, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct05646706-2026-04-23-229db4f2c6e8`](#source-ctg-observation-nct05646706-2026-04-23-229db4f2c6e8))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT05646706 at 2026-07-30T16:20:49.307Z. Its registry update date was 2026-04-23, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct05646706-2026-04-23-229db4f2c6e8`](#source-ctg-observation-nct05646706-2026-04-23-229db4f2c6e8))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct05646706-2026-04-23-229db4f2c6e8`](#source-ctg-observation-nct05646706-2026-04-23-229db4f2c6e8))

### Sources

<a id="source-ctg-observation-nct05646706-2026-04-23-229db4f2c6e8"></a>
- **ClinicalTrials.gov record NCT05646706 · retained source version 2026-04-23:229db4f2c6e8efc3c7c6a3d8a5979869a1a41421cb1d9f77057e92089305f143** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT05646706) (`ctg-observation-nct05646706-2026-04-23-229db4f2c6e8`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT05646706." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct05646706-semaglutide-v1 SHA-256: 2b478f686ef2cab9909145a34b3c3636fec283f7cf7f2059da6badccc7fa2333.

---

<a id="clinicaltrials-gov-nct05702931-semaglutide-v1"></a>

## ClinicalTrials.gov record NCT05702931

> PeptideScanner retained ClinicalTrials.gov record NCT05702931 at 2026-07-30T18:18:33.515Z. Its registry update date was 2025-12-29, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct05702931-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2025-12-29
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct05702931-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct05702931-semaglutide-v1
- Content SHA-256: `2f43679c32f7cf691b04fddeded4518dd6915ba6c361eae89cd2496e8eb3f5de`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT05702931 ([`ctg-observation-nct05702931-2025-12-29-f49fddcbe074`](#source-ctg-observation-nct05702931-2025-12-29-f49fddcbe074))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT05702931 at 2026-07-30T18:18:33.515Z. Its registry update date was 2025-12-29, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct05702931-2025-12-29-f49fddcbe074`](#source-ctg-observation-nct05702931-2025-12-29-f49fddcbe074))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT05702931 at 2026-07-30T18:18:33.515Z. Its registry update date was 2025-12-29, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct05702931-2025-12-29-f49fddcbe074`](#source-ctg-observation-nct05702931-2025-12-29-f49fddcbe074))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct05702931-2025-12-29-f49fddcbe074`](#source-ctg-observation-nct05702931-2025-12-29-f49fddcbe074))

### Sources

<a id="source-ctg-observation-nct05702931-2025-12-29-f49fddcbe074"></a>
- **ClinicalTrials.gov record NCT05702931 · retained source version 2025-12-29:f49fddcbe074059469e3f1c25dd1a381702462abc6ba0ef542592235bad349e7** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT05702931) (`ctg-observation-nct05702931-2025-12-29-f49fddcbe074`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT05702931." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct05702931-semaglutide-v1 SHA-256: 2f43679c32f7cf691b04fddeded4518dd6915ba6c361eae89cd2496e8eb3f5de.

---

<a id="clinicaltrials-gov-nct05714683-semaglutide-v1"></a>

## ClinicalTrials.gov record NCT05714683

> PeptideScanner retained ClinicalTrials.gov record NCT05714683 at 2026-11-14T22:51:22.481Z. Its registry update date was 2026-09-18, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct05714683-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-09-18
- Source checked: 2026-11-14
- Published by PeptideScanner: 2026-11-14
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct05714683-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct05714683-semaglutide-v1
- Content SHA-256: `b66fe5147af7e6d04224fa0866ebe79d498d242589221e99fcff7b17d4f0c04f`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT05714683 ([`ctg-observation-nct05714683-2026-09-18-246789922663`](#source-ctg-observation-nct05714683-2026-09-18-246789922663))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT05714683 at 2026-11-14T22:51:22.481Z. Its registry update date was 2026-09-18, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct05714683-2026-09-18-246789922663`](#source-ctg-observation-nct05714683-2026-09-18-246789922663))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT05714683 at 2026-11-14T22:51:22.481Z. Its registry update date was 2026-09-18, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct05714683-2026-09-18-246789922663`](#source-ctg-observation-nct05714683-2026-09-18-246789922663))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct05714683-2026-09-18-246789922663`](#source-ctg-observation-nct05714683-2026-09-18-246789922663))

### Sources

<a id="source-ctg-observation-nct05714683-2026-09-18-246789922663"></a>
- **ClinicalTrials.gov record NCT05714683 · retained source version 2026-09-18:246789922663bc5f3bfd4f1c675a44b5953d62b25bcc86aab13de9f239cbcdf9** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT05714683) (`ctg-observation-nct05714683-2026-09-18-246789922663`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT05714683." Version 1, published 2026-11-14. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct05714683-semaglutide-v1 SHA-256: b66fe5147af7e6d04224fa0866ebe79d498d242589221e99fcff7b17d4f0c04f.

---

<a id="clinicaltrials-gov-nct05726227-semaglutide-v1"></a>

## ClinicalTrials.gov record NCT05726227

> PeptideScanner retained ClinicalTrials.gov record NCT05726227 at 2026-07-30T16:19:03.202Z. Its registry update date was 2026-06-16, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct05726227-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-06-16
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct05726227-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct05726227-semaglutide-v1
- Content SHA-256: `555a2d60f20b6186edc56862b40122ab66c44c0d4f61a9f13f17768319c420ea`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT05726227 ([`ctg-observation-nct05726227-2026-06-16-0642537affdf`](#source-ctg-observation-nct05726227-2026-06-16-0642537affdf))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT05726227 at 2026-07-30T16:19:03.202Z. Its registry update date was 2026-06-16, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct05726227-2026-06-16-0642537affdf`](#source-ctg-observation-nct05726227-2026-06-16-0642537affdf))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT05726227 at 2026-07-30T16:19:03.202Z. Its registry update date was 2026-06-16, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct05726227-2026-06-16-0642537affdf`](#source-ctg-observation-nct05726227-2026-06-16-0642537affdf))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct05726227-2026-06-16-0642537affdf`](#source-ctg-observation-nct05726227-2026-06-16-0642537affdf))

### Sources

<a id="source-ctg-observation-nct05726227-2026-06-16-0642537affdf"></a>
- **ClinicalTrials.gov record NCT05726227 · retained source version 2026-06-16:0642537affdf5c081112a47bf83383f7476356698bb903d50960cc271ba876bc** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT05726227) (`ctg-observation-nct05726227-2026-06-16-0642537affdf`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT05726227." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct05726227-semaglutide-v1 SHA-256: 555a2d60f20b6186edc56862b40122ab66c44c0d4f61a9f13f17768319c420ea.

---

<a id="clinicaltrials-gov-nct05746039-semaglutide-v1"></a>

## ClinicalTrials.gov record NCT05746039

> PeptideScanner retained ClinicalTrials.gov record NCT05746039 at 2026-07-30T16:20:49.311Z. Its registry update date was 2026-04-21, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct05746039-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-04-21
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct05746039-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct05746039-semaglutide-v1
- Content SHA-256: `107b373cb7d9e1dcd79332d584d25f5b41df86ed00f30ad081b40cbed5851f9c`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT05746039 ([`ctg-observation-nct05746039-2026-04-21-568e36257f46`](#source-ctg-observation-nct05746039-2026-04-21-568e36257f46))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT05746039 at 2026-07-30T16:20:49.311Z. Its registry update date was 2026-04-21, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct05746039-2026-04-21-568e36257f46`](#source-ctg-observation-nct05746039-2026-04-21-568e36257f46))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT05746039 at 2026-07-30T16:20:49.311Z. Its registry update date was 2026-04-21, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct05746039-2026-04-21-568e36257f46`](#source-ctg-observation-nct05746039-2026-04-21-568e36257f46))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct05746039-2026-04-21-568e36257f46`](#source-ctg-observation-nct05746039-2026-04-21-568e36257f46))

### Sources

<a id="source-ctg-observation-nct05746039-2026-04-21-568e36257f46"></a>
- **ClinicalTrials.gov record NCT05746039 · retained source version 2026-04-21:568e36257f466d40e3c74d308fd609191f94f5b9779d02d5b4d7830513df6499** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT05746039) (`ctg-observation-nct05746039-2026-04-21-568e36257f46`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT05746039." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct05746039-semaglutide-v1 SHA-256: 107b373cb7d9e1dcd79332d584d25f5b41df86ed00f30ad081b40cbed5851f9c.

---

<a id="clinicaltrials-gov-nct05788965-semaglutide-v1"></a>

## ClinicalTrials.gov record NCT05788965

> PeptideScanner retained ClinicalTrials.gov record NCT05788965 at 2026-07-30T16:25:18.013Z. Its registry update date was 2026-01-21, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct05788965-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-01-21
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct05788965-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct05788965-semaglutide-v1
- Content SHA-256: `9280d97a8cfcaeb3b555600bef51d23ad9760c258b0ae72fd251e508a58a564c`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT05788965 ([`ctg-observation-nct05788965-2026-01-21-ad731f96bb89`](#source-ctg-observation-nct05788965-2026-01-21-ad731f96bb89))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT05788965 at 2026-07-30T16:25:18.013Z. Its registry update date was 2026-01-21, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct05788965-2026-01-21-ad731f96bb89`](#source-ctg-observation-nct05788965-2026-01-21-ad731f96bb89))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT05788965 at 2026-07-30T16:25:18.013Z. Its registry update date was 2026-01-21, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct05788965-2026-01-21-ad731f96bb89`](#source-ctg-observation-nct05788965-2026-01-21-ad731f96bb89))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct05788965-2026-01-21-ad731f96bb89`](#source-ctg-observation-nct05788965-2026-01-21-ad731f96bb89))

### Sources

<a id="source-ctg-observation-nct05788965-2026-01-21-ad731f96bb89"></a>
- **ClinicalTrials.gov record NCT05788965 · retained source version 2026-01-21:ad731f96bb8960fac4f9f66a84d5ae7f5d54e76be642c95af689218878112d92** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT05788965) (`ctg-observation-nct05788965-2026-01-21-ad731f96bb89`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT05788965." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct05788965-semaglutide-v1 SHA-256: 9280d97a8cfcaeb3b555600bef51d23ad9760c258b0ae72fd251e508a58a564c.

---

<a id="clinicaltrials-gov-nct05813249-semaglutide-v1"></a>

## ClinicalTrials.gov record NCT05813249

> PeptideScanner retained ClinicalTrials.gov record NCT05813249 at 2026-07-30T18:46:20.405Z. Its registry update date was 2024-04-02, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct05813249-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2024-04-02
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct05813249-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct05813249-semaglutide-v1
- Content SHA-256: `6395d4667b95726076cbecf0ac82dcd7b106c065bf8c4f25c202ca713f7297f5`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT05813249 ([`ctg-observation-nct05813249-2024-04-02-699b42ffb551`](#source-ctg-observation-nct05813249-2024-04-02-699b42ffb551))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT05813249 at 2026-07-30T18:46:20.405Z. Its registry update date was 2024-04-02, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct05813249-2024-04-02-699b42ffb551`](#source-ctg-observation-nct05813249-2024-04-02-699b42ffb551))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT05813249 at 2026-07-30T18:46:20.405Z. Its registry update date was 2024-04-02, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct05813249-2024-04-02-699b42ffb551`](#source-ctg-observation-nct05813249-2024-04-02-699b42ffb551))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct05813249-2024-04-02-699b42ffb551`](#source-ctg-observation-nct05813249-2024-04-02-699b42ffb551))

### Sources

<a id="source-ctg-observation-nct05813249-2024-04-02-699b42ffb551"></a>
- **ClinicalTrials.gov record NCT05813249 · retained source version 2024-04-02:699b42ffb55182f6cdb776d9dc948b62263e5e11266d1e75fa552cf0e65fa1ab** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT05813249) (`ctg-observation-nct05813249-2024-04-02-699b42ffb551`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT05813249." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct05813249-semaglutide-v1 SHA-256: 6395d4667b95726076cbecf0ac82dcd7b106c065bf8c4f25c202ca713f7297f5.

---

<a id="clinicaltrials-gov-nct05891496-semaglutide-v1"></a>

## ClinicalTrials.gov record NCT05891496

> PeptideScanner retained ClinicalTrials.gov record NCT05891496 at 2026-07-30T16:23:45.669Z. Its registry update date was 2026-02-24, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct05891496-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-02-24
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct05891496-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct05891496-semaglutide-v1
- Content SHA-256: `4194072c44adbe13ddeaf5131b0381b8ef5dc1a97306302b0ebe38b4a9048e57`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT05891496 ([`ctg-observation-nct05891496-2026-02-24-4bc3500de94e`](#source-ctg-observation-nct05891496-2026-02-24-4bc3500de94e))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT05891496 at 2026-07-30T16:23:45.669Z. Its registry update date was 2026-02-24, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct05891496-2026-02-24-4bc3500de94e`](#source-ctg-observation-nct05891496-2026-02-24-4bc3500de94e))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT05891496 at 2026-07-30T16:23:45.669Z. Its registry update date was 2026-02-24, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct05891496-2026-02-24-4bc3500de94e`](#source-ctg-observation-nct05891496-2026-02-24-4bc3500de94e))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct05891496-2026-02-24-4bc3500de94e`](#source-ctg-observation-nct05891496-2026-02-24-4bc3500de94e))

### Sources

<a id="source-ctg-observation-nct05891496-2026-02-24-4bc3500de94e"></a>
- **ClinicalTrials.gov record NCT05891496 · retained source version 2026-02-24:4bc3500de94ed672737c75e0a14bd84f571ae2e3cad553e5a1899c32ee52794e** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT05891496) (`ctg-observation-nct05891496-2026-02-24-4bc3500de94e`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT05891496." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct05891496-semaglutide-v1 SHA-256: 4194072c44adbe13ddeaf5131b0381b8ef5dc1a97306302b0ebe38b4a9048e57.

---

<a id="clinicaltrials-gov-nct05891587-semaglutide-v1"></a>

## ClinicalTrials.gov record NCT05891587

> PeptideScanner retained ClinicalTrials.gov record NCT05891587 at 2026-07-30T18:18:33.508Z. Its registry update date was 2025-12-17, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct05891587-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2025-12-17
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct05891587-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct05891587-semaglutide-v1
- Content SHA-256: `32265da50c94901aa15c36179efb938697ef9e4dea732ebbf6b4bf200c2d7a6d`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT05891587 ([`ctg-observation-nct05891587-2025-12-17-80fb52e65214`](#source-ctg-observation-nct05891587-2025-12-17-80fb52e65214))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT05891587 at 2026-07-30T18:18:33.508Z. Its registry update date was 2025-12-17, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct05891587-2025-12-17-80fb52e65214`](#source-ctg-observation-nct05891587-2025-12-17-80fb52e65214))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT05891587 at 2026-07-30T18:18:33.508Z. Its registry update date was 2025-12-17, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct05891587-2025-12-17-80fb52e65214`](#source-ctg-observation-nct05891587-2025-12-17-80fb52e65214))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct05891587-2025-12-17-80fb52e65214`](#source-ctg-observation-nct05891587-2025-12-17-80fb52e65214))

### Sources

<a id="source-ctg-observation-nct05891587-2025-12-17-80fb52e65214"></a>
- **ClinicalTrials.gov record NCT05891587 · retained source version 2025-12-17:80fb52e65214d051ea7951c69527841b9c0c023bfd466dbf77079f0a2e582e64** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT05891587) (`ctg-observation-nct05891587-2025-12-17-80fb52e65214`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT05891587." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct05891587-semaglutide-v1 SHA-256: 32265da50c94901aa15c36179efb938697ef9e4dea732ebbf6b4bf200c2d7a6d.

---

<a id="clinicaltrials-gov-nct05895643-semaglutide-v1"></a>

## ClinicalTrials.gov record NCT05895643

> PeptideScanner retained ClinicalTrials.gov record NCT05895643 at 2026-07-30T18:23:09.822Z. Its registry update date was 2025-08-05, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct05895643-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2025-08-05
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct05895643-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct05895643-semaglutide-v1
- Content SHA-256: `b6ffc76c64a37b0b8e23206249e598e6af7822df26fba05a0dee791728790cc9`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT05895643 ([`ctg-observation-nct05895643-2025-08-05-978cd877d517`](#source-ctg-observation-nct05895643-2025-08-05-978cd877d517))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT05895643 at 2026-07-30T18:23:09.822Z. Its registry update date was 2025-08-05, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct05895643-2025-08-05-978cd877d517`](#source-ctg-observation-nct05895643-2025-08-05-978cd877d517))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT05895643 at 2026-07-30T18:23:09.822Z. Its registry update date was 2025-08-05, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct05895643-2025-08-05-978cd877d517`](#source-ctg-observation-nct05895643-2025-08-05-978cd877d517))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct05895643-2025-08-05-978cd877d517`](#source-ctg-observation-nct05895643-2025-08-05-978cd877d517))

### Sources

<a id="source-ctg-observation-nct05895643-2025-08-05-978cd877d517"></a>
- **ClinicalTrials.gov record NCT05895643 · retained source version 2025-08-05:978cd877d517883b1f1a934850d0b10ca2a48a66bf6365a081686d846ca0aeb0** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT05895643) (`ctg-observation-nct05895643-2025-08-05-978cd877d517`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT05895643." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct05895643-semaglutide-v1 SHA-256: b6ffc76c64a37b0b8e23206249e598e6af7822df26fba05a0dee791728790cc9.

---

<a id="clinicaltrials-gov-nct06015893-semaglutide-v1"></a>

## ClinicalTrials.gov record NCT06015893

> PeptideScanner retained ClinicalTrials.gov record NCT06015893 at 2026-08-13T05:52:27.015Z. Its registry update date was 2026-08-03, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct06015893-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-08-03
- Source checked: 2026-08-13
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06015893-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct06015893-semaglutide-v1
- Content SHA-256: `0fb361f4d92968aa467df17b81bded831faf195640789717a363a7cf3fa72860`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06015893 ([`ctg-observation-nct06015893-2026-08-03-32ebc1c71794`](#source-ctg-observation-nct06015893-2026-08-03-32ebc1c71794))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06015893 at 2026-08-13T05:52:27.015Z. Its registry update date was 2026-08-03, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct06015893-2026-08-03-32ebc1c71794`](#source-ctg-observation-nct06015893-2026-08-03-32ebc1c71794))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06015893 at 2026-08-13T05:52:27.015Z. Its registry update date was 2026-08-03, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct06015893-2026-08-03-32ebc1c71794`](#source-ctg-observation-nct06015893-2026-08-03-32ebc1c71794))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06015893-2026-08-03-32ebc1c71794`](#source-ctg-observation-nct06015893-2026-08-03-32ebc1c71794))

### Sources

<a id="source-ctg-observation-nct06015893-2026-08-03-32ebc1c71794"></a>
- **ClinicalTrials.gov record NCT06015893 · retained source version 2026-08-03:32ebc1c717942d8128b28de2c9275840843904be7c4367af1afa5ab9a328e83d** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06015893) (`ctg-observation-nct06015893-2026-08-03-32ebc1c71794`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06015893." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct06015893-semaglutide-v1 SHA-256: 0fb361f4d92968aa467df17b81bded831faf195640789717a363a7cf3fa72860.

---

<a id="clinicaltrials-gov-nct06015893-semaglutide-v2"></a>

## ClinicalTrials.gov record NCT06015893

> PeptideScanner retained ClinicalTrials.gov record NCT06015893 at 2026-11-16T13:28:59.838Z. Its registry update date was 2026-11-16, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct06015893-semaglutide:v2`
- Evidence domain: Clinical trials
- Date in source: 2026-11-16
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06015893-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct06015893-semaglutide-v2
- Content SHA-256: `29a946ed4eab11c6b0b8247d9f50a92bbb18beab71c69eb2b4d699154d4d9da2`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06015893 ([`ctg-observation-nct06015893-2026-08-03-32ebc1c71794-r2`](#source-ctg-observation-nct06015893-2026-08-03-32ebc1c71794-r2))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06015893 at 2026-11-16T13:28:59.838Z. Its registry update date was 2026-11-16, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct06015893-2026-08-03-32ebc1c71794-r2`](#source-ctg-observation-nct06015893-2026-08-03-32ebc1c71794-r2))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06015893 at 2026-11-16T13:28:59.838Z. Its registry update date was 2026-11-16, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct06015893-2026-08-03-32ebc1c71794-r2`](#source-ctg-observation-nct06015893-2026-08-03-32ebc1c71794-r2))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06015893-2026-08-03-32ebc1c71794-r2`](#source-ctg-observation-nct06015893-2026-08-03-32ebc1c71794-r2))

### Sources

<a id="source-ctg-observation-nct06015893-2026-08-03-32ebc1c71794-r2"></a>
- **ClinicalTrials.gov record NCT06015893 · retained source version 2026-11-16:5f57241a3c0175fb796024a17c48915ba71da1ba3a25565b0e2cccdd16ecdd5c** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06015893) (`ctg-observation-nct06015893-2026-08-03-32ebc1c71794-r2`)

### Correction lineage

updated on 2026-11-16: ClinicalTrials.gov posted a newer version of NCT06015893, with a registry update date of 2026-11-16. This version reports that observation; the earlier retained observation remains available as version 1.
- Supersedes version: 1
- Correction sources: [`ctg-observation-nct06015893-2026-08-03-32ebc1c71794-r2`](#source-ctg-observation-nct06015893-2026-08-03-32ebc1c71794-r2)

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06015893." Version 2, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct06015893-semaglutide-v2 SHA-256: 29a946ed4eab11c6b0b8247d9f50a92bbb18beab71c69eb2b4d699154d4d9da2.

---

<a id="clinicaltrials-gov-nct06027567-semaglutide-v1"></a>

## ClinicalTrials.gov record NCT06027567

> PeptideScanner retained ClinicalTrials.gov record NCT06027567 at 2026-07-30T16:23:45.644Z. Its registry update date was 2026-02-27, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct06027567-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-02-27
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06027567-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct06027567-semaglutide-v1
- Content SHA-256: `cecde4255fe5f3829d06cd3610e496c6cf113bd29be8e3cbee2e07bc07d11877`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06027567 ([`ctg-observation-nct06027567-2026-02-27-29a690329861`](#source-ctg-observation-nct06027567-2026-02-27-29a690329861))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06027567 at 2026-07-30T16:23:45.644Z. Its registry update date was 2026-02-27, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct06027567-2026-02-27-29a690329861`](#source-ctg-observation-nct06027567-2026-02-27-29a690329861))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06027567 at 2026-07-30T16:23:45.644Z. Its registry update date was 2026-02-27, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct06027567-2026-02-27-29a690329861`](#source-ctg-observation-nct06027567-2026-02-27-29a690329861))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06027567-2026-02-27-29a690329861`](#source-ctg-observation-nct06027567-2026-02-27-29a690329861))

### Sources

<a id="source-ctg-observation-nct06027567-2026-02-27-29a690329861"></a>
- **ClinicalTrials.gov record NCT06027567 · retained source version 2026-02-27:29a69032986188294f1d5f428a47e8367200284e8cd05d5cb3e4a2beef4b02ac** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06027567) (`ctg-observation-nct06027567-2026-02-27-29a690329861`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06027567." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct06027567-semaglutide-v1 SHA-256: cecde4255fe5f3829d06cd3610e496c6cf113bd29be8e3cbee2e07bc07d11877.

---

<a id="clinicaltrials-gov-nct06041217-semaglutide-v1"></a>

## ClinicalTrials.gov record NCT06041217

> PeptideScanner retained ClinicalTrials.gov record NCT06041217 at 2026-07-30T16:19:36.910Z. Its registry update date was 2026-05-18, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct06041217-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-05-18
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06041217-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct06041217-semaglutide-v1
- Content SHA-256: `169bdba43c9e28b191ebbbeca7d3eb360a95365a7189dbf54d3fc3471a96497f`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06041217 ([`ctg-observation-nct06041217-2026-05-18-4e75c6933fcb`](#source-ctg-observation-nct06041217-2026-05-18-4e75c6933fcb))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06041217 at 2026-07-30T16:19:36.910Z. Its registry update date was 2026-05-18, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct06041217-2026-05-18-4e75c6933fcb`](#source-ctg-observation-nct06041217-2026-05-18-4e75c6933fcb))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06041217 at 2026-07-30T16:19:36.910Z. Its registry update date was 2026-05-18, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct06041217-2026-05-18-4e75c6933fcb`](#source-ctg-observation-nct06041217-2026-05-18-4e75c6933fcb))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06041217-2026-05-18-4e75c6933fcb`](#source-ctg-observation-nct06041217-2026-05-18-4e75c6933fcb))

### Sources

<a id="source-ctg-observation-nct06041217-2026-05-18-4e75c6933fcb"></a>
- **ClinicalTrials.gov record NCT06041217 · retained source version 2026-05-18:4e75c6933fcb614b5d41d603408e4b725a4bc92833f9f8e920c71beacc5a47d1** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06041217) (`ctg-observation-nct06041217-2026-05-18-4e75c6933fcb`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06041217." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct06041217-semaglutide-v1 SHA-256: 169bdba43c9e28b191ebbbeca7d3eb360a95365a7189dbf54d3fc3471a96497f.

---

<a id="clinicaltrials-gov-nct06042153-semaglutide-v1"></a>

## ClinicalTrials.gov record NCT06042153

> PeptideScanner retained ClinicalTrials.gov record NCT06042153 at 2026-07-30T16:25:18.002Z. Its registry update date was 2026-01-13, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct06042153-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-01-13
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06042153-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct06042153-semaglutide-v1
- Content SHA-256: `e30aa2e4417bf8c77369f53ff8e0f5e9b3fa4b4490941bd9be31ae6f8dd4c172`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06042153 ([`ctg-observation-nct06042153-2026-01-13-5fb86d4dfdfd`](#source-ctg-observation-nct06042153-2026-01-13-5fb86d4dfdfd))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06042153 at 2026-07-30T16:25:18.002Z. Its registry update date was 2026-01-13, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct06042153-2026-01-13-5fb86d4dfdfd`](#source-ctg-observation-nct06042153-2026-01-13-5fb86d4dfdfd))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06042153 at 2026-07-30T16:25:18.002Z. Its registry update date was 2026-01-13, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct06042153-2026-01-13-5fb86d4dfdfd`](#source-ctg-observation-nct06042153-2026-01-13-5fb86d4dfdfd))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06042153-2026-01-13-5fb86d4dfdfd`](#source-ctg-observation-nct06042153-2026-01-13-5fb86d4dfdfd))

### Sources

<a id="source-ctg-observation-nct06042153-2026-01-13-5fb86d4dfdfd"></a>
- **ClinicalTrials.gov record NCT06042153 · retained source version 2026-01-13:5fb86d4dfdfde8e98d277d96ca862ec03118b4ba274c9583be83f14b1ec6ed8e** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06042153) (`ctg-observation-nct06042153-2026-01-13-5fb86d4dfdfd`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06042153." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct06042153-semaglutide-v1 SHA-256: e30aa2e4417bf8c77369f53ff8e0f5e9b3fa4b4490941bd9be31ae6f8dd4c172.

---

<a id="clinicaltrials-gov-nct06045221-semaglutide-v1"></a>

## ClinicalTrials.gov record NCT06045221

> PeptideScanner retained ClinicalTrials.gov record NCT06045221 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-15, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct06045221-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-09-15
- Source checked: 2026-11-14
- Published by PeptideScanner: 2026-11-14
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06045221-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct06045221-semaglutide-v1
- Content SHA-256: `5ae89b4fae3078650fbb41f3dd917a8207654533b336fa1c1361365e3ad450bb`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06045221 ([`ctg-observation-nct06045221-2026-09-15-c55ec02abea1`](#source-ctg-observation-nct06045221-2026-09-15-c55ec02abea1))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06045221 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-15, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct06045221-2026-09-15-c55ec02abea1`](#source-ctg-observation-nct06045221-2026-09-15-c55ec02abea1))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06045221 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-15, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct06045221-2026-09-15-c55ec02abea1`](#source-ctg-observation-nct06045221-2026-09-15-c55ec02abea1))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06045221-2026-09-15-c55ec02abea1`](#source-ctg-observation-nct06045221-2026-09-15-c55ec02abea1))

### Sources

<a id="source-ctg-observation-nct06045221-2026-09-15-c55ec02abea1"></a>
- **ClinicalTrials.gov record NCT06045221 · retained source version 2026-09-15:c55ec02abea1bb511a26128c94df0499510f45c1a06b5886e37fd9b5e539cd7d** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06045221) (`ctg-observation-nct06045221-2026-09-15-c55ec02abea1`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06045221." Version 1, published 2026-11-14. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct06045221-semaglutide-v1 SHA-256: 5ae89b4fae3078650fbb41f3dd917a8207654533b336fa1c1361365e3ad450bb.

---

<a id="clinicaltrials-gov-nct06058585-semaglutide-v1"></a>

## ClinicalTrials.gov record NCT06058585

> PeptideScanner retained ClinicalTrials.gov record NCT06058585 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-05, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct06058585-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-10-05
- Source checked: 2026-11-14
- Published by PeptideScanner: 2026-11-14
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06058585-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct06058585-semaglutide-v1
- Content SHA-256: `15d0b20a1e6da2edce477164b016246bcbe74f470a8a611cf95b0cb982739bd1`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06058585 ([`ctg-observation-nct06058585-2026-10-05-e9a3f457a1e6`](#source-ctg-observation-nct06058585-2026-10-05-e9a3f457a1e6))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06058585 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-05, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct06058585-2026-10-05-e9a3f457a1e6`](#source-ctg-observation-nct06058585-2026-10-05-e9a3f457a1e6))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06058585 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-05, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct06058585-2026-10-05-e9a3f457a1e6`](#source-ctg-observation-nct06058585-2026-10-05-e9a3f457a1e6))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06058585-2026-10-05-e9a3f457a1e6`](#source-ctg-observation-nct06058585-2026-10-05-e9a3f457a1e6))

### Sources

<a id="source-ctg-observation-nct06058585-2026-10-05-e9a3f457a1e6"></a>
- **ClinicalTrials.gov record NCT06058585 · retained source version 2026-10-05:e9a3f457a1e60fb17cebabb43bf72d1e6f4c87099e6658858fe4a01c244483c3** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06058585) (`ctg-observation-nct06058585-2026-10-05-e9a3f457a1e6`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06058585." Version 1, published 2026-11-14. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct06058585-semaglutide-v1 SHA-256: 15d0b20a1e6da2edce477164b016246bcbe74f470a8a611cf95b0cb982739bd1.

---

<a id="clinicaltrials-gov-nct06072963-semaglutide-v1"></a>

## ClinicalTrials.gov record NCT06072963

> PeptideScanner retained ClinicalTrials.gov record NCT06072963 at 2026-08-10T18:10:03.864Z. Its registry update date was 2026-07-27, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct06072963-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-07-27
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06072963-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct06072963-semaglutide-v1
- Content SHA-256: `bb7db7c99d29051b4ce9a6636c1bcfddcdd9cbb326a66559cdcdf6432be02e8f`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06072963 ([`ctg-observation-nct06072963-2026-07-27-483414b3f31d`](#source-ctg-observation-nct06072963-2026-07-27-483414b3f31d))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06072963 at 2026-08-10T18:10:03.864Z. Its registry update date was 2026-07-27, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct06072963-2026-07-27-483414b3f31d`](#source-ctg-observation-nct06072963-2026-07-27-483414b3f31d))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06072963 at 2026-08-10T18:10:03.864Z. Its registry update date was 2026-07-27, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct06072963-2026-07-27-483414b3f31d`](#source-ctg-observation-nct06072963-2026-07-27-483414b3f31d))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06072963-2026-07-27-483414b3f31d`](#source-ctg-observation-nct06072963-2026-07-27-483414b3f31d))

### Sources

<a id="source-ctg-observation-nct06072963-2026-07-27-483414b3f31d"></a>
- **ClinicalTrials.gov record NCT06072963 · retained source version 2026-07-27:483414b3f31df2407414d265560b7f9533166f51dda5a15edd5c9335023a83a1** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06072963) (`ctg-observation-nct06072963-2026-07-27-483414b3f31d`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06072963." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct06072963-semaglutide-v1 SHA-256: bb7db7c99d29051b4ce9a6636c1bcfddcdd9cbb326a66559cdcdf6432be02e8f.

---

<a id="clinicaltrials-gov-nct06118203-semaglutide-v1"></a>

## ClinicalTrials.gov record NCT06118203

> PeptideScanner retained ClinicalTrials.gov record NCT06118203 at 2026-07-30T16:22:22.346Z. Its registry update date was 2026-03-27, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct06118203-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-03-27
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06118203-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct06118203-semaglutide-v1
- Content SHA-256: `e8bf72541ce2e1a805e50d77a0712adbd5196bec2fb8f4e73ecb2b16960b950b`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06118203 ([`ctg-observation-nct06118203-2026-03-27-85ceea789aec`](#source-ctg-observation-nct06118203-2026-03-27-85ceea789aec))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06118203 at 2026-07-30T16:22:22.346Z. Its registry update date was 2026-03-27, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct06118203-2026-03-27-85ceea789aec`](#source-ctg-observation-nct06118203-2026-03-27-85ceea789aec))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06118203 at 2026-07-30T16:22:22.346Z. Its registry update date was 2026-03-27, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct06118203-2026-03-27-85ceea789aec`](#source-ctg-observation-nct06118203-2026-03-27-85ceea789aec))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06118203-2026-03-27-85ceea789aec`](#source-ctg-observation-nct06118203-2026-03-27-85ceea789aec))

### Sources

<a id="source-ctg-observation-nct06118203-2026-03-27-85ceea789aec"></a>
- **ClinicalTrials.gov record NCT06118203 · retained source version 2026-03-27:85ceea789aece2c0dc0da854f70d244ddd6d78569b3ad07cba52b968b5183025** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06118203) (`ctg-observation-nct06118203-2026-03-27-85ceea789aec`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06118203." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct06118203-semaglutide-v1 SHA-256: e8bf72541ce2e1a805e50d77a0712adbd5196bec2fb8f4e73ecb2b16960b950b.

---

<a id="clinicaltrials-gov-nct06234111-semaglutide-v1"></a>

## ClinicalTrials.gov record NCT06234111

> PeptideScanner retained ClinicalTrials.gov record NCT06234111 at 2026-07-30T18:37:14.697Z. Its registry update date was 2024-12-12, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct06234111-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2024-12-12
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06234111-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct06234111-semaglutide-v1
- Content SHA-256: `a2658499cf3caca5999d3fe0efd204884e74c35f9834cd5de18413a8ff1fb542`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06234111 ([`ctg-observation-nct06234111-2024-12-12-eb3eba9ee046`](#source-ctg-observation-nct06234111-2024-12-12-eb3eba9ee046))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06234111 at 2026-07-30T18:37:14.697Z. Its registry update date was 2024-12-12, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct06234111-2024-12-12-eb3eba9ee046`](#source-ctg-observation-nct06234111-2024-12-12-eb3eba9ee046))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06234111 at 2026-07-30T18:37:14.697Z. Its registry update date was 2024-12-12, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct06234111-2024-12-12-eb3eba9ee046`](#source-ctg-observation-nct06234111-2024-12-12-eb3eba9ee046))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06234111-2024-12-12-eb3eba9ee046`](#source-ctg-observation-nct06234111-2024-12-12-eb3eba9ee046))

### Sources

<a id="source-ctg-observation-nct06234111-2024-12-12-eb3eba9ee046"></a>
- **ClinicalTrials.gov record NCT06234111 · retained source version 2024-12-12:eb3eba9ee046a16d504b2ba39bd99d61407c208c0e48cd630694dacd54193e06** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06234111) (`ctg-observation-nct06234111-2024-12-12-eb3eba9ee046`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06234111." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct06234111-semaglutide-v1 SHA-256: a2658499cf3caca5999d3fe0efd204884e74c35f9834cd5de18413a8ff1fb542.

---

<a id="clinicaltrials-gov-nct06283667-semaglutide-v1"></a>

## ClinicalTrials.gov record NCT06283667

> PeptideScanner retained ClinicalTrials.gov record NCT06283667 at 2026-07-30T16:20:49.310Z. Its registry update date was 2026-04-22, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct06283667-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-04-22
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06283667-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct06283667-semaglutide-v1
- Content SHA-256: `f1a555c8c6879a88cf7bb7dff8ad011e49ba39cf16eb95ea94eb35d7e8334aec`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06283667 ([`ctg-observation-nct06283667-2026-04-22-926b14c7f3fd`](#source-ctg-observation-nct06283667-2026-04-22-926b14c7f3fd))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06283667 at 2026-07-30T16:20:49.310Z. Its registry update date was 2026-04-22, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct06283667-2026-04-22-926b14c7f3fd`](#source-ctg-observation-nct06283667-2026-04-22-926b14c7f3fd))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06283667 at 2026-07-30T16:20:49.310Z. Its registry update date was 2026-04-22, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct06283667-2026-04-22-926b14c7f3fd`](#source-ctg-observation-nct06283667-2026-04-22-926b14c7f3fd))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06283667-2026-04-22-926b14c7f3fd`](#source-ctg-observation-nct06283667-2026-04-22-926b14c7f3fd))

### Sources

<a id="source-ctg-observation-nct06283667-2026-04-22-926b14c7f3fd"></a>
- **ClinicalTrials.gov record NCT06283667 · retained source version 2026-04-22:926b14c7f3fd986b2c56ceb9099a58e54b4a960eea5222e14c88e6a51600ef52** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06283667) (`ctg-observation-nct06283667-2026-04-22-926b14c7f3fd`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06283667." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct06283667-semaglutide-v1 SHA-256: f1a555c8c6879a88cf7bb7dff8ad011e49ba39cf16eb95ea94eb35d7e8334aec.

---

<a id="clinicaltrials-gov-nct06299098-semaglutide-v1"></a>

## ClinicalTrials.gov record NCT06299098

> PeptideScanner retained ClinicalTrials.gov record NCT06299098 at 2026-08-10T18:10:03.940Z. Its registry update date was 2026-07-21, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct06299098-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-07-21
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06299098-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct06299098-semaglutide-v1
- Content SHA-256: `56050fed7ef74be45db16b9236494b0701bc575a23675fe95d367b132cf43311`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06299098 ([`ctg-observation-nct06299098-2026-07-21-3f43d1be33b9`](#source-ctg-observation-nct06299098-2026-07-21-3f43d1be33b9))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06299098 at 2026-08-10T18:10:03.940Z. Its registry update date was 2026-07-21, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct06299098-2026-07-21-3f43d1be33b9`](#source-ctg-observation-nct06299098-2026-07-21-3f43d1be33b9))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06299098 at 2026-08-10T18:10:03.940Z. Its registry update date was 2026-07-21, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct06299098-2026-07-21-3f43d1be33b9`](#source-ctg-observation-nct06299098-2026-07-21-3f43d1be33b9))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06299098-2026-07-21-3f43d1be33b9`](#source-ctg-observation-nct06299098-2026-07-21-3f43d1be33b9))

### Sources

<a id="source-ctg-observation-nct06299098-2026-07-21-3f43d1be33b9"></a>
- **ClinicalTrials.gov record NCT06299098 · retained source version 2026-07-21:3f43d1be33b9101f71fa8b678d1ddb0ef4ea70c8918e1b8b30959e586e76da9c** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06299098) (`ctg-observation-nct06299098-2026-07-21-3f43d1be33b9`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06299098." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct06299098-semaglutide-v1 SHA-256: 56050fed7ef74be45db16b9236494b0701bc575a23675fe95d367b132cf43311.

---

<a id="clinicaltrials-gov-nct06299098-semaglutide-v2"></a>

## ClinicalTrials.gov record NCT06299098

> PeptideScanner retained ClinicalTrials.gov record NCT06299098 at 2026-11-15T19:17:31.036Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct06299098-semaglutide:v2`
- Evidence domain: Clinical trials
- Date in source: 2026-11-12
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06299098-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct06299098-semaglutide-v2
- Content SHA-256: `2e5079693f7816a2b1ae9b050d4cd0b51939eb633663bea9ea1b6b1b1e3c75aa`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06299098 ([`ctg-observation-nct06299098-2026-07-21-3f43d1be33b9-r2`](#source-ctg-observation-nct06299098-2026-07-21-3f43d1be33b9-r2))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06299098 at 2026-11-15T19:17:31.036Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct06299098-2026-07-21-3f43d1be33b9-r2`](#source-ctg-observation-nct06299098-2026-07-21-3f43d1be33b9-r2))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06299098 at 2026-11-15T19:17:31.036Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct06299098-2026-07-21-3f43d1be33b9-r2`](#source-ctg-observation-nct06299098-2026-07-21-3f43d1be33b9-r2))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06299098-2026-07-21-3f43d1be33b9-r2`](#source-ctg-observation-nct06299098-2026-07-21-3f43d1be33b9-r2))

### Sources

<a id="source-ctg-observation-nct06299098-2026-07-21-3f43d1be33b9-r2"></a>
- **ClinicalTrials.gov record NCT06299098 · retained source version 2026-11-12:c1679275301a635d05f841b65a26d953bda55a1c1d957a48fb93f934e1c46713** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06299098) (`ctg-observation-nct06299098-2026-07-21-3f43d1be33b9-r2`)

### Correction lineage

updated on 2026-11-15: ClinicalTrials.gov posted a newer version of NCT06299098, with a registry update date of 2026-11-12. This version reports that observation; the earlier retained observation remains available as version 1.
- Supersedes version: 1
- Correction sources: [`ctg-observation-nct06299098-2026-07-21-3f43d1be33b9-r2`](#source-ctg-observation-nct06299098-2026-07-21-3f43d1be33b9-r2)

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06299098." Version 2, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct06299098-semaglutide-v2 SHA-256: 2e5079693f7816a2b1ae9b050d4cd0b51939eb633663bea9ea1b6b1b1e3c75aa.

---

<a id="clinicaltrials-gov-nct06446531-semaglutide-v1"></a>

## ClinicalTrials.gov record NCT06446531

> PeptideScanner retained ClinicalTrials.gov record NCT06446531 at 2026-07-30T18:19:48.219Z. Its registry update date was 2025-11-12, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct06446531-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2025-11-12
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06446531-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct06446531-semaglutide-v1
- Content SHA-256: `fc4f53687d570da4078c603683039bb778ce07ad892c29ae1cc96b874b13a76b`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06446531 ([`ctg-observation-nct06446531-2025-11-12-01b2ef0f0896`](#source-ctg-observation-nct06446531-2025-11-12-01b2ef0f0896))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06446531 at 2026-07-30T18:19:48.219Z. Its registry update date was 2025-11-12, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct06446531-2025-11-12-01b2ef0f0896`](#source-ctg-observation-nct06446531-2025-11-12-01b2ef0f0896))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06446531 at 2026-07-30T18:19:48.219Z. Its registry update date was 2025-11-12, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct06446531-2025-11-12-01b2ef0f0896`](#source-ctg-observation-nct06446531-2025-11-12-01b2ef0f0896))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06446531-2025-11-12-01b2ef0f0896`](#source-ctg-observation-nct06446531-2025-11-12-01b2ef0f0896))

### Sources

<a id="source-ctg-observation-nct06446531-2025-11-12-01b2ef0f0896"></a>
- **ClinicalTrials.gov record NCT06446531 · retained source version 2025-11-12:01b2ef0f0896d8e820732bd9c723acdd2a16ced3e974c058f41721b77f4868f5** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06446531) (`ctg-observation-nct06446531-2025-11-12-01b2ef0f0896`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06446531." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct06446531-semaglutide-v1 SHA-256: fc4f53687d570da4078c603683039bb778ce07ad892c29ae1cc96b874b13a76b.

---

<a id="clinicaltrials-gov-nct06499857-semaglutide-v1"></a>

## ClinicalTrials.gov record NCT06499857

> PeptideScanner retained ClinicalTrials.gov record NCT06499857 at 2026-07-30T18:19:48.219Z. Its registry update date was 2025-11-14, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct06499857-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2025-11-14
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06499857-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct06499857-semaglutide-v1
- Content SHA-256: `317cec629607d04593b04cbc204f603fb3f5e5a0ba3752a6f298683102169396`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06499857 ([`ctg-observation-nct06499857-2025-11-14-29679eac5cc2`](#source-ctg-observation-nct06499857-2025-11-14-29679eac5cc2))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06499857 at 2026-07-30T18:19:48.219Z. Its registry update date was 2025-11-14, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct06499857-2025-11-14-29679eac5cc2`](#source-ctg-observation-nct06499857-2025-11-14-29679eac5cc2))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06499857 at 2026-07-30T18:19:48.219Z. Its registry update date was 2025-11-14, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct06499857-2025-11-14-29679eac5cc2`](#source-ctg-observation-nct06499857-2025-11-14-29679eac5cc2))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06499857-2025-11-14-29679eac5cc2`](#source-ctg-observation-nct06499857-2025-11-14-29679eac5cc2))

### Sources

<a id="source-ctg-observation-nct06499857-2025-11-14-29679eac5cc2"></a>
- **ClinicalTrials.gov record NCT06499857 · retained source version 2025-11-14:29679eac5cc2b1a97728ce9d7d7fcee34fe98c729e3280f15635afa61c31b967** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06499857) (`ctg-observation-nct06499857-2025-11-14-29679eac5cc2`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06499857." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct06499857-semaglutide-v1 SHA-256: 317cec629607d04593b04cbc204f603fb3f5e5a0ba3752a6f298683102169396.

---

<a id="clinicaltrials-gov-nct06541509-semaglutide-v1"></a>

## ClinicalTrials.gov record NCT06541509

> PeptideScanner retained ClinicalTrials.gov record NCT06541509 at 2026-07-30T18:41:37.930Z. Its registry update date was 2024-08-07, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct06541509-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2024-08-07
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06541509-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct06541509-semaglutide-v1
- Content SHA-256: `19b864867ab7e729c77e55188aa7a5b739b8cf7e1053c970d394450682c58806`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06541509 ([`ctg-observation-nct06541509-2024-08-07-39ed63ea1768`](#source-ctg-observation-nct06541509-2024-08-07-39ed63ea1768))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06541509 at 2026-07-30T18:41:37.930Z. Its registry update date was 2024-08-07, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct06541509-2024-08-07-39ed63ea1768`](#source-ctg-observation-nct06541509-2024-08-07-39ed63ea1768))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06541509 at 2026-07-30T18:41:37.930Z. Its registry update date was 2024-08-07, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct06541509-2024-08-07-39ed63ea1768`](#source-ctg-observation-nct06541509-2024-08-07-39ed63ea1768))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06541509-2024-08-07-39ed63ea1768`](#source-ctg-observation-nct06541509-2024-08-07-39ed63ea1768))

### Sources

<a id="source-ctg-observation-nct06541509-2024-08-07-39ed63ea1768"></a>
- **ClinicalTrials.gov record NCT06541509 · retained source version 2024-08-07:39ed63ea1768e5fdba5b4eef793eff72f185a20f5fda5d8a500f281acff593bf** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06541509) (`ctg-observation-nct06541509-2024-08-07-39ed63ea1768`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06541509." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct06541509-semaglutide-v1 SHA-256: 19b864867ab7e729c77e55188aa7a5b739b8cf7e1053c970d394450682c58806.

---

<a id="clinicaltrials-gov-nct06571383-semaglutide-v1"></a>

## ClinicalTrials.gov record NCT06571383

> PeptideScanner retained ClinicalTrials.gov record NCT06571383 at 2026-07-30T16:19:03.050Z. Its registry update date was 2026-06-02, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct06571383-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-06-02
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06571383-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct06571383-semaglutide-v1
- Content SHA-256: `4897b38f0b88028f891d71653ce10c117dd461b3e4ad22e06cad3afeefe1a853`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06571383 ([`ctg-observation-nct06571383-2026-06-02-4aa8ed65bf0e`](#source-ctg-observation-nct06571383-2026-06-02-4aa8ed65bf0e))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06571383 at 2026-07-30T16:19:03.050Z. Its registry update date was 2026-06-02, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct06571383-2026-06-02-4aa8ed65bf0e`](#source-ctg-observation-nct06571383-2026-06-02-4aa8ed65bf0e))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06571383 at 2026-07-30T16:19:03.050Z. Its registry update date was 2026-06-02, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct06571383-2026-06-02-4aa8ed65bf0e`](#source-ctg-observation-nct06571383-2026-06-02-4aa8ed65bf0e))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06571383-2026-06-02-4aa8ed65bf0e`](#source-ctg-observation-nct06571383-2026-06-02-4aa8ed65bf0e))

### Sources

<a id="source-ctg-observation-nct06571383-2026-06-02-4aa8ed65bf0e"></a>
- **ClinicalTrials.gov record NCT06571383 · retained source version 2026-06-02:4aa8ed65bf0ea2c43619881fa47a628de91ff1eaf596c92a9ac836e6ea432fdf** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06571383) (`ctg-observation-nct06571383-2026-06-02-4aa8ed65bf0e`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06571383." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct06571383-semaglutide-v1 SHA-256: 4897b38f0b88028f891d71653ce10c117dd461b3e4ad22e06cad3afeefe1a853.

---

<a id="clinicaltrials-gov-nct06604624-semaglutide-v1"></a>

## ClinicalTrials.gov record NCT06604624

> PeptideScanner retained ClinicalTrials.gov record NCT06604624 at 2026-07-30T16:20:49.309Z. Its registry update date was 2026-04-06, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct06604624-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-04-06
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06604624-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct06604624-semaglutide-v1
- Content SHA-256: `2239042caaa38c7ea10e294634a2da574252aa1f7d563597a6b3bde7ad364c01`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06604624 ([`ctg-observation-nct06604624-2026-04-06-4db516f84f98`](#source-ctg-observation-nct06604624-2026-04-06-4db516f84f98))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06604624 at 2026-07-30T16:20:49.309Z. Its registry update date was 2026-04-06, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct06604624-2026-04-06-4db516f84f98`](#source-ctg-observation-nct06604624-2026-04-06-4db516f84f98))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06604624 at 2026-07-30T16:20:49.309Z. Its registry update date was 2026-04-06, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct06604624-2026-04-06-4db516f84f98`](#source-ctg-observation-nct06604624-2026-04-06-4db516f84f98))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06604624-2026-04-06-4db516f84f98`](#source-ctg-observation-nct06604624-2026-04-06-4db516f84f98))

### Sources

<a id="source-ctg-observation-nct06604624-2026-04-06-4db516f84f98"></a>
- **ClinicalTrials.gov record NCT06604624 · retained source version 2026-04-06:4db516f84f98ced3f31d9f95593ef0166071e51c42aadf6dc7003c543306b3c4** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06604624) (`ctg-observation-nct06604624-2026-04-06-4db516f84f98`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06604624." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct06604624-semaglutide-v1 SHA-256: 2239042caaa38c7ea10e294634a2da574252aa1f7d563597a6b3bde7ad364c01.

---

<a id="clinicaltrials-gov-nct06629688-semaglutide-v1"></a>

## ClinicalTrials.gov record NCT06629688

> PeptideScanner retained ClinicalTrials.gov record NCT06629688 at 2026-07-30T18:37:14.696Z. Its registry update date was 2024-12-05, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct06629688-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2024-12-05
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06629688-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct06629688-semaglutide-v1
- Content SHA-256: `d31d8b2df6440d0901131afddebb408559a4e08b097cb1f3133cdc71c85e168a`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06629688 ([`ctg-observation-nct06629688-2024-12-05-b85955a0c9e1`](#source-ctg-observation-nct06629688-2024-12-05-b85955a0c9e1))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06629688 at 2026-07-30T18:37:14.696Z. Its registry update date was 2024-12-05, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct06629688-2024-12-05-b85955a0c9e1`](#source-ctg-observation-nct06629688-2024-12-05-b85955a0c9e1))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06629688 at 2026-07-30T18:37:14.696Z. Its registry update date was 2024-12-05, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct06629688-2024-12-05-b85955a0c9e1`](#source-ctg-observation-nct06629688-2024-12-05-b85955a0c9e1))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06629688-2024-12-05-b85955a0c9e1`](#source-ctg-observation-nct06629688-2024-12-05-b85955a0c9e1))

### Sources

<a id="source-ctg-observation-nct06629688-2024-12-05-b85955a0c9e1"></a>
- **ClinicalTrials.gov record NCT06629688 · retained source version 2024-12-05:b85955a0c9e1b1185187c6b221d5239e0cec8cddb8ba86ab773f3db17f4a8d9c** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06629688) (`ctg-observation-nct06629688-2024-12-05-b85955a0c9e1`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06629688." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct06629688-semaglutide-v1 SHA-256: d31d8b2df6440d0901131afddebb408559a4e08b097cb1f3133cdc71c85e168a.

---

<a id="clinicaltrials-gov-nct06639464-semaglutide-v1"></a>

## ClinicalTrials.gov record NCT06639464

> PeptideScanner retained ClinicalTrials.gov record NCT06639464 at 2026-07-30T18:22:04.916Z. Its registry update date was 2025-09-26, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct06639464-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2025-09-26
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06639464-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct06639464-semaglutide-v1
- Content SHA-256: `c9055f1077ac4f8cfb48ee289f33f98efe8e7816331a6148d768bd72cd6f1bf2`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06639464 ([`ctg-observation-nct06639464-2025-09-26-2e78ab0a6046`](#source-ctg-observation-nct06639464-2025-09-26-2e78ab0a6046))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06639464 at 2026-07-30T18:22:04.916Z. Its registry update date was 2025-09-26, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct06639464-2025-09-26-2e78ab0a6046`](#source-ctg-observation-nct06639464-2025-09-26-2e78ab0a6046))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06639464 at 2026-07-30T18:22:04.916Z. Its registry update date was 2025-09-26, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct06639464-2025-09-26-2e78ab0a6046`](#source-ctg-observation-nct06639464-2025-09-26-2e78ab0a6046))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06639464-2025-09-26-2e78ab0a6046`](#source-ctg-observation-nct06639464-2025-09-26-2e78ab0a6046))

### Sources

<a id="source-ctg-observation-nct06639464-2025-09-26-2e78ab0a6046"></a>
- **ClinicalTrials.gov record NCT06639464 · retained source version 2025-09-26:2e78ab0a6046c746be30a200d8331b895909fc2c999a536372ac03a61245e6bd** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06639464) (`ctg-observation-nct06639464-2025-09-26-2e78ab0a6046`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06639464." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct06639464-semaglutide-v1 SHA-256: c9055f1077ac4f8cfb48ee289f33f98efe8e7816331a6148d768bd72cd6f1bf2.

---

<a id="clinicaltrials-gov-nct06691243-semaglutide-v1"></a>

## ClinicalTrials.gov record NCT06691243

> PeptideScanner retained ClinicalTrials.gov record NCT06691243 at 2026-07-30T18:23:09.829Z. Its registry update date was 2025-08-24, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct06691243-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2025-08-24
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06691243-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct06691243-semaglutide-v1
- Content SHA-256: `7f28487ff68fcc635d3b8b7c70197bb72b5d1e7796d043d65186bdc1a3ed5f2a`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06691243 ([`ctg-observation-nct06691243-2025-08-24-f9daf85ab3c1`](#source-ctg-observation-nct06691243-2025-08-24-f9daf85ab3c1))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06691243 at 2026-07-30T18:23:09.829Z. Its registry update date was 2025-08-24, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct06691243-2025-08-24-f9daf85ab3c1`](#source-ctg-observation-nct06691243-2025-08-24-f9daf85ab3c1))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06691243 at 2026-07-30T18:23:09.829Z. Its registry update date was 2025-08-24, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct06691243-2025-08-24-f9daf85ab3c1`](#source-ctg-observation-nct06691243-2025-08-24-f9daf85ab3c1))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06691243-2025-08-24-f9daf85ab3c1`](#source-ctg-observation-nct06691243-2025-08-24-f9daf85ab3c1))

### Sources

<a id="source-ctg-observation-nct06691243-2025-08-24-f9daf85ab3c1"></a>
- **ClinicalTrials.gov record NCT06691243 · retained source version 2025-08-24:f9daf85ab3c1cd11eeb877492c6480fee35a6fc5a4169f067b1bd63297fbfe3c** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06691243) (`ctg-observation-nct06691243-2025-08-24-f9daf85ab3c1`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06691243." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct06691243-semaglutide-v1 SHA-256: 7f28487ff68fcc635d3b8b7c70197bb72b5d1e7796d043d65186bdc1a3ed5f2a.

---

<a id="clinicaltrials-gov-nct06706284-semaglutide-v1"></a>

## ClinicalTrials.gov record NCT06706284

> PeptideScanner retained ClinicalTrials.gov record NCT06706284 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-05, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct06706284-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-10-05
- Source checked: 2026-11-14
- Published by PeptideScanner: 2026-11-14
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06706284-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct06706284-semaglutide-v1
- Content SHA-256: `7e921ff92bb2d937e5f35dba291420396f3dcf851e6472549f654347fde8b9bf`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06706284 ([`ctg-observation-nct06706284-2026-10-05-fb46a69aa3fb`](#source-ctg-observation-nct06706284-2026-10-05-fb46a69aa3fb))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06706284 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-05, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct06706284-2026-10-05-fb46a69aa3fb`](#source-ctg-observation-nct06706284-2026-10-05-fb46a69aa3fb))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06706284 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-05, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct06706284-2026-10-05-fb46a69aa3fb`](#source-ctg-observation-nct06706284-2026-10-05-fb46a69aa3fb))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06706284-2026-10-05-fb46a69aa3fb`](#source-ctg-observation-nct06706284-2026-10-05-fb46a69aa3fb))

### Sources

<a id="source-ctg-observation-nct06706284-2026-10-05-fb46a69aa3fb"></a>
- **ClinicalTrials.gov record NCT06706284 · retained source version 2026-10-05:fb46a69aa3fbcab3dd3634e30b9c2019bd244e0bda1f8410de08faa95d7d6b2e** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06706284) (`ctg-observation-nct06706284-2026-10-05-fb46a69aa3fb`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06706284." Version 1, published 2026-11-14. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct06706284-semaglutide-v1 SHA-256: 7e921ff92bb2d937e5f35dba291420396f3dcf851e6472549f654347fde8b9bf.

---

<a id="clinicaltrials-gov-nct06715514-semaglutide-v1"></a>

## ClinicalTrials.gov record NCT06715514

> PeptideScanner retained ClinicalTrials.gov record NCT06715514 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-16, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct06715514-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-10-16
- Source checked: 2026-11-14
- Published by PeptideScanner: 2026-11-14
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06715514-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct06715514-semaglutide-v1
- Content SHA-256: `1e3044db005132fc00ec3b1e33a2b1773278909351ff461ee120a99a750bff68`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06715514 ([`ctg-observation-nct06715514-2026-10-16-12aaf25d9b25`](#source-ctg-observation-nct06715514-2026-10-16-12aaf25d9b25))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06715514 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-16, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct06715514-2026-10-16-12aaf25d9b25`](#source-ctg-observation-nct06715514-2026-10-16-12aaf25d9b25))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06715514 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-16, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct06715514-2026-10-16-12aaf25d9b25`](#source-ctg-observation-nct06715514-2026-10-16-12aaf25d9b25))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06715514-2026-10-16-12aaf25d9b25`](#source-ctg-observation-nct06715514-2026-10-16-12aaf25d9b25))

### Sources

<a id="source-ctg-observation-nct06715514-2026-10-16-12aaf25d9b25"></a>
- **ClinicalTrials.gov record NCT06715514 · retained source version 2026-10-16:12aaf25d9b25c3ddd2cdbaeace72eabe90304fc351d85f1cac5ef082e5d49bd6** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06715514) (`ctg-observation-nct06715514-2026-10-16-12aaf25d9b25`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06715514." Version 1, published 2026-11-14. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct06715514-semaglutide-v1 SHA-256: 1e3044db005132fc00ec3b1e33a2b1773278909351ff461ee120a99a750bff68.

---

<a id="clinicaltrials-gov-nct06738979-semaglutide-v1"></a>

## ClinicalTrials.gov record NCT06738979

> PeptideScanner retained ClinicalTrials.gov record NCT06738979 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-25, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct06738979-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-09-25
- Source checked: 2026-11-14
- Published by PeptideScanner: 2026-11-14
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06738979-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct06738979-semaglutide-v1
- Content SHA-256: `28c8afd5b5cafbbed917ede74e2aa7c17c77702dd4a748e1ac9060e448d30c31`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06738979 ([`ctg-observation-nct06738979-2026-09-25-d33d1f5c3c8c`](#source-ctg-observation-nct06738979-2026-09-25-d33d1f5c3c8c))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06738979 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-25, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct06738979-2026-09-25-d33d1f5c3c8c`](#source-ctg-observation-nct06738979-2026-09-25-d33d1f5c3c8c))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06738979 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-25, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct06738979-2026-09-25-d33d1f5c3c8c`](#source-ctg-observation-nct06738979-2026-09-25-d33d1f5c3c8c))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06738979-2026-09-25-d33d1f5c3c8c`](#source-ctg-observation-nct06738979-2026-09-25-d33d1f5c3c8c))

### Sources

<a id="source-ctg-observation-nct06738979-2026-09-25-d33d1f5c3c8c"></a>
- **ClinicalTrials.gov record NCT06738979 · retained source version 2026-09-25:d33d1f5c3c8cad02168de2b04006859b96d1ef608aca274789900a5176a3b32b** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06738979) (`ctg-observation-nct06738979-2026-09-25-d33d1f5c3c8c`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06738979." Version 1, published 2026-11-14. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct06738979-semaglutide-v1 SHA-256: 28c8afd5b5cafbbed917ede74e2aa7c17c77702dd4a748e1ac9060e448d30c31.

---

<a id="clinicaltrials-gov-nct06764056-semaglutide-v1"></a>

## ClinicalTrials.gov record NCT06764056

> PeptideScanner retained ClinicalTrials.gov record NCT06764056 at 2026-07-30T18:32:24.991Z. Its registry update date was 2025-01-08, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct06764056-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2025-01-08
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06764056-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct06764056-semaglutide-v1
- Content SHA-256: `0f2b7edeb2c639f75541bceba98903c059dc8750ecbf2ddf1cc83a62e61d3abc`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06764056 ([`ctg-observation-nct06764056-2025-01-08-efe41cf49c41`](#source-ctg-observation-nct06764056-2025-01-08-efe41cf49c41))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06764056 at 2026-07-30T18:32:24.991Z. Its registry update date was 2025-01-08, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct06764056-2025-01-08-efe41cf49c41`](#source-ctg-observation-nct06764056-2025-01-08-efe41cf49c41))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06764056 at 2026-07-30T18:32:24.991Z. Its registry update date was 2025-01-08, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct06764056-2025-01-08-efe41cf49c41`](#source-ctg-observation-nct06764056-2025-01-08-efe41cf49c41))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06764056-2025-01-08-efe41cf49c41`](#source-ctg-observation-nct06764056-2025-01-08-efe41cf49c41))

### Sources

<a id="source-ctg-observation-nct06764056-2025-01-08-efe41cf49c41"></a>
- **ClinicalTrials.gov record NCT06764056 · retained source version 2025-01-08:efe41cf49c410ae9131d82f5e0304d3aa20f007eed2036f457aeff3e3a95c373** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06764056) (`ctg-observation-nct06764056-2025-01-08-efe41cf49c41`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06764056." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct06764056-semaglutide-v1 SHA-256: 0f2b7edeb2c639f75541bceba98903c059dc8750ecbf2ddf1cc83a62e61d3abc.

---

<a id="clinicaltrials-gov-nct06778967-semaglutide-v1"></a>

## ClinicalTrials.gov record NCT06778967

> PeptideScanner retained ClinicalTrials.gov record NCT06778967 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-10, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct06778967-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-11-10
- Source checked: 2026-11-14
- Published by PeptideScanner: 2026-11-14
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06778967-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct06778967-semaglutide-v1
- Content SHA-256: `c33dfa9ef4b4e7d822b2f91e8f6a888dbe63482b8cde14e75f966d54bc4467e8`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06778967 ([`ctg-observation-nct06778967-2026-11-10-bbce3e1b4b2b`](#source-ctg-observation-nct06778967-2026-11-10-bbce3e1b4b2b))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06778967 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-10, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct06778967-2026-11-10-bbce3e1b4b2b`](#source-ctg-observation-nct06778967-2026-11-10-bbce3e1b4b2b))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06778967 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-10, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct06778967-2026-11-10-bbce3e1b4b2b`](#source-ctg-observation-nct06778967-2026-11-10-bbce3e1b4b2b))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06778967-2026-11-10-bbce3e1b4b2b`](#source-ctg-observation-nct06778967-2026-11-10-bbce3e1b4b2b))

### Sources

<a id="source-ctg-observation-nct06778967-2026-11-10-bbce3e1b4b2b"></a>
- **ClinicalTrials.gov record NCT06778967 · retained source version 2026-11-10:bbce3e1b4b2bcf5ecac0c4e513bf96acecfc51c60108ee882a2f6800b95b1c74** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06778967) (`ctg-observation-nct06778967-2026-11-10-bbce3e1b4b2b`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06778967." Version 1, published 2026-11-14. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct06778967-semaglutide-v1 SHA-256: c33dfa9ef4b4e7d822b2f91e8f6a888dbe63482b8cde14e75f966d54bc4467e8.

---

<a id="clinicaltrials-gov-nct06814938-semaglutide-v1"></a>

## ClinicalTrials.gov record NCT06814938

> PeptideScanner retained ClinicalTrials.gov record NCT06814938 at 2026-08-10T18:10:03.940Z. Its registry update date was 2026-07-16, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct06814938-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-07-16
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06814938-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct06814938-semaglutide-v1
- Content SHA-256: `97698918c7ce8d0c8b92968688408640daa40d671ce123fca5a2a6cc56fa6b3b`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06814938 ([`ctg-observation-nct06814938-2026-07-16-1387446658c6`](#source-ctg-observation-nct06814938-2026-07-16-1387446658c6))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06814938 at 2026-08-10T18:10:03.940Z. Its registry update date was 2026-07-16, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct06814938-2026-07-16-1387446658c6`](#source-ctg-observation-nct06814938-2026-07-16-1387446658c6))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06814938 at 2026-08-10T18:10:03.940Z. Its registry update date was 2026-07-16, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct06814938-2026-07-16-1387446658c6`](#source-ctg-observation-nct06814938-2026-07-16-1387446658c6))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06814938-2026-07-16-1387446658c6`](#source-ctg-observation-nct06814938-2026-07-16-1387446658c6))

### Sources

<a id="source-ctg-observation-nct06814938-2026-07-16-1387446658c6"></a>
- **ClinicalTrials.gov record NCT06814938 · retained source version 2026-07-16:1387446658c61c725b7e71ba0c8ca1e5ad2c5dc405e7026ea5ccdaff45af4b21** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06814938) (`ctg-observation-nct06814938-2026-07-16-1387446658c6`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06814938." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct06814938-semaglutide-v1 SHA-256: 97698918c7ce8d0c8b92968688408640daa40d671ce123fca5a2a6cc56fa6b3b.

---

<a id="clinicaltrials-gov-nct06852391-semaglutide-v1"></a>

## ClinicalTrials.gov record NCT06852391

> PeptideScanner retained ClinicalTrials.gov record NCT06852391 at 2026-07-30T16:25:18.005Z. Its registry update date was 2026-01-14, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct06852391-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-01-14
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06852391-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct06852391-semaglutide-v1
- Content SHA-256: `059d5a5686458686b7f8e82287f829b19999e61529c106d3d4bbb9c63d9c467c`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06852391 ([`ctg-observation-nct06852391-2026-01-14-2d365b029937`](#source-ctg-observation-nct06852391-2026-01-14-2d365b029937))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06852391 at 2026-07-30T16:25:18.005Z. Its registry update date was 2026-01-14, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct06852391-2026-01-14-2d365b029937`](#source-ctg-observation-nct06852391-2026-01-14-2d365b029937))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06852391 at 2026-07-30T16:25:18.005Z. Its registry update date was 2026-01-14, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct06852391-2026-01-14-2d365b029937`](#source-ctg-observation-nct06852391-2026-01-14-2d365b029937))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06852391-2026-01-14-2d365b029937`](#source-ctg-observation-nct06852391-2026-01-14-2d365b029937))

### Sources

<a id="source-ctg-observation-nct06852391-2026-01-14-2d365b029937"></a>
- **ClinicalTrials.gov record NCT06852391 · retained source version 2026-01-14:2d365b0299371b9d9e597f6703c5e205f9b11f613f5ebf7e87a23aa8433ea4a6** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06852391) (`ctg-observation-nct06852391-2026-01-14-2d365b029937`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06852391." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct06852391-semaglutide-v1 SHA-256: 059d5a5686458686b7f8e82287f829b19999e61529c106d3d4bbb9c63d9c467c.

---

<a id="clinicaltrials-gov-nct06908694-semaglutide-v1"></a>

## ClinicalTrials.gov record NCT06908694

> PeptideScanner retained ClinicalTrials.gov record NCT06908694 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-14, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct06908694-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-09-14
- Source checked: 2026-11-14
- Published by PeptideScanner: 2026-11-14
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06908694-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct06908694-semaglutide-v1
- Content SHA-256: `e4b6de12aabc43868a18857750c9fa5ddbb0fb2000278127e1f9b8375fb9bd09`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06908694 ([`ctg-observation-nct06908694-2026-09-14-020baa28dc3a`](#source-ctg-observation-nct06908694-2026-09-14-020baa28dc3a))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06908694 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-14, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct06908694-2026-09-14-020baa28dc3a`](#source-ctg-observation-nct06908694-2026-09-14-020baa28dc3a))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06908694 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-14, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct06908694-2026-09-14-020baa28dc3a`](#source-ctg-observation-nct06908694-2026-09-14-020baa28dc3a))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06908694-2026-09-14-020baa28dc3a`](#source-ctg-observation-nct06908694-2026-09-14-020baa28dc3a))

### Sources

<a id="source-ctg-observation-nct06908694-2026-09-14-020baa28dc3a"></a>
- **ClinicalTrials.gov record NCT06908694 · retained source version 2026-09-14:020baa28dc3a7db459cfc0c5bbcd2319cf68154f321dfd23cb9bf767abb51af6** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06908694) (`ctg-observation-nct06908694-2026-09-14-020baa28dc3a`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06908694." Version 1, published 2026-11-14. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct06908694-semaglutide-v1 SHA-256: e4b6de12aabc43868a18857750c9fa5ddbb0fb2000278127e1f9b8375fb9bd09.

---

<a id="clinicaltrials-gov-nct06914102-semaglutide-v1"></a>

## ClinicalTrials.gov record NCT06914102

> PeptideScanner retained ClinicalTrials.gov record NCT06914102 at 2026-07-30T16:25:18.004Z. Its registry update date was 2026-01-30, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct06914102-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-01-30
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06914102-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct06914102-semaglutide-v1
- Content SHA-256: `976d2070735f90914976cf3dbe63cbba15c771136e79710f2a25e32f509f49e7`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06914102 ([`ctg-observation-nct06914102-2026-01-30-2ff90ae4a7e4`](#source-ctg-observation-nct06914102-2026-01-30-2ff90ae4a7e4))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06914102 at 2026-07-30T16:25:18.004Z. Its registry update date was 2026-01-30, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct06914102-2026-01-30-2ff90ae4a7e4`](#source-ctg-observation-nct06914102-2026-01-30-2ff90ae4a7e4))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06914102 at 2026-07-30T16:25:18.004Z. Its registry update date was 2026-01-30, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct06914102-2026-01-30-2ff90ae4a7e4`](#source-ctg-observation-nct06914102-2026-01-30-2ff90ae4a7e4))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06914102-2026-01-30-2ff90ae4a7e4`](#source-ctg-observation-nct06914102-2026-01-30-2ff90ae4a7e4))

### Sources

<a id="source-ctg-observation-nct06914102-2026-01-30-2ff90ae4a7e4"></a>
- **ClinicalTrials.gov record NCT06914102 · retained source version 2026-01-30:2ff90ae4a7e437cc73ee9b8823ac09fc80d0acc89a98ad7c053e572300ef6f7d** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06914102) (`ctg-observation-nct06914102-2026-01-30-2ff90ae4a7e4`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06914102." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct06914102-semaglutide-v1 SHA-256: 976d2070735f90914976cf3dbe63cbba15c771136e79710f2a25e32f509f49e7.

---

<a id="clinicaltrials-gov-nct06934655-semaglutide-v1"></a>

## ClinicalTrials.gov record NCT06934655

> PeptideScanner retained ClinicalTrials.gov record NCT06934655 at 2026-07-30T16:22:22.326Z. Its registry update date was 2026-03-17, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct06934655-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-03-17
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06934655-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct06934655-semaglutide-v1
- Content SHA-256: `12065f64ba6ffc5937dca7c3e2c7d4aff2ad4d6b64cc305081d7cb946070875d`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06934655 ([`ctg-observation-nct06934655-2026-03-17-7f0c093a3ab2`](#source-ctg-observation-nct06934655-2026-03-17-7f0c093a3ab2))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06934655 at 2026-07-30T16:22:22.326Z. Its registry update date was 2026-03-17, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct06934655-2026-03-17-7f0c093a3ab2`](#source-ctg-observation-nct06934655-2026-03-17-7f0c093a3ab2))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06934655 at 2026-07-30T16:22:22.326Z. Its registry update date was 2026-03-17, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct06934655-2026-03-17-7f0c093a3ab2`](#source-ctg-observation-nct06934655-2026-03-17-7f0c093a3ab2))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06934655-2026-03-17-7f0c093a3ab2`](#source-ctg-observation-nct06934655-2026-03-17-7f0c093a3ab2))

### Sources

<a id="source-ctg-observation-nct06934655-2026-03-17-7f0c093a3ab2"></a>
- **ClinicalTrials.gov record NCT06934655 · retained source version 2026-03-17:7f0c093a3ab2b818736c2235a567fcda6814dd7c5285238d5f87f92b35dccb42** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06934655) (`ctg-observation-nct06934655-2026-03-17-7f0c093a3ab2`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06934655." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct06934655-semaglutide-v1 SHA-256: 12065f64ba6ffc5937dca7c3e2c7d4aff2ad4d6b64cc305081d7cb946070875d.

---

<a id="clinicaltrials-gov-nct06937060-semaglutide-v1"></a>

## ClinicalTrials.gov record NCT06937060

> PeptideScanner retained ClinicalTrials.gov record NCT06937060 at 2026-07-30T18:27:14.162Z. Its registry update date was 2025-05-13, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct06937060-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2025-05-13
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06937060-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct06937060-semaglutide-v1
- Content SHA-256: `f67f2bb889723ad849297f2696da1b2f738b2463dcbcc604104ca5d4883fe971`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06937060 ([`ctg-observation-nct06937060-2025-05-13-c426f426c37c`](#source-ctg-observation-nct06937060-2025-05-13-c426f426c37c))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06937060 at 2026-07-30T18:27:14.162Z. Its registry update date was 2025-05-13, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct06937060-2025-05-13-c426f426c37c`](#source-ctg-observation-nct06937060-2025-05-13-c426f426c37c))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06937060 at 2026-07-30T18:27:14.162Z. Its registry update date was 2025-05-13, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct06937060-2025-05-13-c426f426c37c`](#source-ctg-observation-nct06937060-2025-05-13-c426f426c37c))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06937060-2025-05-13-c426f426c37c`](#source-ctg-observation-nct06937060-2025-05-13-c426f426c37c))

### Sources

<a id="source-ctg-observation-nct06937060-2025-05-13-c426f426c37c"></a>
- **ClinicalTrials.gov record NCT06937060 · retained source version 2025-05-13:c426f426c37cd54bd7676f6b09f8e2472fec54e243b318d9709d716c7d291acc** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06937060) (`ctg-observation-nct06937060-2025-05-13-c426f426c37c`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06937060." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct06937060-semaglutide-v1 SHA-256: f67f2bb889723ad849297f2696da1b2f738b2463dcbcc604104ca5d4883fe971.

---

<a id="clinicaltrials-gov-nct06959784-semaglutide-v1"></a>

## ClinicalTrials.gov record NCT06959784

> PeptideScanner retained ClinicalTrials.gov record NCT06959784 at 2026-07-30T18:27:14.158Z. Its registry update date was 2025-05-07, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct06959784-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2025-05-07
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06959784-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct06959784-semaglutide-v1
- Content SHA-256: `bd842527213f939b379a2ae49e298cddd12a81b3d51d20fdd689f9a07660775e`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06959784 ([`ctg-observation-nct06959784-2025-05-07-950f890f2a91`](#source-ctg-observation-nct06959784-2025-05-07-950f890f2a91))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06959784 at 2026-07-30T18:27:14.158Z. Its registry update date was 2025-05-07, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct06959784-2025-05-07-950f890f2a91`](#source-ctg-observation-nct06959784-2025-05-07-950f890f2a91))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06959784 at 2026-07-30T18:27:14.158Z. Its registry update date was 2025-05-07, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct06959784-2025-05-07-950f890f2a91`](#source-ctg-observation-nct06959784-2025-05-07-950f890f2a91))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06959784-2025-05-07-950f890f2a91`](#source-ctg-observation-nct06959784-2025-05-07-950f890f2a91))

### Sources

<a id="source-ctg-observation-nct06959784-2025-05-07-950f890f2a91"></a>
- **ClinicalTrials.gov record NCT06959784 · retained source version 2025-05-07:950f890f2a91e92f025dc178585ad7dd7250c14d728c653576bb49d73799beab** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06959784) (`ctg-observation-nct06959784-2025-05-07-950f890f2a91`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06959784." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct06959784-semaglutide-v1 SHA-256: bd842527213f939b379a2ae49e298cddd12a81b3d51d20fdd689f9a07660775e.

---

<a id="clinicaltrials-gov-nct06967389-semaglutide-v1"></a>

## ClinicalTrials.gov record NCT06967389

> PeptideScanner retained ClinicalTrials.gov record NCT06967389 at 2026-08-10T18:10:03.916Z. Its registry update date was 2026-07-21, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct06967389-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-07-21
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06967389-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct06967389-semaglutide-v1
- Content SHA-256: `602ca7d75d992fd6669d4e4e670f67f7432d1538a9cd94e72de81e6b5a61d7f1`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06967389 ([`ctg-observation-nct06967389-2026-07-21-7b710d61cdff`](#source-ctg-observation-nct06967389-2026-07-21-7b710d61cdff))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06967389 at 2026-08-10T18:10:03.916Z. Its registry update date was 2026-07-21, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct06967389-2026-07-21-7b710d61cdff`](#source-ctg-observation-nct06967389-2026-07-21-7b710d61cdff))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06967389 at 2026-08-10T18:10:03.916Z. Its registry update date was 2026-07-21, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct06967389-2026-07-21-7b710d61cdff`](#source-ctg-observation-nct06967389-2026-07-21-7b710d61cdff))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06967389-2026-07-21-7b710d61cdff`](#source-ctg-observation-nct06967389-2026-07-21-7b710d61cdff))

### Sources

<a id="source-ctg-observation-nct06967389-2026-07-21-7b710d61cdff"></a>
- **ClinicalTrials.gov record NCT06967389 · retained source version 2026-07-21:7b710d61cdff70f6fe52184fffd8cf70c77aaf39863edb86af41be375ef903f8** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06967389) (`ctg-observation-nct06967389-2026-07-21-7b710d61cdff`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06967389." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct06967389-semaglutide-v1 SHA-256: 602ca7d75d992fd6669d4e4e670f67f7432d1538a9cd94e72de81e6b5a61d7f1.

---

<a id="clinicaltrials-gov-nct06975111-semaglutide-v1"></a>

## ClinicalTrials.gov record NCT06975111

> PeptideScanner retained ClinicalTrials.gov record NCT06975111 at 2026-08-10T18:10:03.862Z. Its registry update date was 2026-07-21, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct06975111-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-07-21
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06975111-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct06975111-semaglutide-v1
- Content SHA-256: `fc6a9efa1640473a0e0ae9761b2e2af6c13a622aa9ba0caa4fda307544757a25`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06975111 ([`ctg-observation-nct06975111-2026-07-21-c184d9da8654`](#source-ctg-observation-nct06975111-2026-07-21-c184d9da8654))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06975111 at 2026-08-10T18:10:03.862Z. Its registry update date was 2026-07-21, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct06975111-2026-07-21-c184d9da8654`](#source-ctg-observation-nct06975111-2026-07-21-c184d9da8654))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06975111 at 2026-08-10T18:10:03.862Z. Its registry update date was 2026-07-21, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct06975111-2026-07-21-c184d9da8654`](#source-ctg-observation-nct06975111-2026-07-21-c184d9da8654))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06975111-2026-07-21-c184d9da8654`](#source-ctg-observation-nct06975111-2026-07-21-c184d9da8654))

### Sources

<a id="source-ctg-observation-nct06975111-2026-07-21-c184d9da8654"></a>
- **ClinicalTrials.gov record NCT06975111 · retained source version 2026-07-21:c184d9da8654abe2cc812788936950e85dd28032d4f17d14acde51815d09d04e** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06975111) (`ctg-observation-nct06975111-2026-07-21-c184d9da8654`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06975111." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct06975111-semaglutide-v1 SHA-256: fc6a9efa1640473a0e0ae9761b2e2af6c13a622aa9ba0caa4fda307544757a25.

---

<a id="clinicaltrials-gov-nct06977438-semaglutide-v1"></a>

## ClinicalTrials.gov record NCT06977438

> PeptideScanner retained ClinicalTrials.gov record NCT06977438 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-20, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct06977438-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-10-20
- Source checked: 2026-11-14
- Published by PeptideScanner: 2026-11-14
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06977438-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct06977438-semaglutide-v1
- Content SHA-256: `6380b2df5617634b9ef60dcf0eafd2c0067fb3a22d72d7fb437f896fa61e3ada`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06977438 ([`ctg-observation-nct06977438-2026-10-20-0d8f4a3bdcc1`](#source-ctg-observation-nct06977438-2026-10-20-0d8f4a3bdcc1))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06977438 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-20, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct06977438-2026-10-20-0d8f4a3bdcc1`](#source-ctg-observation-nct06977438-2026-10-20-0d8f4a3bdcc1))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06977438 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-20, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct06977438-2026-10-20-0d8f4a3bdcc1`](#source-ctg-observation-nct06977438-2026-10-20-0d8f4a3bdcc1))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06977438-2026-10-20-0d8f4a3bdcc1`](#source-ctg-observation-nct06977438-2026-10-20-0d8f4a3bdcc1))

### Sources

<a id="source-ctg-observation-nct06977438-2026-10-20-0d8f4a3bdcc1"></a>
- **ClinicalTrials.gov record NCT06977438 · retained source version 2026-10-20:0d8f4a3bdcc132a045b51a85a6a720c941ce65e2ae416c5b2b6f7614c1414139** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06977438) (`ctg-observation-nct06977438-2026-10-20-0d8f4a3bdcc1`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06977438." Version 1, published 2026-11-14. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct06977438-semaglutide-v1 SHA-256: 6380b2df5617634b9ef60dcf0eafd2c0067fb3a22d72d7fb437f896fa61e3ada.

---

<a id="clinicaltrials-gov-nct06986993-semaglutide-v1"></a>

## ClinicalTrials.gov record NCT06986993

> PeptideScanner retained ClinicalTrials.gov record NCT06986993 at 2026-07-30T18:23:09.822Z. Its registry update date was 2025-08-27, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct06986993-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2025-08-27
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06986993-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct06986993-semaglutide-v1
- Content SHA-256: `a6ffe4e5aa01cbe437bfb3ff9309bd88b15696cb4a31a72a52e022208838c8d0`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06986993 ([`ctg-observation-nct06986993-2025-08-27-5d72dfc9a370`](#source-ctg-observation-nct06986993-2025-08-27-5d72dfc9a370))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06986993 at 2026-07-30T18:23:09.822Z. Its registry update date was 2025-08-27, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct06986993-2025-08-27-5d72dfc9a370`](#source-ctg-observation-nct06986993-2025-08-27-5d72dfc9a370))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06986993 at 2026-07-30T18:23:09.822Z. Its registry update date was 2025-08-27, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct06986993-2025-08-27-5d72dfc9a370`](#source-ctg-observation-nct06986993-2025-08-27-5d72dfc9a370))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06986993-2025-08-27-5d72dfc9a370`](#source-ctg-observation-nct06986993-2025-08-27-5d72dfc9a370))

### Sources

<a id="source-ctg-observation-nct06986993-2025-08-27-5d72dfc9a370"></a>
- **ClinicalTrials.gov record NCT06986993 · retained source version 2025-08-27:5d72dfc9a370d696e8518eb925228b4f4d5c7b83843842933f067e0ff329ce32** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06986993) (`ctg-observation-nct06986993-2025-08-27-5d72dfc9a370`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06986993." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct06986993-semaglutide-v1 SHA-256: a6ffe4e5aa01cbe437bfb3ff9309bd88b15696cb4a31a72a52e022208838c8d0.

---

<a id="clinicaltrials-gov-nct06989177-semaglutide-v1"></a>

## ClinicalTrials.gov record NCT06989177

> PeptideScanner retained ClinicalTrials.gov record NCT06989177 at 2026-07-30T16:22:22.331Z. Its registry update date was 2026-03-17, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct06989177-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-03-17
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06989177-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct06989177-semaglutide-v1
- Content SHA-256: `df0dc3e951ccfca869e0eea1a817c5683b6dd98064643163f361dd5aa1355300`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06989177 ([`ctg-observation-nct06989177-2026-03-17-9c19f944e55e`](#source-ctg-observation-nct06989177-2026-03-17-9c19f944e55e))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06989177 at 2026-07-30T16:22:22.331Z. Its registry update date was 2026-03-17, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct06989177-2026-03-17-9c19f944e55e`](#source-ctg-observation-nct06989177-2026-03-17-9c19f944e55e))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06989177 at 2026-07-30T16:22:22.331Z. Its registry update date was 2026-03-17, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct06989177-2026-03-17-9c19f944e55e`](#source-ctg-observation-nct06989177-2026-03-17-9c19f944e55e))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06989177-2026-03-17-9c19f944e55e`](#source-ctg-observation-nct06989177-2026-03-17-9c19f944e55e))

### Sources

<a id="source-ctg-observation-nct06989177-2026-03-17-9c19f944e55e"></a>
- **ClinicalTrials.gov record NCT06989177 · retained source version 2026-03-17:9c19f944e55eef03829a0e76106f7968a57ffa95fea04e8bd8db66c058c1acba** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06989177) (`ctg-observation-nct06989177-2026-03-17-9c19f944e55e`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06989177." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct06989177-semaglutide-v1 SHA-256: df0dc3e951ccfca869e0eea1a817c5683b6dd98064643163f361dd5aa1355300.

---

<a id="clinicaltrials-gov-nct06989203-semaglutide-v1"></a>

## ClinicalTrials.gov record NCT06989203

> PeptideScanner retained ClinicalTrials.gov record NCT06989203 at 2026-07-30T16:22:22.329Z. Its registry update date was 2026-03-17, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct06989203-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-03-17
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06989203-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct06989203-semaglutide-v1
- Content SHA-256: `3568fdbf94b483f8b68033d168a1c258b7eda08e1e009b356d76f8e55716a59c`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06989203 ([`ctg-observation-nct06989203-2026-03-17-0ae583d75d0a`](#source-ctg-observation-nct06989203-2026-03-17-0ae583d75d0a))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06989203 at 2026-07-30T16:22:22.329Z. Its registry update date was 2026-03-17, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct06989203-2026-03-17-0ae583d75d0a`](#source-ctg-observation-nct06989203-2026-03-17-0ae583d75d0a))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06989203 at 2026-07-30T16:22:22.329Z. Its registry update date was 2026-03-17, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct06989203-2026-03-17-0ae583d75d0a`](#source-ctg-observation-nct06989203-2026-03-17-0ae583d75d0a))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06989203-2026-03-17-0ae583d75d0a`](#source-ctg-observation-nct06989203-2026-03-17-0ae583d75d0a))

### Sources

<a id="source-ctg-observation-nct06989203-2026-03-17-0ae583d75d0a"></a>
- **ClinicalTrials.gov record NCT06989203 · retained source version 2026-03-17:0ae583d75d0aba34bcdde7a7255e855a6c55fb4994aa1838674c9f0bafc81dc2** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06989203) (`ctg-observation-nct06989203-2026-03-17-0ae583d75d0a`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06989203." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct06989203-semaglutide-v1 SHA-256: 3568fdbf94b483f8b68033d168a1c258b7eda08e1e009b356d76f8e55716a59c.

---

<a id="clinicaltrials-gov-nct07018544-semaglutide-v1"></a>

## ClinicalTrials.gov record NCT07018544

> PeptideScanner retained ClinicalTrials.gov record NCT07018544 at 2026-07-30T18:26:04.261Z. Its registry update date was 2025-06-12, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct07018544-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2025-06-12
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07018544-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct07018544-semaglutide-v1
- Content SHA-256: `898610b0a7639037380b4341ef213461fafdd4edd8cf6e86c8f1e92661684e15`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07018544 ([`ctg-observation-nct07018544-2025-06-12-d4e76dbc7507`](#source-ctg-observation-nct07018544-2025-06-12-d4e76dbc7507))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07018544 at 2026-07-30T18:26:04.261Z. Its registry update date was 2025-06-12, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct07018544-2025-06-12-d4e76dbc7507`](#source-ctg-observation-nct07018544-2025-06-12-d4e76dbc7507))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07018544 at 2026-07-30T18:26:04.261Z. Its registry update date was 2025-06-12, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct07018544-2025-06-12-d4e76dbc7507`](#source-ctg-observation-nct07018544-2025-06-12-d4e76dbc7507))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07018544-2025-06-12-d4e76dbc7507`](#source-ctg-observation-nct07018544-2025-06-12-d4e76dbc7507))

### Sources

<a id="source-ctg-observation-nct07018544-2025-06-12-d4e76dbc7507"></a>
- **ClinicalTrials.gov record NCT07018544 · retained source version 2025-06-12:d4e76dbc750712a1bb2b9eddc12c53604e6984771e564f1e87b7f8e2d391e34f** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07018544) (`ctg-observation-nct07018544-2025-06-12-d4e76dbc7507`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07018544." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct07018544-semaglutide-v1 SHA-256: 898610b0a7639037380b4341ef213461fafdd4edd8cf6e86c8f1e92661684e15.

---

<a id="clinicaltrials-gov-nct07043361-semaglutide-v1"></a>

## ClinicalTrials.gov record NCT07043361

> PeptideScanner retained ClinicalTrials.gov record NCT07043361 at 2026-07-30T18:24:37.183Z. Its registry update date was 2025-07-09, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct07043361-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2025-07-09
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07043361-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct07043361-semaglutide-v1
- Content SHA-256: `f268444b87a8e9729c8f415227b5c3cf18bac91bd75dae703c8f85bf774c27f2`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07043361 ([`ctg-observation-nct07043361-2025-07-09-5970ac05ed8c`](#source-ctg-observation-nct07043361-2025-07-09-5970ac05ed8c))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07043361 at 2026-07-30T18:24:37.183Z. Its registry update date was 2025-07-09, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct07043361-2025-07-09-5970ac05ed8c`](#source-ctg-observation-nct07043361-2025-07-09-5970ac05ed8c))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07043361 at 2026-07-30T18:24:37.183Z. Its registry update date was 2025-07-09, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct07043361-2025-07-09-5970ac05ed8c`](#source-ctg-observation-nct07043361-2025-07-09-5970ac05ed8c))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07043361-2025-07-09-5970ac05ed8c`](#source-ctg-observation-nct07043361-2025-07-09-5970ac05ed8c))

### Sources

<a id="source-ctg-observation-nct07043361-2025-07-09-5970ac05ed8c"></a>
- **ClinicalTrials.gov record NCT07043361 · retained source version 2025-07-09:5970ac05ed8cef96ad5aa04f5c114989af9d1563397c1c50ac1d5203770cc5de** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07043361) (`ctg-observation-nct07043361-2025-07-09-5970ac05ed8c`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07043361." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct07043361-semaglutide-v1 SHA-256: f268444b87a8e9729c8f415227b5c3cf18bac91bd75dae703c8f85bf774c27f2.

---

<a id="clinicaltrials-gov-nct07059377-semaglutide-v1"></a>

## ClinicalTrials.gov record NCT07059377

> PeptideScanner retained ClinicalTrials.gov record NCT07059377 at 2026-07-30T16:19:36.906Z. Its registry update date was 2026-05-11, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct07059377-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-05-11
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07059377-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct07059377-semaglutide-v1
- Content SHA-256: `199f2a8c38f075ff9e980aa27c2a81441b8624dcb604454b7543899f62ea32f2`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07059377 ([`ctg-observation-nct07059377-2026-05-11-9c660b4925bc`](#source-ctg-observation-nct07059377-2026-05-11-9c660b4925bc))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07059377 at 2026-07-30T16:19:36.906Z. Its registry update date was 2026-05-11, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct07059377-2026-05-11-9c660b4925bc`](#source-ctg-observation-nct07059377-2026-05-11-9c660b4925bc))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07059377 at 2026-07-30T16:19:36.906Z. Its registry update date was 2026-05-11, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct07059377-2026-05-11-9c660b4925bc`](#source-ctg-observation-nct07059377-2026-05-11-9c660b4925bc))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07059377-2026-05-11-9c660b4925bc`](#source-ctg-observation-nct07059377-2026-05-11-9c660b4925bc))

### Sources

<a id="source-ctg-observation-nct07059377-2026-05-11-9c660b4925bc"></a>
- **ClinicalTrials.gov record NCT07059377 · retained source version 2026-05-11:9c660b4925bc3186de7cbbc889e4e3f386904bfdef01804d5a71c800c9480d6f** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07059377) (`ctg-observation-nct07059377-2026-05-11-9c660b4925bc`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07059377." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct07059377-semaglutide-v1 SHA-256: 199f2a8c38f075ff9e980aa27c2a81441b8624dcb604454b7543899f62ea32f2.

---

<a id="clinicaltrials-gov-nct07064486-semaglutide-v1"></a>

## ClinicalTrials.gov record NCT07064486

> PeptideScanner retained ClinicalTrials.gov record NCT07064486 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-13, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct07064486-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-10-13
- Source checked: 2026-11-14
- Published by PeptideScanner: 2026-11-14
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07064486-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct07064486-semaglutide-v1
- Content SHA-256: `bdff2b54ed448defde3f9e415b3ae07b6459ce7943276028d261962ff9b642e4`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07064486 ([`ctg-observation-nct07064486-2026-10-13-7892aa18d5e9`](#source-ctg-observation-nct07064486-2026-10-13-7892aa18d5e9))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07064486 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-13, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct07064486-2026-10-13-7892aa18d5e9`](#source-ctg-observation-nct07064486-2026-10-13-7892aa18d5e9))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07064486 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-13, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct07064486-2026-10-13-7892aa18d5e9`](#source-ctg-observation-nct07064486-2026-10-13-7892aa18d5e9))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07064486-2026-10-13-7892aa18d5e9`](#source-ctg-observation-nct07064486-2026-10-13-7892aa18d5e9))

### Sources

<a id="source-ctg-observation-nct07064486-2026-10-13-7892aa18d5e9"></a>
- **ClinicalTrials.gov record NCT07064486 · retained source version 2026-10-13:7892aa18d5e92fe7c6e2de5ca5ef98da29d8c4c3d6dc58acdb192f40f83a1596** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07064486) (`ctg-observation-nct07064486-2026-10-13-7892aa18d5e9`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07064486." Version 1, published 2026-11-14. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct07064486-semaglutide-v1 SHA-256: bdff2b54ed448defde3f9e415b3ae07b6459ce7943276028d261962ff9b642e4.

---

<a id="clinicaltrials-gov-nct07087795-semaglutide-v1"></a>

## ClinicalTrials.gov record NCT07087795

> PeptideScanner retained ClinicalTrials.gov record NCT07087795 at 2026-08-13T16:32:13.881Z. Its registry update date was 2026-08-13, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct07087795-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-08-13
- Source checked: 2026-08-13
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07087795-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct07087795-semaglutide-v1
- Content SHA-256: `8553ffad31c92bdcc2cab46c529b28827f8195c4b9e22a9dc0541ee1c02640ad`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07087795 ([`ctg-observation-nct07087795-2026-08-13-7a75ba51f829`](#source-ctg-observation-nct07087795-2026-08-13-7a75ba51f829))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07087795 at 2026-08-13T16:32:13.881Z. Its registry update date was 2026-08-13, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct07087795-2026-08-13-7a75ba51f829`](#source-ctg-observation-nct07087795-2026-08-13-7a75ba51f829))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07087795 at 2026-08-13T16:32:13.881Z. Its registry update date was 2026-08-13, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct07087795-2026-08-13-7a75ba51f829`](#source-ctg-observation-nct07087795-2026-08-13-7a75ba51f829))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07087795-2026-08-13-7a75ba51f829`](#source-ctg-observation-nct07087795-2026-08-13-7a75ba51f829))

### Sources

<a id="source-ctg-observation-nct07087795-2026-08-13-7a75ba51f829"></a>
- **ClinicalTrials.gov record NCT07087795 · retained source version 2026-08-13:7a75ba51f8292e94bf71eeda810aff04a0f5891feda858822f3a08b7b8ae82f1** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07087795) (`ctg-observation-nct07087795-2026-08-13-7a75ba51f829`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07087795." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct07087795-semaglutide-v1 SHA-256: 8553ffad31c92bdcc2cab46c529b28827f8195c4b9e22a9dc0541ee1c02640ad.

---

<a id="clinicaltrials-gov-nct07090343-semaglutide-v1"></a>

## ClinicalTrials.gov record NCT07090343

> PeptideScanner retained ClinicalTrials.gov record NCT07090343 at 2026-07-30T18:24:37.186Z. Its registry update date was 2025-07-29, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct07090343-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2025-07-29
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07090343-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct07090343-semaglutide-v1
- Content SHA-256: `76ad424797252c7e46dd99ec8d0ebf4ccebe096b765fc849ddb1b4f0392ab0d8`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07090343 ([`ctg-observation-nct07090343-2025-07-29-e12ab2502f64`](#source-ctg-observation-nct07090343-2025-07-29-e12ab2502f64))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07090343 at 2026-07-30T18:24:37.186Z. Its registry update date was 2025-07-29, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct07090343-2025-07-29-e12ab2502f64`](#source-ctg-observation-nct07090343-2025-07-29-e12ab2502f64))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07090343 at 2026-07-30T18:24:37.186Z. Its registry update date was 2025-07-29, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct07090343-2025-07-29-e12ab2502f64`](#source-ctg-observation-nct07090343-2025-07-29-e12ab2502f64))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07090343-2025-07-29-e12ab2502f64`](#source-ctg-observation-nct07090343-2025-07-29-e12ab2502f64))

### Sources

<a id="source-ctg-observation-nct07090343-2025-07-29-e12ab2502f64"></a>
- **ClinicalTrials.gov record NCT07090343 · retained source version 2025-07-29:e12ab2502f64ff6a69574be8ddbdd95feac2b63eab8f86b6dbfefa3dcc09586b** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07090343) (`ctg-observation-nct07090343-2025-07-29-e12ab2502f64`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07090343." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct07090343-semaglutide-v1 SHA-256: 76ad424797252c7e46dd99ec8d0ebf4ccebe096b765fc849ddb1b4f0392ab0d8.

---

<a id="clinicaltrials-gov-nct07112872-semaglutide-v1"></a>

## ClinicalTrials.gov record NCT07112872

> PeptideScanner retained ClinicalTrials.gov record NCT07112872 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct07112872-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-11-12
- Source checked: 2026-11-14
- Published by PeptideScanner: 2026-11-14
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07112872-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct07112872-semaglutide-v1
- Content SHA-256: `e31837bb95588afcd5ae87b9c45d97b6d5a1449d5d5c2510f8df75da72a57ab6`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07112872 ([`ctg-observation-nct07112872-2026-11-12-f6bf5cd2b736`](#source-ctg-observation-nct07112872-2026-11-12-f6bf5cd2b736))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07112872 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct07112872-2026-11-12-f6bf5cd2b736`](#source-ctg-observation-nct07112872-2026-11-12-f6bf5cd2b736))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07112872 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct07112872-2026-11-12-f6bf5cd2b736`](#source-ctg-observation-nct07112872-2026-11-12-f6bf5cd2b736))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07112872-2026-11-12-f6bf5cd2b736`](#source-ctg-observation-nct07112872-2026-11-12-f6bf5cd2b736))

### Sources

<a id="source-ctg-observation-nct07112872-2026-11-12-f6bf5cd2b736"></a>
- **ClinicalTrials.gov record NCT07112872 · retained source version 2026-11-12:f6bf5cd2b736fe70f97a98efc67da1c2b561fb675fed6ba1460bfa45c20a8257** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07112872) (`ctg-observation-nct07112872-2026-11-12-f6bf5cd2b736`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07112872." Version 1, published 2026-11-14. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct07112872-semaglutide-v1 SHA-256: e31837bb95588afcd5ae87b9c45d97b6d5a1449d5d5c2510f8df75da72a57ab6.

---

<a id="clinicaltrials-gov-nct07204249-semaglutide-v1"></a>

## ClinicalTrials.gov record NCT07204249

> PeptideScanner retained ClinicalTrials.gov record NCT07204249 at 2026-07-30T16:19:03.057Z. Its registry update date was 2026-06-03, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct07204249-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-06-03
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07204249-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct07204249-semaglutide-v1
- Content SHA-256: `bbeb929f10837eafd49e2c2bdbf00228c72c9bb9f26132293a9d40a4bf1ea41f`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07204249 ([`ctg-observation-nct07204249-2026-06-03-dbdb9267fcbd`](#source-ctg-observation-nct07204249-2026-06-03-dbdb9267fcbd))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07204249 at 2026-07-30T16:19:03.057Z. Its registry update date was 2026-06-03, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct07204249-2026-06-03-dbdb9267fcbd`](#source-ctg-observation-nct07204249-2026-06-03-dbdb9267fcbd))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07204249 at 2026-07-30T16:19:03.057Z. Its registry update date was 2026-06-03, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct07204249-2026-06-03-dbdb9267fcbd`](#source-ctg-observation-nct07204249-2026-06-03-dbdb9267fcbd))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07204249-2026-06-03-dbdb9267fcbd`](#source-ctg-observation-nct07204249-2026-06-03-dbdb9267fcbd))

### Sources

<a id="source-ctg-observation-nct07204249-2026-06-03-dbdb9267fcbd"></a>
- **ClinicalTrials.gov record NCT07204249 · retained source version 2026-06-03:dbdb9267fcbd3009225f9fd26ccdff7c8f54ef682a41b34964d9b7b5fcfd5399** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07204249) (`ctg-observation-nct07204249-2026-06-03-dbdb9267fcbd`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07204249." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct07204249-semaglutide-v1 SHA-256: bbeb929f10837eafd49e2c2bdbf00228c72c9bb9f26132293a9d40a4bf1ea41f.

---

<a id="clinicaltrials-gov-nct07213466-semaglutide-v1"></a>

## ClinicalTrials.gov record NCT07213466

> PeptideScanner retained ClinicalTrials.gov record NCT07213466 at 2026-07-30T16:22:22.332Z. Its registry update date was 2026-03-11, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct07213466-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-03-11
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07213466-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct07213466-semaglutide-v1
- Content SHA-256: `2146067c3f963333f424cd316c588bce3f299b835fc1b57412e41c17edec9ff8`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07213466 ([`ctg-observation-nct07213466-2026-03-11-9e24717863d5`](#source-ctg-observation-nct07213466-2026-03-11-9e24717863d5))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07213466 at 2026-07-30T16:22:22.332Z. Its registry update date was 2026-03-11, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct07213466-2026-03-11-9e24717863d5`](#source-ctg-observation-nct07213466-2026-03-11-9e24717863d5))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07213466 at 2026-07-30T16:22:22.332Z. Its registry update date was 2026-03-11, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct07213466-2026-03-11-9e24717863d5`](#source-ctg-observation-nct07213466-2026-03-11-9e24717863d5))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07213466-2026-03-11-9e24717863d5`](#source-ctg-observation-nct07213466-2026-03-11-9e24717863d5))

### Sources

<a id="source-ctg-observation-nct07213466-2026-03-11-9e24717863d5"></a>
- **ClinicalTrials.gov record NCT07213466 · retained source version 2026-03-11:9e24717863d56c4af3b8d5cf19d387b0835087c5d78b1e24b1ab51128eed12aa** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07213466) (`ctg-observation-nct07213466-2026-03-11-9e24717863d5`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07213466." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct07213466-semaglutide-v1 SHA-256: 2146067c3f963333f424cd316c588bce3f299b835fc1b57412e41c17edec9ff8.

---

<a id="clinicaltrials-gov-nct07218354-semaglutide-v1"></a>

## ClinicalTrials.gov record NCT07218354

> PeptideScanner retained ClinicalTrials.gov record NCT07218354 at 2026-08-13T05:54:14.857Z. Its registry update date was 2026-08-12, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct07218354-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-08-12
- Source checked: 2026-08-13
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07218354-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct07218354-semaglutide-v1
- Content SHA-256: `41792e04ac2350638bbd45219c6173c570543bd62e9605134a33202be6dee23e`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07218354 ([`ctg-observation-nct07218354-2026-08-12-783823bed233`](#source-ctg-observation-nct07218354-2026-08-12-783823bed233))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07218354 at 2026-08-13T05:54:14.857Z. Its registry update date was 2026-08-12, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct07218354-2026-08-12-783823bed233`](#source-ctg-observation-nct07218354-2026-08-12-783823bed233))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07218354 at 2026-08-13T05:54:14.857Z. Its registry update date was 2026-08-12, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct07218354-2026-08-12-783823bed233`](#source-ctg-observation-nct07218354-2026-08-12-783823bed233))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07218354-2026-08-12-783823bed233`](#source-ctg-observation-nct07218354-2026-08-12-783823bed233))

### Sources

<a id="source-ctg-observation-nct07218354-2026-08-12-783823bed233"></a>
- **ClinicalTrials.gov record NCT07218354 · retained source version 2026-08-12:783823bed23352218a1103291f8c7dbd13d0ad17bf40fa15a9471cf6915dc1cc** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07218354) (`ctg-observation-nct07218354-2026-08-12-783823bed233`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07218354." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct07218354-semaglutide-v1 SHA-256: 41792e04ac2350638bbd45219c6173c570543bd62e9605134a33202be6dee23e.

---

<a id="clinicaltrials-gov-nct07227948-semaglutide-v1"></a>

## ClinicalTrials.gov record NCT07227948

> PeptideScanner retained ClinicalTrials.gov record NCT07227948 at 2026-07-30T16:22:22.326Z. Its registry update date was 2026-03-19, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct07227948-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-03-19
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07227948-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct07227948-semaglutide-v1
- Content SHA-256: `d47240119077913a1f3046ea288609358150ceb526fe2afa2d27a6785d520859`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07227948 ([`ctg-observation-nct07227948-2026-03-19-f3ff82a0db5f`](#source-ctg-observation-nct07227948-2026-03-19-f3ff82a0db5f))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07227948 at 2026-07-30T16:22:22.326Z. Its registry update date was 2026-03-19, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct07227948-2026-03-19-f3ff82a0db5f`](#source-ctg-observation-nct07227948-2026-03-19-f3ff82a0db5f))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07227948 at 2026-07-30T16:22:22.326Z. Its registry update date was 2026-03-19, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct07227948-2026-03-19-f3ff82a0db5f`](#source-ctg-observation-nct07227948-2026-03-19-f3ff82a0db5f))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07227948-2026-03-19-f3ff82a0db5f`](#source-ctg-observation-nct07227948-2026-03-19-f3ff82a0db5f))

### Sources

<a id="source-ctg-observation-nct07227948-2026-03-19-f3ff82a0db5f"></a>
- **ClinicalTrials.gov record NCT07227948 · retained source version 2026-03-19:f3ff82a0db5f8871008c255fd599b6deeee648a31a0dae3da2c54dc37116e5c9** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07227948) (`ctg-observation-nct07227948-2026-03-19-f3ff82a0db5f`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07227948." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct07227948-semaglutide-v1 SHA-256: d47240119077913a1f3046ea288609358150ceb526fe2afa2d27a6785d520859.

---

<a id="clinicaltrials-gov-nct07239570-semaglutide-v1"></a>

## ClinicalTrials.gov record NCT07239570

> PeptideScanner retained ClinicalTrials.gov record NCT07239570 at 2026-07-30T18:19:48.218Z. Its registry update date was 2025-11-20, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct07239570-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2025-11-20
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07239570-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct07239570-semaglutide-v1
- Content SHA-256: `a6ee84a0b289758bc9de8588e447550ec082bcee6d0501a0e8b8d0f361881194`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07239570 ([`ctg-observation-nct07239570-2025-11-20-ca98121f940d`](#source-ctg-observation-nct07239570-2025-11-20-ca98121f940d))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07239570 at 2026-07-30T18:19:48.218Z. Its registry update date was 2025-11-20, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct07239570-2025-11-20-ca98121f940d`](#source-ctg-observation-nct07239570-2025-11-20-ca98121f940d))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07239570 at 2026-07-30T18:19:48.218Z. Its registry update date was 2025-11-20, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct07239570-2025-11-20-ca98121f940d`](#source-ctg-observation-nct07239570-2025-11-20-ca98121f940d))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07239570-2025-11-20-ca98121f940d`](#source-ctg-observation-nct07239570-2025-11-20-ca98121f940d))

### Sources

<a id="source-ctg-observation-nct07239570-2025-11-20-ca98121f940d"></a>
- **ClinicalTrials.gov record NCT07239570 · retained source version 2025-11-20:ca98121f940dbe3521b53adad487ba6ddcc64feb11d8535810d3e103f5ff5db0** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07239570) (`ctg-observation-nct07239570-2025-11-20-ca98121f940d`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07239570." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct07239570-semaglutide-v1 SHA-256: a6ee84a0b289758bc9de8588e447550ec082bcee6d0501a0e8b8d0f361881194.

---

<a id="clinicaltrials-gov-nct07242534-semaglutide-v1"></a>

## ClinicalTrials.gov record NCT07242534

> PeptideScanner retained ClinicalTrials.gov record NCT07242534 at 2026-07-30T16:25:18.005Z. Its registry update date was 2026-01-21, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct07242534-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-01-21
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07242534-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct07242534-semaglutide-v1
- Content SHA-256: `bd6ccba07d2c160642c05534b2ffccf9c388bbbb9591c359de6b45b5a325da66`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07242534 ([`ctg-observation-nct07242534-2026-01-21-11abc7e35815`](#source-ctg-observation-nct07242534-2026-01-21-11abc7e35815))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07242534 at 2026-07-30T16:25:18.005Z. Its registry update date was 2026-01-21, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct07242534-2026-01-21-11abc7e35815`](#source-ctg-observation-nct07242534-2026-01-21-11abc7e35815))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07242534 at 2026-07-30T16:25:18.005Z. Its registry update date was 2026-01-21, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct07242534-2026-01-21-11abc7e35815`](#source-ctg-observation-nct07242534-2026-01-21-11abc7e35815))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07242534-2026-01-21-11abc7e35815`](#source-ctg-observation-nct07242534-2026-01-21-11abc7e35815))

### Sources

<a id="source-ctg-observation-nct07242534-2026-01-21-11abc7e35815"></a>
- **ClinicalTrials.gov record NCT07242534 · retained source version 2026-01-21:11abc7e358153ded006411610cdc88d3c62f4a4f35a55fe04aca408fae891e3d** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07242534) (`ctg-observation-nct07242534-2026-01-21-11abc7e35815`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07242534." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct07242534-semaglutide-v1 SHA-256: bd6ccba07d2c160642c05534b2ffccf9c388bbbb9591c359de6b45b5a325da66.

---

<a id="clinicaltrials-gov-nct07280221-semaglutide-v1"></a>

## ClinicalTrials.gov record NCT07280221

> PeptideScanner retained ClinicalTrials.gov record NCT07280221 at 2026-07-30T18:18:33.524Z. Its registry update date was 2025-12-12, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct07280221-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2025-12-12
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07280221-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct07280221-semaglutide-v1
- Content SHA-256: `3c1103539fcb9305b58d9dc890ef6125597659225d9ce9fa091e0feac4f02d37`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07280221 ([`ctg-observation-nct07280221-2025-12-12-b6791dab1012`](#source-ctg-observation-nct07280221-2025-12-12-b6791dab1012))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07280221 at 2026-07-30T18:18:33.524Z. Its registry update date was 2025-12-12, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct07280221-2025-12-12-b6791dab1012`](#source-ctg-observation-nct07280221-2025-12-12-b6791dab1012))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07280221 at 2026-07-30T18:18:33.524Z. Its registry update date was 2025-12-12, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct07280221-2025-12-12-b6791dab1012`](#source-ctg-observation-nct07280221-2025-12-12-b6791dab1012))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07280221-2025-12-12-b6791dab1012`](#source-ctg-observation-nct07280221-2025-12-12-b6791dab1012))

### Sources

<a id="source-ctg-observation-nct07280221-2025-12-12-b6791dab1012"></a>
- **ClinicalTrials.gov record NCT07280221 · retained source version 2025-12-12:b6791dab1012c4116be0c844afe9701ea38993f3294da86ca7d634d2491f1ac6** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07280221) (`ctg-observation-nct07280221-2025-12-12-b6791dab1012`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07280221." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct07280221-semaglutide-v1 SHA-256: 3c1103539fcb9305b58d9dc890ef6125597659225d9ce9fa091e0feac4f02d37.

---

<a id="clinicaltrials-gov-nct07282769-semaglutide-v1"></a>

## ClinicalTrials.gov record NCT07282769

> PeptideScanner retained ClinicalTrials.gov record NCT07282769 at 2026-07-30T16:19:03.054Z. Its registry update date was 2026-06-10, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct07282769-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-06-10
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07282769-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct07282769-semaglutide-v1
- Content SHA-256: `a09d0a56c3b8e52bc9e5a4f6172d501c076df6c2a12338c53883e2e1df277f7a`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07282769 ([`ctg-observation-nct07282769-2026-06-10-434a1fecbf32`](#source-ctg-observation-nct07282769-2026-06-10-434a1fecbf32))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07282769 at 2026-07-30T16:19:03.054Z. Its registry update date was 2026-06-10, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct07282769-2026-06-10-434a1fecbf32`](#source-ctg-observation-nct07282769-2026-06-10-434a1fecbf32))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07282769 at 2026-07-30T16:19:03.054Z. Its registry update date was 2026-06-10, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct07282769-2026-06-10-434a1fecbf32`](#source-ctg-observation-nct07282769-2026-06-10-434a1fecbf32))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07282769-2026-06-10-434a1fecbf32`](#source-ctg-observation-nct07282769-2026-06-10-434a1fecbf32))

### Sources

<a id="source-ctg-observation-nct07282769-2026-06-10-434a1fecbf32"></a>
- **ClinicalTrials.gov record NCT07282769 · retained source version 2026-06-10:434a1fecbf32c8c946967944680023da2977faafd4b29a47d8e71a7b1be40b0b** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07282769) (`ctg-observation-nct07282769-2026-06-10-434a1fecbf32`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07282769." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct07282769-semaglutide-v1 SHA-256: a09d0a56c3b8e52bc9e5a4f6172d501c076df6c2a12338c53883e2e1df277f7a.

---

<a id="clinicaltrials-gov-nct07284979-semaglutide-v1"></a>

## ClinicalTrials.gov record NCT07284979

> PeptideScanner retained ClinicalTrials.gov record NCT07284979 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-06, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct07284979-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-10-06
- Source checked: 2026-11-14
- Published by PeptideScanner: 2026-11-14
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07284979-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct07284979-semaglutide-v1
- Content SHA-256: `f7cfdef2e30a23a1b5d095bced2bbcf915def06a5230327e7108abc6bc8c3308`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07284979 ([`ctg-observation-nct07284979-2026-10-06-dc6a0af1533a`](#source-ctg-observation-nct07284979-2026-10-06-dc6a0af1533a))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07284979 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-06, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct07284979-2026-10-06-dc6a0af1533a`](#source-ctg-observation-nct07284979-2026-10-06-dc6a0af1533a))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07284979 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-06, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct07284979-2026-10-06-dc6a0af1533a`](#source-ctg-observation-nct07284979-2026-10-06-dc6a0af1533a))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07284979-2026-10-06-dc6a0af1533a`](#source-ctg-observation-nct07284979-2026-10-06-dc6a0af1533a))

### Sources

<a id="source-ctg-observation-nct07284979-2026-10-06-dc6a0af1533a"></a>
- **ClinicalTrials.gov record NCT07284979 · retained source version 2026-10-06:dc6a0af1533a4a71e28dd2373774ce8f6d991bdcb0f0bc07445d68cb18be52ce** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07284979) (`ctg-observation-nct07284979-2026-10-06-dc6a0af1533a`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07284979." Version 1, published 2026-11-14. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct07284979-semaglutide-v1 SHA-256: f7cfdef2e30a23a1b5d095bced2bbcf915def06a5230327e7108abc6bc8c3308.

---

<a id="clinicaltrials-gov-nct07400107-semaglutide-v1"></a>

## ClinicalTrials.gov record NCT07400107

> PeptideScanner retained ClinicalTrials.gov record NCT07400107 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-10, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct07400107-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-11-10
- Source checked: 2026-11-14
- Published by PeptideScanner: 2026-11-14
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07400107-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct07400107-semaglutide-v1
- Content SHA-256: `eb88fee4cceb1bf5b7354596946437a45c322ef59b7008c8d5553b41f59be018`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07400107 ([`ctg-observation-nct07400107-2026-11-10-d0f32be4c1f7`](#source-ctg-observation-nct07400107-2026-11-10-d0f32be4c1f7))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07400107 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-10, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct07400107-2026-11-10-d0f32be4c1f7`](#source-ctg-observation-nct07400107-2026-11-10-d0f32be4c1f7))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07400107 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-10, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct07400107-2026-11-10-d0f32be4c1f7`](#source-ctg-observation-nct07400107-2026-11-10-d0f32be4c1f7))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07400107-2026-11-10-d0f32be4c1f7`](#source-ctg-observation-nct07400107-2026-11-10-d0f32be4c1f7))

### Sources

<a id="source-ctg-observation-nct07400107-2026-11-10-d0f32be4c1f7"></a>
- **ClinicalTrials.gov record NCT07400107 · retained source version 2026-11-10:d0f32be4c1f730968f4b34d3428cdb4305d5e277545bdb817e24c3b7b782bef4** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07400107) (`ctg-observation-nct07400107-2026-11-10-d0f32be4c1f7`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07400107." Version 1, published 2026-11-14. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct07400107-semaglutide-v1 SHA-256: eb88fee4cceb1bf5b7354596946437a45c322ef59b7008c8d5553b41f59be018.

---

<a id="clinicaltrials-gov-nct07415954-semaglutide-v1"></a>

## ClinicalTrials.gov record NCT07415954

> PeptideScanner retained ClinicalTrials.gov record NCT07415954 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-11, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct07415954-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-09-11
- Source checked: 2026-11-14
- Published by PeptideScanner: 2026-11-14
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07415954-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct07415954-semaglutide-v1
- Content SHA-256: `d787626a5d5b226fb00dff76bd9561dcde3cf08d843a8acb6ec9345528e2fa87`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07415954 ([`ctg-observation-nct07415954-2026-09-11-5f4f91c093e1`](#source-ctg-observation-nct07415954-2026-09-11-5f4f91c093e1))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07415954 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-11, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct07415954-2026-09-11-5f4f91c093e1`](#source-ctg-observation-nct07415954-2026-09-11-5f4f91c093e1))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07415954 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-11, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct07415954-2026-09-11-5f4f91c093e1`](#source-ctg-observation-nct07415954-2026-09-11-5f4f91c093e1))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07415954-2026-09-11-5f4f91c093e1`](#source-ctg-observation-nct07415954-2026-09-11-5f4f91c093e1))

### Sources

<a id="source-ctg-observation-nct07415954-2026-09-11-5f4f91c093e1"></a>
- **ClinicalTrials.gov record NCT07415954 · retained source version 2026-09-11:5f4f91c093e1f240b2edb0dda4b5af72560e706cf792dfee0bff5ee0b7f5c913** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07415954) (`ctg-observation-nct07415954-2026-09-11-5f4f91c093e1`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07415954." Version 1, published 2026-11-14. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct07415954-semaglutide-v1 SHA-256: d787626a5d5b226fb00dff76bd9561dcde3cf08d843a8acb6ec9345528e2fa87.

---

<a id="clinicaltrials-gov-nct07462663-semaglutide-v1"></a>

## ClinicalTrials.gov record NCT07462663

> PeptideScanner retained ClinicalTrials.gov record NCT07462663 at 2026-07-30T16:19:03.043Z. Its registry update date was 2026-06-10, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct07462663-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-06-10
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07462663-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct07462663-semaglutide-v1
- Content SHA-256: `20c93b0c15a795bd074a08adb429023ceea3647824ff87b52753dfdab88e731b`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07462663 ([`ctg-observation-nct07462663-2026-06-10-7b0660fe97c9`](#source-ctg-observation-nct07462663-2026-06-10-7b0660fe97c9))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07462663 at 2026-07-30T16:19:03.043Z. Its registry update date was 2026-06-10, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct07462663-2026-06-10-7b0660fe97c9`](#source-ctg-observation-nct07462663-2026-06-10-7b0660fe97c9))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07462663 at 2026-07-30T16:19:03.043Z. Its registry update date was 2026-06-10, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct07462663-2026-06-10-7b0660fe97c9`](#source-ctg-observation-nct07462663-2026-06-10-7b0660fe97c9))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07462663-2026-06-10-7b0660fe97c9`](#source-ctg-observation-nct07462663-2026-06-10-7b0660fe97c9))

### Sources

<a id="source-ctg-observation-nct07462663-2026-06-10-7b0660fe97c9"></a>
- **ClinicalTrials.gov record NCT07462663 · retained source version 2026-06-10:7b0660fe97c990d339aadab4e3eb989b34002100b960c7c18b81849674e8d98f** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07462663) (`ctg-observation-nct07462663-2026-06-10-7b0660fe97c9`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07462663." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct07462663-semaglutide-v1 SHA-256: 20c93b0c15a795bd074a08adb429023ceea3647824ff87b52753dfdab88e731b.

---

<a id="clinicaltrials-gov-nct07505303-semaglutide-v1"></a>

## ClinicalTrials.gov record NCT07505303

> PeptideScanner retained ClinicalTrials.gov record NCT07505303 at 2026-07-30T16:19:03.067Z. Its registry update date was 2026-06-25, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct07505303-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-06-25
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07505303-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct07505303-semaglutide-v1
- Content SHA-256: `381d0c3b84d5e4493c22b1fadda9b015f6b9fad6c5e347ca2f5a1ddfc67313cf`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07505303 ([`ctg-observation-nct07505303-2026-06-25-9ba0b60587b8`](#source-ctg-observation-nct07505303-2026-06-25-9ba0b60587b8))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07505303 at 2026-07-30T16:19:03.067Z. Its registry update date was 2026-06-25, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct07505303-2026-06-25-9ba0b60587b8`](#source-ctg-observation-nct07505303-2026-06-25-9ba0b60587b8))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07505303 at 2026-07-30T16:19:03.067Z. Its registry update date was 2026-06-25, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct07505303-2026-06-25-9ba0b60587b8`](#source-ctg-observation-nct07505303-2026-06-25-9ba0b60587b8))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07505303-2026-06-25-9ba0b60587b8`](#source-ctg-observation-nct07505303-2026-06-25-9ba0b60587b8))

### Sources

<a id="source-ctg-observation-nct07505303-2026-06-25-9ba0b60587b8"></a>
- **ClinicalTrials.gov record NCT07505303 · retained source version 2026-06-25:9ba0b60587b8cdbae2c0db1abc274954adec3cbda83f4d9431ff10d4e1b09411** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07505303) (`ctg-observation-nct07505303-2026-06-25-9ba0b60587b8`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07505303." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct07505303-semaglutide-v1 SHA-256: 381d0c3b84d5e4493c22b1fadda9b015f6b9fad6c5e347ca2f5a1ddfc67313cf.

---

<a id="clinicaltrials-gov-nct07511543-semaglutide-v1"></a>

## ClinicalTrials.gov record NCT07511543

> PeptideScanner retained ClinicalTrials.gov record NCT07511543 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-24, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct07511543-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-09-24
- Source checked: 2026-11-14
- Published by PeptideScanner: 2026-11-14
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07511543-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct07511543-semaglutide-v1
- Content SHA-256: `75580142c5b4646bdb968d19fdd7709e72566247b2eeb8d68929d400420b42eb`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07511543 ([`ctg-observation-nct07511543-2026-09-24-3c1166127dd8`](#source-ctg-observation-nct07511543-2026-09-24-3c1166127dd8))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07511543 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-24, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct07511543-2026-09-24-3c1166127dd8`](#source-ctg-observation-nct07511543-2026-09-24-3c1166127dd8))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07511543 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-24, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct07511543-2026-09-24-3c1166127dd8`](#source-ctg-observation-nct07511543-2026-09-24-3c1166127dd8))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07511543-2026-09-24-3c1166127dd8`](#source-ctg-observation-nct07511543-2026-09-24-3c1166127dd8))

### Sources

<a id="source-ctg-observation-nct07511543-2026-09-24-3c1166127dd8"></a>
- **ClinicalTrials.gov record NCT07511543 · retained source version 2026-09-24:3c1166127dd82b8d49b31b850689efec36356b10b2786640890605203b31d59a** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07511543) (`ctg-observation-nct07511543-2026-09-24-3c1166127dd8`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07511543." Version 1, published 2026-11-14. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct07511543-semaglutide-v1 SHA-256: 75580142c5b4646bdb968d19fdd7709e72566247b2eeb8d68929d400420b42eb.

---

<a id="clinicaltrials-gov-nct07523633-semaglutide-v1"></a>

## ClinicalTrials.gov record NCT07523633

> PeptideScanner retained ClinicalTrials.gov record NCT07523633 at 2026-07-30T16:19:36.919Z. Its registry update date was 2026-05-14, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct07523633-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-05-14
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07523633-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct07523633-semaglutide-v1
- Content SHA-256: `db42a445e9e7ea76217218323a172d9625ffcb0f4ba23e850cfb71e9276360cd`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07523633 ([`ctg-observation-nct07523633-2026-05-14-43a2e026c664`](#source-ctg-observation-nct07523633-2026-05-14-43a2e026c664))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07523633 at 2026-07-30T16:19:36.919Z. Its registry update date was 2026-05-14, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct07523633-2026-05-14-43a2e026c664`](#source-ctg-observation-nct07523633-2026-05-14-43a2e026c664))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07523633 at 2026-07-30T16:19:36.919Z. Its registry update date was 2026-05-14, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct07523633-2026-05-14-43a2e026c664`](#source-ctg-observation-nct07523633-2026-05-14-43a2e026c664))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07523633-2026-05-14-43a2e026c664`](#source-ctg-observation-nct07523633-2026-05-14-43a2e026c664))

### Sources

<a id="source-ctg-observation-nct07523633-2026-05-14-43a2e026c664"></a>
- **ClinicalTrials.gov record NCT07523633 · retained source version 2026-05-14:43a2e026c664f29ba44955b00ce8d4b4ed49267434aaf0ae0ed41b3bdeece5dc** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07523633) (`ctg-observation-nct07523633-2026-05-14-43a2e026c664`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07523633." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct07523633-semaglutide-v1 SHA-256: db42a445e9e7ea76217218323a172d9625ffcb0f4ba23e850cfb71e9276360cd.

---

<a id="clinicaltrials-gov-nct07547878-semaglutide-v1"></a>

## ClinicalTrials.gov record NCT07547878

> PeptideScanner retained ClinicalTrials.gov record NCT07547878 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-13, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct07547878-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-10-13
- Source checked: 2026-11-14
- Published by PeptideScanner: 2026-11-14
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07547878-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct07547878-semaglutide-v1
- Content SHA-256: `9f66eaa4077d9890bb0f5f51bd6318bf8995f6b94dd6dd52a8c0214541173a40`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07547878 ([`ctg-observation-nct07547878-2026-10-13-73f0a4ee043d`](#source-ctg-observation-nct07547878-2026-10-13-73f0a4ee043d))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07547878 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-13, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct07547878-2026-10-13-73f0a4ee043d`](#source-ctg-observation-nct07547878-2026-10-13-73f0a4ee043d))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07547878 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-13, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct07547878-2026-10-13-73f0a4ee043d`](#source-ctg-observation-nct07547878-2026-10-13-73f0a4ee043d))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07547878-2026-10-13-73f0a4ee043d`](#source-ctg-observation-nct07547878-2026-10-13-73f0a4ee043d))

### Sources

<a id="source-ctg-observation-nct07547878-2026-10-13-73f0a4ee043d"></a>
- **ClinicalTrials.gov record NCT07547878 · retained source version 2026-10-13:73f0a4ee043dabfd01de306596d76e2ad1d4884b6dfa0a247a156df0fea83d8c** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07547878) (`ctg-observation-nct07547878-2026-10-13-73f0a4ee043d`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07547878." Version 1, published 2026-11-14. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct07547878-semaglutide-v1 SHA-256: 9f66eaa4077d9890bb0f5f51bd6318bf8995f6b94dd6dd52a8c0214541173a40.

---

<a id="clinicaltrials-gov-nct07564414-semaglutide-v1"></a>

## ClinicalTrials.gov record NCT07564414

> PeptideScanner retained ClinicalTrials.gov record NCT07564414 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-30, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct07564414-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-09-30
- Source checked: 2026-11-14
- Published by PeptideScanner: 2026-11-14
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07564414-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct07564414-semaglutide-v1
- Content SHA-256: `3df9424d09ce1a21e9b89bcee47701abc4c321ca3a1f7b21f08bc1ad0165fa47`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07564414 ([`ctg-observation-nct07564414-2026-09-30-09cacfd73702`](#source-ctg-observation-nct07564414-2026-09-30-09cacfd73702))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07564414 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-30, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct07564414-2026-09-30-09cacfd73702`](#source-ctg-observation-nct07564414-2026-09-30-09cacfd73702))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07564414 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-30, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct07564414-2026-09-30-09cacfd73702`](#source-ctg-observation-nct07564414-2026-09-30-09cacfd73702))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07564414-2026-09-30-09cacfd73702`](#source-ctg-observation-nct07564414-2026-09-30-09cacfd73702))

### Sources

<a id="source-ctg-observation-nct07564414-2026-09-30-09cacfd73702"></a>
- **ClinicalTrials.gov record NCT07564414 · retained source version 2026-09-30:09cacfd73702f822f9533da09d99114edea40a9e16a7f1ea6f0c3ff54142d6d8** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07564414) (`ctg-observation-nct07564414-2026-09-30-09cacfd73702`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07564414." Version 1, published 2026-11-14. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct07564414-semaglutide-v1 SHA-256: 3df9424d09ce1a21e9b89bcee47701abc4c321ca3a1f7b21f08bc1ad0165fa47.

---

<a id="clinicaltrials-gov-nct07592546-semaglutide-v1"></a>

## ClinicalTrials.gov record NCT07592546

> PeptideScanner retained ClinicalTrials.gov record NCT07592546 at 2026-07-30T16:19:03.065Z. Its registry update date was 2026-06-26, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct07592546-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-06-26
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-08
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07592546-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct07592546-semaglutide-v1
- Content SHA-256: `83836cabc90f799b61b904fd097682662a6b3f68118246b3b9e1ea10eb38ecd5`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07592546 ([`ctg-observation-nct07592546-2026-06-26-a8d7ba3bc801`](#source-ctg-observation-nct07592546-2026-06-26-a8d7ba3bc801))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07592546 at 2026-07-30T16:19:03.065Z. Its registry update date was 2026-06-26, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct07592546-2026-06-26-a8d7ba3bc801`](#source-ctg-observation-nct07592546-2026-06-26-a8d7ba3bc801))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07592546 at 2026-07-30T16:19:03.065Z. Its registry update date was 2026-06-26, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct07592546-2026-06-26-a8d7ba3bc801`](#source-ctg-observation-nct07592546-2026-06-26-a8d7ba3bc801))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07592546-2026-06-26-a8d7ba3bc801`](#source-ctg-observation-nct07592546-2026-06-26-a8d7ba3bc801))

### Sources

<a id="source-ctg-observation-nct07592546-2026-06-26-a8d7ba3bc801"></a>
- **ClinicalTrials.gov record NCT07592546 · retained source version 2026-06-26:a8d7ba3bc801010cd62d49919267c50cb0b8cf9a7618b0a8ff9f5dcb77a3b905** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07592546) (`ctg-observation-nct07592546-2026-06-26-a8d7ba3bc801`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07592546." Version 1, published 2026-08-08. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct07592546-semaglutide-v1 SHA-256: 83836cabc90f799b61b904fd097682662a6b3f68118246b3b9e1ea10eb38ecd5.

---

<a id="clinicaltrials-gov-nct07610174-semaglutide-v1"></a>

## ClinicalTrials.gov record NCT07610174

> PeptideScanner retained ClinicalTrials.gov record NCT07610174 at 2026-07-30T16:19:36.923Z. Its registry update date was 2026-05-29, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct07610174-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-05-29
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07610174-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct07610174-semaglutide-v1
- Content SHA-256: `c5caa84d14230e061ae52cec96b6c370c2ec08c298663368ed015783aeb444a3`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07610174 ([`ctg-observation-nct07610174-2026-05-29-4c195126b648`](#source-ctg-observation-nct07610174-2026-05-29-4c195126b648))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07610174 at 2026-07-30T16:19:36.923Z. Its registry update date was 2026-05-29, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct07610174-2026-05-29-4c195126b648`](#source-ctg-observation-nct07610174-2026-05-29-4c195126b648))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07610174 at 2026-07-30T16:19:36.923Z. Its registry update date was 2026-05-29, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct07610174-2026-05-29-4c195126b648`](#source-ctg-observation-nct07610174-2026-05-29-4c195126b648))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07610174-2026-05-29-4c195126b648`](#source-ctg-observation-nct07610174-2026-05-29-4c195126b648))

### Sources

<a id="source-ctg-observation-nct07610174-2026-05-29-4c195126b648"></a>
- **ClinicalTrials.gov record NCT07610174 · retained source version 2026-05-29:4c195126b648df9f0c66c2d46b868526682b1e20a20f1590e5cd9041673f8374** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07610174) (`ctg-observation-nct07610174-2026-05-29-4c195126b648`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07610174." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct07610174-semaglutide-v1 SHA-256: c5caa84d14230e061ae52cec96b6c370c2ec08c298663368ed015783aeb444a3.

---

<a id="clinicaltrials-gov-nct07627074-semaglutide-v1"></a>

## ClinicalTrials.gov record NCT07627074

> PeptideScanner retained ClinicalTrials.gov record NCT07627074 at 2026-07-30T16:19:03.066Z. Its registry update date was 2026-06-04, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct07627074-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-06-04
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07627074-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct07627074-semaglutide-v1
- Content SHA-256: `4ff6957806b0b367a449c2c6bd638a9a251624efb2488a72f5618e63b0783a6d`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07627074 ([`ctg-observation-nct07627074-2026-06-04-672580055aed`](#source-ctg-observation-nct07627074-2026-06-04-672580055aed))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07627074 at 2026-07-30T16:19:03.066Z. Its registry update date was 2026-06-04, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct07627074-2026-06-04-672580055aed`](#source-ctg-observation-nct07627074-2026-06-04-672580055aed))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07627074 at 2026-07-30T16:19:03.066Z. Its registry update date was 2026-06-04, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct07627074-2026-06-04-672580055aed`](#source-ctg-observation-nct07627074-2026-06-04-672580055aed))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07627074-2026-06-04-672580055aed`](#source-ctg-observation-nct07627074-2026-06-04-672580055aed))

### Sources

<a id="source-ctg-observation-nct07627074-2026-06-04-672580055aed"></a>
- **ClinicalTrials.gov record NCT07627074 · retained source version 2026-06-04:672580055aed038559485ce66b7f5d8c995e135612a7df490639a6f8f1bbc101** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07627074) (`ctg-observation-nct07627074-2026-06-04-672580055aed`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07627074." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct07627074-semaglutide-v1 SHA-256: 4ff6957806b0b367a449c2c6bd638a9a251624efb2488a72f5618e63b0783a6d.

---

<a id="clinicaltrials-gov-nct07639021-semaglutide-v1"></a>

## ClinicalTrials.gov record NCT07639021

> PeptideScanner retained ClinicalTrials.gov record NCT07639021 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-16, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct07639021-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-09-16
- Source checked: 2026-11-14
- Published by PeptideScanner: 2026-11-14
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07639021-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct07639021-semaglutide-v1
- Content SHA-256: `acf105c32a79da01b9a6633499350e25260debf57009c3e65b9710e1769e0614`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07639021 ([`ctg-observation-nct07639021-2026-09-16-dfe174038d07`](#source-ctg-observation-nct07639021-2026-09-16-dfe174038d07))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07639021 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-16, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct07639021-2026-09-16-dfe174038d07`](#source-ctg-observation-nct07639021-2026-09-16-dfe174038d07))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07639021 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-16, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct07639021-2026-09-16-dfe174038d07`](#source-ctg-observation-nct07639021-2026-09-16-dfe174038d07))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07639021-2026-09-16-dfe174038d07`](#source-ctg-observation-nct07639021-2026-09-16-dfe174038d07))

### Sources

<a id="source-ctg-observation-nct07639021-2026-09-16-dfe174038d07"></a>
- **ClinicalTrials.gov record NCT07639021 · retained source version 2026-09-16:dfe174038d0705d8f43db5280508cbe021f95b131bf62d3e0fb1f7f07d7e73c7** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07639021) (`ctg-observation-nct07639021-2026-09-16-dfe174038d07`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07639021." Version 1, published 2026-11-14. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct07639021-semaglutide-v1 SHA-256: acf105c32a79da01b9a6633499350e25260debf57009c3e65b9710e1769e0614.

---

<a id="clinicaltrials-gov-nct07642635-semaglutide-v1"></a>

## ClinicalTrials.gov record NCT07642635

> PeptideScanner retained ClinicalTrials.gov record NCT07642635 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct07642635-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-11-12
- Source checked: 2026-11-14
- Published by PeptideScanner: 2026-11-14
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07642635-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct07642635-semaglutide-v1
- Content SHA-256: `1cb8868389210813b457b542e7fc733eeeb468dd04eac34b7111c99277d6322c`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07642635 ([`ctg-observation-nct07642635-2026-11-12-afb55589ce58`](#source-ctg-observation-nct07642635-2026-11-12-afb55589ce58))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07642635 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct07642635-2026-11-12-afb55589ce58`](#source-ctg-observation-nct07642635-2026-11-12-afb55589ce58))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07642635 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct07642635-2026-11-12-afb55589ce58`](#source-ctg-observation-nct07642635-2026-11-12-afb55589ce58))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07642635-2026-11-12-afb55589ce58`](#source-ctg-observation-nct07642635-2026-11-12-afb55589ce58))

### Sources

<a id="source-ctg-observation-nct07642635-2026-11-12-afb55589ce58"></a>
- **ClinicalTrials.gov record NCT07642635 · retained source version 2026-11-12:afb55589ce58042e93f3c2d16b78e12af727b8ae959fee5c46c807c3ae6fb779** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07642635) (`ctg-observation-nct07642635-2026-11-12-afb55589ce58`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07642635." Version 1, published 2026-11-14. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct07642635-semaglutide-v1 SHA-256: 1cb8868389210813b457b542e7fc733eeeb468dd04eac34b7111c99277d6322c.

---

<a id="clinicaltrials-gov-nct07662213-semaglutide-v1"></a>

## ClinicalTrials.gov record NCT07662213

> PeptideScanner retained ClinicalTrials.gov record NCT07662213 at 2026-09-09T19:17:17.121Z. Its registry update date was 2026-09-09, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct07662213-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-09-09
- Source checked: 2026-09-09
- Published by PeptideScanner: 2026-09-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07662213-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct07662213-semaglutide-v1
- Content SHA-256: `9761e723f4c4ad876fac09c22b50b80d5e573315c80615244035de7144f00b3d`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07662213 ([`ctg-observation-nct07662213-2026-09-09-41b1816f43df`](#source-ctg-observation-nct07662213-2026-09-09-41b1816f43df))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07662213 at 2026-09-09T19:17:17.121Z. Its registry update date was 2026-09-09, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct07662213-2026-09-09-41b1816f43df`](#source-ctg-observation-nct07662213-2026-09-09-41b1816f43df))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07662213 at 2026-09-09T19:17:17.121Z. Its registry update date was 2026-09-09, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct07662213-2026-09-09-41b1816f43df`](#source-ctg-observation-nct07662213-2026-09-09-41b1816f43df))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07662213-2026-09-09-41b1816f43df`](#source-ctg-observation-nct07662213-2026-09-09-41b1816f43df))

### Sources

<a id="source-ctg-observation-nct07662213-2026-09-09-41b1816f43df"></a>
- **ClinicalTrials.gov record NCT07662213 · retained source version 2026-09-09:41b1816f43df5d6c64ba5025037cbbcd29a06789b9824efef4db571be5760890** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07662213) (`ctg-observation-nct07662213-2026-09-09-41b1816f43df`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07662213." Version 1, published 2026-09-09. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct07662213-semaglutide-v1 SHA-256: 9761e723f4c4ad876fac09c22b50b80d5e573315c80615244035de7144f00b3d.

---

<a id="clinicaltrials-gov-nct07668388-semaglutide-v1"></a>

## ClinicalTrials.gov record NCT07668388

> PeptideScanner retained ClinicalTrials.gov record NCT07668388 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-07, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct07668388-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-10-07
- Source checked: 2026-11-14
- Published by PeptideScanner: 2026-11-14
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07668388-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct07668388-semaglutide-v1
- Content SHA-256: `2f4c7316d744e5794b270cfe202513e7d5355a5b31e16d5282f03a6d5a2a2140`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07668388 ([`ctg-observation-nct07668388-2026-10-07-cca4e6d89abe`](#source-ctg-observation-nct07668388-2026-10-07-cca4e6d89abe))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07668388 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-07, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct07668388-2026-10-07-cca4e6d89abe`](#source-ctg-observation-nct07668388-2026-10-07-cca4e6d89abe))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07668388 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-07, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct07668388-2026-10-07-cca4e6d89abe`](#source-ctg-observation-nct07668388-2026-10-07-cca4e6d89abe))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07668388-2026-10-07-cca4e6d89abe`](#source-ctg-observation-nct07668388-2026-10-07-cca4e6d89abe))

### Sources

<a id="source-ctg-observation-nct07668388-2026-10-07-cca4e6d89abe"></a>
- **ClinicalTrials.gov record NCT07668388 · retained source version 2026-10-07:cca4e6d89abeed3b054378b9cd1bab2c31941dd1de3185eed8e1b1cceb26a857** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07668388) (`ctg-observation-nct07668388-2026-10-07-cca4e6d89abe`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07668388." Version 1, published 2026-11-14. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct07668388-semaglutide-v1 SHA-256: 2f4c7316d744e5794b270cfe202513e7d5355a5b31e16d5282f03a6d5a2a2140.

---

<a id="clinicaltrials-gov-nct07668414-semaglutide-v1"></a>

## ClinicalTrials.gov record NCT07668414

> PeptideScanner retained ClinicalTrials.gov record NCT07668414 at 2026-07-30T16:19:03.061Z. Its registry update date was 2026-06-25, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct07668414-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-06-25
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07668414-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct07668414-semaglutide-v1
- Content SHA-256: `5c29d82ca7d2de0205cbb97283bfcc86d0f4b79c38b68d6adf2694055265db85`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07668414 ([`ctg-observation-nct07668414-2026-06-25-ecf8aa8774d3`](#source-ctg-observation-nct07668414-2026-06-25-ecf8aa8774d3))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07668414 at 2026-07-30T16:19:03.061Z. Its registry update date was 2026-06-25, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct07668414-2026-06-25-ecf8aa8774d3`](#source-ctg-observation-nct07668414-2026-06-25-ecf8aa8774d3))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07668414 at 2026-07-30T16:19:03.061Z. Its registry update date was 2026-06-25, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct07668414-2026-06-25-ecf8aa8774d3`](#source-ctg-observation-nct07668414-2026-06-25-ecf8aa8774d3))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07668414-2026-06-25-ecf8aa8774d3`](#source-ctg-observation-nct07668414-2026-06-25-ecf8aa8774d3))

### Sources

<a id="source-ctg-observation-nct07668414-2026-06-25-ecf8aa8774d3"></a>
- **ClinicalTrials.gov record NCT07668414 · retained source version 2026-06-25:ecf8aa8774d35a932647774f0ecb004a4fec4b6ca93b1af761e7fd94c98630fd** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07668414) (`ctg-observation-nct07668414-2026-06-25-ecf8aa8774d3`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07668414." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct07668414-semaglutide-v1 SHA-256: 5c29d82ca7d2de0205cbb97283bfcc86d0f4b79c38b68d6adf2694055265db85.

---

<a id="clinicaltrials-gov-nct07732426-semaglutide-v1"></a>

## ClinicalTrials.gov record NCT07732426

> PeptideScanner retained ClinicalTrials.gov record NCT07732426 at 2026-08-10T18:10:03.951Z. Its registry update date was 2026-07-28, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct07732426-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-07-28
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07732426-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct07732426-semaglutide-v1
- Content SHA-256: `945f2195333f6d4263d24f0ebde25d4080a5e96eb6507b36745668f3d3b6cb5d`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07732426 ([`ctg-observation-nct07732426-2026-07-28-8b2f88005f52`](#source-ctg-observation-nct07732426-2026-07-28-8b2f88005f52))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07732426 at 2026-08-10T18:10:03.951Z. Its registry update date was 2026-07-28, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct07732426-2026-07-28-8b2f88005f52`](#source-ctg-observation-nct07732426-2026-07-28-8b2f88005f52))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07732426 at 2026-08-10T18:10:03.951Z. Its registry update date was 2026-07-28, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct07732426-2026-07-28-8b2f88005f52`](#source-ctg-observation-nct07732426-2026-07-28-8b2f88005f52))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07732426-2026-07-28-8b2f88005f52`](#source-ctg-observation-nct07732426-2026-07-28-8b2f88005f52))

### Sources

<a id="source-ctg-observation-nct07732426-2026-07-28-8b2f88005f52"></a>
- **ClinicalTrials.gov record NCT07732426 · retained source version 2026-07-28:8b2f88005f52ca03d9b5eee89c48a95e11bbc50c4561d98cac6e5483c25742b0** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07732426) (`ctg-observation-nct07732426-2026-07-28-8b2f88005f52`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07732426." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct07732426-semaglutide-v1 SHA-256: 945f2195333f6d4263d24f0ebde25d4080a5e96eb6507b36745668f3d3b6cb5d.

---

<a id="clinicaltrials-gov-nct07743983-semaglutide-v1"></a>

## ClinicalTrials.gov record NCT07743983

> PeptideScanner retained ClinicalTrials.gov record NCT07743983 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-13, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct07743983-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-10-13
- Source checked: 2026-11-14
- Published by PeptideScanner: 2026-11-14
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07743983-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct07743983-semaglutide-v1
- Content SHA-256: `de18fb13d11fc5a38d2a3964a3554f839acae80c9596cd468b270ab0298cb75f`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07743983 ([`ctg-observation-nct07743983-2026-10-13-bff458d0dd98`](#source-ctg-observation-nct07743983-2026-10-13-bff458d0dd98))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07743983 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-13, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct07743983-2026-10-13-bff458d0dd98`](#source-ctg-observation-nct07743983-2026-10-13-bff458d0dd98))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07743983 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-13, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct07743983-2026-10-13-bff458d0dd98`](#source-ctg-observation-nct07743983-2026-10-13-bff458d0dd98))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07743983-2026-10-13-bff458d0dd98`](#source-ctg-observation-nct07743983-2026-10-13-bff458d0dd98))

### Sources

<a id="source-ctg-observation-nct07743983-2026-10-13-bff458d0dd98"></a>
- **ClinicalTrials.gov record NCT07743983 · retained source version 2026-10-13:bff458d0dd9842ddf482c53cc630bbe336eff39fc78479fde5566e68f33f2ecd** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07743983) (`ctg-observation-nct07743983-2026-10-13-bff458d0dd98`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07743983." Version 1, published 2026-11-14. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct07743983-semaglutide-v1 SHA-256: de18fb13d11fc5a38d2a3964a3554f839acae80c9596cd468b270ab0298cb75f.

---

<a id="clinicaltrials-gov-nct07770841-semaglutide-v1"></a>

## ClinicalTrials.gov record NCT07770841

> PeptideScanner retained ClinicalTrials.gov record NCT07770841 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-09, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct07770841-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-09-09
- Source checked: 2026-11-14
- Published by PeptideScanner: 2026-11-14
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07770841-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct07770841-semaglutide-v1
- Content SHA-256: `276ff4c2933df348e1455dfa5e0ccda5391a0445a5f76b152a57f9a8fc4b2d33`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07770841 ([`ctg-observation-nct07770841-2026-09-09-40d1ba7db8a3`](#source-ctg-observation-nct07770841-2026-09-09-40d1ba7db8a3))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07770841 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-09, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct07770841-2026-09-09-40d1ba7db8a3`](#source-ctg-observation-nct07770841-2026-09-09-40d1ba7db8a3))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07770841 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-09, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct07770841-2026-09-09-40d1ba7db8a3`](#source-ctg-observation-nct07770841-2026-09-09-40d1ba7db8a3))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07770841-2026-09-09-40d1ba7db8a3`](#source-ctg-observation-nct07770841-2026-09-09-40d1ba7db8a3))

### Sources

<a id="source-ctg-observation-nct07770841-2026-09-09-40d1ba7db8a3"></a>
- **ClinicalTrials.gov record NCT07770841 · retained source version 2026-09-09:40d1ba7db8a33ca6eaed8a92095c2b84f17e5d95f377cc264dd1b62c29def114** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07770841) (`ctg-observation-nct07770841-2026-09-09-40d1ba7db8a3`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07770841." Version 1, published 2026-11-14. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct07770841-semaglutide-v1 SHA-256: 276ff4c2933df348e1455dfa5e0ccda5391a0445a5f76b152a57f9a8fc4b2d33.

---

<a id="clinicaltrials-gov-nct07812597-semaglutide-v1"></a>

## ClinicalTrials.gov record NCT07812597

> PeptideScanner retained ClinicalTrials.gov record NCT07812597 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-10, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct07812597-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-09-10
- Source checked: 2026-11-14
- Published by PeptideScanner: 2026-11-14
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07812597-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct07812597-semaglutide-v1
- Content SHA-256: `d978a74b92e5db75db53859227f9a741893ec723a45b69863f43f90fcf700d29`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07812597 ([`ctg-observation-nct07812597-2026-09-10-aa87fa3fd054`](#source-ctg-observation-nct07812597-2026-09-10-aa87fa3fd054))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07812597 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-10, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct07812597-2026-09-10-aa87fa3fd054`](#source-ctg-observation-nct07812597-2026-09-10-aa87fa3fd054))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07812597 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-10, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct07812597-2026-09-10-aa87fa3fd054`](#source-ctg-observation-nct07812597-2026-09-10-aa87fa3fd054))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07812597-2026-09-10-aa87fa3fd054`](#source-ctg-observation-nct07812597-2026-09-10-aa87fa3fd054))

### Sources

<a id="source-ctg-observation-nct07812597-2026-09-10-aa87fa3fd054"></a>
- **ClinicalTrials.gov record NCT07812597 · retained source version 2026-09-10:aa87fa3fd054659d4441a5ab0abd27fc502c7fc8f180e483f8cd1f9d005e65e4** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07812597) (`ctg-observation-nct07812597-2026-09-10-aa87fa3fd054`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07812597." Version 1, published 2026-11-14. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct07812597-semaglutide-v1 SHA-256: d978a74b92e5db75db53859227f9a741893ec723a45b69863f43f90fcf700d29.

---

<a id="clinicaltrials-gov-nct07836140-semaglutide-v1"></a>

## ClinicalTrials.gov record NCT07836140

> PeptideScanner retained ClinicalTrials.gov record NCT07836140 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-23, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct07836140-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-09-23
- Source checked: 2026-11-14
- Published by PeptideScanner: 2026-11-14
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07836140-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct07836140-semaglutide-v1
- Content SHA-256: `28845957705a4258a473d83168d9883bdae2a3b20f395f3039a5debe2a2c287a`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07836140 ([`ctg-observation-nct07836140-2026-09-23-cd95c999eabd`](#source-ctg-observation-nct07836140-2026-09-23-cd95c999eabd))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07836140 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-23, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct07836140-2026-09-23-cd95c999eabd`](#source-ctg-observation-nct07836140-2026-09-23-cd95c999eabd))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07836140 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-23, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct07836140-2026-09-23-cd95c999eabd`](#source-ctg-observation-nct07836140-2026-09-23-cd95c999eabd))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07836140-2026-09-23-cd95c999eabd`](#source-ctg-observation-nct07836140-2026-09-23-cd95c999eabd))

### Sources

<a id="source-ctg-observation-nct07836140-2026-09-23-cd95c999eabd"></a>
- **ClinicalTrials.gov record NCT07836140 · retained source version 2026-09-23:cd95c999eabd9d45b8ee186b17f7463c5348fc6403f377690d04b249a3c305c0** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07836140) (`ctg-observation-nct07836140-2026-09-23-cd95c999eabd`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07836140." Version 1, published 2026-11-14. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct07836140-semaglutide-v1 SHA-256: 28845957705a4258a473d83168d9883bdae2a3b20f395f3039a5debe2a2c287a.

---

<a id="clinicaltrials-gov-nct07845578-semaglutide-v1"></a>

## ClinicalTrials.gov record NCT07845578

> PeptideScanner retained ClinicalTrials.gov record NCT07845578 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-29, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct07845578-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-09-29
- Source checked: 2026-11-14
- Published by PeptideScanner: 2026-11-14
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07845578-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct07845578-semaglutide-v1
- Content SHA-256: `dbbd51c20d46d4e24f67bd84abdd31dd2be4d0df3f3f79d1ab135d21a1e39e4c`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07845578 ([`ctg-observation-nct07845578-2026-09-29-52051f3ee658`](#source-ctg-observation-nct07845578-2026-09-29-52051f3ee658))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07845578 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-29, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct07845578-2026-09-29-52051f3ee658`](#source-ctg-observation-nct07845578-2026-09-29-52051f3ee658))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07845578 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-29, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct07845578-2026-09-29-52051f3ee658`](#source-ctg-observation-nct07845578-2026-09-29-52051f3ee658))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07845578-2026-09-29-52051f3ee658`](#source-ctg-observation-nct07845578-2026-09-29-52051f3ee658))

### Sources

<a id="source-ctg-observation-nct07845578-2026-09-29-52051f3ee658"></a>
- **ClinicalTrials.gov record NCT07845578 · retained source version 2026-09-29:52051f3ee6584a8194d6a1616d68a4cc889593ed9f59502b2980e47ef71981bd** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07845578) (`ctg-observation-nct07845578-2026-09-29-52051f3ee658`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07845578." Version 1, published 2026-11-14. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct07845578-semaglutide-v1 SHA-256: dbbd51c20d46d4e24f67bd84abdd31dd2be4d0df3f3f79d1ab135d21a1e39e4c.

---

<a id="clinicaltrials-gov-nct07849348-semaglutide-v1"></a>

## ClinicalTrials.gov record NCT07849348

> PeptideScanner retained ClinicalTrials.gov record NCT07849348 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-30, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct07849348-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-09-30
- Source checked: 2026-11-14
- Published by PeptideScanner: 2026-11-14
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07849348-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct07849348-semaglutide-v1
- Content SHA-256: `5c4e0aacef7862bc7a89bf097b090ceb67e70a5a1b3c24baa044a6db9f7a15e1`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07849348 ([`ctg-observation-nct07849348-2026-09-30-8b4d4d88bffb`](#source-ctg-observation-nct07849348-2026-09-30-8b4d4d88bffb))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07849348 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-30, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct07849348-2026-09-30-8b4d4d88bffb`](#source-ctg-observation-nct07849348-2026-09-30-8b4d4d88bffb))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07849348 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-30, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct07849348-2026-09-30-8b4d4d88bffb`](#source-ctg-observation-nct07849348-2026-09-30-8b4d4d88bffb))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07849348-2026-09-30-8b4d4d88bffb`](#source-ctg-observation-nct07849348-2026-09-30-8b4d4d88bffb))

### Sources

<a id="source-ctg-observation-nct07849348-2026-09-30-8b4d4d88bffb"></a>
- **ClinicalTrials.gov record NCT07849348 · retained source version 2026-09-30:8b4d4d88bffb800490b0ac25e3303cb407ba9f4c9ed148d320c53a39f0703c56** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07849348) (`ctg-observation-nct07849348-2026-09-30-8b4d4d88bffb`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07849348." Version 1, published 2026-11-14. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct07849348-semaglutide-v1 SHA-256: 5c4e0aacef7862bc7a89bf097b090ceb67e70a5a1b3c24baa044a6db9f7a15e1.

---

<a id="clinicaltrials-gov-nct07850765-semaglutide-v1"></a>

## ClinicalTrials.gov record NCT07850765

> PeptideScanner retained ClinicalTrials.gov record NCT07850765 at 2026-11-14T22:51:22.481Z. Its registry update date was 2026-09-30, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct07850765-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-09-30
- Source checked: 2026-11-14
- Published by PeptideScanner: 2026-11-14
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07850765-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct07850765-semaglutide-v1
- Content SHA-256: `15048425d50523cbfce9b0b19955a4b98d1f881eda18c408f60e55b702ff8535`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07850765 ([`ctg-observation-nct07850765-2026-09-30-d43990dd9fd4`](#source-ctg-observation-nct07850765-2026-09-30-d43990dd9fd4))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07850765 at 2026-11-14T22:51:22.481Z. Its registry update date was 2026-09-30, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct07850765-2026-09-30-d43990dd9fd4`](#source-ctg-observation-nct07850765-2026-09-30-d43990dd9fd4))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07850765 at 2026-11-14T22:51:22.481Z. Its registry update date was 2026-09-30, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct07850765-2026-09-30-d43990dd9fd4`](#source-ctg-observation-nct07850765-2026-09-30-d43990dd9fd4))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07850765-2026-09-30-d43990dd9fd4`](#source-ctg-observation-nct07850765-2026-09-30-d43990dd9fd4))

### Sources

<a id="source-ctg-observation-nct07850765-2026-09-30-d43990dd9fd4"></a>
- **ClinicalTrials.gov record NCT07850765 · retained source version 2026-09-30:d43990dd9fd43b92a63e7d51bc297831278e93e68bc1f2d2a0a73457e1d83f4f** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07850765) (`ctg-observation-nct07850765-2026-09-30-d43990dd9fd4`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07850765." Version 1, published 2026-11-14. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct07850765-semaglutide-v1 SHA-256: 15048425d50523cbfce9b0b19955a4b98d1f881eda18c408f60e55b702ff8535.

---

<a id="clinicaltrials-gov-nct07855133-semaglutide-v1"></a>

## ClinicalTrials.gov record NCT07855133

> PeptideScanner retained ClinicalTrials.gov record NCT07855133 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-16, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct07855133-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-10-16
- Source checked: 2026-11-14
- Published by PeptideScanner: 2026-11-14
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07855133-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct07855133-semaglutide-v1
- Content SHA-256: `b7a818729f46c968a64788c695d3c85e683b75640c57c220a9400f3dc7888b50`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07855133 ([`ctg-observation-nct07855133-2026-10-16-48bcd8b544be`](#source-ctg-observation-nct07855133-2026-10-16-48bcd8b544be))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07855133 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-16, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct07855133-2026-10-16-48bcd8b544be`](#source-ctg-observation-nct07855133-2026-10-16-48bcd8b544be))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07855133 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-16, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct07855133-2026-10-16-48bcd8b544be`](#source-ctg-observation-nct07855133-2026-10-16-48bcd8b544be))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07855133-2026-10-16-48bcd8b544be`](#source-ctg-observation-nct07855133-2026-10-16-48bcd8b544be))

### Sources

<a id="source-ctg-observation-nct07855133-2026-10-16-48bcd8b544be"></a>
- **ClinicalTrials.gov record NCT07855133 · retained source version 2026-10-16:48bcd8b544bed8ef7def09e2cf5c84a343ca02a68b8f86542169e8b6b59f3af7** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07855133) (`ctg-observation-nct07855133-2026-10-16-48bcd8b544be`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07855133." Version 1, published 2026-11-14. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct07855133-semaglutide-v1 SHA-256: b7a818729f46c968a64788c695d3c85e683b75640c57c220a9400f3dc7888b50.

---

<a id="clinicaltrials-gov-nct07858331-semaglutide-v1"></a>

## ClinicalTrials.gov record NCT07858331

> PeptideScanner retained ClinicalTrials.gov record NCT07858331 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-05, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct07858331-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-10-05
- Source checked: 2026-11-14
- Published by PeptideScanner: 2026-11-14
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07858331-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct07858331-semaglutide-v1
- Content SHA-256: `691a8136b42facf25242b138bb0d2b9b882d4a7e4d9b60fde51c98229b76d585`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07858331 ([`ctg-observation-nct07858331-2026-10-05-285fdf186e0b`](#source-ctg-observation-nct07858331-2026-10-05-285fdf186e0b))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07858331 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-05, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct07858331-2026-10-05-285fdf186e0b`](#source-ctg-observation-nct07858331-2026-10-05-285fdf186e0b))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07858331 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-05, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct07858331-2026-10-05-285fdf186e0b`](#source-ctg-observation-nct07858331-2026-10-05-285fdf186e0b))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07858331-2026-10-05-285fdf186e0b`](#source-ctg-observation-nct07858331-2026-10-05-285fdf186e0b))

### Sources

<a id="source-ctg-observation-nct07858331-2026-10-05-285fdf186e0b"></a>
- **ClinicalTrials.gov record NCT07858331 · retained source version 2026-10-05:285fdf186e0b6df636f7f136ee768991966fa219a7df00bb651b0aa9a0f3ee42** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07858331) (`ctg-observation-nct07858331-2026-10-05-285fdf186e0b`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07858331." Version 1, published 2026-11-14. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct07858331-semaglutide-v1 SHA-256: 691a8136b42facf25242b138bb0d2b9b882d4a7e4d9b60fde51c98229b76d585.

---

<a id="clinicaltrials-gov-nct07871799-semaglutide-v1"></a>

## ClinicalTrials.gov record NCT07871799

> PeptideScanner retained ClinicalTrials.gov record NCT07871799 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-13, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct07871799-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-10-13
- Source checked: 2026-11-14
- Published by PeptideScanner: 2026-11-14
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07871799-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct07871799-semaglutide-v1
- Content SHA-256: `242c1af9e4cbba93eb3fc3cf7ccd19f6b313c7a104a03f68f21cde80a7872999`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07871799 ([`ctg-observation-nct07871799-2026-10-13-1e40b63367b4`](#source-ctg-observation-nct07871799-2026-10-13-1e40b63367b4))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07871799 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-13, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct07871799-2026-10-13-1e40b63367b4`](#source-ctg-observation-nct07871799-2026-10-13-1e40b63367b4))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07871799 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-13, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct07871799-2026-10-13-1e40b63367b4`](#source-ctg-observation-nct07871799-2026-10-13-1e40b63367b4))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07871799-2026-10-13-1e40b63367b4`](#source-ctg-observation-nct07871799-2026-10-13-1e40b63367b4))

### Sources

<a id="source-ctg-observation-nct07871799-2026-10-13-1e40b63367b4"></a>
- **ClinicalTrials.gov record NCT07871799 · retained source version 2026-10-13:1e40b63367b47908e48955017527e2e21c14bd73ac8d5dadbe9aba0b07c18a4f** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07871799) (`ctg-observation-nct07871799-2026-10-13-1e40b63367b4`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07871799." Version 1, published 2026-11-14. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct07871799-semaglutide-v1 SHA-256: 242c1af9e4cbba93eb3fc3cf7ccd19f6b313c7a104a03f68f21cde80a7872999.

---

<a id="clinicaltrials-gov-nct07879612-semaglutide-v1"></a>

## ClinicalTrials.gov record NCT07879612

> PeptideScanner retained ClinicalTrials.gov record NCT07879612 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-19, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct07879612-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-10-19
- Source checked: 2026-11-14
- Published by PeptideScanner: 2026-11-14
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07879612-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct07879612-semaglutide-v1
- Content SHA-256: `84d14d8eb845d048827ac97c59da8e87532f8a4614f4c4dd8f1e81994ea79ff4`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07879612 ([`ctg-observation-nct07879612-2026-10-19-cfd94c53afe3`](#source-ctg-observation-nct07879612-2026-10-19-cfd94c53afe3))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07879612 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-19, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct07879612-2026-10-19-cfd94c53afe3`](#source-ctg-observation-nct07879612-2026-10-19-cfd94c53afe3))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07879612 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-19, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct07879612-2026-10-19-cfd94c53afe3`](#source-ctg-observation-nct07879612-2026-10-19-cfd94c53afe3))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07879612-2026-10-19-cfd94c53afe3`](#source-ctg-observation-nct07879612-2026-10-19-cfd94c53afe3))

### Sources

<a id="source-ctg-observation-nct07879612-2026-10-19-cfd94c53afe3"></a>
- **ClinicalTrials.gov record NCT07879612 · retained source version 2026-10-19:cfd94c53afe300f30077c91a7efbb2b7ef4d04814a94f930662b67f6a7d9f8d6** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07879612) (`ctg-observation-nct07879612-2026-10-19-cfd94c53afe3`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07879612." Version 1, published 2026-11-14. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct07879612-semaglutide-v1 SHA-256: 84d14d8eb845d048827ac97c59da8e87532f8a4614f4c4dd8f1e81994ea79ff4.

---

<a id="clinicaltrials-gov-nct07881770-semaglutide-v1"></a>

## ClinicalTrials.gov record NCT07881770

> PeptideScanner retained ClinicalTrials.gov record NCT07881770 at 2026-11-14T22:51:22.481Z. Its registry update date was 2026-10-19, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct07881770-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-10-19
- Source checked: 2026-11-14
- Published by PeptideScanner: 2026-11-14
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07881770-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct07881770-semaglutide-v1
- Content SHA-256: `9e9a8a5cd388e259de366dfd06729a2d374fe9659b39cb73d8f27fa87315000d`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07881770 ([`ctg-observation-nct07881770-2026-10-19-e6de1d69b873`](#source-ctg-observation-nct07881770-2026-10-19-e6de1d69b873))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07881770 at 2026-11-14T22:51:22.481Z. Its registry update date was 2026-10-19, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct07881770-2026-10-19-e6de1d69b873`](#source-ctg-observation-nct07881770-2026-10-19-e6de1d69b873))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07881770 at 2026-11-14T22:51:22.481Z. Its registry update date was 2026-10-19, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct07881770-2026-10-19-e6de1d69b873`](#source-ctg-observation-nct07881770-2026-10-19-e6de1d69b873))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07881770-2026-10-19-e6de1d69b873`](#source-ctg-observation-nct07881770-2026-10-19-e6de1d69b873))

### Sources

<a id="source-ctg-observation-nct07881770-2026-10-19-e6de1d69b873"></a>
- **ClinicalTrials.gov record NCT07881770 · retained source version 2026-10-19:e6de1d69b873c1679623e6e2e017f87169a206ab1880ab97bbb3385764f8b566** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07881770) (`ctg-observation-nct07881770-2026-10-19-e6de1d69b873`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07881770." Version 1, published 2026-11-14. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct07881770-semaglutide-v1 SHA-256: 9e9a8a5cd388e259de366dfd06729a2d374fe9659b39cb73d8f27fa87315000d.

---

<a id="clinicaltrials-gov-nct07891156-semaglutide-v1"></a>

## ClinicalTrials.gov record NCT07891156

> PeptideScanner retained ClinicalTrials.gov record NCT07891156 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-23, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct07891156-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-10-23
- Source checked: 2026-11-14
- Published by PeptideScanner: 2026-11-14
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07891156-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct07891156-semaglutide-v1
- Content SHA-256: `7b9f19be773d1d749ea42711fcf541784104188324251dc45d16549067c01ce3`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07891156 ([`ctg-observation-nct07891156-2026-10-23-063e6f58bd6a`](#source-ctg-observation-nct07891156-2026-10-23-063e6f58bd6a))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07891156 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-23, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct07891156-2026-10-23-063e6f58bd6a`](#source-ctg-observation-nct07891156-2026-10-23-063e6f58bd6a))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07891156 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-23, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct07891156-2026-10-23-063e6f58bd6a`](#source-ctg-observation-nct07891156-2026-10-23-063e6f58bd6a))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07891156-2026-10-23-063e6f58bd6a`](#source-ctg-observation-nct07891156-2026-10-23-063e6f58bd6a))

### Sources

<a id="source-ctg-observation-nct07891156-2026-10-23-063e6f58bd6a"></a>
- **ClinicalTrials.gov record NCT07891156 · retained source version 2026-10-23:063e6f58bd6a8efb5c2a16d6d485e41421aff907cd7cf661e4e710484c048864** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07891156) (`ctg-observation-nct07891156-2026-10-23-063e6f58bd6a`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07891156." Version 1, published 2026-11-14. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct07891156-semaglutide-v1 SHA-256: 7b9f19be773d1d749ea42711fcf541784104188324251dc45d16549067c01ce3.

---

<a id="clinicaltrials-gov-nct07900438-semaglutide-v1"></a>

## ClinicalTrials.gov record NCT07900438

> PeptideScanner retained ClinicalTrials.gov record NCT07900438 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-28, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct07900438-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-10-28
- Source checked: 2026-11-14
- Published by PeptideScanner: 2026-11-14
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07900438-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct07900438-semaglutide-v1
- Content SHA-256: `4f1f47a0b0678fcdcdd4278987124e7b9170f1d14bb2a2f3d068f9016c4f68e8`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07900438 ([`ctg-observation-nct07900438-2026-10-28-5ac112662ed5`](#source-ctg-observation-nct07900438-2026-10-28-5ac112662ed5))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07900438 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-28, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct07900438-2026-10-28-5ac112662ed5`](#source-ctg-observation-nct07900438-2026-10-28-5ac112662ed5))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07900438 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-28, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct07900438-2026-10-28-5ac112662ed5`](#source-ctg-observation-nct07900438-2026-10-28-5ac112662ed5))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07900438-2026-10-28-5ac112662ed5`](#source-ctg-observation-nct07900438-2026-10-28-5ac112662ed5))

### Sources

<a id="source-ctg-observation-nct07900438-2026-10-28-5ac112662ed5"></a>
- **ClinicalTrials.gov record NCT07900438 · retained source version 2026-10-28:5ac112662ed5c03a167b3f8f4544d1264e5a3c1740043265bbbb54aa241f8f60** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07900438) (`ctg-observation-nct07900438-2026-10-28-5ac112662ed5`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07900438." Version 1, published 2026-11-14. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct07900438-semaglutide-v1 SHA-256: 4f1f47a0b0678fcdcdd4278987124e7b9170f1d14bb2a2f3d068f9016c4f68e8.

---

<a id="clinicaltrials-gov-nct07909889-semaglutide-v1"></a>

## ClinicalTrials.gov record NCT07909889

> PeptideScanner retained ClinicalTrials.gov record NCT07909889 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-02, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct07909889-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-11-02
- Source checked: 2026-11-14
- Published by PeptideScanner: 2026-11-14
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07909889-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct07909889-semaglutide-v1
- Content SHA-256: `853da3316b1e5b33cd75e4536ec20d79dcc77562852cc88961eecba990a3a529`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07909889 ([`ctg-observation-nct07909889-2026-11-02-067018240365`](#source-ctg-observation-nct07909889-2026-11-02-067018240365))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07909889 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-02, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct07909889-2026-11-02-067018240365`](#source-ctg-observation-nct07909889-2026-11-02-067018240365))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07909889 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-02, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct07909889-2026-11-02-067018240365`](#source-ctg-observation-nct07909889-2026-11-02-067018240365))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07909889-2026-11-02-067018240365`](#source-ctg-observation-nct07909889-2026-11-02-067018240365))

### Sources

<a id="source-ctg-observation-nct07909889-2026-11-02-067018240365"></a>
- **ClinicalTrials.gov record NCT07909889 · retained source version 2026-11-02:06701824036588f58362760c232767e8631d7338adc3bf9a3d0f0a7437bef640** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07909889) (`ctg-observation-nct07909889-2026-11-02-067018240365`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07909889." Version 1, published 2026-11-14. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct07909889-semaglutide-v1 SHA-256: 853da3316b1e5b33cd75e4536ec20d79dcc77562852cc88961eecba990a3a529.

---

<a id="clinicaltrials-gov-nct07911046-semaglutide-v1"></a>

## ClinicalTrials.gov record NCT07911046

> PeptideScanner retained ClinicalTrials.gov record NCT07911046 at 2026-11-14T22:51:22.481Z. Its registry update date was 2026-11-02, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct07911046-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-11-02
- Source checked: 2026-11-14
- Published by PeptideScanner: 2026-11-14
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07911046-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct07911046-semaglutide-v1
- Content SHA-256: `c40fc9499d6b496aadef8974610b3bf0253db2e9d27f5328ce93b81fcbf00557`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07911046 ([`ctg-observation-nct07911046-2026-11-02-2e22a857981f`](#source-ctg-observation-nct07911046-2026-11-02-2e22a857981f))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07911046 at 2026-11-14T22:51:22.481Z. Its registry update date was 2026-11-02, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct07911046-2026-11-02-2e22a857981f`](#source-ctg-observation-nct07911046-2026-11-02-2e22a857981f))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07911046 at 2026-11-14T22:51:22.481Z. Its registry update date was 2026-11-02, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct07911046-2026-11-02-2e22a857981f`](#source-ctg-observation-nct07911046-2026-11-02-2e22a857981f))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07911046-2026-11-02-2e22a857981f`](#source-ctg-observation-nct07911046-2026-11-02-2e22a857981f))

### Sources

<a id="source-ctg-observation-nct07911046-2026-11-02-2e22a857981f"></a>
- **ClinicalTrials.gov record NCT07911046 · retained source version 2026-11-02:2e22a857981ff0d10e054e58f512d447e8b0b5d7dbe112cdf1916213e0dd76a0** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07911046) (`ctg-observation-nct07911046-2026-11-02-2e22a857981f`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07911046." Version 1, published 2026-11-14. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct07911046-semaglutide-v1 SHA-256: c40fc9499d6b496aadef8974610b3bf0253db2e9d27f5328ce93b81fcbf00557.

---

<a id="clinicaltrials-gov-nct07931573-semaglutide-v1"></a>

## ClinicalTrials.gov record NCT07931573

> PeptideScanner retained ClinicalTrials.gov record NCT07931573 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct07931573-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-11-12
- Source checked: 2026-11-14
- Published by PeptideScanner: 2026-11-14
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07931573-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct07931573-semaglutide-v1
- Content SHA-256: `2ad4d47d4d1b752cafc511f671f7d3ecd91b35465b919ab6023ac83893303180`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07931573 ([`ctg-observation-nct07931573-2026-11-12-a6eaf6e89170`](#source-ctg-observation-nct07931573-2026-11-12-a6eaf6e89170))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07931573 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct07931573-2026-11-12-a6eaf6e89170`](#source-ctg-observation-nct07931573-2026-11-12-a6eaf6e89170))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07931573 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct07931573-2026-11-12-a6eaf6e89170`](#source-ctg-observation-nct07931573-2026-11-12-a6eaf6e89170))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07931573-2026-11-12-a6eaf6e89170`](#source-ctg-observation-nct07931573-2026-11-12-a6eaf6e89170))

### Sources

<a id="source-ctg-observation-nct07931573-2026-11-12-a6eaf6e89170"></a>
- **ClinicalTrials.gov record NCT07931573 · retained source version 2026-11-12:a6eaf6e891704765ae92b0f6b1af60430645351a2f19f6b5051e273a26ac57e7** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07931573) (`ctg-observation-nct07931573-2026-11-12-a6eaf6e89170`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07931573." Version 1, published 2026-11-14. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct07931573-semaglutide-v1 SHA-256: 2ad4d47d4d1b752cafc511f671f7d3ecd91b35465b919ab6023ac83893303180.

---

<a id="clinicaltrials-gov-nct07931599-semaglutide-v1"></a>

## ClinicalTrials.gov record NCT07931599

> PeptideScanner retained ClinicalTrials.gov record NCT07931599 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct07931599-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-11-12
- Source checked: 2026-11-14
- Published by PeptideScanner: 2026-11-14
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07931599-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct07931599-semaglutide-v1
- Content SHA-256: `a34a0fe2e12e75e6d41d27c77f62c8f68af909850ebe7c0825fca222cdc266fa`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07931599 ([`ctg-observation-nct07931599-2026-11-12-9ae78c8cd174`](#source-ctg-observation-nct07931599-2026-11-12-9ae78c8cd174))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07931599 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct07931599-2026-11-12-9ae78c8cd174`](#source-ctg-observation-nct07931599-2026-11-12-9ae78c8cd174))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07931599 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct07931599-2026-11-12-9ae78c8cd174`](#source-ctg-observation-nct07931599-2026-11-12-9ae78c8cd174))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07931599-2026-11-12-9ae78c8cd174`](#source-ctg-observation-nct07931599-2026-11-12-9ae78c8cd174))

### Sources

<a id="source-ctg-observation-nct07931599-2026-11-12-9ae78c8cd174"></a>
- **ClinicalTrials.gov record NCT07931599 · retained source version 2026-11-12:9ae78c8cd174868599703389a882ae4d5917527d2ffdace314d1498cce5d1902** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07931599) (`ctg-observation-nct07931599-2026-11-12-9ae78c8cd174`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07931599." Version 1, published 2026-11-14. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct07931599-semaglutide-v1 SHA-256: a34a0fe2e12e75e6d41d27c77f62c8f68af909850ebe7c0825fca222cdc266fa.

---

<a id="clinicaltrials-gov-nct07935200-semaglutide-v1"></a>

## ClinicalTrials.gov record NCT07935200

> PeptideScanner retained ClinicalTrials.gov record NCT07935200 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-13, and PeptideScanner's reviewed identity mapping was semaglutide.

- Evidence object: `story:clinicaltrials-gov-nct07935200-semaglutide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-11-13
- Source checked: 2026-11-14
- Published by PeptideScanner: 2026-11-14
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07935200-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct07935200-semaglutide-v1
- Content SHA-256: `892afb548d01ec4edb9b868bd15e4580bb54f18a7159fca8d6e10ea5e5988272`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07935200 ([`ctg-observation-nct07935200-2026-11-13-0ffa0889a74d`](#source-ctg-observation-nct07935200-2026-11-13-0ffa0889a74d))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07935200 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-13, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct07935200-2026-11-13-0ffa0889a74d`](#source-ctg-observation-nct07935200-2026-11-13-0ffa0889a74d))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07935200 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-13, and PeptideScanner's reviewed identity mapping was semaglutide. ([`ctg-observation-nct07935200-2026-11-13-0ffa0889a74d`](#source-ctg-observation-nct07935200-2026-11-13-0ffa0889a74d))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07935200-2026-11-13-0ffa0889a74d`](#source-ctg-observation-nct07935200-2026-11-13-0ffa0889a74d))

### Sources

<a id="source-ctg-observation-nct07935200-2026-11-13-0ffa0889a74d"></a>
- **ClinicalTrials.gov record NCT07935200 · retained source version 2026-11-13:0ffa0889a74d12e23ff4102dec5806e259bf533f5ba1e12f46cf71970be0ffa5** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07935200) (`ctg-observation-nct07935200-2026-11-13-0ffa0889a74d`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07935200." Version 1, published 2026-11-14. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#clinicaltrials-gov-nct07935200-semaglutide-v1 SHA-256: 892afb548d01ec4edb9b868bd15e4580bb54f18a7159fca8d6e10ea5e5988272.

---

<a id="dailymed-label-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v10-v1"></a>

## Semaglutide DailyMed SPL version 10

> DailyMed lists Structured Product Labeling version 10 for the reviewed Semaglutide label family with a published date of 2024-12-12. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

- Evidence object: `story:dailymed-label-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v10:v1`
- Evidence domain: Regulatory
- Date in source: 2024-12-12
- Source checked: 2026-08-22
- Published by PeptideScanner: 2026-08-22
- Story landing page: https://peptidescanner.com/stories/dailymed-label-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v10/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#dailymed-label-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v10-v1
- Content SHA-256: `bab4526f323915ff1776a80b58ae4388b9a3f48217da551c40e3daeb34d665b3`

### Claims and source pins

#### Headline

Semaglutide DailyMed SPL version 10 ([`dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v10-history`](#source-dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v10-history))

#### Summary

DailyMed lists Structured Product Labeling version 10 for the reviewed Semaglutide label family with a published date of 2024-12-12. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v10-history`](#source-dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v10-history))

#### Paragraph 1

DailyMed lists Structured Product Labeling version 10 for the reviewed Semaglutide label family with a published date of 2024-12-12. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v10-history`](#source-dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v10-history))

#### Paragraph 2

This page reports that DailyMed lists an available Structured Product Labeling version for the reviewed label family and links the exact historical ZIP. It does not reproduce label text, identify which sections changed, establish FDA approval, interpret safety or effectiveness, or provide medical guidance. ([`dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v10-history`](#source-dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v10-history))

### Sources

<a id="source-dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v10-history"></a>
- **DailyMed SPL SET ID ee06186f-2aa3-4990-a760-757579d8f77b · SPL version 10 · published 2024-12-12 · retained ZIP SHA-256 5a795dc1d1fedb2b7e8844a74940dc6853183f76595d1f62ffc0c094e68cb6bf** — DailyMed · U.S. National Library of Medicine; class A. [Open source](https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=ee06186f-2aa3-4990-a760-757579d8f77b&version=10) (`dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v10-history`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Semaglutide DailyMed SPL version 10." Version 1, published 2026-08-22. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#dailymed-label-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v10-v1 SHA-256: bab4526f323915ff1776a80b58ae4388b9a3f48217da551c40e3daeb34d665b3.

---

<a id="dailymed-label-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v11-v1"></a>

## Semaglutide DailyMed SPL version 11

> DailyMed lists Structured Product Labeling version 11 for the reviewed Semaglutide label family with a published date of 2025-08-29. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

- Evidence object: `story:dailymed-label-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v11:v1`
- Evidence domain: Regulatory
- Date in source: 2025-08-29
- Source checked: 2026-08-22
- Published by PeptideScanner: 2026-08-22
- Story landing page: https://peptidescanner.com/stories/dailymed-label-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v11/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#dailymed-label-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v11-v1
- Content SHA-256: `cc52526b5370dbaff11a5e71dafe98308845063f6caa9126f4c8816d57f5ef43`

### Claims and source pins

#### Headline

Semaglutide DailyMed SPL version 11 ([`dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v11-history`](#source-dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v11-history))

#### Summary

DailyMed lists Structured Product Labeling version 11 for the reviewed Semaglutide label family with a published date of 2025-08-29. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v11-history`](#source-dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v11-history))

#### Paragraph 1

DailyMed lists Structured Product Labeling version 11 for the reviewed Semaglutide label family with a published date of 2025-08-29. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v11-history`](#source-dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v11-history))

#### Paragraph 2

This page reports that DailyMed lists an available Structured Product Labeling version for the reviewed label family and links the exact historical ZIP. It does not reproduce label text, identify which sections changed, establish FDA approval, interpret safety or effectiveness, or provide medical guidance. ([`dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v11-history`](#source-dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v11-history))

### Sources

<a id="source-dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v11-history"></a>
- **DailyMed SPL SET ID ee06186f-2aa3-4990-a760-757579d8f77b · SPL version 11 · published 2025-08-29 · retained ZIP SHA-256 285c053371034d14a017d44d96ea76be0f02d637cb9e12ed97eb209c3f059eef** — DailyMed · U.S. National Library of Medicine; class A. [Open source](https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=ee06186f-2aa3-4990-a760-757579d8f77b&version=11) (`dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v11-history`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Semaglutide DailyMed SPL version 11." Version 1, published 2026-08-22. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#dailymed-label-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v11-v1 SHA-256: cc52526b5370dbaff11a5e71dafe98308845063f6caa9126f4c8816d57f5ef43.

---

<a id="dailymed-label-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v12-v1"></a>

## Semaglutide DailyMed SPL version 12

> DailyMed lists Structured Product Labeling version 12 for the reviewed Semaglutide label family with a published date of 2025-11-17. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

- Evidence object: `story:dailymed-label-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v12:v1`
- Evidence domain: Regulatory
- Date in source: 2025-11-17
- Source checked: 2026-08-22
- Published by PeptideScanner: 2026-08-22
- Story landing page: https://peptidescanner.com/stories/dailymed-label-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v12/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#dailymed-label-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v12-v1
- Content SHA-256: `fe0aa120a05205674c329586bd07a0ddc9f779794833ada448e405ee2ecec428`

### Claims and source pins

#### Headline

Semaglutide DailyMed SPL version 12 ([`dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v12-history`](#source-dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v12-history))

#### Summary

DailyMed lists Structured Product Labeling version 12 for the reviewed Semaglutide label family with a published date of 2025-11-17. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v12-history`](#source-dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v12-history))

#### Paragraph 1

DailyMed lists Structured Product Labeling version 12 for the reviewed Semaglutide label family with a published date of 2025-11-17. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v12-history`](#source-dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v12-history))

#### Paragraph 2

This page reports that DailyMed lists an available Structured Product Labeling version for the reviewed label family and links the exact historical ZIP. It does not reproduce label text, identify which sections changed, establish FDA approval, interpret safety or effectiveness, or provide medical guidance. ([`dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v12-history`](#source-dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v12-history))

### Sources

<a id="source-dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v12-history"></a>
- **DailyMed SPL SET ID ee06186f-2aa3-4990-a760-757579d8f77b · SPL version 12 · published 2025-11-17 · retained ZIP SHA-256 fdb36d1117b02967640969d94ea0943c92ec5e5280ceb09c69b5905eed52f2db** — DailyMed · U.S. National Library of Medicine; class A. [Open source](https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=ee06186f-2aa3-4990-a760-757579d8f77b&version=12) (`dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v12-history`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Semaglutide DailyMed SPL version 12." Version 1, published 2026-08-22. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#dailymed-label-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v12-v1 SHA-256: fe0aa120a05205674c329586bd07a0ddc9f779794833ada448e405ee2ecec428.

---

<a id="dailymed-label-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v13-v1"></a>

## Semaglutide DailyMed SPL version 13

> DailyMed lists Structured Product Labeling version 13 for the reviewed Semaglutide label family with a published date of 2025-12-05. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

- Evidence object: `story:dailymed-label-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v13:v1`
- Evidence domain: Regulatory
- Date in source: 2025-12-05
- Source checked: 2026-08-22
- Published by PeptideScanner: 2026-08-22
- Story landing page: https://peptidescanner.com/stories/dailymed-label-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v13/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#dailymed-label-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v13-v1
- Content SHA-256: `de766c2a20a7333f33528c08c3fdbe125d261e66e3e5e935464f0116179d96d3`

### Claims and source pins

#### Headline

Semaglutide DailyMed SPL version 13 ([`dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v13-history`](#source-dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v13-history))

#### Summary

DailyMed lists Structured Product Labeling version 13 for the reviewed Semaglutide label family with a published date of 2025-12-05. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v13-history`](#source-dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v13-history))

#### Paragraph 1

DailyMed lists Structured Product Labeling version 13 for the reviewed Semaglutide label family with a published date of 2025-12-05. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v13-history`](#source-dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v13-history))

#### Paragraph 2

This page reports that DailyMed lists an available Structured Product Labeling version for the reviewed label family and links the exact historical ZIP. It does not reproduce label text, identify which sections changed, establish FDA approval, interpret safety or effectiveness, or provide medical guidance. ([`dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v13-history`](#source-dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v13-history))

### Sources

<a id="source-dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v13-history"></a>
- **DailyMed SPL SET ID ee06186f-2aa3-4990-a760-757579d8f77b · SPL version 13 · published 2025-12-05 · retained ZIP SHA-256 2bca5462ee4f8953045a17562b74589653271dad64605958e898745f210d33cf** — DailyMed · U.S. National Library of Medicine; class A. [Open source](https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=ee06186f-2aa3-4990-a760-757579d8f77b&version=13) (`dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v13-history`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Semaglutide DailyMed SPL version 13." Version 1, published 2026-08-22. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#dailymed-label-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v13-v1 SHA-256: de766c2a20a7333f33528c08c3fdbe125d261e66e3e5e935464f0116179d96d3.

---

<a id="dailymed-label-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v14-v1"></a>

## Semaglutide DailyMed SPL version 14

> DailyMed lists Structured Product Labeling version 14 for the reviewed Semaglutide label family with a published date of 2026-01-06. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

- Evidence object: `story:dailymed-label-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v14:v1`
- Evidence domain: Regulatory
- Date in source: 2026-01-06
- Source checked: 2026-08-22
- Published by PeptideScanner: 2026-08-22
- Story landing page: https://peptidescanner.com/stories/dailymed-label-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v14/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#dailymed-label-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v14-v1
- Content SHA-256: `8c6efd8a6ff43b60d632543cd6c92d961794a1a6469afdb8881cc4aa26d0cdc5`

### Claims and source pins

#### Headline

Semaglutide DailyMed SPL version 14 ([`dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v14-history`](#source-dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v14-history))

#### Summary

DailyMed lists Structured Product Labeling version 14 for the reviewed Semaglutide label family with a published date of 2026-01-06. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v14-history`](#source-dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v14-history))

#### Paragraph 1

DailyMed lists Structured Product Labeling version 14 for the reviewed Semaglutide label family with a published date of 2026-01-06. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v14-history`](#source-dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v14-history))

#### Paragraph 2

This page reports that DailyMed lists an available Structured Product Labeling version for the reviewed label family and links the exact historical ZIP. It does not reproduce label text, identify which sections changed, establish FDA approval, interpret safety or effectiveness, or provide medical guidance. ([`dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v14-history`](#source-dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v14-history))

### Sources

<a id="source-dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v14-history"></a>
- **DailyMed SPL SET ID ee06186f-2aa3-4990-a760-757579d8f77b · SPL version 14 · published 2026-01-06 · retained ZIP SHA-256 1d4df55df936db92e34382dbb13611963f41926e6b80eea62466ef2da94fe170** — DailyMed · U.S. National Library of Medicine; class A. [Open source](https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=ee06186f-2aa3-4990-a760-757579d8f77b&version=14) (`dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v14-history`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Semaglutide DailyMed SPL version 14." Version 1, published 2026-08-22. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#dailymed-label-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v14-v1 SHA-256: 8c6efd8a6ff43b60d632543cd6c92d961794a1a6469afdb8881cc4aa26d0cdc5.

---

<a id="dailymed-label-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v15-v1"></a>

## Semaglutide DailyMed SPL version 15

> DailyMed lists Structured Product Labeling version 15 for the reviewed Semaglutide label family with a published date of 2026-02-12. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

- Evidence object: `story:dailymed-label-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v15:v1`
- Evidence domain: Regulatory
- Date in source: 2026-02-12
- Source checked: 2026-08-22
- Published by PeptideScanner: 2026-08-22
- Story landing page: https://peptidescanner.com/stories/dailymed-label-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v15/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#dailymed-label-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v15-v1
- Content SHA-256: `d18335345468b9f2acf3236029cb10846ffc8dee81e9cb521a772a7d63490a2b`

### Claims and source pins

#### Headline

Semaglutide DailyMed SPL version 15 ([`dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v15-history`](#source-dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v15-history))

#### Summary

DailyMed lists Structured Product Labeling version 15 for the reviewed Semaglutide label family with a published date of 2026-02-12. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v15-history`](#source-dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v15-history))

#### Paragraph 1

DailyMed lists Structured Product Labeling version 15 for the reviewed Semaglutide label family with a published date of 2026-02-12. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v15-history`](#source-dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v15-history))

#### Paragraph 2

This page reports that DailyMed lists an available Structured Product Labeling version for the reviewed label family and links the exact historical ZIP. It does not reproduce label text, identify which sections changed, establish FDA approval, interpret safety or effectiveness, or provide medical guidance. ([`dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v15-history`](#source-dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v15-history))

### Sources

<a id="source-dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v15-history"></a>
- **DailyMed SPL SET ID ee06186f-2aa3-4990-a760-757579d8f77b · SPL version 15 · published 2026-02-12 · retained ZIP SHA-256 521dffd6648a7822ff51aa2cd5af4c9ebdfba1c4b8480412b33d764abf888c54** — DailyMed · U.S. National Library of Medicine; class A. [Open source](https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=ee06186f-2aa3-4990-a760-757579d8f77b&version=15) (`dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v15-history`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Semaglutide DailyMed SPL version 15." Version 1, published 2026-08-22. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#dailymed-label-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v15-v1 SHA-256: d18335345468b9f2acf3236029cb10846ffc8dee81e9cb521a772a7d63490a2b.

---

<a id="dailymed-label-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v16-v1"></a>

## Semaglutide DailyMed SPL version 16

> DailyMed lists Structured Product Labeling version 16 for the reviewed Semaglutide label family with a published date of 2026-03-05. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

- Evidence object: `story:dailymed-label-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v16:v1`
- Evidence domain: Regulatory
- Date in source: 2026-03-05
- Source checked: 2026-08-22
- Published by PeptideScanner: 2026-08-22
- Story landing page: https://peptidescanner.com/stories/dailymed-label-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v16/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#dailymed-label-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v16-v1
- Content SHA-256: `7c3fb620d284b684f71dde4721126564c650f52656606e4b7e63f2653aa28d24`

### Claims and source pins

#### Headline

Semaglutide DailyMed SPL version 16 ([`dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v16-history`](#source-dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v16-history))

#### Summary

DailyMed lists Structured Product Labeling version 16 for the reviewed Semaglutide label family with a published date of 2026-03-05. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v16-history`](#source-dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v16-history))

#### Paragraph 1

DailyMed lists Structured Product Labeling version 16 for the reviewed Semaglutide label family with a published date of 2026-03-05. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v16-history`](#source-dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v16-history))

#### Paragraph 2

This page reports that DailyMed lists an available Structured Product Labeling version for the reviewed label family and links the exact historical ZIP. It does not reproduce label text, identify which sections changed, establish FDA approval, interpret safety or effectiveness, or provide medical guidance. ([`dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v16-history`](#source-dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v16-history))

### Sources

<a id="source-dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v16-history"></a>
- **DailyMed SPL SET ID ee06186f-2aa3-4990-a760-757579d8f77b · SPL version 16 · published 2026-03-05 · retained ZIP SHA-256 121930978afdd5c3e33fe544d0ba840b93ace937ead04abcabedfb438a68c2f1** — DailyMed · U.S. National Library of Medicine; class A. [Open source](https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=ee06186f-2aa3-4990-a760-757579d8f77b&version=16) (`dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v16-history`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Semaglutide DailyMed SPL version 16." Version 1, published 2026-08-22. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#dailymed-label-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v16-v1 SHA-256: 7c3fb620d284b684f71dde4721126564c650f52656606e4b7e63f2653aa28d24.

---

<a id="dailymed-label-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v17-v1"></a>

## Semaglutide DailyMed SPL version 17

> DailyMed lists Structured Product Labeling version 17 for the reviewed Semaglutide label family with a published date of 2026-04-02. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

- Evidence object: `story:dailymed-label-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v17:v1`
- Evidence domain: Regulatory
- Date in source: 2026-04-02
- Source checked: 2026-08-22
- Published by PeptideScanner: 2026-08-22
- Story landing page: https://peptidescanner.com/stories/dailymed-label-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v17/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#dailymed-label-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v17-v1
- Content SHA-256: `0ff55240ee8fafb6823138268bd618a70f5427eb7dca157cf6908d51defa1a20`

### Claims and source pins

#### Headline

Semaglutide DailyMed SPL version 17 ([`dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v17-history`](#source-dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v17-history))

#### Summary

DailyMed lists Structured Product Labeling version 17 for the reviewed Semaglutide label family with a published date of 2026-04-02. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v17-history`](#source-dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v17-history))

#### Paragraph 1

DailyMed lists Structured Product Labeling version 17 for the reviewed Semaglutide label family with a published date of 2026-04-02. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v17-history`](#source-dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v17-history))

#### Paragraph 2

This page reports that DailyMed lists an available Structured Product Labeling version for the reviewed label family and links the exact historical ZIP. It does not reproduce label text, identify which sections changed, establish FDA approval, interpret safety or effectiveness, or provide medical guidance. ([`dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v17-history`](#source-dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v17-history))

### Sources

<a id="source-dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v17-history"></a>
- **DailyMed SPL SET ID ee06186f-2aa3-4990-a760-757579d8f77b · SPL version 17 · published 2026-04-02 · retained ZIP SHA-256 32ff68a3805caa3512b3f68e417b43f48698030f1e3ab8d088e4ac65b03d1288** — DailyMed · U.S. National Library of Medicine; class A. [Open source](https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=ee06186f-2aa3-4990-a760-757579d8f77b&version=17) (`dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v17-history`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Semaglutide DailyMed SPL version 17." Version 1, published 2026-08-22. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#dailymed-label-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v17-v1 SHA-256: 0ff55240ee8fafb6823138268bd618a70f5427eb7dca157cf6908d51defa1a20.

---

<a id="dailymed-label-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v18-v1"></a>

## Semaglutide DailyMed SPL version 18

> DailyMed lists Structured Product Labeling version 18 for the reviewed Semaglutide label family with a published date of 2026-05-22. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

- Evidence object: `story:dailymed-label-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v18:v1`
- Evidence domain: Regulatory
- Date in source: 2026-05-22
- Source checked: 2026-08-22
- Published by PeptideScanner: 2026-08-22
- Story landing page: https://peptidescanner.com/stories/dailymed-label-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v18/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#dailymed-label-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v18-v1
- Content SHA-256: `77076d3e1226f5b582ece769daa9f83be896e2bf53688128c2c628ab3dcf6b78`

### Claims and source pins

#### Headline

Semaglutide DailyMed SPL version 18 ([`dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v18-history`](#source-dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v18-history))

#### Summary

DailyMed lists Structured Product Labeling version 18 for the reviewed Semaglutide label family with a published date of 2026-05-22. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v18-history`](#source-dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v18-history))

#### Paragraph 1

DailyMed lists Structured Product Labeling version 18 for the reviewed Semaglutide label family with a published date of 2026-05-22. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v18-history`](#source-dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v18-history))

#### Paragraph 2

This page reports that DailyMed lists an available Structured Product Labeling version for the reviewed label family and links the exact historical ZIP. It does not reproduce label text, identify which sections changed, establish FDA approval, interpret safety or effectiveness, or provide medical guidance. ([`dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v18-history`](#source-dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v18-history))

### Sources

<a id="source-dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v18-history"></a>
- **DailyMed SPL SET ID ee06186f-2aa3-4990-a760-757579d8f77b · SPL version 18 · published 2026-05-22 · retained ZIP SHA-256 42a72412a3cb469b63c2395c1f3b64a2a10c7f14a562121ce059346cc59495ee** — DailyMed · U.S. National Library of Medicine; class A. [Open source](https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=ee06186f-2aa3-4990-a760-757579d8f77b&version=18) (`dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v18-history`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Semaglutide DailyMed SPL version 18." Version 1, published 2026-08-22. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#dailymed-label-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v18-v1 SHA-256: 77076d3e1226f5b582ece769daa9f83be896e2bf53688128c2c628ab3dcf6b78.

---

<a id="dailymed-label-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v19-v1"></a>

## Semaglutide DailyMed SPL version 19

> DailyMed lists Structured Product Labeling version 19 for the reviewed Semaglutide label family with a published date of 2026-06-30. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

- Evidence object: `story:dailymed-label-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v19:v1`
- Evidence domain: Regulatory
- Date in source: 2026-06-30
- Source checked: 2026-08-22
- Published by PeptideScanner: 2026-08-22
- Story landing page: https://peptidescanner.com/stories/dailymed-label-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v19/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#dailymed-label-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v19-v1
- Content SHA-256: `717064b1cdc9004da310e2a29a43541b7cefdd3c7b1913b3a06137cf7bfca85f`

### Claims and source pins

#### Headline

Semaglutide DailyMed SPL version 19 ([`dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v19-history`](#source-dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v19-history))

#### Summary

DailyMed lists Structured Product Labeling version 19 for the reviewed Semaglutide label family with a published date of 2026-06-30. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v19-history`](#source-dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v19-history))

#### Paragraph 1

DailyMed lists Structured Product Labeling version 19 for the reviewed Semaglutide label family with a published date of 2026-06-30. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v19-history`](#source-dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v19-history))

#### Paragraph 2

This page reports that DailyMed lists an available Structured Product Labeling version for the reviewed label family and links the exact historical ZIP. It does not reproduce label text, identify which sections changed, establish FDA approval, interpret safety or effectiveness, or provide medical guidance. ([`dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v19-history`](#source-dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v19-history))

### Sources

<a id="source-dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v19-history"></a>
- **DailyMed SPL SET ID ee06186f-2aa3-4990-a760-757579d8f77b · SPL version 19 · published 2026-06-30 · retained ZIP SHA-256 a8c57f3e8cf2c89501ac3b6077dd7480fb4bf72bb0b42135078f0d3a1f20f8f8** — DailyMed · U.S. National Library of Medicine; class A. [Open source](https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=ee06186f-2aa3-4990-a760-757579d8f77b&version=19) (`dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v19-history`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Semaglutide DailyMed SPL version 19." Version 1, published 2026-08-22. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#dailymed-label-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v19-v1 SHA-256: 717064b1cdc9004da310e2a29a43541b7cefdd3c7b1913b3a06137cf7bfca85f.

---

<a id="dailymed-label-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v1-v1"></a>

## Semaglutide DailyMed SPL version 1

> DailyMed lists Structured Product Labeling version 1 for the reviewed Semaglutide label family with a published date of 2021-06-07. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

- Evidence object: `story:dailymed-label-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v1:v1`
- Evidence domain: Regulatory
- Date in source: 2021-06-07
- Source checked: 2026-08-22
- Published by PeptideScanner: 2026-08-22
- Story landing page: https://peptidescanner.com/stories/dailymed-label-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v1/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#dailymed-label-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v1-v1
- Content SHA-256: `4bc642da3d8b4ef1c43f5122c0b601c1af19dffad1b6b72106ff5f6584ecdc6b`

### Claims and source pins

#### Headline

Semaglutide DailyMed SPL version 1 ([`dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v1-history`](#source-dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v1-history))

#### Summary

DailyMed lists Structured Product Labeling version 1 for the reviewed Semaglutide label family with a published date of 2021-06-07. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v1-history`](#source-dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v1-history))

#### Paragraph 1

DailyMed lists Structured Product Labeling version 1 for the reviewed Semaglutide label family with a published date of 2021-06-07. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v1-history`](#source-dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v1-history))

#### Paragraph 2

This page reports that DailyMed lists an available Structured Product Labeling version for the reviewed label family and links the exact historical ZIP. It does not reproduce label text, identify which sections changed, establish FDA approval, interpret safety or effectiveness, or provide medical guidance. ([`dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v1-history`](#source-dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v1-history))

### Sources

<a id="source-dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v1-history"></a>
- **DailyMed SPL SET ID ee06186f-2aa3-4990-a760-757579d8f77b · SPL version 1 · published 2021-06-07 · retained ZIP SHA-256 c472b10b3657de91ab5cdae62a7ee600dd2cb0c653b553589878ab04fa512476** — DailyMed · U.S. National Library of Medicine; class A. [Open source](https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=ee06186f-2aa3-4990-a760-757579d8f77b&version=1) (`dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v1-history`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Semaglutide DailyMed SPL version 1." Version 1, published 2026-08-22. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#dailymed-label-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v1-v1 SHA-256: 4bc642da3d8b4ef1c43f5122c0b601c1af19dffad1b6b72106ff5f6584ecdc6b.

---

<a id="dailymed-label-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v2-v1"></a>

## Semaglutide DailyMed SPL version 2

> DailyMed lists Structured Product Labeling version 2 for the reviewed Semaglutide label family with a published date of 2022-11-11. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

- Evidence object: `story:dailymed-label-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v2:v1`
- Evidence domain: Regulatory
- Date in source: 2022-11-11
- Source checked: 2026-08-22
- Published by PeptideScanner: 2026-08-22
- Story landing page: https://peptidescanner.com/stories/dailymed-label-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v2/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#dailymed-label-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v2-v1
- Content SHA-256: `3db957502c5bd1e0bef9478051c7b1aa56d25f1bad38587f8857e1bb9718acbb`

### Claims and source pins

#### Headline

Semaglutide DailyMed SPL version 2 ([`dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v2-history`](#source-dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v2-history))

#### Summary

DailyMed lists Structured Product Labeling version 2 for the reviewed Semaglutide label family with a published date of 2022-11-11. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v2-history`](#source-dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v2-history))

#### Paragraph 1

DailyMed lists Structured Product Labeling version 2 for the reviewed Semaglutide label family with a published date of 2022-11-11. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v2-history`](#source-dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v2-history))

#### Paragraph 2

This page reports that DailyMed lists an available Structured Product Labeling version for the reviewed label family and links the exact historical ZIP. It does not reproduce label text, identify which sections changed, establish FDA approval, interpret safety or effectiveness, or provide medical guidance. ([`dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v2-history`](#source-dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v2-history))

### Sources

<a id="source-dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v2-history"></a>
- **DailyMed SPL SET ID ee06186f-2aa3-4990-a760-757579d8f77b · SPL version 2 · published 2022-11-11 · retained ZIP SHA-256 c38b9bb4f7782417b13fd3e8a803d8d8e28c66c80af6a40fb4e495f7ef54d595** — DailyMed · U.S. National Library of Medicine; class A. [Open source](https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=ee06186f-2aa3-4990-a760-757579d8f77b&version=2) (`dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v2-history`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Semaglutide DailyMed SPL version 2." Version 1, published 2026-08-22. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#dailymed-label-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v2-v1 SHA-256: 3db957502c5bd1e0bef9478051c7b1aa56d25f1bad38587f8857e1bb9718acbb.

---

<a id="dailymed-label-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v3-v1"></a>

## Semaglutide DailyMed SPL version 3

> DailyMed lists Structured Product Labeling version 3 for the reviewed Semaglutide label family with a published date of 2023-01-09. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

- Evidence object: `story:dailymed-label-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v3:v1`
- Evidence domain: Regulatory
- Date in source: 2023-01-09
- Source checked: 2026-08-22
- Published by PeptideScanner: 2026-08-22
- Story landing page: https://peptidescanner.com/stories/dailymed-label-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v3/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#dailymed-label-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v3-v1
- Content SHA-256: `cec2455d8abd15c8d7a15c4e360cc8d9e84b0be49648ed6aaee4eff04cb4a4d4`

### Claims and source pins

#### Headline

Semaglutide DailyMed SPL version 3 ([`dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v3-history`](#source-dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v3-history))

#### Summary

DailyMed lists Structured Product Labeling version 3 for the reviewed Semaglutide label family with a published date of 2023-01-09. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v3-history`](#source-dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v3-history))

#### Paragraph 1

DailyMed lists Structured Product Labeling version 3 for the reviewed Semaglutide label family with a published date of 2023-01-09. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v3-history`](#source-dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v3-history))

#### Paragraph 2

This page reports that DailyMed lists an available Structured Product Labeling version for the reviewed label family and links the exact historical ZIP. It does not reproduce label text, identify which sections changed, establish FDA approval, interpret safety or effectiveness, or provide medical guidance. ([`dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v3-history`](#source-dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v3-history))

### Sources

<a id="source-dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v3-history"></a>
- **DailyMed SPL SET ID ee06186f-2aa3-4990-a760-757579d8f77b · SPL version 3 · published 2023-01-09 · retained ZIP SHA-256 400e50ebd85410257fb038bb3d10939606885e348a7f63d9a49a22859a15747d** — DailyMed · U.S. National Library of Medicine; class A. [Open source](https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=ee06186f-2aa3-4990-a760-757579d8f77b&version=3) (`dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v3-history`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Semaglutide DailyMed SPL version 3." Version 1, published 2026-08-22. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#dailymed-label-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v3-v1 SHA-256: cec2455d8abd15c8d7a15c4e360cc8d9e84b0be49648ed6aaee4eff04cb4a4d4.

---

<a id="dailymed-label-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v4-v1"></a>

## Semaglutide DailyMed SPL version 4

> DailyMed lists Structured Product Labeling version 4 for the reviewed Semaglutide label family with a published date of 2023-02-27. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

- Evidence object: `story:dailymed-label-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v4:v1`
- Evidence domain: Regulatory
- Date in source: 2023-02-27
- Source checked: 2026-08-22
- Published by PeptideScanner: 2026-08-22
- Story landing page: https://peptidescanner.com/stories/dailymed-label-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v4/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#dailymed-label-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v4-v1
- Content SHA-256: `a39d83e20b20a3245ba9ba7fccdc06a66b7fd7476030055d1891ffbbf7be5f34`

### Claims and source pins

#### Headline

Semaglutide DailyMed SPL version 4 ([`dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v4-history`](#source-dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v4-history))

#### Summary

DailyMed lists Structured Product Labeling version 4 for the reviewed Semaglutide label family with a published date of 2023-02-27. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v4-history`](#source-dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v4-history))

#### Paragraph 1

DailyMed lists Structured Product Labeling version 4 for the reviewed Semaglutide label family with a published date of 2023-02-27. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v4-history`](#source-dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v4-history))

#### Paragraph 2

This page reports that DailyMed lists an available Structured Product Labeling version for the reviewed label family and links the exact historical ZIP. It does not reproduce label text, identify which sections changed, establish FDA approval, interpret safety or effectiveness, or provide medical guidance. ([`dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v4-history`](#source-dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v4-history))

### Sources

<a id="source-dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v4-history"></a>
- **DailyMed SPL SET ID ee06186f-2aa3-4990-a760-757579d8f77b · SPL version 4 · published 2023-02-27 · retained ZIP SHA-256 88ba2449fe57721bfc048a0fb4d17d93e87b399b035da34e3d5d1762099eb624** — DailyMed · U.S. National Library of Medicine; class A. [Open source](https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=ee06186f-2aa3-4990-a760-757579d8f77b&version=4) (`dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v4-history`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Semaglutide DailyMed SPL version 4." Version 1, published 2026-08-22. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#dailymed-label-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v4-v1 SHA-256: a39d83e20b20a3245ba9ba7fccdc06a66b7fd7476030055d1891ffbbf7be5f34.

---

<a id="dailymed-label-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v5-v1"></a>

## Semaglutide DailyMed SPL version 5

> DailyMed lists Structured Product Labeling version 5 for the reviewed Semaglutide label family with a published date of 2023-03-08. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

- Evidence object: `story:dailymed-label-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v5:v1`
- Evidence domain: Regulatory
- Date in source: 2023-03-08
- Source checked: 2026-08-22
- Published by PeptideScanner: 2026-08-22
- Story landing page: https://peptidescanner.com/stories/dailymed-label-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v5/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#dailymed-label-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v5-v1
- Content SHA-256: `83e48db695ce954d89cdd07cbb5dd42f71d9f9be3431c35ada99d90fca69d925`

### Claims and source pins

#### Headline

Semaglutide DailyMed SPL version 5 ([`dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v5-history`](#source-dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v5-history))

#### Summary

DailyMed lists Structured Product Labeling version 5 for the reviewed Semaglutide label family with a published date of 2023-03-08. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v5-history`](#source-dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v5-history))

#### Paragraph 1

DailyMed lists Structured Product Labeling version 5 for the reviewed Semaglutide label family with a published date of 2023-03-08. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v5-history`](#source-dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v5-history))

#### Paragraph 2

This page reports that DailyMed lists an available Structured Product Labeling version for the reviewed label family and links the exact historical ZIP. It does not reproduce label text, identify which sections changed, establish FDA approval, interpret safety or effectiveness, or provide medical guidance. ([`dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v5-history`](#source-dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v5-history))

### Sources

<a id="source-dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v5-history"></a>
- **DailyMed SPL SET ID ee06186f-2aa3-4990-a760-757579d8f77b · SPL version 5 · published 2023-03-08 · retained ZIP SHA-256 b45670375887263d53719bf07e56c7ae3cd3be74a580d4ea91d9fb96298cfaf0** — DailyMed · U.S. National Library of Medicine; class A. [Open source](https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=ee06186f-2aa3-4990-a760-757579d8f77b&version=5) (`dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v5-history`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Semaglutide DailyMed SPL version 5." Version 1, published 2026-08-22. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#dailymed-label-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v5-v1 SHA-256: 83e48db695ce954d89cdd07cbb5dd42f71d9f9be3431c35ada99d90fca69d925.

---

<a id="dailymed-label-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v6-v1"></a>

## Semaglutide DailyMed SPL version 6

> DailyMed lists Structured Product Labeling version 6 for the reviewed Semaglutide label family with a published date of 2023-08-01. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

- Evidence object: `story:dailymed-label-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v6:v1`
- Evidence domain: Regulatory
- Date in source: 2023-08-01
- Source checked: 2026-08-22
- Published by PeptideScanner: 2026-08-22
- Story landing page: https://peptidescanner.com/stories/dailymed-label-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v6/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#dailymed-label-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v6-v1
- Content SHA-256: `30f815eb5d4ff4d27f5b61773be603e6b835ec6ae88a9dced285022256778803`

### Claims and source pins

#### Headline

Semaglutide DailyMed SPL version 6 ([`dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v6-history`](#source-dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v6-history))

#### Summary

DailyMed lists Structured Product Labeling version 6 for the reviewed Semaglutide label family with a published date of 2023-08-01. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v6-history`](#source-dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v6-history))

#### Paragraph 1

DailyMed lists Structured Product Labeling version 6 for the reviewed Semaglutide label family with a published date of 2023-08-01. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v6-history`](#source-dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v6-history))

#### Paragraph 2

This page reports that DailyMed lists an available Structured Product Labeling version for the reviewed label family and links the exact historical ZIP. It does not reproduce label text, identify which sections changed, establish FDA approval, interpret safety or effectiveness, or provide medical guidance. ([`dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v6-history`](#source-dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v6-history))

### Sources

<a id="source-dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v6-history"></a>
- **DailyMed SPL SET ID ee06186f-2aa3-4990-a760-757579d8f77b · SPL version 6 · published 2023-08-01 · retained ZIP SHA-256 b885bedf479cfdf5b50336481b4b536a36a137b8fd3aec3e2c2785739b1f6a3a** — DailyMed · U.S. National Library of Medicine; class A. [Open source](https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=ee06186f-2aa3-4990-a760-757579d8f77b&version=6) (`dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v6-history`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Semaglutide DailyMed SPL version 6." Version 1, published 2026-08-22. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#dailymed-label-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v6-v1 SHA-256: 30f815eb5d4ff4d27f5b61773be603e6b835ec6ae88a9dced285022256778803.

---

<a id="dailymed-label-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v7-v1"></a>

## Semaglutide DailyMed SPL version 7

> DailyMed lists Structured Product Labeling version 7 for the reviewed Semaglutide label family with a published date of 2024-03-18. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

- Evidence object: `story:dailymed-label-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v7:v1`
- Evidence domain: Regulatory
- Date in source: 2024-03-18
- Source checked: 2026-08-22
- Published by PeptideScanner: 2026-08-22
- Story landing page: https://peptidescanner.com/stories/dailymed-label-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v7/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#dailymed-label-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v7-v1
- Content SHA-256: `099da06b96820fda3a3c17ab69b95e8d0a0e02fb74f3fbbab44b0552b4bf718c`

### Claims and source pins

#### Headline

Semaglutide DailyMed SPL version 7 ([`dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v7-history`](#source-dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v7-history))

#### Summary

DailyMed lists Structured Product Labeling version 7 for the reviewed Semaglutide label family with a published date of 2024-03-18. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v7-history`](#source-dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v7-history))

#### Paragraph 1

DailyMed lists Structured Product Labeling version 7 for the reviewed Semaglutide label family with a published date of 2024-03-18. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v7-history`](#source-dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v7-history))

#### Paragraph 2

This page reports that DailyMed lists an available Structured Product Labeling version for the reviewed label family and links the exact historical ZIP. It does not reproduce label text, identify which sections changed, establish FDA approval, interpret safety or effectiveness, or provide medical guidance. ([`dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v7-history`](#source-dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v7-history))

### Sources

<a id="source-dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v7-history"></a>
- **DailyMed SPL SET ID ee06186f-2aa3-4990-a760-757579d8f77b · SPL version 7 · published 2024-03-18 · retained ZIP SHA-256 6bca6d599a7c100bd6b54d3e4c603a3e0ba52981e08ce9e4d6bb23f9b119c0aa** — DailyMed · U.S. National Library of Medicine; class A. [Open source](https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=ee06186f-2aa3-4990-a760-757579d8f77b&version=7) (`dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v7-history`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Semaglutide DailyMed SPL version 7." Version 1, published 2026-08-22. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#dailymed-label-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v7-v1 SHA-256: 099da06b96820fda3a3c17ab69b95e8d0a0e02fb74f3fbbab44b0552b4bf718c.

---

<a id="dailymed-label-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v8-v1"></a>

## Semaglutide DailyMed SPL version 8

> DailyMed lists Structured Product Labeling version 8 for the reviewed Semaglutide label family with a published date of 2024-04-12. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

- Evidence object: `story:dailymed-label-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v8:v1`
- Evidence domain: Regulatory
- Date in source: 2024-04-12
- Source checked: 2026-08-22
- Published by PeptideScanner: 2026-08-22
- Story landing page: https://peptidescanner.com/stories/dailymed-label-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v8/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#dailymed-label-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v8-v1
- Content SHA-256: `fd2554cfb085d7e8943c7effccd67a3eff9c4d7e5bb95620390e9499b6ba535f`

### Claims and source pins

#### Headline

Semaglutide DailyMed SPL version 8 ([`dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v8-history`](#source-dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v8-history))

#### Summary

DailyMed lists Structured Product Labeling version 8 for the reviewed Semaglutide label family with a published date of 2024-04-12. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v8-history`](#source-dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v8-history))

#### Paragraph 1

DailyMed lists Structured Product Labeling version 8 for the reviewed Semaglutide label family with a published date of 2024-04-12. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v8-history`](#source-dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v8-history))

#### Paragraph 2

This page reports that DailyMed lists an available Structured Product Labeling version for the reviewed label family and links the exact historical ZIP. It does not reproduce label text, identify which sections changed, establish FDA approval, interpret safety or effectiveness, or provide medical guidance. ([`dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v8-history`](#source-dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v8-history))

### Sources

<a id="source-dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v8-history"></a>
- **DailyMed SPL SET ID ee06186f-2aa3-4990-a760-757579d8f77b · SPL version 8 · published 2024-04-12 · retained ZIP SHA-256 9aa99e5a84eccc0b7ce0f4396e3dcee9275e6398f5905c018c91f34878c0d125** — DailyMed · U.S. National Library of Medicine; class A. [Open source](https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=ee06186f-2aa3-4990-a760-757579d8f77b&version=8) (`dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v8-history`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Semaglutide DailyMed SPL version 8." Version 1, published 2026-08-22. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#dailymed-label-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v8-v1 SHA-256: fd2554cfb085d7e8943c7effccd67a3eff9c4d7e5bb95620390e9499b6ba535f.

---

<a id="dailymed-label-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v9-v1"></a>

## Semaglutide DailyMed SPL version 9

> DailyMed lists Structured Product Labeling version 9 for the reviewed Semaglutide label family with a published date of 2024-11-15. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

- Evidence object: `story:dailymed-label-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v9:v1`
- Evidence domain: Regulatory
- Date in source: 2024-11-15
- Source checked: 2026-08-22
- Published by PeptideScanner: 2026-08-22
- Story landing page: https://peptidescanner.com/stories/dailymed-label-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v9/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#dailymed-label-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v9-v1
- Content SHA-256: `702f9340bb3efddc6a7d0e6865764bc7aaefcb1d7dc6801a0886514f78531e3f`

### Claims and source pins

#### Headline

Semaglutide DailyMed SPL version 9 ([`dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v9-history`](#source-dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v9-history))

#### Summary

DailyMed lists Structured Product Labeling version 9 for the reviewed Semaglutide label family with a published date of 2024-11-15. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v9-history`](#source-dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v9-history))

#### Paragraph 1

DailyMed lists Structured Product Labeling version 9 for the reviewed Semaglutide label family with a published date of 2024-11-15. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v9-history`](#source-dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v9-history))

#### Paragraph 2

This page reports that DailyMed lists an available Structured Product Labeling version for the reviewed label family and links the exact historical ZIP. It does not reproduce label text, identify which sections changed, establish FDA approval, interpret safety or effectiveness, or provide medical guidance. ([`dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v9-history`](#source-dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v9-history))

### Sources

<a id="source-dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v9-history"></a>
- **DailyMed SPL SET ID ee06186f-2aa3-4990-a760-757579d8f77b · SPL version 9 · published 2024-11-15 · retained ZIP SHA-256 e44a9e70eeac88f472e3a86c2d274a9e217e49925720b0af748cbaa48c705e4a** — DailyMed · U.S. National Library of Medicine; class A. [Open source](https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=ee06186f-2aa3-4990-a760-757579d8f77b&version=9) (`dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v9-history`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Semaglutide DailyMed SPL version 9." Version 1, published 2026-08-22. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#dailymed-label-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v9-v1 SHA-256: 702f9340bb3efddc6a7d0e6865764bc7aaefcb1d7dc6801a0886514f78531e3f.

---

<a id="fda-drugs-nda209637-v1"></a>

## Drugs@FDA application NDA209637

> The official Drugs@FDA dataset lists original submission 1 for NDA 209637 with status AP dated 2017-12-05, and names semaglutide among the application record's active ingredients.

- Evidence object: `story:fda-drugs-nda209637:v1`
- Evidence domain: Regulatory
- Date in source: 2017-12-05
- Source checked: 2026-08-14
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/fda-drugs-nda209637/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#fda-drugs-nda209637-v1
- Content SHA-256: `d20ef54b905048224b5ee94c464fc2ff4ef372239f92209d9693a0d2216630f0`

### Claims and source pins

#### Headline

Drugs@FDA application NDA209637 ([`fda-drugs-nda209637-2017-12-05-0b9e82eeabee`](#source-fda-drugs-nda209637-2017-12-05-0b9e82eeabee))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for NDA 209637 with status AP dated 2017-12-05, and names semaglutide among the application record's active ingredients. ([`fda-drugs-nda209637-2017-12-05-0b9e82eeabee`](#source-fda-drugs-nda209637-2017-12-05-0b9e82eeabee))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for NDA 209637 with status AP dated 2017-12-05, and names semaglutide among the application record's active ingredients. ([`fda-drugs-nda209637-2017-12-05-0b9e82eeabee`](#source-fda-drugs-nda209637-2017-12-05-0b9e82eeabee))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-nda209637-2017-12-05-0b9e82eeabee`](#source-fda-drugs-nda209637-2017-12-05-0b9e82eeabee))

### Sources

<a id="source-fda-drugs-nda209637-2017-12-05-0b9e82eeabee"></a>
- **Drugs@FDA application NDA209637 · original submission status AP · 2017-12-05 · dataset 2026-08-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22NDA209637%22&limit=1) (`fda-drugs-nda209637-2017-12-05-0b9e82eeabee`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application NDA209637." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#fda-drugs-nda209637-v1 SHA-256: d20ef54b905048224b5ee94c464fc2ff4ef372239f92209d9693a0d2216630f0.

---

<a id="fda-drugs-nda213051-v1"></a>

## Drugs@FDA application NDA213051

> The official Drugs@FDA dataset lists original submission 1 for NDA 213051 with status AP dated 2019-09-20, and names semaglutide among the application record's active ingredients.

- Evidence object: `story:fda-drugs-nda213051:v1`
- Evidence domain: Regulatory
- Date in source: 2019-09-20
- Source checked: 2026-08-14
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/fda-drugs-nda213051/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#fda-drugs-nda213051-v1
- Content SHA-256: `b8c171639b168cce800ad7d5234f40011262d5c82ee72b73412b4b79d153e0dd`

### Claims and source pins

#### Headline

Drugs@FDA application NDA213051 ([`fda-drugs-nda213051-2019-09-20-2bce5be175e9`](#source-fda-drugs-nda213051-2019-09-20-2bce5be175e9))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for NDA 213051 with status AP dated 2019-09-20, and names semaglutide among the application record's active ingredients. ([`fda-drugs-nda213051-2019-09-20-2bce5be175e9`](#source-fda-drugs-nda213051-2019-09-20-2bce5be175e9))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for NDA 213051 with status AP dated 2019-09-20, and names semaglutide among the application record's active ingredients. ([`fda-drugs-nda213051-2019-09-20-2bce5be175e9`](#source-fda-drugs-nda213051-2019-09-20-2bce5be175e9))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-nda213051-2019-09-20-2bce5be175e9`](#source-fda-drugs-nda213051-2019-09-20-2bce5be175e9))

### Sources

<a id="source-fda-drugs-nda213051-2019-09-20-2bce5be175e9"></a>
- **Drugs@FDA application NDA213051 · original submission status AP · 2019-09-20 · dataset 2026-08-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22NDA213051%22&limit=1) (`fda-drugs-nda213051-2019-09-20-2bce5be175e9`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application NDA213051." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#fda-drugs-nda213051-v1 SHA-256: b8c171639b168cce800ad7d5234f40011262d5c82ee72b73412b4b79d153e0dd.

---

<a id="fda-drugs-nda213182-v1"></a>

## Drugs@FDA application NDA213182

> The official Drugs@FDA dataset lists original submission 1 for NDA 213182 with status AP dated 2020-01-16, and names semaglutide among the application record's active ingredients.

- Evidence object: `story:fda-drugs-nda213182:v1`
- Evidence domain: Regulatory
- Date in source: 2020-01-16
- Source checked: 2026-08-14
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/fda-drugs-nda213182/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#fda-drugs-nda213182-v1
- Content SHA-256: `4f263c5f20aba60f5b53e6840f617dae66aa5be2703645dfd5e7d7524863f248`

### Claims and source pins

#### Headline

Drugs@FDA application NDA213182 ([`fda-drugs-nda213182-2020-01-16-5d704c2c28f8`](#source-fda-drugs-nda213182-2020-01-16-5d704c2c28f8))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for NDA 213182 with status AP dated 2020-01-16, and names semaglutide among the application record's active ingredients. ([`fda-drugs-nda213182-2020-01-16-5d704c2c28f8`](#source-fda-drugs-nda213182-2020-01-16-5d704c2c28f8))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for NDA 213182 with status AP dated 2020-01-16, and names semaglutide among the application record's active ingredients. ([`fda-drugs-nda213182-2020-01-16-5d704c2c28f8`](#source-fda-drugs-nda213182-2020-01-16-5d704c2c28f8))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-nda213182-2020-01-16-5d704c2c28f8`](#source-fda-drugs-nda213182-2020-01-16-5d704c2c28f8))

### Sources

<a id="source-fda-drugs-nda213182-2020-01-16-5d704c2c28f8"></a>
- **Drugs@FDA application NDA213182 · original submission status AP · 2020-01-16 · dataset 2026-08-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22NDA213182%22&limit=1) (`fda-drugs-nda213182-2020-01-16-5d704c2c28f8`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application NDA213182." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#fda-drugs-nda213182-v1 SHA-256: 4f263c5f20aba60f5b53e6840f617dae66aa5be2703645dfd5e7d7524863f248.

---

<a id="fda-drugs-nda215256-v1"></a>

## Drugs@FDA application NDA215256

> The official Drugs@FDA dataset lists original submission 1 for NDA 215256 with status AP dated 2021-06-04, and names semaglutide among the application record's active ingredients.

- Evidence object: `story:fda-drugs-nda215256:v1`
- Evidence domain: Regulatory
- Date in source: 2021-06-04
- Source checked: 2026-08-14
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/fda-drugs-nda215256/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#fda-drugs-nda215256-v1
- Content SHA-256: `803a9148572f7b484595d053d041a14743cc360ab5d31582e319efe2448fafe2`

### Claims and source pins

#### Headline

Drugs@FDA application NDA215256 ([`fda-drugs-nda215256-2021-06-04-bead2c63a813`](#source-fda-drugs-nda215256-2021-06-04-bead2c63a813))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for NDA 215256 with status AP dated 2021-06-04, and names semaglutide among the application record's active ingredients. ([`fda-drugs-nda215256-2021-06-04-bead2c63a813`](#source-fda-drugs-nda215256-2021-06-04-bead2c63a813))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for NDA 215256 with status AP dated 2021-06-04, and names semaglutide among the application record's active ingredients. ([`fda-drugs-nda215256-2021-06-04-bead2c63a813`](#source-fda-drugs-nda215256-2021-06-04-bead2c63a813))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-nda215256-2021-06-04-bead2c63a813`](#source-fda-drugs-nda215256-2021-06-04-bead2c63a813))

### Sources

<a id="source-fda-drugs-nda215256-2021-06-04-bead2c63a813"></a>
- **Drugs@FDA application NDA215256 · original submission status AP · 2021-06-04 · dataset 2026-08-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22NDA215256%22&limit=1) (`fda-drugs-nda215256-2021-06-04-bead2c63a813`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application NDA215256." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#fda-drugs-nda215256-v1 SHA-256: 803a9148572f7b484595d053d041a14743cc360ab5d31582e319efe2448fafe2.

---

<a id="fda-drugs-nda218316-v1"></a>

## Drugs@FDA application NDA218316

> The official Drugs@FDA dataset lists original submission 1 for NDA 218316 with status AP dated 2025-12-22, and names semaglutide among the application record's active ingredients.

- Evidence object: `story:fda-drugs-nda218316:v1`
- Evidence domain: Regulatory
- Date in source: 2025-12-22
- Source checked: 2026-08-14
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/fda-drugs-nda218316/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#fda-drugs-nda218316-v1
- Content SHA-256: `7bcb3d8279ab6047d469455fa79530e0dad264405f5c57a7ece8220bdd1bc5e6`

### Claims and source pins

#### Headline

Drugs@FDA application NDA218316 ([`fda-drugs-nda218316-2025-12-22-e39b0518156a`](#source-fda-drugs-nda218316-2025-12-22-e39b0518156a))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for NDA 218316 with status AP dated 2025-12-22, and names semaglutide among the application record's active ingredients. ([`fda-drugs-nda218316-2025-12-22-e39b0518156a`](#source-fda-drugs-nda218316-2025-12-22-e39b0518156a))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for NDA 218316 with status AP dated 2025-12-22, and names semaglutide among the application record's active ingredients. ([`fda-drugs-nda218316-2025-12-22-e39b0518156a`](#source-fda-drugs-nda218316-2025-12-22-e39b0518156a))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-nda218316-2025-12-22-e39b0518156a`](#source-fda-drugs-nda218316-2025-12-22-e39b0518156a))

### Sources

<a id="source-fda-drugs-nda218316-2025-12-22-e39b0518156a"></a>
- **Drugs@FDA application NDA218316 · original submission status AP · 2025-12-22 · dataset 2026-08-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22NDA218316%22&limit=1) (`fda-drugs-nda218316-2025-12-22-e39b0518156a`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application NDA218316." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#fda-drugs-nda218316-v1 SHA-256: 7bcb3d8279ab6047d469455fa79530e0dad264405f5c57a7ece8220bdd1bc5e6.

---

<a id="fda-enforcement-d-0536-2021-v1"></a>

## FDA enforcement report D-0536-2021

> FDA's dated enforcement report D-0536-2021 lists Class II and source status Terminated for Cardinal Health Inc. PeptideScanner connects the report to reviewed application NDA213051 through exact openFDA application-number annotations.

- Evidence object: `story:fda-enforcement-d-0536-2021:v1`
- Evidence domain: Safety
- Date in source: 2021-06-02
- Source checked: 2026-08-25
- Published by PeptideScanner: 2026-08-25
- Story landing page: https://peptidescanner.com/stories/fda-enforcement-d-0536-2021/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#fda-enforcement-d-0536-2021-v1
- Content SHA-256: `4cf46ed4def84621de064243cc6b768de4fbb5955c0487fd44a95966fd75fc18`

### Claims and source pins

#### Headline

FDA enforcement report D-0536-2021 ([`fda-enforcement-d-0536-2021-3daefeca5dc6`](#source-fda-enforcement-d-0536-2021-3daefeca5dc6))

#### Summary

FDA's dated enforcement report D-0536-2021 lists Class II and source status Terminated for Cardinal Health Inc. PeptideScanner connects the report to reviewed application NDA213051 through exact openFDA application-number annotations. ([`fda-enforcement-d-0536-2021-3daefeca5dc6`](#source-fda-enforcement-d-0536-2021-3daefeca5dc6))

#### Paragraph 1

FDA's dated enforcement report D-0536-2021 lists Class II and source status Terminated for Cardinal Health Inc. PeptideScanner connects the report to reviewed application NDA213051 through exact openFDA application-number annotations. ([`fda-enforcement-d-0536-2021-3daefeca5dc6`](#source-fda-enforcement-d-0536-2021-3daefeca5dc6))

#### Paragraph 2

FDA's source-reported reason is: CGMP Deviations: Intermittent exposure to temperature excursion during storage. ([`fda-enforcement-d-0536-2021-3daefeca5dc6`](#source-fda-enforcement-d-0536-2021-3daefeca5dc6))

#### Paragraph 3

This PeptideScanner lane is a bounded, dated FDA enforcement-report snapshot connected through an exact openFDA application-number annotation. It is not a medical alert or complete recall-lifecycle tracker, does not establish current product or recall status, does not identify affected lots, and does not provide medical guidance. ([`fda-enforcement-d-0536-2021-3daefeca5dc6`](#source-fda-enforcement-d-0536-2021-3daefeca5dc6))

### Sources

<a id="source-fda-enforcement-d-0536-2021-3daefeca5dc6"></a>
- **FDA enforcement report D-0536-2021 · Class II · report date 2021-06-02 · source status Terminated** — FDA enforcement reports via openFDA; class A. [Open source](https://api.fda.gov/drug/enforcement.json?search=recall_number%3A%22D-0536-2021%22&limit=1) (`fda-enforcement-d-0536-2021-3daefeca5dc6`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited safety or enforcement record. It is not an individualized risk assessment or medical recommendation.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "FDA enforcement report D-0536-2021." Version 1, published 2026-08-25. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#fda-enforcement-d-0536-2021-v1 SHA-256: 4cf46ed4def84621de064243cc6b768de4fbb5955c0487fd44a95966fd75fc18.

---

<a id="fda-glp1-503b-bulks-list-proposal-v1"></a>

## FDA proposes excluding three GLP-1 ingredients from the 503B bulks list

> FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the list of bulk substances that 503B outsourcing facilities may use for compounding.

- Evidence object: `story:fda-glp1-503b-bulks-list-proposal:v1`
- Evidence domain: Regulatory
- Date in source: 2026-04-30
- Source checked: 2026-07-29
- Published by PeptideScanner: 2026-07-29
- Story landing page: https://peptidescanner.com/stories/fda-glp1-503b-bulks-list-proposal/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#fda-glp1-503b-bulks-list-proposal-v1
- Content SHA-256: `cfa6ed74438a5b894a6a50745efd2b474900a19de3b27cc4101b1f0bbb351b1b`

### Claims and source pins

#### Headline

FDA proposes excluding three GLP-1 ingredients from the 503B bulks list ([`fda-glp1-bulks-proposal-2026`](#source-fda-glp1-bulks-proposal-2026))

#### Summary

FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the list of bulk substances that 503B outsourcing facilities may use for compounding. ([`fda-glp1-bulks-proposal-2026`](#source-fda-glp1-bulks-proposal-2026))

#### Paragraph 1

FDA announced a proposal concerning semaglutide, tirzepatide, and liraglutide and the 503B bulks list used by outsourcing facilities. ([`fda-glp1-bulks-proposal-2026`](#source-fda-glp1-bulks-proposal-2026))

#### Paragraph 2

The agency action is a proposal, not a final rule or a statement that all compounding circumstances are identical. This update preserves that procedural distinction. ([`fda-glp1-bulks-proposal-2026`](#source-fda-glp1-bulks-proposal-2026))

### Sources

<a id="source-fda-glp1-bulks-proposal-2026"></a>
- **FDA proposes to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list** — U.S. Food and Drug Administration; class A. [Open source](https://www.fda.gov/news-events/press-announcements/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list) (`fda-glp1-bulks-proposal-2026`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "FDA proposes excluding three GLP-1 ingredients from the 503B bulks list." Version 1, published 2026-07-29. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#fda-glp1-503b-bulks-list-proposal-v1 SHA-256: cfa6ed74438a5b894a6a50745efd2b474900a19de3b27cc4101b1f0bbb351b1b.

---

<a id="fda-glp1-label-warning-removal-request-v1"></a>

## FDA requests removal of a warning from certain GLP-1 drug labels

> FDA asked manufacturers to remove suicidal behavior and ideation warning language from certain semaglutide, tirzepatide, and liraglutide labels.

- Evidence object: `story:fda-glp1-label-warning-removal-request:v1`
- Evidence domain: Safety
- Date in source: 2026-01-13
- Source checked: 2026-07-29
- Published by PeptideScanner: 2026-07-29
- Story landing page: https://peptidescanner.com/stories/fda-glp1-label-warning-removal-request/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#fda-glp1-label-warning-removal-request-v1
- Content SHA-256: `05344160d978d16172191aa9bc415125cbff83af1eb729cde6d77e28a693c67c`

### Claims and source pins

#### Headline

FDA requests removal of a warning from certain GLP-1 drug labels ([`fda-glp1-label-warning-request-2026`](#source-fda-glp1-label-warning-request-2026))

#### Summary

FDA asked manufacturers to remove suicidal behavior and ideation warning language from certain semaglutide, tirzepatide, and liraglutide labels. ([`fda-glp1-label-warning-request-2026`](#source-fda-glp1-label-warning-request-2026))

#### Paragraph 1

FDA's communication says the agency requested that manufacturers remove suicidal behavior and ideation warning language from the labels of certain GLP-1 receptor agonist medicines. ([`fda-glp1-label-warning-request-2026`](#source-fda-glp1-label-warning-request-2026))

#### Paragraph 2

The FDA communication names Wegovy, Zepbound, and Saxenda. This update reports the agency's labeling request and does not provide an individualized interpretation of safety. ([`fda-glp1-label-warning-request-2026`](#source-fda-glp1-label-warning-request-2026))

### Sources

<a id="source-fda-glp1-label-warning-request-2026"></a>
- **FDA requests removal of suicidal behavior and ideation warning from certain GLP-1 RA labels** — U.S. Food and Drug Administration; class A. [Open source](https://www.fda.gov/drugs/drug-safety-communications/fda-requests-removal-suicidal-behavior-and-ideation-warning-glucagon-peptide-1-receptor-agonist-glp) (`fda-glp1-label-warning-request-2026`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited safety or enforcement record. It is not an individualized risk assessment or medical recommendation.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "FDA requests removal of a warning from certain GLP-1 drug labels." Version 1, published 2026-07-29. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#fda-glp1-label-warning-removal-request-v1 SHA-256: 05344160d978d16172191aa9bc415125cbff83af1eb729cde6d77e28a693c67c.

---

<a id="fda-higher-dose-semaglutide-approval-v1"></a>

## FDA announces approval of a higher-dose semaglutide product

> FDA announced approval of a higher-dose Wegovy product, adding a regulatory event to the semaglutide profile's selected official records.

- Evidence object: `story:fda-higher-dose-semaglutide-approval:v1`
- Evidence domain: Regulatory
- Date in source: 2026-03-19
- Source checked: 2026-07-22
- Published by PeptideScanner: 2026-07-29
- Story landing page: https://peptidescanner.com/stories/fda-higher-dose-semaglutide-approval/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#fda-higher-dose-semaglutide-approval-v1
- Content SHA-256: `2d7542f1e739a12c97884e76c8ccac92686ffeb63c5e77c9d31418bec12d8629`

### Claims and source pins

#### Headline

FDA announces approval of a higher-dose semaglutide product ([`fda-semaglutide-2026`](#source-fda-semaglutide-2026))

#### Summary

FDA announced approval of a higher-dose Wegovy product, adding a regulatory event to the semaglutide profile's selected official records. ([`fda-semaglutide-2026`](#source-fda-semaglutide-2026))

#### Paragraph 1

FDA's announcement describes its approval of a higher-dose Wegovy product containing semaglutide under the agency's national-priority voucher program. ([`fda-semaglutide-2026`](#source-fda-semaglutide-2026))

#### Paragraph 2

This update reports the regulatory action and links to FDA's announcement. It does not restate indications, compare products, or provide treatment guidance. ([`fda-semaglutide-2026`](#source-fda-semaglutide-2026))

### Sources

<a id="source-fda-semaglutide-2026"></a>
- **FDA approves higher-dose semaglutide** — U.S. Food and Drug Administration; class A. [Open source](https://www.fda.gov/news-events/press-announcements/fda-approves-fourth-product-under-national-priority-voucher-program-higher-dose-semaglutide) (`fda-semaglutide-2026`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "FDA announces approval of a higher-dose semaglutide product." Version 1, published 2026-07-29. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#fda-higher-dose-semaglutide-approval-v1 SHA-256: 2d7542f1e739a12c97884e76c8ccac92686ffeb63c5e77c9d31418bec12d8629.

---

<a id="fda-unapproved-glp1-concerns-record-v1"></a>

## FDA details concerns with unapproved GLP-1 products

> FDA's public page describes agency concerns and actions involving unapproved versions of semaglutide and tirzepatide, with adverse-event information dated May 31, 2026.

- Evidence object: `story:fda-unapproved-glp1-concerns-record:v1`
- Evidence domain: Safety
- Date in source: 2026-05-31
- Source checked: 2026-07-29
- Published by PeptideScanner: 2026-07-29
- Story landing page: https://peptidescanner.com/stories/fda-unapproved-glp1-concerns-record/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#fda-unapproved-glp1-concerns-record-v1
- Content SHA-256: `d335f52648addef0eb60f86d227db44f501f044c4be120c979e403efd98ec6e3`

### Claims and source pins

#### Headline

FDA details concerns with unapproved GLP-1 products ([`fda-unapproved-glp1-concerns-2026`](#source-fda-unapproved-glp1-concerns-2026))

#### Summary

FDA's public page describes agency concerns and actions involving unapproved versions of semaglutide and tirzepatide, with adverse-event information dated May 31, 2026. ([`fda-unapproved-glp1-concerns-2026`](#source-fda-unapproved-glp1-concerns-2026))

#### Paragraph 1

FDA's page distinguishes FDA-approved products from unapproved versions and compiles agency concerns, enforcement activity, reported quality problems, and adverse-event information dated May 31, 2026. ([`fda-unapproved-glp1-concerns-2026`](#source-fda-unapproved-glp1-concerns-2026))

#### Paragraph 2

This update attributes those statements to FDA and does not evaluate a product, pharmacy, treatment choice, or individual report. It also does not turn FDA's examples into a complete market survey. ([`fda-unapproved-glp1-concerns-2026`](#source-fda-unapproved-glp1-concerns-2026))

### Sources

<a id="source-fda-unapproved-glp1-concerns-2026"></a>
- **FDA concerns with unapproved GLP-1 drugs used for weight loss** — U.S. Food and Drug Administration; class A. [Open source](https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss) (`fda-unapproved-glp1-concerns-2026`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited safety or enforcement record. It is not an individualized risk assessment or medical recommendation.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "FDA details concerns with unapproved GLP-1 products." Version 1, published 2026-07-29. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#fda-unapproved-glp1-concerns-record-v1 SHA-256: d335f52648addef0eb60f86d227db44f501f044c4be120c979e403efd98ec6e3.

---

<a id="federal-register-2017-21176-v1"></a>

## Federal Register notice 2017-21176

> The Federal Register published notice 2017-21176, attributed to FDA and its parent HHS department, on 2017-10-03. Its official title is “Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments,” and PeptideScanner's exact reviewed identity mapping connects the document to Semaglutide.

- Evidence object: `story:federal-register-2017-21176:v1`
- Evidence domain: Regulatory
- Date in source: 2017-10-03
- Source checked: 2026-08-21
- Published by PeptideScanner: 2026-08-21
- Story landing page: https://peptidescanner.com/stories/federal-register-2017-21176/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#federal-register-2017-21176-v1
- Content SHA-256: `c60c199be7b1a2d7fef90c94185109584ec47d5b4251705182705fefeef46edd`

### Claims and source pins

#### Headline

Federal Register notice 2017-21176 ([`federal-register-2017-21176-d033a61858ef`](#source-federal-register-2017-21176-d033a61858ef))

#### Summary

The Federal Register published notice 2017-21176, attributed to FDA and its parent HHS department, on 2017-10-03. Its official title is “Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments,” and PeptideScanner's exact reviewed identity mapping connects the document to Semaglutide. ([`federal-register-2017-21176-d033a61858ef`](#source-federal-register-2017-21176-d033a61858ef))

#### Paragraph 1

The Federal Register published notice 2017-21176, attributed to FDA and its parent HHS department, on 2017-10-03. Its official title is “Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments,” and PeptideScanner's exact reviewed identity mapping connects the document to Semaglutide. ([`federal-register-2017-21176-d033a61858ef`](#source-federal-register-2017-21176-d033a61858ef))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-2017-21176-d033a61858ef`](#source-federal-register-2017-21176-d033a61858ef))

### Sources

<a id="source-federal-register-2017-21176-d033a61858ef"></a>
- **Federal Register notice 2017-21176 · published 2017-10-03 · Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2017-10-03/pdf/2017-21176.pdf) (`federal-register-2017-21176-d033a61858ef`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice 2017-21176." Version 1, published 2026-08-21. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#federal-register-2017-21176-v1 SHA-256: c60c199be7b1a2d7fef90c94185109584ec47d5b4251705182705fefeef46edd.

---

<a id="federal-register-2019-25850-v1"></a>

## Federal Register notice 2019-25850

> The Federal Register published notice 2019-25850, attributed to FDA and its parent HHS department, on 2019-11-29. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; OZEMPIC,” and PeptideScanner's exact reviewed identity mapping connects the document to Semaglutide.

- Evidence object: `story:federal-register-2019-25850:v1`
- Evidence domain: Regulatory
- Date in source: 2019-11-29
- Source checked: 2026-08-21
- Published by PeptideScanner: 2026-08-21
- Story landing page: https://peptidescanner.com/stories/federal-register-2019-25850/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#federal-register-2019-25850-v1
- Content SHA-256: `09d8bd5d8211ab6def74a0911efc36ec55719652e3feb5ac51b02ad1a5700dd3`

### Claims and source pins

#### Headline

Federal Register notice 2019-25850 ([`federal-register-2019-25850-8476e49edc27`](#source-federal-register-2019-25850-8476e49edc27))

#### Summary

The Federal Register published notice 2019-25850, attributed to FDA and its parent HHS department, on 2019-11-29. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; OZEMPIC,” and PeptideScanner's exact reviewed identity mapping connects the document to Semaglutide. ([`federal-register-2019-25850-8476e49edc27`](#source-federal-register-2019-25850-8476e49edc27))

#### Paragraph 1

The Federal Register published notice 2019-25850, attributed to FDA and its parent HHS department, on 2019-11-29. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; OZEMPIC,” and PeptideScanner's exact reviewed identity mapping connects the document to Semaglutide. ([`federal-register-2019-25850-8476e49edc27`](#source-federal-register-2019-25850-8476e49edc27))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-2019-25850-8476e49edc27`](#source-federal-register-2019-25850-8476e49edc27))

### Sources

<a id="source-federal-register-2019-25850-8476e49edc27"></a>
- **Federal Register notice 2019-25850 · published 2019-11-29 · Determination of Regulatory Review Period for Purposes of Patent Extension; OZEMPIC** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2019-11-29/pdf/2019-25850.pdf) (`federal-register-2019-25850-8476e49edc27`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice 2019-25850." Version 1, published 2026-08-21. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#federal-register-2019-25850-v1 SHA-256: 09d8bd5d8211ab6def74a0911efc36ec55719652e3feb5ac51b02ad1a5700dd3.

---

<a id="federal-register-2023-25485-v1"></a>

## Federal Register notice 2023-25485

> The Federal Register published notice 2023-25485, attributed to FDA and its parent HHS department, on 2023-11-17. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Semaglutide.

- Evidence object: `story:federal-register-2023-25485:v1`
- Evidence domain: Regulatory
- Date in source: 2023-11-17
- Source checked: 2026-08-21
- Published by PeptideScanner: 2026-08-21
- Story landing page: https://peptidescanner.com/stories/federal-register-2023-25485/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#federal-register-2023-25485-v1
- Content SHA-256: `2582a4df94aa60b9537bf32e990babe510bf7a1467a605db708530e9166a0c31`

### Claims and source pins

#### Headline

Federal Register notice 2023-25485 ([`federal-register-2023-25485-5f4de9c1a25b`](#source-federal-register-2023-25485-5f4de9c1a25b))

#### Summary

The Federal Register published notice 2023-25485, attributed to FDA and its parent HHS department, on 2023-11-17. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Semaglutide. ([`federal-register-2023-25485-5f4de9c1a25b`](#source-federal-register-2023-25485-5f4de9c1a25b))

#### Paragraph 1

The Federal Register published notice 2023-25485, attributed to FDA and its parent HHS department, on 2023-11-17. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Semaglutide. ([`federal-register-2023-25485-5f4de9c1a25b`](#source-federal-register-2023-25485-5f4de9c1a25b))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-2023-25485-5f4de9c1a25b`](#source-federal-register-2023-25485-5f4de9c1a25b))

### Sources

<a id="source-federal-register-2023-25485-5f4de9c1a25b"></a>
- **Federal Register notice 2023-25485 · published 2023-11-17 · Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2023-11-17/pdf/2023-25485.pdf) (`federal-register-2023-25485-5f4de9c1a25b`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice 2023-25485." Version 1, published 2026-08-21. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#federal-register-2023-25485-v1 SHA-256: 2582a4df94aa60b9537bf32e990babe510bf7a1467a605db708530e9166a0c31.

---

<a id="federal-register-2025-19345-v1"></a>

## Federal Register notice 2025-19345

> The Federal Register published notice 2025-19345, attributed to FDA and its parent HHS department, on 2025-10-02. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Semaglutide.

- Evidence object: `story:federal-register-2025-19345:v1`
- Evidence domain: Regulatory
- Date in source: 2025-10-02
- Source checked: 2026-08-21
- Published by PeptideScanner: 2026-08-21
- Story landing page: https://peptidescanner.com/stories/federal-register-2025-19345/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#federal-register-2025-19345-v1
- Content SHA-256: `cea508c7b7b85753df54aa162a646870e57405c145fb95e8c72b12e8287b0372`

### Claims and source pins

#### Headline

Federal Register notice 2025-19345 ([`federal-register-2025-19345-9fce4db692ac`](#source-federal-register-2025-19345-9fce4db692ac))

#### Summary

The Federal Register published notice 2025-19345, attributed to FDA and its parent HHS department, on 2025-10-02. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Semaglutide. ([`federal-register-2025-19345-9fce4db692ac`](#source-federal-register-2025-19345-9fce4db692ac))

#### Paragraph 1

The Federal Register published notice 2025-19345, attributed to FDA and its parent HHS department, on 2025-10-02. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Semaglutide. ([`federal-register-2025-19345-9fce4db692ac`](#source-federal-register-2025-19345-9fce4db692ac))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-2025-19345-9fce4db692ac`](#source-federal-register-2025-19345-9fce4db692ac))

### Sources

<a id="source-federal-register-2025-19345-9fce4db692ac"></a>
- **Federal Register notice 2025-19345 · published 2025-10-02 · Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2025-10-02/pdf/2025-19345.pdf) (`federal-register-2025-19345-9fce4db692ac`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice 2025-19345." Version 1, published 2026-08-21. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#federal-register-2025-19345-v1 SHA-256: cea508c7b7b85753df54aa162a646870e57405c145fb95e8c72b12e8287b0372.

---

<a id="federal-register-2026-02786-v1"></a>

## Federal Register notice 2026-02786

> The Federal Register published notice 2026-02786, attributed to FDA and its parent HHS department, on 2026-02-12. Its official title is “Jeremy Spencer Brown: Final Debarment Order,” and PeptideScanner's exact reviewed identity mapping connects the document to Semaglutide.

- Evidence object: `story:federal-register-2026-02786:v1`
- Evidence domain: Regulatory
- Date in source: 2026-02-12
- Source checked: 2026-08-21
- Published by PeptideScanner: 2026-08-21
- Story landing page: https://peptidescanner.com/stories/federal-register-2026-02786/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#federal-register-2026-02786-v1
- Content SHA-256: `a2b5d817c01e670eb8cbe112eeb3920bd5fb009181eba3e2297f741559357e41`

### Claims and source pins

#### Headline

Federal Register notice 2026-02786 ([`federal-register-2026-02786-9eb11814aec1`](#source-federal-register-2026-02786-9eb11814aec1))

#### Summary

The Federal Register published notice 2026-02786, attributed to FDA and its parent HHS department, on 2026-02-12. Its official title is “Jeremy Spencer Brown: Final Debarment Order,” and PeptideScanner's exact reviewed identity mapping connects the document to Semaglutide. ([`federal-register-2026-02786-9eb11814aec1`](#source-federal-register-2026-02786-9eb11814aec1))

#### Paragraph 1

The Federal Register published notice 2026-02786, attributed to FDA and its parent HHS department, on 2026-02-12. Its official title is “Jeremy Spencer Brown: Final Debarment Order,” and PeptideScanner's exact reviewed identity mapping connects the document to Semaglutide. ([`federal-register-2026-02786-9eb11814aec1`](#source-federal-register-2026-02786-9eb11814aec1))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-2026-02786-9eb11814aec1`](#source-federal-register-2026-02786-9eb11814aec1))

### Sources

<a id="source-federal-register-2026-02786-9eb11814aec1"></a>
- **Federal Register notice 2026-02786 · published 2026-02-12 · Jeremy Spencer Brown: Final Debarment Order** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2026-02-12/pdf/2026-02786.pdf) (`federal-register-2026-02786-9eb11814aec1`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice 2026-02786." Version 1, published 2026-08-21. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#federal-register-2026-02786-v1 SHA-256: a2b5d817c01e670eb8cbe112eeb3920bd5fb009181eba3e2297f741559357e41.

---

<a id="federal-register-2026-08435-v1"></a>

## Federal Register notice 2026-08435

> The Federal Register published notice 2026-08435, attributed to FDA and its parent HHS department, on 2026-04-30. Its official title is “Determination That OZEMPIC (Semaglutide) Solution, 2 Milligrams Per 1.5 Milliliters Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness,” and PeptideScanner's exact reviewed identity mapping connects the document to Semaglutide.

- Evidence object: `story:federal-register-2026-08435:v1`
- Evidence domain: Regulatory
- Date in source: 2026-04-30
- Source checked: 2026-08-21
- Published by PeptideScanner: 2026-08-21
- Story landing page: https://peptidescanner.com/stories/federal-register-2026-08435/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#federal-register-2026-08435-v1
- Content SHA-256: `c9ffc67a8ead1188553af547a110bb3277fe59d4747094c221ad4ca429e63249`

### Claims and source pins

#### Headline

Federal Register notice 2026-08435 ([`federal-register-2026-08435-f6c2e886f30d`](#source-federal-register-2026-08435-f6c2e886f30d))

#### Summary

The Federal Register published notice 2026-08435, attributed to FDA and its parent HHS department, on 2026-04-30. Its official title is “Determination That OZEMPIC (Semaglutide) Solution, 2 Milligrams Per 1.5 Milliliters Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness,” and PeptideScanner's exact reviewed identity mapping connects the document to Semaglutide. ([`federal-register-2026-08435-f6c2e886f30d`](#source-federal-register-2026-08435-f6c2e886f30d))

#### Paragraph 1

The Federal Register published notice 2026-08435, attributed to FDA and its parent HHS department, on 2026-04-30. Its official title is “Determination That OZEMPIC (Semaglutide) Solution, 2 Milligrams Per 1.5 Milliliters Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness,” and PeptideScanner's exact reviewed identity mapping connects the document to Semaglutide. ([`federal-register-2026-08435-f6c2e886f30d`](#source-federal-register-2026-08435-f6c2e886f30d))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-2026-08435-f6c2e886f30d`](#source-federal-register-2026-08435-f6c2e886f30d))

### Sources

<a id="source-federal-register-2026-08435-f6c2e886f30d"></a>
- **Federal Register notice 2026-08435 · published 2026-04-30 · Determination That OZEMPIC (Semaglutide) Solution, 2 Milligrams Per 1.5 Milliliters Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2026-04-30/pdf/2026-08435.pdf) (`federal-register-2026-08435-f6c2e886f30d`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice 2026-08435." Version 1, published 2026-08-21. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#federal-register-2026-08435-v1 SHA-256: c9ffc67a8ead1188553af547a110bb3277fe59d4747094c221ad4ca429e63249.

---

<a id="pubmed-pmid-38016699-semaglutide-v1"></a>

## PubMed record PMID 38016699

> PeptideScanner retained PubMed bibliographic metadata for PMID 38016699 at 2026-08-10T10:49:06.852Z. PubMed recorded a metadata revision date of 2026-08-05 and an Entrez history date of 2023-11-28. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-38016699-semaglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-05
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-11
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-38016699-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-38016699-semaglutide-v1
- Content SHA-256: `d7392959baf96eae8876cec5742e9c97f5bba26509cc8b7aa4e3a52d887ff344`

### Claims and source pins

#### Headline

PubMed record PMID 38016699 ([`pubmed-observation-pmid-38016699-2026-08-05-7d8aa9b3a758`](#source-pubmed-observation-pmid-38016699-2026-08-05-7d8aa9b3a758))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 38016699 at 2026-08-10T10:49:06.852Z. PubMed recorded a metadata revision date of 2026-08-05 and an Entrez history date of 2023-11-28. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-38016699-2026-08-05-7d8aa9b3a758`](#source-pubmed-observation-pmid-38016699-2026-08-05-7d8aa9b3a758))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 38016699 at 2026-08-10T10:49:06.852Z. PubMed recorded a metadata revision date of 2026-08-05 and an Entrez history date of 2023-11-28. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-38016699-2026-08-05-7d8aa9b3a758`](#source-pubmed-observation-pmid-38016699-2026-08-05-7d8aa9b3a758))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-38016699-2026-08-05-7d8aa9b3a758`](#source-pubmed-observation-pmid-38016699-2026-08-05-7d8aa9b3a758))

### Sources

<a id="source-pubmed-observation-pmid-38016699-2026-08-05-7d8aa9b3a758"></a>
- **PubMed record PMID 38016699 · retained source version 1:2026-08-05:current:7d8aa9b3a75894729d0047abf21fc796b2ca54fd5d9054c11ed715229d358a3f** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/38016699/) (`pubmed-observation-pmid-38016699-2026-08-05-7d8aa9b3a758`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 38016699." Version 1, published 2026-08-11. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-38016699-semaglutide-v1 SHA-256: d7392959baf96eae8876cec5742e9c97f5bba26509cc8b7aa4e3a52d887ff344.

---

<a id="pubmed-pmid-38073422-semaglutide-v1"></a>

## PubMed record PMID 38073422

> PeptideScanner retained PubMed bibliographic metadata for PMID 38073422 at 2026-08-10T10:49:06.856Z. PubMed recorded a metadata revision date of 2026-08-05 and an Entrez history date of 2023-12-11. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-38073422-semaglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-05
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-11
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-38073422-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-38073422-semaglutide-v1
- Content SHA-256: `fa66b3e5ddf0d8c119179c22085660f197610f9d48a11a8f7329c98053271d4d`

### Claims and source pins

#### Headline

PubMed record PMID 38073422 ([`pubmed-observation-pmid-38073422-2026-08-05-10f112f0b0a1`](#source-pubmed-observation-pmid-38073422-2026-08-05-10f112f0b0a1))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 38073422 at 2026-08-10T10:49:06.856Z. PubMed recorded a metadata revision date of 2026-08-05 and an Entrez history date of 2023-12-11. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-38073422-2026-08-05-10f112f0b0a1`](#source-pubmed-observation-pmid-38073422-2026-08-05-10f112f0b0a1))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 38073422 at 2026-08-10T10:49:06.856Z. PubMed recorded a metadata revision date of 2026-08-05 and an Entrez history date of 2023-12-11. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-38073422-2026-08-05-10f112f0b0a1`](#source-pubmed-observation-pmid-38073422-2026-08-05-10f112f0b0a1))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-38073422-2026-08-05-10f112f0b0a1`](#source-pubmed-observation-pmid-38073422-2026-08-05-10f112f0b0a1))

### Sources

<a id="source-pubmed-observation-pmid-38073422-2026-08-05-10f112f0b0a1"></a>
- **PubMed record PMID 38073422 · retained source version 1:2026-08-05:current:10f112f0b0a12d1f606fec4a53e134beab60d4013dedfecbc6cf2a4b211e2886** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/38073422/) (`pubmed-observation-pmid-38073422-2026-08-05-10f112f0b0a1`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 38073422." Version 1, published 2026-08-11. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-38073422-semaglutide-v1 SHA-256: fa66b3e5ddf0d8c119179c22085660f197610f9d48a11a8f7329c98053271d4d.

---

<a id="pubmed-pmid-38082468-semaglutide-v1"></a>

## PubMed record PMID 38082468

> PeptideScanner retained PubMed bibliographic metadata for PMID 38082468 at 2026-08-10T10:49:06.856Z. PubMed recorded a metadata revision date of 2026-08-06 and an Entrez history date of 2023-12-12. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-38082468-semaglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-06
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-11
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-38082468-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-38082468-semaglutide-v1
- Content SHA-256: `1f377785c176ea382e7c869badf83cdebf712c81c05ef1e316f58280c4f4187c`

### Claims and source pins

#### Headline

PubMed record PMID 38082468 ([`pubmed-observation-pmid-38082468-2026-08-06-4ac68c1b6f72`](#source-pubmed-observation-pmid-38082468-2026-08-06-4ac68c1b6f72))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 38082468 at 2026-08-10T10:49:06.856Z. PubMed recorded a metadata revision date of 2026-08-06 and an Entrez history date of 2023-12-12. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-38082468-2026-08-06-4ac68c1b6f72`](#source-pubmed-observation-pmid-38082468-2026-08-06-4ac68c1b6f72))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 38082468 at 2026-08-10T10:49:06.856Z. PubMed recorded a metadata revision date of 2026-08-06 and an Entrez history date of 2023-12-12. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-38082468-2026-08-06-4ac68c1b6f72`](#source-pubmed-observation-pmid-38082468-2026-08-06-4ac68c1b6f72))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-38082468-2026-08-06-4ac68c1b6f72`](#source-pubmed-observation-pmid-38082468-2026-08-06-4ac68c1b6f72))

### Sources

<a id="source-pubmed-observation-pmid-38082468-2026-08-06-4ac68c1b6f72"></a>
- **PubMed record PMID 38082468 · retained source version 1:2026-08-06:current:4ac68c1b6f72a2444c18b4d714b58f635e68ba0f4651439f09807f5b4ff18dc0** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/38082468/) (`pubmed-observation-pmid-38082468-2026-08-06-4ac68c1b6f72`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 38082468." Version 1, published 2026-08-11. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-38082468-semaglutide-v1 SHA-256: 1f377785c176ea382e7c869badf83cdebf712c81c05ef1e316f58280c4f4187c.

---

<a id="pubmed-pmid-38151966-semaglutide-v1"></a>

## PubMed record PMID 38151966

> PeptideScanner retained PubMed bibliographic metadata for PMID 38151966 at 2026-08-10T10:49:06.863Z. PubMed recorded a metadata revision date of 2026-08-08 and an Entrez history date of 2023-12-28. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-38151966-semaglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-08
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-10
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-38151966-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-38151966-semaglutide-v1
- Content SHA-256: `770735fe7e26055de98b87b7bb47da421963c937419ea55d07f372f0b0101287`

### Claims and source pins

#### Headline

PubMed record PMID 38151966 ([`pubmed-observation-pmid-38151966-2026-08-08-8718f243fbc1`](#source-pubmed-observation-pmid-38151966-2026-08-08-8718f243fbc1))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 38151966 at 2026-08-10T10:49:06.863Z. PubMed recorded a metadata revision date of 2026-08-08 and an Entrez history date of 2023-12-28. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-38151966-2026-08-08-8718f243fbc1`](#source-pubmed-observation-pmid-38151966-2026-08-08-8718f243fbc1))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 38151966 at 2026-08-10T10:49:06.863Z. PubMed recorded a metadata revision date of 2026-08-08 and an Entrez history date of 2023-12-28. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-38151966-2026-08-08-8718f243fbc1`](#source-pubmed-observation-pmid-38151966-2026-08-08-8718f243fbc1))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-38151966-2026-08-08-8718f243fbc1`](#source-pubmed-observation-pmid-38151966-2026-08-08-8718f243fbc1))

### Sources

<a id="source-pubmed-observation-pmid-38151966-2026-08-08-8718f243fbc1"></a>
- **PubMed record PMID 38151966 · retained source version 1:2026-08-08:current:8718f243fbc1b25420ec526521a7c1cb394d5a076ad20dfb354d4607d7141456** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/38151966/) (`pubmed-observation-pmid-38151966-2026-08-08-8718f243fbc1`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 38151966." Version 1, published 2026-08-10. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-38151966-semaglutide-v1 SHA-256: 770735fe7e26055de98b87b7bb47da421963c937419ea55d07f372f0b0101287.

---

<a id="pubmed-pmid-38195847-semaglutide-v1"></a>

## PubMed record PMID 38195847

> PeptideScanner retained PubMed bibliographic metadata for PMID 38195847 at 2026-08-10T10:49:06.868Z. PubMed recorded a metadata revision date of 2026-08-06 and an Entrez history date of 2024-01-10. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-38195847-semaglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-06
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-11
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-38195847-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-38195847-semaglutide-v1
- Content SHA-256: `7a773e7d7614b5f4083f6662cba2f0f120e639735207e223a0ad75c7dae459e0`

### Claims and source pins

#### Headline

PubMed record PMID 38195847 ([`pubmed-observation-pmid-38195847-2026-08-06-fde77ad07349`](#source-pubmed-observation-pmid-38195847-2026-08-06-fde77ad07349))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 38195847 at 2026-08-10T10:49:06.868Z. PubMed recorded a metadata revision date of 2026-08-06 and an Entrez history date of 2024-01-10. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-38195847-2026-08-06-fde77ad07349`](#source-pubmed-observation-pmid-38195847-2026-08-06-fde77ad07349))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 38195847 at 2026-08-10T10:49:06.868Z. PubMed recorded a metadata revision date of 2026-08-06 and an Entrez history date of 2024-01-10. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-38195847-2026-08-06-fde77ad07349`](#source-pubmed-observation-pmid-38195847-2026-08-06-fde77ad07349))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-38195847-2026-08-06-fde77ad07349`](#source-pubmed-observation-pmid-38195847-2026-08-06-fde77ad07349))

### Sources

<a id="source-pubmed-observation-pmid-38195847-2026-08-06-fde77ad07349"></a>
- **PubMed record PMID 38195847 · retained source version 1:2026-08-06:current:fde77ad0734968ddc29aa9be89a81b764cb77bf89b3f9de0092c05c427dc8423** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/38195847/) (`pubmed-observation-pmid-38195847-2026-08-06-fde77ad07349`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 38195847." Version 1, published 2026-08-11. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-38195847-semaglutide-v1 SHA-256: 7a773e7d7614b5f4083f6662cba2f0f120e639735207e223a0ad75c7dae459e0.

---

<a id="pubmed-pmid-38321235-semaglutide-v1"></a>

## Redefining peptide therapeutics with semaglutide.

> PubMed lists PMID 38321235 in Nature chemistry as Journal Article, with publication-date metadata of 2024-02 (month precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-38321235-semaglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-16
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-38321235-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-38321235-semaglutide-v1
- Content SHA-256: `b3013a7e7c4a55a76a59b98c29f00a54fdb824b8c52d668d5f0b5d444a7a16e4`

### Claims and source pins

#### Headline

Redefining peptide therapeutics with semaglutide. ([`pubmed-observation-pmid-38321235-2026-07-16-d50762aa8e1d`](#source-pubmed-observation-pmid-38321235-2026-07-16-d50762aa8e1d))

#### Summary

PubMed lists PMID 38321235 in Nature chemistry as Journal Article, with publication-date metadata of 2024-02 (month precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-38321235-2026-07-16-d50762aa8e1d`](#source-pubmed-observation-pmid-38321235-2026-07-16-d50762aa8e1d))

#### Paragraph 1

PubMed lists PMID 38321235 in Nature chemistry as Journal Article, with publication-date metadata of 2024-02 (month precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-38321235-2026-07-16-d50762aa8e1d`](#source-pubmed-observation-pmid-38321235-2026-07-16-d50762aa8e1d))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-38321235-2026-07-16-d50762aa8e1d`](#source-pubmed-observation-pmid-38321235-2026-07-16-d50762aa8e1d))

### Sources

<a id="source-pubmed-observation-pmid-38321235-2026-07-16-d50762aa8e1d"></a>
- **Redefining peptide therapeutics with semaglutide. · retained source version 1:2026-07-16:current:d50762aa8e1dd707937323c10f300b350d7d8ce3358d3b43571ebdf1bfa50120** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/38321235/) (`pubmed-observation-pmid-38321235-2026-07-16-d50762aa8e1d`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Redefining peptide therapeutics with semaglutide." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-38321235-semaglutide-v1 SHA-256: b3013a7e7c4a55a76a59b98c29f00a54fdb824b8c52d668d5f0b5d444a7a16e4.

---

<a id="pubmed-pmid-38471743-semaglutide-v1"></a>

## Semaglutide treatment for children with obesity: an observational study.

> PubMed lists PMID 38471743 in Archives of disease in childhood as Journal Article, Observational Study, with publication-date metadata of 2024-09-25 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-38471743-semaglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-14
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-38471743-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-38471743-semaglutide-v1
- Content SHA-256: `3f1ff3c2473bf20dd1357d8e61452ac24c4ef8c5877c59a604e5310ceeb7ffb1`

### Claims and source pins

#### Headline

Semaglutide treatment for children with obesity: an observational study. ([`pubmed-observation-pmid-38471743-2026-07-14-925c3b5c4f3b`](#source-pubmed-observation-pmid-38471743-2026-07-14-925c3b5c4f3b))

#### Summary

PubMed lists PMID 38471743 in Archives of disease in childhood as Journal Article, Observational Study, with publication-date metadata of 2024-09-25 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-38471743-2026-07-14-925c3b5c4f3b`](#source-pubmed-observation-pmid-38471743-2026-07-14-925c3b5c4f3b))

#### Paragraph 1

PubMed lists PMID 38471743 in Archives of disease in childhood as Journal Article, Observational Study, with publication-date metadata of 2024-09-25 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-38471743-2026-07-14-925c3b5c4f3b`](#source-pubmed-observation-pmid-38471743-2026-07-14-925c3b5c4f3b))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-38471743-2026-07-14-925c3b5c4f3b`](#source-pubmed-observation-pmid-38471743-2026-07-14-925c3b5c4f3b))

### Sources

<a id="source-pubmed-observation-pmid-38471743-2026-07-14-925c3b5c4f3b"></a>
- **Semaglutide treatment for children with obesity: an observational study. · retained source version 1:2026-07-14:current:925c3b5c4f3b0aa3e170402d93fbf080644f573deaf649f2621e5090bb87a99f** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/38471743/) (`pubmed-observation-pmid-38471743-2026-07-14-925c3b5c4f3b`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Semaglutide treatment for children with obesity: an observational study." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-38471743-semaglutide-v1 SHA-256: 3f1ff3c2473bf20dd1357d8e61452ac24c4ef8c5877c59a604e5310ceeb7ffb1.

---

<a id="pubmed-pmid-39655973-semaglutide-v1"></a>

## PubMed record PMID 39655973

> PeptideScanner retained PubMed bibliographic metadata for PMID 39655973 at 2026-08-10T18:13:36.057Z. PubMed recorded a metadata revision date of 2026-07-28 and an Entrez history date of 2024-12-10. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-39655973-semaglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-28
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-39655973-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-39655973-semaglutide-v1
- Content SHA-256: `23175000c080f4d56a206dbdf8caaebc791a5ce9cf9e95af23de18aedfe90584`

### Claims and source pins

#### Headline

PubMed record PMID 39655973 ([`pubmed-observation-pmid-39655973-2026-07-28-94b847bcb6e7`](#source-pubmed-observation-pmid-39655973-2026-07-28-94b847bcb6e7))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 39655973 at 2026-08-10T18:13:36.057Z. PubMed recorded a metadata revision date of 2026-07-28 and an Entrez history date of 2024-12-10. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-39655973-2026-07-28-94b847bcb6e7`](#source-pubmed-observation-pmid-39655973-2026-07-28-94b847bcb6e7))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 39655973 at 2026-08-10T18:13:36.057Z. PubMed recorded a metadata revision date of 2026-07-28 and an Entrez history date of 2024-12-10. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-39655973-2026-07-28-94b847bcb6e7`](#source-pubmed-observation-pmid-39655973-2026-07-28-94b847bcb6e7))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-39655973-2026-07-28-94b847bcb6e7`](#source-pubmed-observation-pmid-39655973-2026-07-28-94b847bcb6e7))

### Sources

<a id="source-pubmed-observation-pmid-39655973-2026-07-28-94b847bcb6e7"></a>
- **PubMed record PMID 39655973 · retained source version 1:2026-07-28:current:94b847bcb6e72ced8c37a0203cef3a0323cceb55fff4669a67056d4f6baaf5b0** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/39655973/) (`pubmed-observation-pmid-39655973-2026-07-28-94b847bcb6e7`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 39655973." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-39655973-semaglutide-v1 SHA-256: 23175000c080f4d56a206dbdf8caaebc791a5ce9cf9e95af23de18aedfe90584.

---

<a id="pubmed-pmid-39776038-semaglutide-v1"></a>

## PubMed record PMID 39776038

> PeptideScanner retained PubMed bibliographic metadata for PMID 39776038 at 2026-08-10T10:49:06.923Z. PubMed recorded a metadata revision date of 2026-08-08 and an Entrez history date of 2025-01-08. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-39776038-semaglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-08
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-10
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-39776038-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-39776038-semaglutide-v1
- Content SHA-256: `3e2b829a73d80047385e0d1c8e19515b8a8be24ed9359499ec349bc926343531`

### Claims and source pins

#### Headline

PubMed record PMID 39776038 ([`pubmed-observation-pmid-39776038-2026-08-08-887b7c67d433`](#source-pubmed-observation-pmid-39776038-2026-08-08-887b7c67d433))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 39776038 at 2026-08-10T10:49:06.923Z. PubMed recorded a metadata revision date of 2026-08-08 and an Entrez history date of 2025-01-08. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-39776038-2026-08-08-887b7c67d433`](#source-pubmed-observation-pmid-39776038-2026-08-08-887b7c67d433))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 39776038 at 2026-08-10T10:49:06.923Z. PubMed recorded a metadata revision date of 2026-08-08 and an Entrez history date of 2025-01-08. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-39776038-2026-08-08-887b7c67d433`](#source-pubmed-observation-pmid-39776038-2026-08-08-887b7c67d433))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-39776038-2026-08-08-887b7c67d433`](#source-pubmed-observation-pmid-39776038-2026-08-08-887b7c67d433))

### Sources

<a id="source-pubmed-observation-pmid-39776038-2026-08-08-887b7c67d433"></a>
- **PubMed record PMID 39776038 · retained source version 1:2026-08-08:current:887b7c67d433240f9bf8a7d36c8574106e0f5c6cb19363b318360cbf711bb431** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/39776038/) (`pubmed-observation-pmid-39776038-2026-08-08-887b7c67d433`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 39776038." Version 1, published 2026-08-10. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-39776038-semaglutide-v1 SHA-256: 3e2b829a73d80047385e0d1c8e19515b8a8be24ed9359499ec349bc926343531.

---

<a id="pubmed-pmid-40015592-semaglutide-v1"></a>

## PubMed record PMID 40015592

> PeptideScanner retained PubMed bibliographic metadata for PMID 40015592 at 2026-08-10T10:49:06.932Z. PubMed recorded a metadata revision date of 2026-08-05 and an Entrez history date of 2025-02-27. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-40015592-semaglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-05
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-11
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-40015592-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-40015592-semaglutide-v1
- Content SHA-256: `c85c44738adef017e52394a99efe64c398a99def9bade2921508f32dc91f1d04`

### Claims and source pins

#### Headline

PubMed record PMID 40015592 ([`pubmed-observation-pmid-40015592-2026-08-05-4cf567c11e76`](#source-pubmed-observation-pmid-40015592-2026-08-05-4cf567c11e76))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 40015592 at 2026-08-10T10:49:06.932Z. PubMed recorded a metadata revision date of 2026-08-05 and an Entrez history date of 2025-02-27. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-40015592-2026-08-05-4cf567c11e76`](#source-pubmed-observation-pmid-40015592-2026-08-05-4cf567c11e76))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 40015592 at 2026-08-10T10:49:06.932Z. PubMed recorded a metadata revision date of 2026-08-05 and an Entrez history date of 2025-02-27. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-40015592-2026-08-05-4cf567c11e76`](#source-pubmed-observation-pmid-40015592-2026-08-05-4cf567c11e76))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-40015592-2026-08-05-4cf567c11e76`](#source-pubmed-observation-pmid-40015592-2026-08-05-4cf567c11e76))

### Sources

<a id="source-pubmed-observation-pmid-40015592-2026-08-05-4cf567c11e76"></a>
- **PubMed record PMID 40015592 · retained source version 1:2026-08-05:current:4cf567c11e76a4854d5ae52b0a38ffe2d7b02ac0dd7721a53eab3d9c7094d8ed** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/40015592/) (`pubmed-observation-pmid-40015592-2026-08-05-4cf567c11e76`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 40015592." Version 1, published 2026-08-11. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-40015592-semaglutide-v1 SHA-256: c85c44738adef017e52394a99efe64c398a99def9bade2921508f32dc91f1d04.

---

<a id="pubmed-pmid-40464214-semaglutide-v1"></a>

## Titration and discontinuation of semaglutide for weight management in commercially insured US adults.

> PubMed lists PMID 40464214 in Obesity (Silver Spring, Md.) as Journal Article, with publication-date metadata of 2025-06-04 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-40464214-semaglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-26
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-40464214-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-40464214-semaglutide-v1
- Content SHA-256: `0432679b8841748df4a09de78cdbff76a2e7d75dea9429553be39544e2f453b6`

### Claims and source pins

#### Headline

Titration and discontinuation of semaglutide for weight management in commercially insured US adults. ([`pubmed-observation-pmid-40464214-2026-07-26-fe094647205b`](#source-pubmed-observation-pmid-40464214-2026-07-26-fe094647205b))

#### Summary

PubMed lists PMID 40464214 in Obesity (Silver Spring, Md.) as Journal Article, with publication-date metadata of 2025-06-04 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-40464214-2026-07-26-fe094647205b`](#source-pubmed-observation-pmid-40464214-2026-07-26-fe094647205b))

#### Paragraph 1

PubMed lists PMID 40464214 in Obesity (Silver Spring, Md.) as Journal Article, with publication-date metadata of 2025-06-04 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-40464214-2026-07-26-fe094647205b`](#source-pubmed-observation-pmid-40464214-2026-07-26-fe094647205b))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-40464214-2026-07-26-fe094647205b`](#source-pubmed-observation-pmid-40464214-2026-07-26-fe094647205b))

### Sources

<a id="source-pubmed-observation-pmid-40464214-2026-07-26-fe094647205b"></a>
- **Titration and discontinuation of semaglutide for weight management in commercially insured US adults. · retained source version 1:2026-07-26:current:fe094647205bf41c28e96b4efc5c33bf0f00151b9d85f0e799aeff274688afd5** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/40464214/) (`pubmed-observation-pmid-40464214-2026-07-26-fe094647205b`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Titration and discontinuation of semaglutide for weight management in commercially insured US adults." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-40464214-semaglutide-v1 SHA-256: 0432679b8841748df4a09de78cdbff76a2e7d75dea9429553be39544e2f453b6.

---

<a id="pubmed-pmid-40536021-semaglutide-v1"></a>

## "I Believe in Santa Claus" and Ozempic: A Foucauldian Discourse Analysis of Holiday Health Advertising.

> PubMed lists PMID 40536021 in Qualitative health research as Journal Article, with publication-date metadata of 2025-06-19 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-40536021-semaglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-09-09
- Source checked: 2026-09-09
- Published by PeptideScanner: 2026-09-09
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-40536021-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-40536021-semaglutide-v1
- Content SHA-256: `d20b8e3355a71aedeafc6cf91f7e6d8f16ca98fc89692446431e123dccf0b818`

### Claims and source pins

#### Headline

"I Believe in Santa Claus" and Ozempic: A Foucauldian Discourse Analysis of Holiday Health Advertising. ([`pubmed-observation-pmid-40536021-2026-09-09-cc6ee533feac`](#source-pubmed-observation-pmid-40536021-2026-09-09-cc6ee533feac))

#### Summary

PubMed lists PMID 40536021 in Qualitative health research as Journal Article, with publication-date metadata of 2025-06-19 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-40536021-2026-09-09-cc6ee533feac`](#source-pubmed-observation-pmid-40536021-2026-09-09-cc6ee533feac))

#### Paragraph 1

PubMed lists PMID 40536021 in Qualitative health research as Journal Article, with publication-date metadata of 2025-06-19 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-40536021-2026-09-09-cc6ee533feac`](#source-pubmed-observation-pmid-40536021-2026-09-09-cc6ee533feac))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-40536021-2026-09-09-cc6ee533feac`](#source-pubmed-observation-pmid-40536021-2026-09-09-cc6ee533feac))

### Sources

<a id="source-pubmed-observation-pmid-40536021-2026-09-09-cc6ee533feac"></a>
- **"I Believe in Santa Claus" and Ozempic: A Foucauldian Discourse Analysis of Holiday Health Advertising. · retained source version 1:2026-09-09:current:cc6ee533feac82aee9e1e6e31730f4730c7345c174dd2d964bc2ec5a69921982** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/40536021/) (`pubmed-observation-pmid-40536021-2026-09-09-cc6ee533feac`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "'I Believe in Santa Claus' and Ozempic: A Foucauldian Discourse Analysis of Holiday Health Advertising." Version 1, published 2026-09-09. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-40536021-semaglutide-v1 SHA-256: d20b8e3355a71aedeafc6cf91f7e6d8f16ca98fc89692446431e123dccf0b818.

---

<a id="pubmed-pmid-40686549-semaglutide-v1"></a>

## Oral absorption of semaglutide: pharmacokinetic modeling and molecular dynamics simulations.

> PubMed lists PMID 40686549 in In silico pharmacology as Journal Article, with publication-date metadata of 2025-07-16 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-40686549-semaglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-26
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-40686549-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-40686549-semaglutide-v1
- Content SHA-256: `c8598029c82b45caf879865a3f42f781f8e68649830a7a95f13fd7953e19f6d0`

### Claims and source pins

#### Headline

Oral absorption of semaglutide: pharmacokinetic modeling and molecular dynamics simulations. ([`pubmed-observation-pmid-40686549-2026-07-26-6a6c1eb0c3b8`](#source-pubmed-observation-pmid-40686549-2026-07-26-6a6c1eb0c3b8))

#### Summary

PubMed lists PMID 40686549 in In silico pharmacology as Journal Article, with publication-date metadata of 2025-07-16 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-40686549-2026-07-26-6a6c1eb0c3b8`](#source-pubmed-observation-pmid-40686549-2026-07-26-6a6c1eb0c3b8))

#### Paragraph 1

PubMed lists PMID 40686549 in In silico pharmacology as Journal Article, with publication-date metadata of 2025-07-16 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-40686549-2026-07-26-6a6c1eb0c3b8`](#source-pubmed-observation-pmid-40686549-2026-07-26-6a6c1eb0c3b8))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-40686549-2026-07-26-6a6c1eb0c3b8`](#source-pubmed-observation-pmid-40686549-2026-07-26-6a6c1eb0c3b8))

### Sources

<a id="source-pubmed-observation-pmid-40686549-2026-07-26-6a6c1eb0c3b8"></a>
- **Oral absorption of semaglutide: pharmacokinetic modeling and molecular dynamics simulations. · retained source version 1:2026-07-26:current:6a6c1eb0c3b8fc830a88387c71bd20250ed4e0fe35a894df6f10a0c44aacd161** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/40686549/) (`pubmed-observation-pmid-40686549-2026-07-26-6a6c1eb0c3b8`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Oral absorption of semaglutide: pharmacokinetic modeling and molecular dynamics simulations." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-40686549-semaglutide-v1 SHA-256: c8598029c82b45caf879865a3f42f781f8e68649830a7a95f13fd7953e19f6d0.

---

<a id="pubmed-pmid-40850442-semaglutide-v1"></a>

## Ileum targeted semaglutide delivery and pharmacokinetic study in an experimental porcine animal model via oesophagogastroduodenoscopic administration.

> PubMed lists PMID 40850442 in Journal of controlled release : official journal of the Controlled Release Society as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2025-08-22 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-40850442-semaglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-06-26
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-40850442-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-40850442-semaglutide-v1
- Content SHA-256: `c715eb1e4e2e9e54cc43a210977d8fd16ae9f36d1773ad3332452ed3e1ca9ad5`

### Claims and source pins

#### Headline

Ileum targeted semaglutide delivery and pharmacokinetic study in an experimental porcine animal model via oesophagogastroduodenoscopic administration. ([`pubmed-observation-pmid-40850442-2026-06-26-dd6596df5f2e`](#source-pubmed-observation-pmid-40850442-2026-06-26-dd6596df5f2e))

#### Summary

PubMed lists PMID 40850442 in Journal of controlled release : official journal of the Controlled Release Society as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2025-08-22 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-40850442-2026-06-26-dd6596df5f2e`](#source-pubmed-observation-pmid-40850442-2026-06-26-dd6596df5f2e))

#### Paragraph 1

PubMed lists PMID 40850442 in Journal of controlled release : official journal of the Controlled Release Society as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2025-08-22 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-40850442-2026-06-26-dd6596df5f2e`](#source-pubmed-observation-pmid-40850442-2026-06-26-dd6596df5f2e))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-40850442-2026-06-26-dd6596df5f2e`](#source-pubmed-observation-pmid-40850442-2026-06-26-dd6596df5f2e))

### Sources

<a id="source-pubmed-observation-pmid-40850442-2026-06-26-dd6596df5f2e"></a>
- **Ileum targeted semaglutide delivery and pharmacokinetic study in an experimental porcine animal model via oesophagogastroduodenoscopic administration. · retained source version 1:2026-06-26:current:dd6596df5f2e809ce6be2e8fc83bc0ab217637780b0ae6c5218a376677e7c356** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/40850442/) (`pubmed-observation-pmid-40850442-2026-06-26-dd6596df5f2e`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Ileum targeted semaglutide delivery and pharmacokinetic study in an experimental porcine animal model via oesophagogastroduodenoscopic administration." Version 1, published 2026-08-16. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-40850442-semaglutide-v1 SHA-256: c715eb1e4e2e9e54cc43a210977d8fd16ae9f36d1773ad3332452ed3e1ca9ad5.

---

<a id="pubmed-pmid-41083011-semaglutide-v1"></a>

## Balancing oral sequential absorption barriers of semaglutide-loaded nanoparticles by optimization of surface glycocholic acid density.

> PubMed lists PMID 41083011 in Journal of controlled release : official journal of the Controlled Release Society as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2025-10-11 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-41083011-semaglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-06-29
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-41083011-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-41083011-semaglutide-v1
- Content SHA-256: `239e488e4312f8469ddb961303b0f9cf4e84e52accfff94056b3a5e5849a02fa`

### Claims and source pins

#### Headline

Balancing oral sequential absorption barriers of semaglutide-loaded nanoparticles by optimization of surface glycocholic acid density. ([`pubmed-observation-pmid-41083011-2026-06-29-34a9ec8bd4a4`](#source-pubmed-observation-pmid-41083011-2026-06-29-34a9ec8bd4a4))

#### Summary

PubMed lists PMID 41083011 in Journal of controlled release : official journal of the Controlled Release Society as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2025-10-11 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41083011-2026-06-29-34a9ec8bd4a4`](#source-pubmed-observation-pmid-41083011-2026-06-29-34a9ec8bd4a4))

#### Paragraph 1

PubMed lists PMID 41083011 in Journal of controlled release : official journal of the Controlled Release Society as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2025-10-11 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41083011-2026-06-29-34a9ec8bd4a4`](#source-pubmed-observation-pmid-41083011-2026-06-29-34a9ec8bd4a4))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-41083011-2026-06-29-34a9ec8bd4a4`](#source-pubmed-observation-pmid-41083011-2026-06-29-34a9ec8bd4a4))

### Sources

<a id="source-pubmed-observation-pmid-41083011-2026-06-29-34a9ec8bd4a4"></a>
- **Balancing oral sequential absorption barriers of semaglutide-loaded nanoparticles by optimization of surface glycocholic acid density. · retained source version 1:2026-06-29:current:34a9ec8bd4a40f52ec7370dba17e894b245c25404247f07518af2adf9ce77b3a** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/41083011/) (`pubmed-observation-pmid-41083011-2026-06-29-34a9ec8bd4a4`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Balancing oral sequential absorption barriers of semaglutide-loaded nanoparticles by optimization of surface glycocholic acid density." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-41083011-semaglutide-v1 SHA-256: 239e488e4312f8469ddb961303b0f9cf4e84e52accfff94056b3a5e5849a02fa.

---

<a id="pubmed-pmid-41419187-semaglutide-v1"></a>

## PubMed record PMID 41419187

> PeptideScanner retained PubMed bibliographic metadata for PMID 41419187 at 2026-08-10T10:49:08.723Z. PubMed recorded a metadata revision date of 2026-07-30 and an Entrez history date of 2025-12-19. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-41419187-semaglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-30
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-41419187-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-41419187-semaglutide-v1
- Content SHA-256: `c052f451ae3402f31c0e860cb2c43b234453b9eb66f96aa7c8295966bc54b64c`

### Claims and source pins

#### Headline

PubMed record PMID 41419187 ([`pubmed-observation-pmid-41419187-2026-07-30-868c548b7802`](#source-pubmed-observation-pmid-41419187-2026-07-30-868c548b7802))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 41419187 at 2026-08-10T10:49:08.723Z. PubMed recorded a metadata revision date of 2026-07-30 and an Entrez history date of 2025-12-19. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-41419187-2026-07-30-868c548b7802`](#source-pubmed-observation-pmid-41419187-2026-07-30-868c548b7802))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 41419187 at 2026-08-10T10:49:08.723Z. PubMed recorded a metadata revision date of 2026-07-30 and an Entrez history date of 2025-12-19. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-41419187-2026-07-30-868c548b7802`](#source-pubmed-observation-pmid-41419187-2026-07-30-868c548b7802))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-41419187-2026-07-30-868c548b7802`](#source-pubmed-observation-pmid-41419187-2026-07-30-868c548b7802))

### Sources

<a id="source-pubmed-observation-pmid-41419187-2026-07-30-868c548b7802"></a>
- **PubMed record PMID 41419187 · retained source version 1:2026-07-30:current:868c548b7802cfc0fc45ef72d608724bf8c3c09230efa0e9ea087d3121da4dc8** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/41419187/) (`pubmed-observation-pmid-41419187-2026-07-30-868c548b7802`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 41419187." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-41419187-semaglutide-v1 SHA-256: c052f451ae3402f31c0e860cb2c43b234453b9eb66f96aa7c8295966bc54b64c.

---

<a id="pubmed-pmid-41475544-semaglutide-v1"></a>

## PubMed record PMID 41475544

> PeptideScanner retained PubMed bibliographic metadata for PMID 41475544 at 2026-08-10T10:49:08.728Z. PubMed recorded a metadata revision date of 2026-07-30 and an Entrez history date of 2025-12-31. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-41475544-semaglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-30
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-41475544-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-41475544-semaglutide-v1
- Content SHA-256: `2c13814d8976313980372dde31353fe672945d97705ca8ca2645403a0da76ba3`

### Claims and source pins

#### Headline

PubMed record PMID 41475544 ([`pubmed-observation-pmid-41475544-2026-07-30-c31bb1d7ba31`](#source-pubmed-observation-pmid-41475544-2026-07-30-c31bb1d7ba31))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 41475544 at 2026-08-10T10:49:08.728Z. PubMed recorded a metadata revision date of 2026-07-30 and an Entrez history date of 2025-12-31. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-41475544-2026-07-30-c31bb1d7ba31`](#source-pubmed-observation-pmid-41475544-2026-07-30-c31bb1d7ba31))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 41475544 at 2026-08-10T10:49:08.728Z. PubMed recorded a metadata revision date of 2026-07-30 and an Entrez history date of 2025-12-31. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-41475544-2026-07-30-c31bb1d7ba31`](#source-pubmed-observation-pmid-41475544-2026-07-30-c31bb1d7ba31))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-41475544-2026-07-30-c31bb1d7ba31`](#source-pubmed-observation-pmid-41475544-2026-07-30-c31bb1d7ba31))

### Sources

<a id="source-pubmed-observation-pmid-41475544-2026-07-30-c31bb1d7ba31"></a>
- **PubMed record PMID 41475544 · retained source version 1:2026-07-30:current:c31bb1d7ba31b323bac98aa1d6328e224bde8d94ed8038f6794c62b6a2774ce6** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/41475544/) (`pubmed-observation-pmid-41475544-2026-07-30-c31bb1d7ba31`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 41475544." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-41475544-semaglutide-v1 SHA-256: 2c13814d8976313980372dde31353fe672945d97705ca8ca2645403a0da76ba3.

---

<a id="pubmed-pmid-41483046-semaglutide-v1"></a>

## PubMed record PMID 41483046

> PeptideScanner retained PubMed bibliographic metadata for PMID 41483046 at 2026-08-10T10:49:08.730Z. PubMed recorded a metadata revision date of 2026-07-30 and an Entrez history date of 2026-01-03. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-41483046-semaglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-30
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-41483046-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-41483046-semaglutide-v1
- Content SHA-256: `389543698e4953856bc6b7d6a40850391e28b1b7a4592170cc9a16182d37e1ce`

### Claims and source pins

#### Headline

PubMed record PMID 41483046 ([`pubmed-observation-pmid-41483046-2026-07-30-e842edfc34c1`](#source-pubmed-observation-pmid-41483046-2026-07-30-e842edfc34c1))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 41483046 at 2026-08-10T10:49:08.730Z. PubMed recorded a metadata revision date of 2026-07-30 and an Entrez history date of 2026-01-03. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-41483046-2026-07-30-e842edfc34c1`](#source-pubmed-observation-pmid-41483046-2026-07-30-e842edfc34c1))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 41483046 at 2026-08-10T10:49:08.730Z. PubMed recorded a metadata revision date of 2026-07-30 and an Entrez history date of 2026-01-03. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-41483046-2026-07-30-e842edfc34c1`](#source-pubmed-observation-pmid-41483046-2026-07-30-e842edfc34c1))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-41483046-2026-07-30-e842edfc34c1`](#source-pubmed-observation-pmid-41483046-2026-07-30-e842edfc34c1))

### Sources

<a id="source-pubmed-observation-pmid-41483046-2026-07-30-e842edfc34c1"></a>
- **PubMed record PMID 41483046 · retained source version 1:2026-07-30:current:e842edfc34c1e427da2f46cb92f0e7105b8b5c75e5fa0fbf1f157825dede8228** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/41483046/) (`pubmed-observation-pmid-41483046-2026-07-30-e842edfc34c1`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 41483046." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-41483046-semaglutide-v1 SHA-256: 389543698e4953856bc6b7d6a40850391e28b1b7a4592170cc9a16182d37e1ce.

---

<a id="pubmed-pmid-41524543-semaglutide-v1"></a>

## Real-world healthcare resource utilization and medical costs in patients with overweight or obesity and multimorbidity treated with semaglutide in the United States.

> PubMed lists PMID 41524543 in Expert review of pharmacoeconomics & outcomes research as Journal Article, Observational Study, with publication-date metadata of 2026-01-12 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-41524543-semaglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-06-26
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-41524543-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-41524543-semaglutide-v1
- Content SHA-256: `474d933206f511123dedbc87d2be677af8185324ff4fc12dfc95895862bfe52d`

### Claims and source pins

#### Headline

Real-world healthcare resource utilization and medical costs in patients with overweight or obesity and multimorbidity treated with semaglutide in the United States. ([`pubmed-observation-pmid-41524543-2026-06-26-bbb71d7f68d0`](#source-pubmed-observation-pmid-41524543-2026-06-26-bbb71d7f68d0))

#### Summary

PubMed lists PMID 41524543 in Expert review of pharmacoeconomics & outcomes research as Journal Article, Observational Study, with publication-date metadata of 2026-01-12 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41524543-2026-06-26-bbb71d7f68d0`](#source-pubmed-observation-pmid-41524543-2026-06-26-bbb71d7f68d0))

#### Paragraph 1

PubMed lists PMID 41524543 in Expert review of pharmacoeconomics & outcomes research as Journal Article, Observational Study, with publication-date metadata of 2026-01-12 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41524543-2026-06-26-bbb71d7f68d0`](#source-pubmed-observation-pmid-41524543-2026-06-26-bbb71d7f68d0))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-41524543-2026-06-26-bbb71d7f68d0`](#source-pubmed-observation-pmid-41524543-2026-06-26-bbb71d7f68d0))

### Sources

<a id="source-pubmed-observation-pmid-41524543-2026-06-26-bbb71d7f68d0"></a>
- **Real-world healthcare resource utilization and medical costs in patients with overweight or obesity and multimorbidity treated with semaglutide in the United States. · retained source version 1:2026-06-26:current:bbb71d7f68d0069e0fc86a1ce914b34739ea949e7302b1548d9f6b19bfc5987e** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/41524543/) (`pubmed-observation-pmid-41524543-2026-06-26-bbb71d7f68d0`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Real-world healthcare resource utilization and medical costs in patients with overweight or obesity and multimorbidity treated with semaglutide in the United States." Version 1, published 2026-08-16. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-41524543-semaglutide-v1 SHA-256: 474d933206f511123dedbc87d2be677af8185324ff4fc12dfc95895862bfe52d.

---

<a id="pubmed-pmid-41532935-semaglutide-v1"></a>

## PubMed record PMID 41532935

> PeptideScanner retained PubMed bibliographic metadata for PMID 41532935 at 2026-08-10T10:49:08.747Z. PubMed recorded a metadata revision date of 2026-08-05 and an Entrez history date of 2026-01-14. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-41532935-semaglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-05
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-11
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-41532935-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-41532935-semaglutide-v1
- Content SHA-256: `bace2d1d54be88ce2ba8ef8c15d823202e3c8c32b1395aa39365b3fa3b53b47f`

### Claims and source pins

#### Headline

PubMed record PMID 41532935 ([`pubmed-observation-pmid-41532935-2026-08-05-227f1b7b473b`](#source-pubmed-observation-pmid-41532935-2026-08-05-227f1b7b473b))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 41532935 at 2026-08-10T10:49:08.747Z. PubMed recorded a metadata revision date of 2026-08-05 and an Entrez history date of 2026-01-14. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-41532935-2026-08-05-227f1b7b473b`](#source-pubmed-observation-pmid-41532935-2026-08-05-227f1b7b473b))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 41532935 at 2026-08-10T10:49:08.747Z. PubMed recorded a metadata revision date of 2026-08-05 and an Entrez history date of 2026-01-14. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-41532935-2026-08-05-227f1b7b473b`](#source-pubmed-observation-pmid-41532935-2026-08-05-227f1b7b473b))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-41532935-2026-08-05-227f1b7b473b`](#source-pubmed-observation-pmid-41532935-2026-08-05-227f1b7b473b))

### Sources

<a id="source-pubmed-observation-pmid-41532935-2026-08-05-227f1b7b473b"></a>
- **PubMed record PMID 41532935 · retained source version 1:2026-08-05:current:227f1b7b473ba47cfc6b66d5668ee3058e20b7033546acfec8ced285d9433c66** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/41532935/) (`pubmed-observation-pmid-41532935-2026-08-05-227f1b7b473b`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 41532935." Version 1, published 2026-08-11. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-41532935-semaglutide-v1 SHA-256: bace2d1d54be88ce2ba8ef8c15d823202e3c8c32b1395aa39365b3fa3b53b47f.

---

<a id="pubmed-pmid-41627802-semaglutide-v1"></a>

## PubMed record PMID 41627802

> PeptideScanner retained PubMed bibliographic metadata for PMID 41627802 at 2026-08-10T18:13:40.591Z. PubMed recorded a metadata revision date of 2026-07-29 and an Entrez history date of 2026-02-02. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-41627802-semaglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-29
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-41627802-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-41627802-semaglutide-v1
- Content SHA-256: `b5822b1cc7a8c2fa1f6d397b212f64dd340d7c3b4fb1d3f5067f736bb7873b71`

### Claims and source pins

#### Headline

PubMed record PMID 41627802 ([`pubmed-observation-pmid-41627802-2026-07-29-4607f30ed8a7`](#source-pubmed-observation-pmid-41627802-2026-07-29-4607f30ed8a7))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 41627802 at 2026-08-10T18:13:40.591Z. PubMed recorded a metadata revision date of 2026-07-29 and an Entrez history date of 2026-02-02. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-41627802-2026-07-29-4607f30ed8a7`](#source-pubmed-observation-pmid-41627802-2026-07-29-4607f30ed8a7))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 41627802 at 2026-08-10T18:13:40.591Z. PubMed recorded a metadata revision date of 2026-07-29 and an Entrez history date of 2026-02-02. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-41627802-2026-07-29-4607f30ed8a7`](#source-pubmed-observation-pmid-41627802-2026-07-29-4607f30ed8a7))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-41627802-2026-07-29-4607f30ed8a7`](#source-pubmed-observation-pmid-41627802-2026-07-29-4607f30ed8a7))

### Sources

<a id="source-pubmed-observation-pmid-41627802-2026-07-29-4607f30ed8a7"></a>
- **PubMed record PMID 41627802 · retained source version 1:2026-07-29:current:4607f30ed8a715f1df541f51ea884bbc4461172b7affa080feddffd1fe0b1794** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/41627802/) (`pubmed-observation-pmid-41627802-2026-07-29-4607f30ed8a7`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 41627802." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-41627802-semaglutide-v1 SHA-256: b5822b1cc7a8c2fa1f6d397b212f64dd340d7c3b4fb1d3f5067f736bb7873b71.

---

<a id="pubmed-pmid-41729594-semaglutide-v1"></a>

## The use of semaglutide as an add-on therapy in patients with latent autoimmune diabetes in adults.

> PubMed lists PMID 41729594 in The Journal of clinical endocrinology and metabolism as Journal Article, with publication-date metadata of 2026-06-17 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-41729594-semaglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-26
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-41729594-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-41729594-semaglutide-v1
- Content SHA-256: `8878adfb2c87601b24f7577c764b9382e29b1f3bc52eefe4a75dfb26833bd249`

### Claims and source pins

#### Headline

The use of semaglutide as an add-on therapy in patients with latent autoimmune diabetes in adults. ([`pubmed-observation-pmid-41729594-2026-07-26-901b44be3e25`](#source-pubmed-observation-pmid-41729594-2026-07-26-901b44be3e25))

#### Summary

PubMed lists PMID 41729594 in The Journal of clinical endocrinology and metabolism as Journal Article, with publication-date metadata of 2026-06-17 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41729594-2026-07-26-901b44be3e25`](#source-pubmed-observation-pmid-41729594-2026-07-26-901b44be3e25))

#### Paragraph 1

PubMed lists PMID 41729594 in The Journal of clinical endocrinology and metabolism as Journal Article, with publication-date metadata of 2026-06-17 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41729594-2026-07-26-901b44be3e25`](#source-pubmed-observation-pmid-41729594-2026-07-26-901b44be3e25))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-41729594-2026-07-26-901b44be3e25`](#source-pubmed-observation-pmid-41729594-2026-07-26-901b44be3e25))

### Sources

<a id="source-pubmed-observation-pmid-41729594-2026-07-26-901b44be3e25"></a>
- **The use of semaglutide as an add-on therapy in patients with latent autoimmune diabetes in adults. · retained source version 1:2026-07-26:current:901b44be3e2553d33938699b02bb6c52359918d847ca9fad5a4d18b6422d532e** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/41729594/) (`pubmed-observation-pmid-41729594-2026-07-26-901b44be3e25`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "The use of semaglutide as an add-on therapy in patients with latent autoimmune diabetes in adults." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-41729594-semaglutide-v1 SHA-256: 8878adfb2c87601b24f7577c764b9382e29b1f3bc52eefe4a75dfb26833bd249.

---

<a id="pubmed-pmid-41734897-semaglutide-v1"></a>

## Topic and Sentiment Trends in Semaglutide Discussions on X: Subpopulation-Based Longitudinal Analysis.

> PubMed lists PMID 41734897 in Online journal of public health informatics as Journal Article, with publication-date metadata of 2026-02-24 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-41734897-semaglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-13
- Source checked: 2026-08-13
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-41734897-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-41734897-semaglutide-v1
- Content SHA-256: `8269d7aa26a0a52920ef412de3a4fab466485ee00a308e1a4958ce33627cbb68`

### Claims and source pins

#### Headline

Topic and Sentiment Trends in Semaglutide Discussions on X: Subpopulation-Based Longitudinal Analysis. ([`pubmed-observation-pmid-41734897-2026-08-13-9b700312a14f`](#source-pubmed-observation-pmid-41734897-2026-08-13-9b700312a14f))

#### Summary

PubMed lists PMID 41734897 in Online journal of public health informatics as Journal Article, with publication-date metadata of 2026-02-24 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41734897-2026-08-13-9b700312a14f`](#source-pubmed-observation-pmid-41734897-2026-08-13-9b700312a14f))

#### Paragraph 1

PubMed lists PMID 41734897 in Online journal of public health informatics as Journal Article, with publication-date metadata of 2026-02-24 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41734897-2026-08-13-9b700312a14f`](#source-pubmed-observation-pmid-41734897-2026-08-13-9b700312a14f))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-41734897-2026-08-13-9b700312a14f`](#source-pubmed-observation-pmid-41734897-2026-08-13-9b700312a14f))

### Sources

<a id="source-pubmed-observation-pmid-41734897-2026-08-13-9b700312a14f"></a>
- **Topic and Sentiment Trends in Semaglutide Discussions on X: Subpopulation-Based Longitudinal Analysis. · retained source version 1:2026-08-13:current:9b700312a14f671a8c03ede42aabc4766ec4c0dbf1b1d65e07dc16ecbc35f50a** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/41734897/) (`pubmed-observation-pmid-41734897-2026-08-13-9b700312a14f`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Topic and Sentiment Trends in Semaglutide Discussions on X: Subpopulation-Based Longitudinal Analysis." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-41734897-semaglutide-v1 SHA-256: 8269d7aa26a0a52920ef412de3a4fab466485ee00a308e1a4958ce33627cbb68.

---

<a id="pubmed-pmid-41744415-semaglutide-v1"></a>

## Ozempic and Wegovy Meet Congress: Political Economy Without Critique and Sociology Without Society.

> PubMed lists PMID 41744415 in International journal of social determinants of health and health services as Journal Article, with publication-date metadata of 2026-02-26 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-41744415-semaglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-26
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-41744415-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-41744415-semaglutide-v1
- Content SHA-256: `3582b02399ce0433d255e8edc6bcead8583ff75c423176e3ab2f74152b97211b`

### Claims and source pins

#### Headline

Ozempic and Wegovy Meet Congress: Political Economy Without Critique and Sociology Without Society. ([`pubmed-observation-pmid-41744415-2026-07-26-2f7c53d73dc7`](#source-pubmed-observation-pmid-41744415-2026-07-26-2f7c53d73dc7))

#### Summary

PubMed lists PMID 41744415 in International journal of social determinants of health and health services as Journal Article, with publication-date metadata of 2026-02-26 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41744415-2026-07-26-2f7c53d73dc7`](#source-pubmed-observation-pmid-41744415-2026-07-26-2f7c53d73dc7))

#### Paragraph 1

PubMed lists PMID 41744415 in International journal of social determinants of health and health services as Journal Article, with publication-date metadata of 2026-02-26 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41744415-2026-07-26-2f7c53d73dc7`](#source-pubmed-observation-pmid-41744415-2026-07-26-2f7c53d73dc7))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-41744415-2026-07-26-2f7c53d73dc7`](#source-pubmed-observation-pmid-41744415-2026-07-26-2f7c53d73dc7))

### Sources

<a id="source-pubmed-observation-pmid-41744415-2026-07-26-2f7c53d73dc7"></a>
- **Ozempic and Wegovy Meet Congress: Political Economy Without Critique and Sociology Without Society. · retained source version 1:2026-07-26:current:2f7c53d73dc7a537fe865714b1de770ae3e3325d97fc0fcf93f9776ac9b49d23** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/41744415/) (`pubmed-observation-pmid-41744415-2026-07-26-2f7c53d73dc7`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Ozempic and Wegovy Meet Congress: Political Economy Without Critique and Sociology Without Society." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-41744415-semaglutide-v1 SHA-256: 3582b02399ce0433d255e8edc6bcead8583ff75c423176e3ab2f74152b97211b.

---

<a id="pubmed-pmid-41766347-semaglutide-v1"></a>

## PubMed record PMID 41766347

> PeptideScanner retained PubMed bibliographic metadata for PMID 41766347 at 2026-08-10T10:49:08.779Z. PubMed recorded a metadata revision date of 2026-08-06 and an Entrez history date of 2026-03-02. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-41766347-semaglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-06
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-11
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-41766347-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-41766347-semaglutide-v1
- Content SHA-256: `7fd5c04d325ecd4de91bf04f7e9f85dc8c0760d62184456284b62b366c0e2844`

### Claims and source pins

#### Headline

PubMed record PMID 41766347 ([`pubmed-observation-pmid-41766347-2026-08-06-5db797b8a829`](#source-pubmed-observation-pmid-41766347-2026-08-06-5db797b8a829))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 41766347 at 2026-08-10T10:49:08.779Z. PubMed recorded a metadata revision date of 2026-08-06 and an Entrez history date of 2026-03-02. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-41766347-2026-08-06-5db797b8a829`](#source-pubmed-observation-pmid-41766347-2026-08-06-5db797b8a829))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 41766347 at 2026-08-10T10:49:08.779Z. PubMed recorded a metadata revision date of 2026-08-06 and an Entrez history date of 2026-03-02. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-41766347-2026-08-06-5db797b8a829`](#source-pubmed-observation-pmid-41766347-2026-08-06-5db797b8a829))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-41766347-2026-08-06-5db797b8a829`](#source-pubmed-observation-pmid-41766347-2026-08-06-5db797b8a829))

### Sources

<a id="source-pubmed-observation-pmid-41766347-2026-08-06-5db797b8a829"></a>
- **PubMed record PMID 41766347 · retained source version 1:2026-08-06:current:5db797b8a82970bfa96cb392a4cc922afd0f1049e5887b30b741167fb351e881** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/41766347/) (`pubmed-observation-pmid-41766347-2026-08-06-5db797b8a829`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 41766347." Version 1, published 2026-08-11. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-41766347-semaglutide-v1 SHA-256: 7fd5c04d325ecd4de91bf04f7e9f85dc8c0760d62184456284b62b366c0e2844.

---

<a id="pubmed-pmid-41771053-semaglutide-v1"></a>

## Comment on Rossing et al. Nuances in Interpretation: Assessing the Interaction Between Semaglutide and MRAs in the FLOW Trial.

> PubMed lists PMID 41771053 in Diabetes care as Letter, with publication-date metadata of 2026-06-01 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-41771053-semaglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-13
- Source checked: 2026-08-13
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-41771053-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-41771053-semaglutide-v1
- Content SHA-256: `c05b17a32b87a2093840938535324e17a86c5366abb417b5d6fb0a16fa299fbf`

### Claims and source pins

#### Headline

Comment on Rossing et al. Nuances in Interpretation: Assessing the Interaction Between Semaglutide and MRAs in the FLOW Trial. ([`pubmed-observation-pmid-41771053-2026-08-13-0e06086c0a13`](#source-pubmed-observation-pmid-41771053-2026-08-13-0e06086c0a13))

#### Summary

PubMed lists PMID 41771053 in Diabetes care as Letter, with publication-date metadata of 2026-06-01 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41771053-2026-08-13-0e06086c0a13`](#source-pubmed-observation-pmid-41771053-2026-08-13-0e06086c0a13))

#### Paragraph 1

PubMed lists PMID 41771053 in Diabetes care as Letter, with publication-date metadata of 2026-06-01 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41771053-2026-08-13-0e06086c0a13`](#source-pubmed-observation-pmid-41771053-2026-08-13-0e06086c0a13))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-41771053-2026-08-13-0e06086c0a13`](#source-pubmed-observation-pmid-41771053-2026-08-13-0e06086c0a13))

### Sources

<a id="source-pubmed-observation-pmid-41771053-2026-08-13-0e06086c0a13"></a>
- **Comment on Rossing et al. Nuances in Interpretation: Assessing the Interaction Between Semaglutide and MRAs in the FLOW Trial. · retained source version 1:2026-08-13:current:0e06086c0a136f12f9bda58fdf47cf9c839c1a040d1922d2f4520623be36dcbf** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/41771053/) (`pubmed-observation-pmid-41771053-2026-08-13-0e06086c0a13`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Comment on Rossing et al. Nuances in Interpretation: Assessing the Interaction Between Semaglutide and MRAs in the FLOW Trial." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-41771053-semaglutide-v1 SHA-256: c05b17a32b87a2093840938535324e17a86c5366abb417b5d6fb0a16fa299fbf.

---

<a id="pubmed-pmid-41772149-semaglutide-v1"></a>

## Bimagrumab plus semaglutide alone or in combination for the treatment of obesity: a randomized phase 2 trial.

> PubMed lists PMID 41772149 in Nature medicine as Journal Article, Randomized Controlled Trial, Clinical Trial, Phase II, with publication-date metadata of 2026-03-02 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-41772149-semaglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-10
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-41772149-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-41772149-semaglutide-v1
- Content SHA-256: `ab021fe3044e0d4105ee6e035f93e3b6bf91730f49eacfaefbf462b54a4b6477`

### Claims and source pins

#### Headline

Bimagrumab plus semaglutide alone or in combination for the treatment of obesity: a randomized phase 2 trial. ([`pubmed-observation-pmid-41772149-2026-07-10-fa03fbbeb8bd`](#source-pubmed-observation-pmid-41772149-2026-07-10-fa03fbbeb8bd))

#### Summary

PubMed lists PMID 41772149 in Nature medicine as Journal Article, Randomized Controlled Trial, Clinical Trial, Phase II, with publication-date metadata of 2026-03-02 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41772149-2026-07-10-fa03fbbeb8bd`](#source-pubmed-observation-pmid-41772149-2026-07-10-fa03fbbeb8bd))

#### Paragraph 1

PubMed lists PMID 41772149 in Nature medicine as Journal Article, Randomized Controlled Trial, Clinical Trial, Phase II, with publication-date metadata of 2026-03-02 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41772149-2026-07-10-fa03fbbeb8bd`](#source-pubmed-observation-pmid-41772149-2026-07-10-fa03fbbeb8bd))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-41772149-2026-07-10-fa03fbbeb8bd`](#source-pubmed-observation-pmid-41772149-2026-07-10-fa03fbbeb8bd))

### Sources

<a id="source-pubmed-observation-pmid-41772149-2026-07-10-fa03fbbeb8bd"></a>
- **Bimagrumab plus semaglutide alone or in combination for the treatment of obesity: a randomized phase 2 trial. · retained source version 1:2026-07-10:current:fa03fbbeb8bd051c19fee899331a07ff6c40320343154ba67107bf893a9edb4a** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/41772149/) (`pubmed-observation-pmid-41772149-2026-07-10-fa03fbbeb8bd`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Bimagrumab plus semaglutide alone or in combination for the treatment of obesity: a randomized phase 2 trial." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-41772149-semaglutide-v1 SHA-256: ab021fe3044e0d4105ee6e035f93e3b6bf91730f49eacfaefbf462b54a4b6477.

---

<a id="pubmed-pmid-41778920-semaglutide-v1"></a>

## PubMed record PMID 41778920

> PeptideScanner retained PubMed bibliographic metadata for PMID 41778920 at 2026-08-10T18:13:42.771Z. PubMed recorded a metadata revision date of 2026-07-28 and an Entrez history date of 2026-03-04. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-41778920-semaglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-28
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-41778920-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-41778920-semaglutide-v1
- Content SHA-256: `3ce31f739acae716bdd82eef8e7aec59614da515c2404e3c77bea0aa94b46d7a`

### Claims and source pins

#### Headline

PubMed record PMID 41778920 ([`pubmed-observation-pmid-41778920-2026-07-28-14edc65c8e88`](#source-pubmed-observation-pmid-41778920-2026-07-28-14edc65c8e88))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 41778920 at 2026-08-10T18:13:42.771Z. PubMed recorded a metadata revision date of 2026-07-28 and an Entrez history date of 2026-03-04. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-41778920-2026-07-28-14edc65c8e88`](#source-pubmed-observation-pmid-41778920-2026-07-28-14edc65c8e88))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 41778920 at 2026-08-10T18:13:42.771Z. PubMed recorded a metadata revision date of 2026-07-28 and an Entrez history date of 2026-03-04. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-41778920-2026-07-28-14edc65c8e88`](#source-pubmed-observation-pmid-41778920-2026-07-28-14edc65c8e88))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-41778920-2026-07-28-14edc65c8e88`](#source-pubmed-observation-pmid-41778920-2026-07-28-14edc65c8e88))

### Sources

<a id="source-pubmed-observation-pmid-41778920-2026-07-28-14edc65c8e88"></a>
- **PubMed record PMID 41778920 · retained source version 1:2026-07-28:current:14edc65c8e88db42603798783eb9b6854afb5657c9a676672899d73e89f915df** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/41778920/) (`pubmed-observation-pmid-41778920-2026-07-28-14edc65c8e88`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 41778920." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-41778920-semaglutide-v1 SHA-256: 3ce31f739acae716bdd82eef8e7aec59614da515c2404e3c77bea0aa94b46d7a.

---

<a id="pubmed-pmid-41780559-semaglutide-v1"></a>

## Semaglutide in peripheral artery disease and diabetes by baseline disease severity and age: the STRIDE trial.

> PubMed lists PMID 41780559 in European heart journal as Journal Article, with publication-date metadata of 2026-07-01 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-41780559-semaglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-26
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-41780559-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-41780559-semaglutide-v1
- Content SHA-256: `32f46ddca9c8f6462a1bb11e580431b87f5acb3317c7aaef5d84dff53c242ffd`

### Claims and source pins

#### Headline

Semaglutide in peripheral artery disease and diabetes by baseline disease severity and age: the STRIDE trial. ([`pubmed-observation-pmid-41780559-2026-07-26-3133e70acd79`](#source-pubmed-observation-pmid-41780559-2026-07-26-3133e70acd79))

#### Summary

PubMed lists PMID 41780559 in European heart journal as Journal Article, with publication-date metadata of 2026-07-01 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41780559-2026-07-26-3133e70acd79`](#source-pubmed-observation-pmid-41780559-2026-07-26-3133e70acd79))

#### Paragraph 1

PubMed lists PMID 41780559 in European heart journal as Journal Article, with publication-date metadata of 2026-07-01 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41780559-2026-07-26-3133e70acd79`](#source-pubmed-observation-pmid-41780559-2026-07-26-3133e70acd79))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-41780559-2026-07-26-3133e70acd79`](#source-pubmed-observation-pmid-41780559-2026-07-26-3133e70acd79))

### Sources

<a id="source-pubmed-observation-pmid-41780559-2026-07-26-3133e70acd79"></a>
- **Semaglutide in peripheral artery disease and diabetes by baseline disease severity and age: the STRIDE trial. · retained source version 1:2026-07-26:current:3133e70acd79edb4b7f07f32ba5182143ff7ffe3cf69f13ad7a4ad7ff788b5a9** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/41780559/) (`pubmed-observation-pmid-41780559-2026-07-26-3133e70acd79`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Semaglutide in peripheral artery disease and diabetes by baseline disease severity and age: the STRIDE trial." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-41780559-semaglutide-v1 SHA-256: 32f46ddca9c8f6462a1bb11e580431b87f5acb3317c7aaef5d84dff53c242ffd.

---

<a id="pubmed-pmid-41832804-semaglutide-v1"></a>

## Semaglutide in patients with hidradenitis suppurativa and obesity.

> PubMed lists PMID 41832804 in Medicina clinica as Journal Article, with publication-date metadata of 2026-03-12 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-41832804-semaglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-11
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-41832804-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-41832804-semaglutide-v1
- Content SHA-256: `7d0781e1b4b01c5c12f3d6e12e61dfd9b06ff5f8846f1a9dee4a42eb7445cf3b`

### Claims and source pins

#### Headline

Semaglutide in patients with hidradenitis suppurativa and obesity. ([`pubmed-observation-pmid-41832804-2026-07-11-9d1a9810bc26`](#source-pubmed-observation-pmid-41832804-2026-07-11-9d1a9810bc26))

#### Summary

PubMed lists PMID 41832804 in Medicina clinica as Journal Article, with publication-date metadata of 2026-03-12 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41832804-2026-07-11-9d1a9810bc26`](#source-pubmed-observation-pmid-41832804-2026-07-11-9d1a9810bc26))

#### Paragraph 1

PubMed lists PMID 41832804 in Medicina clinica as Journal Article, with publication-date metadata of 2026-03-12 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41832804-2026-07-11-9d1a9810bc26`](#source-pubmed-observation-pmid-41832804-2026-07-11-9d1a9810bc26))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-41832804-2026-07-11-9d1a9810bc26`](#source-pubmed-observation-pmid-41832804-2026-07-11-9d1a9810bc26))

### Sources

<a id="source-pubmed-observation-pmid-41832804-2026-07-11-9d1a9810bc26"></a>
- **Semaglutide in patients with hidradenitis suppurativa and obesity. · retained source version 1:2026-07-11:current:9d1a9810bc26f3fdbf706a17c999acd212b6ee3e63cbbaec0c9230c1a208c9fb** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/41832804/) (`pubmed-observation-pmid-41832804-2026-07-11-9d1a9810bc26`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Semaglutide in patients with hidradenitis suppurativa and obesity." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-41832804-semaglutide-v1 SHA-256: 7d0781e1b4b01c5c12f3d6e12e61dfd9b06ff5f8846f1a9dee4a42eb7445cf3b.

---

<a id="pubmed-pmid-41848818-semaglutide-v1"></a>

## Real-World Cohort Study of Semaglutide in Adults with Type 2 Diabetes Using an Electronic Health Records Database in Tianjin, China.

> PubMed lists PMID 41848818 in Diabetes therapy : research, treatment and education of diabetes and related disorders as Journal Article, with publication-date metadata of 2026-03-18 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-41848818-semaglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-13
- Source checked: 2026-08-13
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-41848818-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-41848818-semaglutide-v1
- Content SHA-256: `ca663f60c1a405bac0660725f9dfd308f8a2513e3ddb499a20b68b4deef735d3`

### Claims and source pins

#### Headline

Real-World Cohort Study of Semaglutide in Adults with Type 2 Diabetes Using an Electronic Health Records Database in Tianjin, China. ([`pubmed-observation-pmid-41848818-2026-08-13-7e136182a1c9`](#source-pubmed-observation-pmid-41848818-2026-08-13-7e136182a1c9))

#### Summary

PubMed lists PMID 41848818 in Diabetes therapy : research, treatment and education of diabetes and related disorders as Journal Article, with publication-date metadata of 2026-03-18 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41848818-2026-08-13-7e136182a1c9`](#source-pubmed-observation-pmid-41848818-2026-08-13-7e136182a1c9))

#### Paragraph 1

PubMed lists PMID 41848818 in Diabetes therapy : research, treatment and education of diabetes and related disorders as Journal Article, with publication-date metadata of 2026-03-18 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41848818-2026-08-13-7e136182a1c9`](#source-pubmed-observation-pmid-41848818-2026-08-13-7e136182a1c9))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-41848818-2026-08-13-7e136182a1c9`](#source-pubmed-observation-pmid-41848818-2026-08-13-7e136182a1c9))

### Sources

<a id="source-pubmed-observation-pmid-41848818-2026-08-13-7e136182a1c9"></a>
- **Real-World Cohort Study of Semaglutide in Adults with Type 2 Diabetes Using an Electronic Health Records Database in Tianjin, China. · retained source version 1:2026-08-13:current:7e136182a1c9156a58d76ce0729d7a8c8312299eb1b72582609eea98f9738b39** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/41848818/) (`pubmed-observation-pmid-41848818-2026-08-13-7e136182a1c9`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Real-World Cohort Study of Semaglutide in Adults with Type 2 Diabetes Using an Electronic Health Records Database in Tianjin, China." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-41848818-semaglutide-v1 SHA-256: ca663f60c1a405bac0660725f9dfd308f8a2513e3ddb499a20b68b4deef735d3.

---

<a id="pubmed-pmid-41877445-semaglutide-v1"></a>

## Readability and understandability of online patient education on semaglutide.

> PubMed lists PMID 41877445 in Health informatics journal as Journal Article, with publication-date metadata of 2026-03-24 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-41877445-semaglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-19
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-41877445-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-41877445-semaglutide-v1
- Content SHA-256: `f43254a492840d983e39e9298cd1f272de4cbdb3b13a38ebb9cf47d728c72206`

### Claims and source pins

#### Headline

Readability and understandability of online patient education on semaglutide. ([`pubmed-observation-pmid-41877445-2026-07-19-c63be2173d87`](#source-pubmed-observation-pmid-41877445-2026-07-19-c63be2173d87))

#### Summary

PubMed lists PMID 41877445 in Health informatics journal as Journal Article, with publication-date metadata of 2026-03-24 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41877445-2026-07-19-c63be2173d87`](#source-pubmed-observation-pmid-41877445-2026-07-19-c63be2173d87))

#### Paragraph 1

PubMed lists PMID 41877445 in Health informatics journal as Journal Article, with publication-date metadata of 2026-03-24 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41877445-2026-07-19-c63be2173d87`](#source-pubmed-observation-pmid-41877445-2026-07-19-c63be2173d87))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-41877445-2026-07-19-c63be2173d87`](#source-pubmed-observation-pmid-41877445-2026-07-19-c63be2173d87))

### Sources

<a id="source-pubmed-observation-pmid-41877445-2026-07-19-c63be2173d87"></a>
- **Readability and understandability of online patient education on semaglutide. · retained source version 1:2026-07-19:current:c63be2173d8713ff62ecb89ebb7d6e86270dd3767ef933715035ad6dfc1f6a35** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/41877445/) (`pubmed-observation-pmid-41877445-2026-07-19-c63be2173d87`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Readability and understandability of online patient education on semaglutide." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-41877445-semaglutide-v1 SHA-256: f43254a492840d983e39e9298cd1f272de4cbdb3b13a38ebb9cf47d728c72206.

---

<a id="pubmed-pmid-41938304-semaglutide-v1"></a>

## Semaglutide and Non-arteritic Anterior Ischemic Optic Neuropathy: A Systematic Review and Narrative Synthesis.

> PubMed lists PMID 41938304 in AACE endocrinology and diabetes as Journal Article, Review, with publication-date metadata of 2026-01-17 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-41938304-semaglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-13
- Source checked: 2026-08-14
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-41938304-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-41938304-semaglutide-v1
- Content SHA-256: `3488cd95fefc6df04137e9c05201d5da61686c75d3b3982cea9bec6902d1c5ce`

### Claims and source pins

#### Headline

Semaglutide and Non-arteritic Anterior Ischemic Optic Neuropathy: A Systematic Review and Narrative Synthesis. ([`pubmed-observation-pmid-41938304-2026-08-13-2ea8ee5dcfc2`](#source-pubmed-observation-pmid-41938304-2026-08-13-2ea8ee5dcfc2))

#### Summary

PubMed lists PMID 41938304 in AACE endocrinology and diabetes as Journal Article, Review, with publication-date metadata of 2026-01-17 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41938304-2026-08-13-2ea8ee5dcfc2`](#source-pubmed-observation-pmid-41938304-2026-08-13-2ea8ee5dcfc2))

#### Paragraph 1

PubMed lists PMID 41938304 in AACE endocrinology and diabetes as Journal Article, Review, with publication-date metadata of 2026-01-17 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41938304-2026-08-13-2ea8ee5dcfc2`](#source-pubmed-observation-pmid-41938304-2026-08-13-2ea8ee5dcfc2))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-41938304-2026-08-13-2ea8ee5dcfc2`](#source-pubmed-observation-pmid-41938304-2026-08-13-2ea8ee5dcfc2))

### Sources

<a id="source-pubmed-observation-pmid-41938304-2026-08-13-2ea8ee5dcfc2"></a>
- **Semaglutide and Non-arteritic Anterior Ischemic Optic Neuropathy: A Systematic Review and Narrative Synthesis. · retained source version 1:2026-08-13:current:2ea8ee5dcfc214f0ca25674823b33690a839e781e74430980e6137ba7721c140** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/41938304/) (`pubmed-observation-pmid-41938304-2026-08-13-2ea8ee5dcfc2`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Semaglutide and Non-arteritic Anterior Ischemic Optic Neuropathy: A Systematic Review and Narrative Synthesis." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-41938304-semaglutide-v1 SHA-256: 3488cd95fefc6df04137e9c05201d5da61686c75d3b3982cea9bec6902d1c5ce.

---

<a id="pubmed-pmid-41944572-semaglutide-v1"></a>

## PubMed record PMID 41944572

> PeptideScanner retained PubMed bibliographic metadata for PMID 41944572 at 2026-08-10T10:49:08.831Z. PubMed recorded a metadata revision date of 2026-08-04 and an Entrez history date of 2026-04-07. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-41944572-semaglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-04
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-11
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-41944572-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-41944572-semaglutide-v1
- Content SHA-256: `f410c38ee7d073b4def1bbd66831b6db8b52e87c1bfbf3b450a13b48979f2092`

### Claims and source pins

#### Headline

PubMed record PMID 41944572 ([`pubmed-observation-pmid-41944572-2026-08-04-46c61ab307c1`](#source-pubmed-observation-pmid-41944572-2026-08-04-46c61ab307c1))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 41944572 at 2026-08-10T10:49:08.831Z. PubMed recorded a metadata revision date of 2026-08-04 and an Entrez history date of 2026-04-07. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-41944572-2026-08-04-46c61ab307c1`](#source-pubmed-observation-pmid-41944572-2026-08-04-46c61ab307c1))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 41944572 at 2026-08-10T10:49:08.831Z. PubMed recorded a metadata revision date of 2026-08-04 and an Entrez history date of 2026-04-07. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-41944572-2026-08-04-46c61ab307c1`](#source-pubmed-observation-pmid-41944572-2026-08-04-46c61ab307c1))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-41944572-2026-08-04-46c61ab307c1`](#source-pubmed-observation-pmid-41944572-2026-08-04-46c61ab307c1))

### Sources

<a id="source-pubmed-observation-pmid-41944572-2026-08-04-46c61ab307c1"></a>
- **PubMed record PMID 41944572 · retained source version 1:2026-08-04:current:46c61ab307c1810f4a2644afb780f2e74e9f1437c7da379288a2d93706a87f05** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/41944572/) (`pubmed-observation-pmid-41944572-2026-08-04-46c61ab307c1`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 41944572." Version 1, published 2026-08-11. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-41944572-semaglutide-v1 SHA-256: f410c38ee7d073b4def1bbd66831b6db8b52e87c1bfbf3b450a13b48979f2092.

---

<a id="pubmed-pmid-41994903-semaglutide-v1"></a>

## Semaglutide Treatment in Young Adults Living With Type 2 Diabetes: A Post Hoc Analysis From the SUSTAIN and PIONEER Clinical Trials.

> PubMed lists PMID 41994903 in Diabetes, obesity & metabolism as Journal Article, Randomized Controlled Trial, with publication-date metadata of 2026-04-17 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-41994903-semaglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-26
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-41994903-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-41994903-semaglutide-v1
- Content SHA-256: `11657a3643d439172645589e453622b89ce98829ff737f9758bb71dc49fee8ac`

### Claims and source pins

#### Headline

Semaglutide Treatment in Young Adults Living With Type 2 Diabetes: A Post Hoc Analysis From the SUSTAIN and PIONEER Clinical Trials. ([`pubmed-observation-pmid-41994903-2026-07-26-e594bc768391`](#source-pubmed-observation-pmid-41994903-2026-07-26-e594bc768391))

#### Summary

PubMed lists PMID 41994903 in Diabetes, obesity & metabolism as Journal Article, Randomized Controlled Trial, with publication-date metadata of 2026-04-17 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41994903-2026-07-26-e594bc768391`](#source-pubmed-observation-pmid-41994903-2026-07-26-e594bc768391))

#### Paragraph 1

PubMed lists PMID 41994903 in Diabetes, obesity & metabolism as Journal Article, Randomized Controlled Trial, with publication-date metadata of 2026-04-17 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41994903-2026-07-26-e594bc768391`](#source-pubmed-observation-pmid-41994903-2026-07-26-e594bc768391))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-41994903-2026-07-26-e594bc768391`](#source-pubmed-observation-pmid-41994903-2026-07-26-e594bc768391))

### Sources

<a id="source-pubmed-observation-pmid-41994903-2026-07-26-e594bc768391"></a>
- **Semaglutide Treatment in Young Adults Living With Type 2 Diabetes: A Post Hoc Analysis From the SUSTAIN and PIONEER Clinical Trials. · retained source version 1:2026-07-26:current:e594bc76839100b1f0657dc359621e707f00b1ed715392107f51cc07f26ba667** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/41994903/) (`pubmed-observation-pmid-41994903-2026-07-26-e594bc768391`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Semaglutide Treatment in Young Adults Living With Type 2 Diabetes: A Post Hoc Analysis From the SUSTAIN and PIONEER Clinical Trials." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-41994903-semaglutide-v1 SHA-256: 11657a3643d439172645589e453622b89ce98829ff737f9758bb71dc49fee8ac.

---

<a id="pubmed-pmid-42014432-semaglutide-v1"></a>

## PubMed record PMID 42014432

> PeptideScanner retained PubMed bibliographic metadata for PMID 42014432 at 2026-08-10T18:13:48.770Z. PubMed recorded a metadata revision date of 2026-07-28 and an Entrez history date of 2026-04-21. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-42014432-semaglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-28
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42014432-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-42014432-semaglutide-v1
- Content SHA-256: `7d432791558ee3d6eea6b2c34f0402ba5ad26e5c2585825d2416c541359f140f`

### Claims and source pins

#### Headline

PubMed record PMID 42014432 ([`pubmed-observation-pmid-42014432-2026-07-28-1406aa9772bc`](#source-pubmed-observation-pmid-42014432-2026-07-28-1406aa9772bc))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 42014432 at 2026-08-10T18:13:48.770Z. PubMed recorded a metadata revision date of 2026-07-28 and an Entrez history date of 2026-04-21. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42014432-2026-07-28-1406aa9772bc`](#source-pubmed-observation-pmid-42014432-2026-07-28-1406aa9772bc))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 42014432 at 2026-08-10T18:13:48.770Z. PubMed recorded a metadata revision date of 2026-07-28 and an Entrez history date of 2026-04-21. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42014432-2026-07-28-1406aa9772bc`](#source-pubmed-observation-pmid-42014432-2026-07-28-1406aa9772bc))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42014432-2026-07-28-1406aa9772bc`](#source-pubmed-observation-pmid-42014432-2026-07-28-1406aa9772bc))

### Sources

<a id="source-pubmed-observation-pmid-42014432-2026-07-28-1406aa9772bc"></a>
- **PubMed record PMID 42014432 · retained source version 1:2026-07-28:current:1406aa9772bcb2dbd0b49d0a885dcb43bdd1e5623e5c0acb611f6658fa88ccfa** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42014432/) (`pubmed-observation-pmid-42014432-2026-07-28-1406aa9772bc`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 42014432." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-42014432-semaglutide-v1 SHA-256: 7d432791558ee3d6eea6b2c34f0402ba5ad26e5c2585825d2416c541359f140f.

---

<a id="pubmed-pmid-42076092-semaglutide-v1"></a>

## Quality by Design-Based Formulation Development of an Oral Semaglutide Tablet.

> PubMed lists PMID 42076092 in Pharmaceutics as Journal Article, with publication-date metadata of 2026-04-01 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42076092-semaglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-13
- Source checked: 2026-08-14
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42076092-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-42076092-semaglutide-v1
- Content SHA-256: `ccabd794c731b93ec1c94836108abc228f07410e585f8b6acf0c1d5d055bc731`

### Claims and source pins

#### Headline

Quality by Design-Based Formulation Development of an Oral Semaglutide Tablet. ([`pubmed-observation-pmid-42076092-2026-08-13-2e51dea7a672`](#source-pubmed-observation-pmid-42076092-2026-08-13-2e51dea7a672))

#### Summary

PubMed lists PMID 42076092 in Pharmaceutics as Journal Article, with publication-date metadata of 2026-04-01 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42076092-2026-08-13-2e51dea7a672`](#source-pubmed-observation-pmid-42076092-2026-08-13-2e51dea7a672))

#### Paragraph 1

PubMed lists PMID 42076092 in Pharmaceutics as Journal Article, with publication-date metadata of 2026-04-01 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42076092-2026-08-13-2e51dea7a672`](#source-pubmed-observation-pmid-42076092-2026-08-13-2e51dea7a672))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42076092-2026-08-13-2e51dea7a672`](#source-pubmed-observation-pmid-42076092-2026-08-13-2e51dea7a672))

### Sources

<a id="source-pubmed-observation-pmid-42076092-2026-08-13-2e51dea7a672"></a>
- **Quality by Design-Based Formulation Development of an Oral Semaglutide Tablet. · retained source version 1:2026-08-13:current:2e51dea7a67206253f86e951e4444f4bbb8d67075ec302936bcf4500ae72849d** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42076092/) (`pubmed-observation-pmid-42076092-2026-08-13-2e51dea7a672`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Quality by Design-Based Formulation Development of an Oral Semaglutide Tablet." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-42076092-semaglutide-v1 SHA-256: ccabd794c731b93ec1c94836108abc228f07410e585f8b6acf0c1d5d055bc731.

---

<a id="pubmed-pmid-42076118-semaglutide-v1"></a>

## Is Oral Semaglutide a Good Fit for Patients After Metabolic Bariatric Surgery? A Biopharmaceutical Mechanistic Perspective.

> PubMed lists PMID 42076118 in Pharmaceutics as Journal Article, with publication-date metadata of 2026-04-10 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42076118-semaglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-13
- Source checked: 2026-08-14
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42076118-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-42076118-semaglutide-v1
- Content SHA-256: `c1061725d465dfaee4eef71f9f809dcebd6c8a530c803b9701e82a7a1978bf2f`

### Claims and source pins

#### Headline

Is Oral Semaglutide a Good Fit for Patients After Metabolic Bariatric Surgery? A Biopharmaceutical Mechanistic Perspective. ([`pubmed-observation-pmid-42076118-2026-08-13-a2c2902cb293`](#source-pubmed-observation-pmid-42076118-2026-08-13-a2c2902cb293))

#### Summary

PubMed lists PMID 42076118 in Pharmaceutics as Journal Article, with publication-date metadata of 2026-04-10 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42076118-2026-08-13-a2c2902cb293`](#source-pubmed-observation-pmid-42076118-2026-08-13-a2c2902cb293))

#### Paragraph 1

PubMed lists PMID 42076118 in Pharmaceutics as Journal Article, with publication-date metadata of 2026-04-10 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42076118-2026-08-13-a2c2902cb293`](#source-pubmed-observation-pmid-42076118-2026-08-13-a2c2902cb293))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42076118-2026-08-13-a2c2902cb293`](#source-pubmed-observation-pmid-42076118-2026-08-13-a2c2902cb293))

### Sources

<a id="source-pubmed-observation-pmid-42076118-2026-08-13-a2c2902cb293"></a>
- **Is Oral Semaglutide a Good Fit for Patients After Metabolic Bariatric Surgery? A Biopharmaceutical Mechanistic Perspective. · retained source version 1:2026-08-13:current:a2c2902cb293dd690ae2c89ab36c9a90ee26ef586cd330a254faaef297b8b48b** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42076118/) (`pubmed-observation-pmid-42076118-2026-08-13-a2c2902cb293`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Is Oral Semaglutide a Good Fit for Patients After Metabolic Bariatric Surgery? A Biopharmaceutical Mechanistic Perspective." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-42076118-semaglutide-v1 SHA-256: c1061725d465dfaee4eef71f9f809dcebd6c8a530c803b9701e82a7a1978bf2f.

---

<a id="pubmed-pmid-42086873-semaglutide-v1"></a>

## Thermally Stressed Solid-State Stability of Semaglutide: Understanding the Influence of Temperature on Protein Content, Secondary Structure, Phase Transition, and Chemical Degradation.

> PubMed lists PMID 42086873 in Pharmaceutical research as Journal Article, with publication-date metadata of 2026-05-05 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42086873-semaglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-06-29
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42086873-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-42086873-semaglutide-v1
- Content SHA-256: `3396cd0cbd6e098c40cf724f3db85459405a6085f249c3b44928a22e5c9bf9e0`

### Claims and source pins

#### Headline

Thermally Stressed Solid-State Stability of Semaglutide: Understanding the Influence of Temperature on Protein Content, Secondary Structure, Phase Transition, and Chemical Degradation. ([`pubmed-observation-pmid-42086873-2026-06-29-01df55bc35ba`](#source-pubmed-observation-pmid-42086873-2026-06-29-01df55bc35ba))

#### Summary

PubMed lists PMID 42086873 in Pharmaceutical research as Journal Article, with publication-date metadata of 2026-05-05 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42086873-2026-06-29-01df55bc35ba`](#source-pubmed-observation-pmid-42086873-2026-06-29-01df55bc35ba))

#### Paragraph 1

PubMed lists PMID 42086873 in Pharmaceutical research as Journal Article, with publication-date metadata of 2026-05-05 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42086873-2026-06-29-01df55bc35ba`](#source-pubmed-observation-pmid-42086873-2026-06-29-01df55bc35ba))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42086873-2026-06-29-01df55bc35ba`](#source-pubmed-observation-pmid-42086873-2026-06-29-01df55bc35ba))

### Sources

<a id="source-pubmed-observation-pmid-42086873-2026-06-29-01df55bc35ba"></a>
- **Thermally Stressed Solid-State Stability of Semaglutide: Understanding the Influence of Temperature on Protein Content, Secondary Structure, Phase Transition, and Chemical Degradation. · retained source version 1:2026-06-29:current:01df55bc35ba61dcdf88511fdbd5b239443c93fc0c78b7c86aa7f1e3e39caa6f** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42086873/) (`pubmed-observation-pmid-42086873-2026-06-29-01df55bc35ba`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Thermally Stressed Solid-State Stability of Semaglutide: Understanding the Influence of Temperature on Protein Content, Secondary Structure, Phase Transition, and Chemical Degradation." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-42086873-semaglutide-v1 SHA-256: 3396cd0cbd6e098c40cf724f3db85459405a6085f249c3b44928a22e5c9bf9e0.

---

<a id="pubmed-pmid-42158165-semaglutide-v1"></a>

## Semaglutide use for hypothalamic obesity and type 2 diabetes mellitus after suprasellar germinoma treatment.

> PubMed lists PMID 42158165 in JCEM case reports as Case Reports, Journal Article, with publication-date metadata of 2026-05-18 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42158165-semaglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-13
- Source checked: 2026-08-14
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42158165-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-42158165-semaglutide-v1
- Content SHA-256: `fc182bade58eaee3754c8001950efb62e49b190ef9426a99c153e69fc135710c`

### Claims and source pins

#### Headline

Semaglutide use for hypothalamic obesity and type 2 diabetes mellitus after suprasellar germinoma treatment. ([`pubmed-observation-pmid-42158165-2026-08-13-ccb89642cb0b`](#source-pubmed-observation-pmid-42158165-2026-08-13-ccb89642cb0b))

#### Summary

PubMed lists PMID 42158165 in JCEM case reports as Case Reports, Journal Article, with publication-date metadata of 2026-05-18 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42158165-2026-08-13-ccb89642cb0b`](#source-pubmed-observation-pmid-42158165-2026-08-13-ccb89642cb0b))

#### Paragraph 1

PubMed lists PMID 42158165 in JCEM case reports as Case Reports, Journal Article, with publication-date metadata of 2026-05-18 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42158165-2026-08-13-ccb89642cb0b`](#source-pubmed-observation-pmid-42158165-2026-08-13-ccb89642cb0b))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42158165-2026-08-13-ccb89642cb0b`](#source-pubmed-observation-pmid-42158165-2026-08-13-ccb89642cb0b))

### Sources

<a id="source-pubmed-observation-pmid-42158165-2026-08-13-ccb89642cb0b"></a>
- **Semaglutide use for hypothalamic obesity and type 2 diabetes mellitus after suprasellar germinoma treatment. · retained source version 1:2026-08-13:current:ccb89642cb0b45e2091f4c302f091c0ec37fe096014974289b8bc6418e48c159** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42158165/) (`pubmed-observation-pmid-42158165-2026-08-13-ccb89642cb0b`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Semaglutide use for hypothalamic obesity and type 2 diabetes mellitus after suprasellar germinoma treatment." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-42158165-semaglutide-v1 SHA-256: fc182bade58eaee3754c8001950efb62e49b190ef9426a99c153e69fc135710c.

---

<a id="pubmed-pmid-42166306-semaglutide-v1"></a>

## Real-world use of semaglutide for obesity treatment: A cohort study in an integrated health care delivery system.

> PubMed lists PMID 42166306 in Journal of managed care & specialty pharmacy as Journal Article, Observational Study, with publication-date metadata of 2026-06 (month precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42166306-semaglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-17
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42166306-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-42166306-semaglutide-v1
- Content SHA-256: `9862da64e4a78954eac3d368fb566211762c11e93a0bb9f470edacfd2d474522`

### Claims and source pins

#### Headline

Real-world use of semaglutide for obesity treatment: A cohort study in an integrated health care delivery system. ([`pubmed-observation-pmid-42166306-2026-07-17-2eacf6296f80`](#source-pubmed-observation-pmid-42166306-2026-07-17-2eacf6296f80))

#### Summary

PubMed lists PMID 42166306 in Journal of managed care & specialty pharmacy as Journal Article, Observational Study, with publication-date metadata of 2026-06 (month precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42166306-2026-07-17-2eacf6296f80`](#source-pubmed-observation-pmid-42166306-2026-07-17-2eacf6296f80))

#### Paragraph 1

PubMed lists PMID 42166306 in Journal of managed care & specialty pharmacy as Journal Article, Observational Study, with publication-date metadata of 2026-06 (month precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42166306-2026-07-17-2eacf6296f80`](#source-pubmed-observation-pmid-42166306-2026-07-17-2eacf6296f80))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42166306-2026-07-17-2eacf6296f80`](#source-pubmed-observation-pmid-42166306-2026-07-17-2eacf6296f80))

### Sources

<a id="source-pubmed-observation-pmid-42166306-2026-07-17-2eacf6296f80"></a>
- **Real-world use of semaglutide for obesity treatment: A cohort study in an integrated health care delivery system. · retained source version 1:2026-07-17:current:2eacf6296f80723422e69ea69f8258fa20cfa7ccbe241af69354c66d9df6b4ca** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42166306/) (`pubmed-observation-pmid-42166306-2026-07-17-2eacf6296f80`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Real-world use of semaglutide for obesity treatment: A cohort study in an integrated health care delivery system." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-42166306-semaglutide-v1 SHA-256: 9862da64e4a78954eac3d368fb566211762c11e93a0bb9f470edacfd2d474522.

---

<a id="pubmed-pmid-42196730-semaglutide-v1"></a>

## Influence of Social Media on Self-Medication Behavior: A Study on Ozempic Use Among Emirati University Students.

> PubMed lists PMID 42196730 in International journal of environmental research and public health as Journal Article, with publication-date metadata of 2026-05-12 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42196730-semaglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-17
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42196730-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-42196730-semaglutide-v1
- Content SHA-256: `75755fad633744228160727790c7ac0ad99936b1eec0aeac8f032b9fb502dc7b`

### Claims and source pins

#### Headline

Influence of Social Media on Self-Medication Behavior: A Study on Ozempic Use Among Emirati University Students. ([`pubmed-observation-pmid-42196730-2026-07-17-4b8a02c2889c`](#source-pubmed-observation-pmid-42196730-2026-07-17-4b8a02c2889c))

#### Summary

PubMed lists PMID 42196730 in International journal of environmental research and public health as Journal Article, with publication-date metadata of 2026-05-12 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42196730-2026-07-17-4b8a02c2889c`](#source-pubmed-observation-pmid-42196730-2026-07-17-4b8a02c2889c))

#### Paragraph 1

PubMed lists PMID 42196730 in International journal of environmental research and public health as Journal Article, with publication-date metadata of 2026-05-12 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42196730-2026-07-17-4b8a02c2889c`](#source-pubmed-observation-pmid-42196730-2026-07-17-4b8a02c2889c))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42196730-2026-07-17-4b8a02c2889c`](#source-pubmed-observation-pmid-42196730-2026-07-17-4b8a02c2889c))

### Sources

<a id="source-pubmed-observation-pmid-42196730-2026-07-17-4b8a02c2889c"></a>
- **Influence of Social Media on Self-Medication Behavior: A Study on Ozempic Use Among Emirati University Students. · retained source version 1:2026-07-17:current:4b8a02c2889cbb274bf8c90830dddb2fed0a187490ab3d4db9ba42c4712f7d7c** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42196730/) (`pubmed-observation-pmid-42196730-2026-07-17-4b8a02c2889c`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Influence of Social Media on Self-Medication Behavior: A Study on Ozempic Use Among Emirati University Students." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-42196730-semaglutide-v1 SHA-256: 75755fad633744228160727790c7ac0ad99936b1eec0aeac8f032b9fb502dc7b.

---

<a id="pubmed-pmid-42196730-semaglutide-v2"></a>

## Influence of Social Media on Self-Medication Behavior: A Study on Ozempic Use Among Emirati University Students.

> PubMed lists PMID 42196730 in International journal of environmental research and public health as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2026-05-12 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42196730-semaglutide:v2`
- Evidence domain: Literature metadata
- Date in source: 2026-11-01
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42196730-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-42196730-semaglutide-v2
- Content SHA-256: `8fb7f2a693ce099ff67f4c544be77d074a622ba22f0fccb9a0b195c4857aaf92`

### Claims and source pins

#### Headline

Influence of Social Media on Self-Medication Behavior: A Study on Ozempic Use Among Emirati University Students. ([`pubmed-observation-pmid-42196730-2026-07-17-4b8a02c2889c-r2`](#source-pubmed-observation-pmid-42196730-2026-07-17-4b8a02c2889c-r2))

#### Summary

PubMed lists PMID 42196730 in International journal of environmental research and public health as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2026-05-12 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42196730-2026-07-17-4b8a02c2889c-r2`](#source-pubmed-observation-pmid-42196730-2026-07-17-4b8a02c2889c-r2))

#### Paragraph 1

PubMed lists PMID 42196730 in International journal of environmental research and public health as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2026-05-12 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42196730-2026-07-17-4b8a02c2889c-r2`](#source-pubmed-observation-pmid-42196730-2026-07-17-4b8a02c2889c-r2))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42196730-2026-07-17-4b8a02c2889c-r2`](#source-pubmed-observation-pmid-42196730-2026-07-17-4b8a02c2889c-r2))

### Sources

<a id="source-pubmed-observation-pmid-42196730-2026-07-17-4b8a02c2889c-r2"></a>
- **Influence of Social Media on Self-Medication Behavior: A Study on Ozempic Use Among Emirati University Students. · retained source version 1:2026-11-01:current:1b19af9af51d5b05e743f7d0f9ee2dfaaedf16b072a5d403866141fa0aa75948** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42196730/) (`pubmed-observation-pmid-42196730-2026-07-17-4b8a02c2889c-r2`)

### Correction lineage

updated on 2026-11-16: PubMed revised the bibliographic metadata of PMID 42196730, with a metadata revision date of 2026-11-01. This version reports that observation; the earlier retained observation remains available as version 1.
- Supersedes version: 1
- Correction sources: [`pubmed-observation-pmid-42196730-2026-07-17-4b8a02c2889c-r2`](#source-pubmed-observation-pmid-42196730-2026-07-17-4b8a02c2889c-r2)

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Influence of Social Media on Self-Medication Behavior: A Study on Ozempic Use Among Emirati University Students." Version 2, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-42196730-semaglutide-v2 SHA-256: 8fb7f2a693ce099ff67f4c544be77d074a622ba22f0fccb9a0b195c4857aaf92.

---

<a id="pubmed-pmid-42210124-semaglutide-v1"></a>

## PubMed record PMID 42210124

> PeptideScanner retained PubMed bibliographic metadata for PMID 42210124 at 2026-08-10T10:49:10.656Z. PubMed recorded a metadata revision date of 2026-07-31 and an Entrez history date of 2026-05-28. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-42210124-semaglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-31
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42210124-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-42210124-semaglutide-v1
- Content SHA-256: `e08eb6843bb5de81d007ef33d4d141b0ffedd9f664fa68d081cf8a722782c2d1`

### Claims and source pins

#### Headline

PubMed record PMID 42210124 ([`pubmed-observation-pmid-42210124-2026-07-31-378b27c65d83`](#source-pubmed-observation-pmid-42210124-2026-07-31-378b27c65d83))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 42210124 at 2026-08-10T10:49:10.656Z. PubMed recorded a metadata revision date of 2026-07-31 and an Entrez history date of 2026-05-28. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42210124-2026-07-31-378b27c65d83`](#source-pubmed-observation-pmid-42210124-2026-07-31-378b27c65d83))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 42210124 at 2026-08-10T10:49:10.656Z. PubMed recorded a metadata revision date of 2026-07-31 and an Entrez history date of 2026-05-28. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42210124-2026-07-31-378b27c65d83`](#source-pubmed-observation-pmid-42210124-2026-07-31-378b27c65d83))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42210124-2026-07-31-378b27c65d83`](#source-pubmed-observation-pmid-42210124-2026-07-31-378b27c65d83))

### Sources

<a id="source-pubmed-observation-pmid-42210124-2026-07-31-378b27c65d83"></a>
- **PubMed record PMID 42210124 · retained source version 1:2026-07-31:current:378b27c65d83e08bbd4bc6e585aa223de62ac53ef75b5973f034744e6b2777e3** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42210124/) (`pubmed-observation-pmid-42210124-2026-07-31-378b27c65d83`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 42210124." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-42210124-semaglutide-v1 SHA-256: e08eb6843bb5de81d007ef33d4d141b0ffedd9f664fa68d081cf8a722782c2d1.

---

<a id="pubmed-pmid-42217600-semaglutide-v1"></a>

## Semaglutide use in patients undergoing atrial fibrillation ablation and recurrent arrhythmia: A focused time-to-event meta-analysis.

> PubMed lists PMID 42217600 in Heart rhythm as Journal Article, with publication-date metadata of 2026-05-30 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42217600-semaglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-06-28
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42217600-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-42217600-semaglutide-v1
- Content SHA-256: `8332f0d10adaf3e14440422eb6a661c3d28d2ca488ca583d3712c5c5894754b0`

### Claims and source pins

#### Headline

Semaglutide use in patients undergoing atrial fibrillation ablation and recurrent arrhythmia: A focused time-to-event meta-analysis. ([`pubmed-observation-pmid-42217600-2026-06-28-63aa11a5b519`](#source-pubmed-observation-pmid-42217600-2026-06-28-63aa11a5b519))

#### Summary

PubMed lists PMID 42217600 in Heart rhythm as Journal Article, with publication-date metadata of 2026-05-30 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42217600-2026-06-28-63aa11a5b519`](#source-pubmed-observation-pmid-42217600-2026-06-28-63aa11a5b519))

#### Paragraph 1

PubMed lists PMID 42217600 in Heart rhythm as Journal Article, with publication-date metadata of 2026-05-30 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42217600-2026-06-28-63aa11a5b519`](#source-pubmed-observation-pmid-42217600-2026-06-28-63aa11a5b519))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42217600-2026-06-28-63aa11a5b519`](#source-pubmed-observation-pmid-42217600-2026-06-28-63aa11a5b519))

### Sources

<a id="source-pubmed-observation-pmid-42217600-2026-06-28-63aa11a5b519"></a>
- **Semaglutide use in patients undergoing atrial fibrillation ablation and recurrent arrhythmia: A focused time-to-event meta-analysis. · retained source version 1:2026-06-28:current:63aa11a5b51915c66ee4a30b06f00c853f7fbe5bd63e23838da4515605785351** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42217600/) (`pubmed-observation-pmid-42217600-2026-06-28-63aa11a5b519`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Semaglutide use in patients undergoing atrial fibrillation ablation and recurrent arrhythmia: A focused time-to-event meta-analysis." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-42217600-semaglutide-v1 SHA-256: 8332f0d10adaf3e14440422eb6a661c3d28d2ca488ca583d3712c5c5894754b0.

---

<a id="pubmed-pmid-42219226-semaglutide-v1"></a>

## PubMed record PMID 42219226

> PeptideScanner retained PubMed bibliographic metadata for PMID 42219226 at 2026-08-10T18:13:50.707Z. PubMed recorded a metadata revision date of 2026-07-29 and an Entrez history date of 2026-05-31. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-42219226-semaglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-29
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42219226-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-42219226-semaglutide-v1
- Content SHA-256: `4a7e9de9524b619bc0aae0bdfaeb2d42e44f097369c6a032cd06230e8b663ec7`

### Claims and source pins

#### Headline

PubMed record PMID 42219226 ([`pubmed-observation-pmid-42219226-2026-07-29-e891befdb3c0`](#source-pubmed-observation-pmid-42219226-2026-07-29-e891befdb3c0))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 42219226 at 2026-08-10T18:13:50.707Z. PubMed recorded a metadata revision date of 2026-07-29 and an Entrez history date of 2026-05-31. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42219226-2026-07-29-e891befdb3c0`](#source-pubmed-observation-pmid-42219226-2026-07-29-e891befdb3c0))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 42219226 at 2026-08-10T18:13:50.707Z. PubMed recorded a metadata revision date of 2026-07-29 and an Entrez history date of 2026-05-31. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42219226-2026-07-29-e891befdb3c0`](#source-pubmed-observation-pmid-42219226-2026-07-29-e891befdb3c0))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42219226-2026-07-29-e891befdb3c0`](#source-pubmed-observation-pmid-42219226-2026-07-29-e891befdb3c0))

### Sources

<a id="source-pubmed-observation-pmid-42219226-2026-07-29-e891befdb3c0"></a>
- **PubMed record PMID 42219226 · retained source version 1:2026-07-29:current:e891befdb3c0182f070608e8e75f428312b8e54f144c454daf8763c042baaba5** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42219226/) (`pubmed-observation-pmid-42219226-2026-07-29-e891befdb3c0`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 42219226." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-42219226-semaglutide-v1 SHA-256: 4a7e9de9524b619bc0aae0bdfaeb2d42e44f097369c6a032cd06230e8b663ec7.

---

<a id="pubmed-pmid-42225300-semaglutide-v1"></a>

## PubMed record PMID 42225300

> PeptideScanner retained PubMed bibliographic metadata for PMID 42225300 at 2026-08-10T18:13:50.717Z. PubMed recorded a metadata revision date of 2026-07-29 and an Entrez history date of 2026-06-01. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-42225300-semaglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-29
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42225300-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-42225300-semaglutide-v1
- Content SHA-256: `8dc5640cc410ea33f99b048a87c6f70b6ed36391f582117f044354e38b92f77a`

### Claims and source pins

#### Headline

PubMed record PMID 42225300 ([`pubmed-observation-pmid-42225300-2026-07-29-e5bca7d8ef72`](#source-pubmed-observation-pmid-42225300-2026-07-29-e5bca7d8ef72))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 42225300 at 2026-08-10T18:13:50.717Z. PubMed recorded a metadata revision date of 2026-07-29 and an Entrez history date of 2026-06-01. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42225300-2026-07-29-e5bca7d8ef72`](#source-pubmed-observation-pmid-42225300-2026-07-29-e5bca7d8ef72))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 42225300 at 2026-08-10T18:13:50.717Z. PubMed recorded a metadata revision date of 2026-07-29 and an Entrez history date of 2026-06-01. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42225300-2026-07-29-e5bca7d8ef72`](#source-pubmed-observation-pmid-42225300-2026-07-29-e5bca7d8ef72))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42225300-2026-07-29-e5bca7d8ef72`](#source-pubmed-observation-pmid-42225300-2026-07-29-e5bca7d8ef72))

### Sources

<a id="source-pubmed-observation-pmid-42225300-2026-07-29-e5bca7d8ef72"></a>
- **PubMed record PMID 42225300 · retained source version 1:2026-07-29:current:e5bca7d8ef725a8616b5caba6a1a30e9972dcd3d0d122d33279e9d5618585f4b** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42225300/) (`pubmed-observation-pmid-42225300-2026-07-29-e5bca7d8ef72`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 42225300." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-42225300-semaglutide-v1 SHA-256: 8dc5640cc410ea33f99b048a87c6f70b6ed36391f582117f044354e38b92f77a.

---

<a id="pubmed-pmid-42232304-semaglutide-v1"></a>

## Optimization of nursing strategies for semaglutide treatment in overweight type 2 diabetes based on gene polymorphism.

> PubMed lists PMID 42232304 in Frontiers in clinical diabetes and healthcare as Journal Article, with publication-date metadata of 2026-05-18 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42232304-semaglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-13
- Source checked: 2026-08-14
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42232304-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-42232304-semaglutide-v1
- Content SHA-256: `ad648291405b35e74806acb6e0b336372e236f375196353b1877634fc61a80a2`

### Claims and source pins

#### Headline

Optimization of nursing strategies for semaglutide treatment in overweight type 2 diabetes based on gene polymorphism. ([`pubmed-observation-pmid-42232304-2026-08-13-deff750a84c4`](#source-pubmed-observation-pmid-42232304-2026-08-13-deff750a84c4))

#### Summary

PubMed lists PMID 42232304 in Frontiers in clinical diabetes and healthcare as Journal Article, with publication-date metadata of 2026-05-18 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42232304-2026-08-13-deff750a84c4`](#source-pubmed-observation-pmid-42232304-2026-08-13-deff750a84c4))

#### Paragraph 1

PubMed lists PMID 42232304 in Frontiers in clinical diabetes and healthcare as Journal Article, with publication-date metadata of 2026-05-18 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42232304-2026-08-13-deff750a84c4`](#source-pubmed-observation-pmid-42232304-2026-08-13-deff750a84c4))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42232304-2026-08-13-deff750a84c4`](#source-pubmed-observation-pmid-42232304-2026-08-13-deff750a84c4))

### Sources

<a id="source-pubmed-observation-pmid-42232304-2026-08-13-deff750a84c4"></a>
- **Optimization of nursing strategies for semaglutide treatment in overweight type 2 diabetes based on gene polymorphism. · retained source version 1:2026-08-13:current:deff750a84c40ffc200de9a1cb7e76e157de7339abb99ad9cfc4dbf8809d984c** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42232304/) (`pubmed-observation-pmid-42232304-2026-08-13-deff750a84c4`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Optimization of nursing strategies for semaglutide treatment in overweight type 2 diabetes based on gene polymorphism." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-42232304-semaglutide-v1 SHA-256: ad648291405b35e74806acb6e0b336372e236f375196353b1877634fc61a80a2.

---

<a id="pubmed-pmid-42253285-semaglutide-v1"></a>

## PubMed record PMID 42253285

> PeptideScanner retained PubMed bibliographic metadata for PMID 42253285 at 2026-08-10T10:49:10.672Z. PubMed recorded a metadata revision date of 2026-08-07 and an Entrez history date of 2026-06-08. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-42253285-semaglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-07
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-10
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42253285-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-42253285-semaglutide-v1
- Content SHA-256: `80f303a58f59132c0527347a83deb2acb200d3f5f1cdef1769fab0fe2f4cba8d`

### Claims and source pins

#### Headline

PubMed record PMID 42253285 ([`pubmed-observation-pmid-42253285-2026-08-07-8cfa158e7b22`](#source-pubmed-observation-pmid-42253285-2026-08-07-8cfa158e7b22))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 42253285 at 2026-08-10T10:49:10.672Z. PubMed recorded a metadata revision date of 2026-08-07 and an Entrez history date of 2026-06-08. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42253285-2026-08-07-8cfa158e7b22`](#source-pubmed-observation-pmid-42253285-2026-08-07-8cfa158e7b22))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 42253285 at 2026-08-10T10:49:10.672Z. PubMed recorded a metadata revision date of 2026-08-07 and an Entrez history date of 2026-06-08. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42253285-2026-08-07-8cfa158e7b22`](#source-pubmed-observation-pmid-42253285-2026-08-07-8cfa158e7b22))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42253285-2026-08-07-8cfa158e7b22`](#source-pubmed-observation-pmid-42253285-2026-08-07-8cfa158e7b22))

### Sources

<a id="source-pubmed-observation-pmid-42253285-2026-08-07-8cfa158e7b22"></a>
- **PubMed record PMID 42253285 · retained source version 1:2026-08-07:current:8cfa158e7b22c0a9ef03b43651c5cd5e684eb2a411ceb4b4bf97b86abd81c0fa** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42253285/) (`pubmed-observation-pmid-42253285-2026-08-07-8cfa158e7b22`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 42253285." Version 1, published 2026-08-10. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-42253285-semaglutide-v1 SHA-256: 80f303a58f59132c0527347a83deb2acb200d3f5f1cdef1769fab0fe2f4cba8d.

---

<a id="pubmed-pmid-42258199-semaglutide-v1"></a>

## PubMed record PMID 42258199

> PeptideScanner retained PubMed bibliographic metadata for PMID 42258199 at 2026-08-10T10:49:10.672Z. PubMed recorded a metadata revision date of 2026-08-03 and an Entrez history date of 2026-06-08. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-42258199-semaglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-03
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-11
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42258199-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-42258199-semaglutide-v1
- Content SHA-256: `2da52d458d8fa567700434940b7216447b53e8e9e7e2a9cda82f55fb7f60f130`

### Claims and source pins

#### Headline

PubMed record PMID 42258199 ([`pubmed-observation-pmid-42258199-2026-08-03-76061244dacf`](#source-pubmed-observation-pmid-42258199-2026-08-03-76061244dacf))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 42258199 at 2026-08-10T10:49:10.672Z. PubMed recorded a metadata revision date of 2026-08-03 and an Entrez history date of 2026-06-08. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42258199-2026-08-03-76061244dacf`](#source-pubmed-observation-pmid-42258199-2026-08-03-76061244dacf))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 42258199 at 2026-08-10T10:49:10.672Z. PubMed recorded a metadata revision date of 2026-08-03 and an Entrez history date of 2026-06-08. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42258199-2026-08-03-76061244dacf`](#source-pubmed-observation-pmid-42258199-2026-08-03-76061244dacf))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42258199-2026-08-03-76061244dacf`](#source-pubmed-observation-pmid-42258199-2026-08-03-76061244dacf))

### Sources

<a id="source-pubmed-observation-pmid-42258199-2026-08-03-76061244dacf"></a>
- **PubMed record PMID 42258199 · retained source version 1:2026-08-03:current:76061244dacf7dc0666ee0ab2d41161d2c88d493a3f063b7d8db1857a3d424d6** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42258199/) (`pubmed-observation-pmid-42258199-2026-08-03-76061244dacf`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 42258199." Version 1, published 2026-08-11. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-42258199-semaglutide-v1 SHA-256: 2da52d458d8fa567700434940b7216447b53e8e9e7e2a9cda82f55fb7f60f130.

---

<a id="pubmed-pmid-42264960-semaglutide-v1"></a>

## PubMed record PMID 42264960

> PeptideScanner retained PubMed bibliographic metadata for PMID 42264960 at 2026-08-10T10:49:10.674Z. PubMed recorded a metadata revision date of 2026-08-09 and an Entrez history date of 2026-06-09. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-42264960-semaglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-09
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-10
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42264960-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-42264960-semaglutide-v1
- Content SHA-256: `c1ca60fb7aedddd624f8615af7f3921488582e9cfd44d360be13e25bbe17c64e`

### Claims and source pins

#### Headline

PubMed record PMID 42264960 ([`pubmed-observation-pmid-42264960-2026-08-09-bc760f5b5962`](#source-pubmed-observation-pmid-42264960-2026-08-09-bc760f5b5962))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 42264960 at 2026-08-10T10:49:10.674Z. PubMed recorded a metadata revision date of 2026-08-09 and an Entrez history date of 2026-06-09. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42264960-2026-08-09-bc760f5b5962`](#source-pubmed-observation-pmid-42264960-2026-08-09-bc760f5b5962))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 42264960 at 2026-08-10T10:49:10.674Z. PubMed recorded a metadata revision date of 2026-08-09 and an Entrez history date of 2026-06-09. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42264960-2026-08-09-bc760f5b5962`](#source-pubmed-observation-pmid-42264960-2026-08-09-bc760f5b5962))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42264960-2026-08-09-bc760f5b5962`](#source-pubmed-observation-pmid-42264960-2026-08-09-bc760f5b5962))

### Sources

<a id="source-pubmed-observation-pmid-42264960-2026-08-09-bc760f5b5962"></a>
- **PubMed record PMID 42264960 · retained source version 1:2026-08-09:current:bc760f5b596228429e7495bf779eda7821e540d9bb0582152b7c504bf229609d** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42264960/) (`pubmed-observation-pmid-42264960-2026-08-09-bc760f5b5962`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 42264960." Version 1, published 2026-08-10. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-42264960-semaglutide-v1 SHA-256: c1ca60fb7aedddd624f8615af7f3921488582e9cfd44d360be13e25bbe17c64e.

---

<a id="pubmed-pmid-42273973-semaglutide-v1"></a>

## PubMed record PMID 42273973

> PeptideScanner retained PubMed bibliographic metadata for PMID 42273973 at 2026-08-10T10:49:10.675Z. PubMed recorded a metadata revision date of 2026-08-01 and an Entrez history date of 2026-06-11. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-42273973-semaglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-01
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42273973-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-42273973-semaglutide-v1
- Content SHA-256: `1784b143cd95a32ae54baa203b4ea4d78902bff19a480df9c6e5d4357e4d685f`

### Claims and source pins

#### Headline

PubMed record PMID 42273973 ([`pubmed-observation-pmid-42273973-2026-08-01-784e6217641e`](#source-pubmed-observation-pmid-42273973-2026-08-01-784e6217641e))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 42273973 at 2026-08-10T10:49:10.675Z. PubMed recorded a metadata revision date of 2026-08-01 and an Entrez history date of 2026-06-11. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42273973-2026-08-01-784e6217641e`](#source-pubmed-observation-pmid-42273973-2026-08-01-784e6217641e))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 42273973 at 2026-08-10T10:49:10.675Z. PubMed recorded a metadata revision date of 2026-08-01 and an Entrez history date of 2026-06-11. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42273973-2026-08-01-784e6217641e`](#source-pubmed-observation-pmid-42273973-2026-08-01-784e6217641e))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42273973-2026-08-01-784e6217641e`](#source-pubmed-observation-pmid-42273973-2026-08-01-784e6217641e))

### Sources

<a id="source-pubmed-observation-pmid-42273973-2026-08-01-784e6217641e"></a>
- **PubMed record PMID 42273973 · retained source version 1:2026-08-01:current:784e6217641e5c09385c4afac6805fc020b8ba80feea962b8a2ce604a77ba1c2** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42273973/) (`pubmed-observation-pmid-42273973-2026-08-01-784e6217641e`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 42273973." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-42273973-semaglutide-v1 SHA-256: 1784b143cd95a32ae54baa203b4ea4d78902bff19a480df9c6e5d4357e4d685f.

---

<a id="pubmed-pmid-42288971-semaglutide-v1"></a>

## PubMed record PMID 42288971

> PeptideScanner retained PubMed bibliographic metadata for PMID 42288971 at 2026-08-10T10:49:10.679Z. PubMed recorded a metadata revision date of 2026-08-03 and an Entrez history date of 2026-06-14. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-42288971-semaglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-03
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-11
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42288971-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-42288971-semaglutide-v1
- Content SHA-256: `6ffeb8fbac98d920a9d60c5a20c91ab6240d6e614f28698a7a9b9c4f0e554db2`

### Claims and source pins

#### Headline

PubMed record PMID 42288971 ([`pubmed-observation-pmid-42288971-2026-08-03-020e2615e052`](#source-pubmed-observation-pmid-42288971-2026-08-03-020e2615e052))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 42288971 at 2026-08-10T10:49:10.679Z. PubMed recorded a metadata revision date of 2026-08-03 and an Entrez history date of 2026-06-14. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42288971-2026-08-03-020e2615e052`](#source-pubmed-observation-pmid-42288971-2026-08-03-020e2615e052))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 42288971 at 2026-08-10T10:49:10.679Z. PubMed recorded a metadata revision date of 2026-08-03 and an Entrez history date of 2026-06-14. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42288971-2026-08-03-020e2615e052`](#source-pubmed-observation-pmid-42288971-2026-08-03-020e2615e052))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42288971-2026-08-03-020e2615e052`](#source-pubmed-observation-pmid-42288971-2026-08-03-020e2615e052))

### Sources

<a id="source-pubmed-observation-pmid-42288971-2026-08-03-020e2615e052"></a>
- **PubMed record PMID 42288971 · retained source version 1:2026-08-03:current:020e2615e0522b5440709712ad64b69fdf94665b19313548ecfc4328dd4c7c52** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42288971/) (`pubmed-observation-pmid-42288971-2026-08-03-020e2615e052`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 42288971." Version 1, published 2026-08-11. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-42288971-semaglutide-v1 SHA-256: 6ffeb8fbac98d920a9d60c5a20c91ab6240d6e614f28698a7a9b9c4f0e554db2.

---

<a id="pubmed-pmid-42297751-semaglutide-v1"></a>

## PubMed record PMID 42297751

> PeptideScanner retained PubMed bibliographic metadata for PMID 42297751 at 2026-08-10T10:49:10.683Z. PubMed recorded a metadata revision date of 2026-08-09 and an Entrez history date of 2026-06-15. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-42297751-semaglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-09
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-10
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42297751-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-42297751-semaglutide-v1
- Content SHA-256: `387e7792838d2c1698c69cd4f9345f721c53222e0679df9179e7d1391c60da70`

### Claims and source pins

#### Headline

PubMed record PMID 42297751 ([`pubmed-observation-pmid-42297751-2026-08-09-d04531f92f08`](#source-pubmed-observation-pmid-42297751-2026-08-09-d04531f92f08))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 42297751 at 2026-08-10T10:49:10.683Z. PubMed recorded a metadata revision date of 2026-08-09 and an Entrez history date of 2026-06-15. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42297751-2026-08-09-d04531f92f08`](#source-pubmed-observation-pmid-42297751-2026-08-09-d04531f92f08))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 42297751 at 2026-08-10T10:49:10.683Z. PubMed recorded a metadata revision date of 2026-08-09 and an Entrez history date of 2026-06-15. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42297751-2026-08-09-d04531f92f08`](#source-pubmed-observation-pmid-42297751-2026-08-09-d04531f92f08))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42297751-2026-08-09-d04531f92f08`](#source-pubmed-observation-pmid-42297751-2026-08-09-d04531f92f08))

### Sources

<a id="source-pubmed-observation-pmid-42297751-2026-08-09-d04531f92f08"></a>
- **PubMed record PMID 42297751 · retained source version 1:2026-08-09:current:d04531f92f088d74efa8d3784c25a58fbc53dc87576d921952aa9f54cd28ea2c** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42297751/) (`pubmed-observation-pmid-42297751-2026-08-09-d04531f92f08`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 42297751." Version 1, published 2026-08-10. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-42297751-semaglutide-v1 SHA-256: 387e7792838d2c1698c69cd4f9345f721c53222e0679df9179e7d1391c60da70.

---

<a id="pubmed-pmid-42297754-semaglutide-v1"></a>

## PubMed record PMID 42297754

> PeptideScanner retained PubMed bibliographic metadata for PMID 42297754 at 2026-08-10T10:49:10.683Z. PubMed recorded a metadata revision date of 2026-08-09 and an Entrez history date of 2026-06-15. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-42297754-semaglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-09
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-10
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42297754-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-42297754-semaglutide-v1
- Content SHA-256: `9e115b132d02c147ea1d1aeef374d206c8a34702ab440e27b2cc5819ec02e1e5`

### Claims and source pins

#### Headline

PubMed record PMID 42297754 ([`pubmed-observation-pmid-42297754-2026-08-09-9972f16fbc04`](#source-pubmed-observation-pmid-42297754-2026-08-09-9972f16fbc04))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 42297754 at 2026-08-10T10:49:10.683Z. PubMed recorded a metadata revision date of 2026-08-09 and an Entrez history date of 2026-06-15. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42297754-2026-08-09-9972f16fbc04`](#source-pubmed-observation-pmid-42297754-2026-08-09-9972f16fbc04))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 42297754 at 2026-08-10T10:49:10.683Z. PubMed recorded a metadata revision date of 2026-08-09 and an Entrez history date of 2026-06-15. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42297754-2026-08-09-9972f16fbc04`](#source-pubmed-observation-pmid-42297754-2026-08-09-9972f16fbc04))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42297754-2026-08-09-9972f16fbc04`](#source-pubmed-observation-pmid-42297754-2026-08-09-9972f16fbc04))

### Sources

<a id="source-pubmed-observation-pmid-42297754-2026-08-09-9972f16fbc04"></a>
- **PubMed record PMID 42297754 · retained source version 1:2026-08-09:current:9972f16fbc04ef1a5fb7a6a3ee3f81b5c1a36b7ba0aabd8e33ad2ce67bca3d2a** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42297754/) (`pubmed-observation-pmid-42297754-2026-08-09-9972f16fbc04`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 42297754." Version 1, published 2026-08-10. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-42297754-semaglutide-v1 SHA-256: 9e115b132d02c147ea1d1aeef374d206c8a34702ab440e27b2cc5819ec02e1e5.

---

<a id="pubmed-pmid-42297758-semaglutide-v1"></a>

## PubMed record PMID 42297758

> PeptideScanner retained PubMed bibliographic metadata for PMID 42297758 at 2026-08-10T10:49:10.684Z. PubMed recorded a metadata revision date of 2026-08-09 and an Entrez history date of 2026-06-15. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-42297758-semaglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-09
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-10
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42297758-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-42297758-semaglutide-v1
- Content SHA-256: `8e50ca4e241f0bb58c97352c1becf853d71d56989f927d72b86640e9332e3a7a`

### Claims and source pins

#### Headline

PubMed record PMID 42297758 ([`pubmed-observation-pmid-42297758-2026-08-09-5930b1317d40`](#source-pubmed-observation-pmid-42297758-2026-08-09-5930b1317d40))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 42297758 at 2026-08-10T10:49:10.684Z. PubMed recorded a metadata revision date of 2026-08-09 and an Entrez history date of 2026-06-15. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42297758-2026-08-09-5930b1317d40`](#source-pubmed-observation-pmid-42297758-2026-08-09-5930b1317d40))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 42297758 at 2026-08-10T10:49:10.684Z. PubMed recorded a metadata revision date of 2026-08-09 and an Entrez history date of 2026-06-15. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42297758-2026-08-09-5930b1317d40`](#source-pubmed-observation-pmid-42297758-2026-08-09-5930b1317d40))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42297758-2026-08-09-5930b1317d40`](#source-pubmed-observation-pmid-42297758-2026-08-09-5930b1317d40))

### Sources

<a id="source-pubmed-observation-pmid-42297758-2026-08-09-5930b1317d40"></a>
- **PubMed record PMID 42297758 · retained source version 1:2026-08-09:current:5930b1317d408764c5ffd0561ff1a34943f2f765c99fd418f469cffef5e90ad9** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42297758/) (`pubmed-observation-pmid-42297758-2026-08-09-5930b1317d40`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 42297758." Version 1, published 2026-08-10. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-42297758-semaglutide-v1 SHA-256: 8e50ca4e241f0bb58c97352c1becf853d71d56989f927d72b86640e9332e3a7a.

---

<a id="pubmed-pmid-42308137-semaglutide-v1"></a>

## What the Scale Does Not Show: A Patient's Reflection on Semaglutide, Strength, and the SMART Trial.

> PubMed lists PMID 42308137 in Clinical journal of the American Society of Nephrology : CJASN as Journal Article, with publication-date metadata of 2026-06-18 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42308137-semaglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-26
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42308137-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-42308137-semaglutide-v1
- Content SHA-256: `edd567c560e2bf3668e054093664f2bd5ebd034b194fed469af2d150cefcfe2a`

### Claims and source pins

#### Headline

What the Scale Does Not Show: A Patient's Reflection on Semaglutide, Strength, and the SMART Trial. ([`pubmed-observation-pmid-42308137-2026-07-26-cc893d47a8ba`](#source-pubmed-observation-pmid-42308137-2026-07-26-cc893d47a8ba))

#### Summary

PubMed lists PMID 42308137 in Clinical journal of the American Society of Nephrology : CJASN as Journal Article, with publication-date metadata of 2026-06-18 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42308137-2026-07-26-cc893d47a8ba`](#source-pubmed-observation-pmid-42308137-2026-07-26-cc893d47a8ba))

#### Paragraph 1

PubMed lists PMID 42308137 in Clinical journal of the American Society of Nephrology : CJASN as Journal Article, with publication-date metadata of 2026-06-18 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42308137-2026-07-26-cc893d47a8ba`](#source-pubmed-observation-pmid-42308137-2026-07-26-cc893d47a8ba))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42308137-2026-07-26-cc893d47a8ba`](#source-pubmed-observation-pmid-42308137-2026-07-26-cc893d47a8ba))

### Sources

<a id="source-pubmed-observation-pmid-42308137-2026-07-26-cc893d47a8ba"></a>
- **What the Scale Does Not Show: A Patient's Reflection on Semaglutide, Strength, and the SMART Trial. · retained source version 1:2026-07-26:current:cc893d47a8ba0020a019a1c6566d448ab12e7ff7b028d907c439d3b5f3fa735a** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42308137/) (`pubmed-observation-pmid-42308137-2026-07-26-cc893d47a8ba`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "What the Scale Does Not Show: A Patient's Reflection on Semaglutide, Strength, and the SMART Trial." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-42308137-semaglutide-v1 SHA-256: edd567c560e2bf3668e054093664f2bd5ebd034b194fed469af2d150cefcfe2a.

---

<a id="pubmed-pmid-42313535-semaglutide-v1"></a>

## A New GLP-1 Pill for Diabetes, Semaglutide With Amylin, Data From China, and More From ADA 2026.

> PubMed lists PMID 42313535 in JAMA as Journal Article, with publication-date metadata of 2026-07-14 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42313535-semaglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-14
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42313535-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-42313535-semaglutide-v1
- Content SHA-256: `67062539e86792f737172816a7fe8ce2bc893cca2dfc7314e49b4d099e7df4d7`

### Claims and source pins

#### Headline

A New GLP-1 Pill for Diabetes, Semaglutide With Amylin, Data From China, and More From ADA 2026. ([`pubmed-observation-pmid-42313535-2026-07-14-61052405099d`](#source-pubmed-observation-pmid-42313535-2026-07-14-61052405099d))

#### Summary

PubMed lists PMID 42313535 in JAMA as Journal Article, with publication-date metadata of 2026-07-14 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42313535-2026-07-14-61052405099d`](#source-pubmed-observation-pmid-42313535-2026-07-14-61052405099d))

#### Paragraph 1

PubMed lists PMID 42313535 in JAMA as Journal Article, with publication-date metadata of 2026-07-14 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42313535-2026-07-14-61052405099d`](#source-pubmed-observation-pmid-42313535-2026-07-14-61052405099d))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42313535-2026-07-14-61052405099d`](#source-pubmed-observation-pmid-42313535-2026-07-14-61052405099d))

### Sources

<a id="source-pubmed-observation-pmid-42313535-2026-07-14-61052405099d"></a>
- **A New GLP-1 Pill for Diabetes, Semaglutide With Amylin, Data From China, and More From ADA 2026. · retained source version 1:2026-07-14:current:61052405099deb295acba3bc90321721298307fc56408b44128064001d13e1c3** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42313535/) (`pubmed-observation-pmid-42313535-2026-07-14-61052405099d`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "A New GLP-1 Pill for Diabetes, Semaglutide With Amylin, Data From China, and More From ADA 2026." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-42313535-semaglutide-v1 SHA-256: 67062539e86792f737172816a7fe8ce2bc893cca2dfc7314e49b4d099e7df4d7.

---

<a id="pubmed-pmid-42314683-semaglutide-v1"></a>

## PubMed record PMID 42314683

> PeptideScanner retained PubMed bibliographic metadata for PMID 42314683 at 2026-08-10T18:13:52.286Z. PubMed recorded a metadata revision date of 2026-07-27 and an Entrez history date of 2026-06-18. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-42314683-semaglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-27
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42314683-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-42314683-semaglutide-v1
- Content SHA-256: `d9a0842a58e2959de53217ffb69ff28740d18f3567dffb27945b25ebc844384c`

### Claims and source pins

#### Headline

PubMed record PMID 42314683 ([`pubmed-observation-pmid-42314683-2026-07-27-4d6dbb0cb59e`](#source-pubmed-observation-pmid-42314683-2026-07-27-4d6dbb0cb59e))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 42314683 at 2026-08-10T18:13:52.286Z. PubMed recorded a metadata revision date of 2026-07-27 and an Entrez history date of 2026-06-18. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42314683-2026-07-27-4d6dbb0cb59e`](#source-pubmed-observation-pmid-42314683-2026-07-27-4d6dbb0cb59e))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 42314683 at 2026-08-10T18:13:52.286Z. PubMed recorded a metadata revision date of 2026-07-27 and an Entrez history date of 2026-06-18. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42314683-2026-07-27-4d6dbb0cb59e`](#source-pubmed-observation-pmid-42314683-2026-07-27-4d6dbb0cb59e))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42314683-2026-07-27-4d6dbb0cb59e`](#source-pubmed-observation-pmid-42314683-2026-07-27-4d6dbb0cb59e))

### Sources

<a id="source-pubmed-observation-pmid-42314683-2026-07-27-4d6dbb0cb59e"></a>
- **PubMed record PMID 42314683 · retained source version 1:2026-07-27:current:4d6dbb0cb59e37881cf58a891475e0797ff3872c174ec8431673d2a8a3a166b7** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42314683/) (`pubmed-observation-pmid-42314683-2026-07-27-4d6dbb0cb59e`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 42314683." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-42314683-semaglutide-v1 SHA-256: d9a0842a58e2959de53217ffb69ff28740d18f3567dffb27945b25ebc844384c.

---

<a id="pubmed-pmid-42361988-semaglutide-v1"></a>

## PubMed record PMID 42361988

> PeptideScanner retained PubMed bibliographic metadata for PMID 42361988 at 2026-08-10T18:13:53.774Z. PubMed recorded a metadata revision date of 2026-07-29 and an Entrez history date of 2026-06-26. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-42361988-semaglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-29
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42361988-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-42361988-semaglutide-v1
- Content SHA-256: `0f823d690676fd13bae9b55f2f625c002304f03f663f126d2ee4b6c8f3fffee1`

### Claims and source pins

#### Headline

PubMed record PMID 42361988 ([`pubmed-observation-pmid-42361988-2026-07-29-3259b3a314ee`](#source-pubmed-observation-pmid-42361988-2026-07-29-3259b3a314ee))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 42361988 at 2026-08-10T18:13:53.774Z. PubMed recorded a metadata revision date of 2026-07-29 and an Entrez history date of 2026-06-26. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42361988-2026-07-29-3259b3a314ee`](#source-pubmed-observation-pmid-42361988-2026-07-29-3259b3a314ee))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 42361988 at 2026-08-10T18:13:53.774Z. PubMed recorded a metadata revision date of 2026-07-29 and an Entrez history date of 2026-06-26. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42361988-2026-07-29-3259b3a314ee`](#source-pubmed-observation-pmid-42361988-2026-07-29-3259b3a314ee))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42361988-2026-07-29-3259b3a314ee`](#source-pubmed-observation-pmid-42361988-2026-07-29-3259b3a314ee))

### Sources

<a id="source-pubmed-observation-pmid-42361988-2026-07-29-3259b3a314ee"></a>
- **PubMed record PMID 42361988 · retained source version 1:2026-07-29:current:3259b3a314ee79c0eef34129901211b8174f8351cee8ad6c980db4b3241250d9** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42361988/) (`pubmed-observation-pmid-42361988-2026-07-29-3259b3a314ee`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 42361988." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-42361988-semaglutide-v1 SHA-256: 0f823d690676fd13bae9b55f2f625c002304f03f663f126d2ee4b6c8f3fffee1.

---

<a id="pubmed-pmid-42364353-semaglutide-v1"></a>

## Secondary alopecia due to semaglutide.

> PubMed lists PMID 42364353 in Medicina clinica as Letter, with publication-date metadata of 2026-06-27 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42364353-semaglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-06-27
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42364353-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-42364353-semaglutide-v1
- Content SHA-256: `2b73cf03a0d251172603c6594413f164fac35a8bb2810cb3ac14432fb4070aa3`

### Claims and source pins

#### Headline

Secondary alopecia due to semaglutide. ([`pubmed-observation-pmid-42364353-2026-06-27-fe397cdcc044`](#source-pubmed-observation-pmid-42364353-2026-06-27-fe397cdcc044))

#### Summary

PubMed lists PMID 42364353 in Medicina clinica as Letter, with publication-date metadata of 2026-06-27 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42364353-2026-06-27-fe397cdcc044`](#source-pubmed-observation-pmid-42364353-2026-06-27-fe397cdcc044))

#### Paragraph 1

PubMed lists PMID 42364353 in Medicina clinica as Letter, with publication-date metadata of 2026-06-27 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42364353-2026-06-27-fe397cdcc044`](#source-pubmed-observation-pmid-42364353-2026-06-27-fe397cdcc044))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42364353-2026-06-27-fe397cdcc044`](#source-pubmed-observation-pmid-42364353-2026-06-27-fe397cdcc044))

### Sources

<a id="source-pubmed-observation-pmid-42364353-2026-06-27-fe397cdcc044"></a>
- **Secondary alopecia due to semaglutide. · retained source version 1:2026-06-27:current:fe397cdcc044c416140262cd61d154e87c2beca956d333a1be982c1e4f1b397a** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42364353/) (`pubmed-observation-pmid-42364353-2026-06-27-fe397cdcc044`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Secondary alopecia due to semaglutide." Version 1, published 2026-08-16. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-42364353-semaglutide-v1 SHA-256: 2b73cf03a0d251172603c6594413f164fac35a8bb2810cb3ac14432fb4070aa3.

---

<a id="pubmed-pmid-42365987-semaglutide-v1"></a>

## PubMed record PMID 42365987

> PeptideScanner retained PubMed bibliographic metadata for PMID 42365987 at 2026-08-10T10:49:10.730Z. PubMed recorded a metadata revision date of 2026-08-09 and an Entrez history date of 2026-06-28. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-42365987-semaglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-09
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-10
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42365987-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-42365987-semaglutide-v1
- Content SHA-256: `761c4a40fac24bf0b519f4c7955de3b307944368b91ead0e96c8c899adbf03ab`

### Claims and source pins

#### Headline

PubMed record PMID 42365987 ([`pubmed-observation-pmid-42365987-2026-08-09-8ee94ac277ae`](#source-pubmed-observation-pmid-42365987-2026-08-09-8ee94ac277ae))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 42365987 at 2026-08-10T10:49:10.730Z. PubMed recorded a metadata revision date of 2026-08-09 and an Entrez history date of 2026-06-28. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42365987-2026-08-09-8ee94ac277ae`](#source-pubmed-observation-pmid-42365987-2026-08-09-8ee94ac277ae))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 42365987 at 2026-08-10T10:49:10.730Z. PubMed recorded a metadata revision date of 2026-08-09 and an Entrez history date of 2026-06-28. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42365987-2026-08-09-8ee94ac277ae`](#source-pubmed-observation-pmid-42365987-2026-08-09-8ee94ac277ae))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42365987-2026-08-09-8ee94ac277ae`](#source-pubmed-observation-pmid-42365987-2026-08-09-8ee94ac277ae))

### Sources

<a id="source-pubmed-observation-pmid-42365987-2026-08-09-8ee94ac277ae"></a>
- **PubMed record PMID 42365987 · retained source version 1:2026-08-09:current:8ee94ac277ae8a27fc9f650323797305c67c3836ba49c884bf12e29d7271e8c2** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42365987/) (`pubmed-observation-pmid-42365987-2026-08-09-8ee94ac277ae`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 42365987." Version 1, published 2026-08-10. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-42365987-semaglutide-v1 SHA-256: 761c4a40fac24bf0b519f4c7955de3b307944368b91ead0e96c8c899adbf03ab.

---

<a id="pubmed-pmid-42384388-semaglutide-v1"></a>

## Semaglutide in Schizophrenia-A Top Clinical Trial.

> PubMed lists PMID 42384388 in JAMA psychiatry as Journal Article, with publication-date metadata of 2026-07-01 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42384388-semaglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-01
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42384388-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-42384388-semaglutide-v1
- Content SHA-256: `9f4a5cd442b1151ff979e41dec5024d0790880dcb330a2c6a12c9749c07650d5`

### Claims and source pins

#### Headline

Semaglutide in Schizophrenia-A Top Clinical Trial. ([`pubmed-observation-pmid-42384388-2026-07-01-7625ed8753e3`](#source-pubmed-observation-pmid-42384388-2026-07-01-7625ed8753e3))

#### Summary

PubMed lists PMID 42384388 in JAMA psychiatry as Journal Article, with publication-date metadata of 2026-07-01 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42384388-2026-07-01-7625ed8753e3`](#source-pubmed-observation-pmid-42384388-2026-07-01-7625ed8753e3))

#### Paragraph 1

PubMed lists PMID 42384388 in JAMA psychiatry as Journal Article, with publication-date metadata of 2026-07-01 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42384388-2026-07-01-7625ed8753e3`](#source-pubmed-observation-pmid-42384388-2026-07-01-7625ed8753e3))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42384388-2026-07-01-7625ed8753e3`](#source-pubmed-observation-pmid-42384388-2026-07-01-7625ed8753e3))

### Sources

<a id="source-pubmed-observation-pmid-42384388-2026-07-01-7625ed8753e3"></a>
- **Semaglutide in Schizophrenia-A Top Clinical Trial. · retained source version 1:2026-07-01:current:7625ed8753e36bc33c47804e38a7ef996f3e33eb3b40e41716fc264f4861ef72** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42384388/) (`pubmed-observation-pmid-42384388-2026-07-01-7625ed8753e3`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Semaglutide in Schizophrenia-A Top Clinical Trial." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-42384388-semaglutide-v1 SHA-256: 9f4a5cd442b1151ff979e41dec5024d0790880dcb330a2c6a12c9749c07650d5.

---

<a id="pubmed-pmid-42403263-semaglutide-v1"></a>

## PubMed record PMID 42403263

> PeptideScanner retained PubMed bibliographic metadata for PMID 42403263 at 2026-08-10T10:49:10.745Z. PubMed recorded a metadata revision date of 2026-08-09 and an Entrez history date of 2026-07-06. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-42403263-semaglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-09
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-10
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42403263-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-42403263-semaglutide-v1
- Content SHA-256: `aecd2a250625fd66a8fc1cd58049859cf45de223c0591465aa4bd01157fe0009`

### Claims and source pins

#### Headline

PubMed record PMID 42403263 ([`pubmed-observation-pmid-42403263-2026-08-09-c5ae25e11107`](#source-pubmed-observation-pmid-42403263-2026-08-09-c5ae25e11107))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 42403263 at 2026-08-10T10:49:10.745Z. PubMed recorded a metadata revision date of 2026-08-09 and an Entrez history date of 2026-07-06. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42403263-2026-08-09-c5ae25e11107`](#source-pubmed-observation-pmid-42403263-2026-08-09-c5ae25e11107))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 42403263 at 2026-08-10T10:49:10.745Z. PubMed recorded a metadata revision date of 2026-08-09 and an Entrez history date of 2026-07-06. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42403263-2026-08-09-c5ae25e11107`](#source-pubmed-observation-pmid-42403263-2026-08-09-c5ae25e11107))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42403263-2026-08-09-c5ae25e11107`](#source-pubmed-observation-pmid-42403263-2026-08-09-c5ae25e11107))

### Sources

<a id="source-pubmed-observation-pmid-42403263-2026-08-09-c5ae25e11107"></a>
- **PubMed record PMID 42403263 · retained source version 1:2026-08-09:current:c5ae25e1110700330b2ee946c4b29309289c502f2826ed6ad5b5d516a04829ec** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42403263/) (`pubmed-observation-pmid-42403263-2026-08-09-c5ae25e11107`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 42403263." Version 1, published 2026-08-10. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-42403263-semaglutide-v1 SHA-256: aecd2a250625fd66a8fc1cd58049859cf45de223c0591465aa4bd01157fe0009.

---

<a id="pubmed-pmid-42420782-semaglutide-v1"></a>

## PubMed record PMID 42420782

> PeptideScanner retained PubMed bibliographic metadata for PMID 42420782 at 2026-08-10T10:49:10.753Z. PubMed recorded a metadata revision date of 2026-08-09 and an Entrez history date of 2026-07-08. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-42420782-semaglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-09
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-10
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42420782-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-42420782-semaglutide-v1
- Content SHA-256: `6ccfa3a0e71a39d0d5950ccceea40e44b07cfadf2f45159e0ad84829ae6e5abe`

### Claims and source pins

#### Headline

PubMed record PMID 42420782 ([`pubmed-observation-pmid-42420782-2026-08-09-b0df66e642ec`](#source-pubmed-observation-pmid-42420782-2026-08-09-b0df66e642ec))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 42420782 at 2026-08-10T10:49:10.753Z. PubMed recorded a metadata revision date of 2026-08-09 and an Entrez history date of 2026-07-08. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42420782-2026-08-09-b0df66e642ec`](#source-pubmed-observation-pmid-42420782-2026-08-09-b0df66e642ec))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 42420782 at 2026-08-10T10:49:10.753Z. PubMed recorded a metadata revision date of 2026-08-09 and an Entrez history date of 2026-07-08. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42420782-2026-08-09-b0df66e642ec`](#source-pubmed-observation-pmid-42420782-2026-08-09-b0df66e642ec))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42420782-2026-08-09-b0df66e642ec`](#source-pubmed-observation-pmid-42420782-2026-08-09-b0df66e642ec))

### Sources

<a id="source-pubmed-observation-pmid-42420782-2026-08-09-b0df66e642ec"></a>
- **PubMed record PMID 42420782 · retained source version 1:2026-08-09:current:b0df66e642ec69aea8aa62af5e8038e3b6dce1aaf0fee359b8d008e9f28ea06c** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42420782/) (`pubmed-observation-pmid-42420782-2026-08-09-b0df66e642ec`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 42420782." Version 1, published 2026-08-10. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-42420782-semaglutide-v1 SHA-256: 6ccfa3a0e71a39d0d5950ccceea40e44b07cfadf2f45159e0ad84829ae6e5abe.

---

<a id="pubmed-pmid-42432542-semaglutide-v1"></a>

## Partially reversible bilateral non-arteritic anterior ischemic optic neuropathy and branch retinal artery occlusion following semaglutide use. a case report.

> PubMed lists PMID 42432542 in BMC ophthalmology as Journal Article, with publication-date metadata of 2026-07-10 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42432542-semaglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-10
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42432542-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-42432542-semaglutide-v1
- Content SHA-256: `87bee1f8af711e4fb51520968b0242ef1a52808b0f122e6010a3f4f4dbc0a1b2`

### Claims and source pins

#### Headline

Partially reversible bilateral non-arteritic anterior ischemic optic neuropathy and branch retinal artery occlusion following semaglutide use. a case report. ([`pubmed-observation-pmid-42432542-2026-07-10-5adc8b896313`](#source-pubmed-observation-pmid-42432542-2026-07-10-5adc8b896313))

#### Summary

PubMed lists PMID 42432542 in BMC ophthalmology as Journal Article, with publication-date metadata of 2026-07-10 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42432542-2026-07-10-5adc8b896313`](#source-pubmed-observation-pmid-42432542-2026-07-10-5adc8b896313))

#### Paragraph 1

PubMed lists PMID 42432542 in BMC ophthalmology as Journal Article, with publication-date metadata of 2026-07-10 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42432542-2026-07-10-5adc8b896313`](#source-pubmed-observation-pmid-42432542-2026-07-10-5adc8b896313))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42432542-2026-07-10-5adc8b896313`](#source-pubmed-observation-pmid-42432542-2026-07-10-5adc8b896313))

### Sources

<a id="source-pubmed-observation-pmid-42432542-2026-07-10-5adc8b896313"></a>
- **Partially reversible bilateral non-arteritic anterior ischemic optic neuropathy and branch retinal artery occlusion following semaglutide use. a case report. · retained source version 1:2026-07-10:current:5adc8b896313640a52fb7fe92599f2cde17d398f9a9118b41f8407a5eef5af9b** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42432542/) (`pubmed-observation-pmid-42432542-2026-07-10-5adc8b896313`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Partially reversible bilateral non-arteritic anterior ischemic optic neuropathy and branch retinal artery occlusion following semaglutide use. a case report." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-42432542-semaglutide-v1 SHA-256: 87bee1f8af711e4fb51520968b0242ef1a52808b0f122e6010a3f4f4dbc0a1b2.

---

<a id="pubmed-pmid-42432542-semaglutide-v2"></a>

## Partially reversible bilateral non-arteritic anterior ischemic optic neuropathy and branch retinal artery occlusion following semaglutide use. a case report.

> PubMed lists PMID 42432542 in BMC ophthalmology as Journal Article, Case Reports, with publication-date metadata of 2026-07-10 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42432542-semaglutide:v2`
- Evidence domain: Literature metadata
- Date in source: 2026-10-09
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42432542-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-42432542-semaglutide-v2
- Content SHA-256: `2029fd3e7e307ea4a304be7163db75d817288cb76fadb85573197e42df0c4017`

### Claims and source pins

#### Headline

Partially reversible bilateral non-arteritic anterior ischemic optic neuropathy and branch retinal artery occlusion following semaglutide use. a case report. ([`pubmed-observation-pmid-42432542-2026-07-10-5adc8b896313-r2`](#source-pubmed-observation-pmid-42432542-2026-07-10-5adc8b896313-r2))

#### Summary

PubMed lists PMID 42432542 in BMC ophthalmology as Journal Article, Case Reports, with publication-date metadata of 2026-07-10 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42432542-2026-07-10-5adc8b896313-r2`](#source-pubmed-observation-pmid-42432542-2026-07-10-5adc8b896313-r2))

#### Paragraph 1

PubMed lists PMID 42432542 in BMC ophthalmology as Journal Article, Case Reports, with publication-date metadata of 2026-07-10 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42432542-2026-07-10-5adc8b896313-r2`](#source-pubmed-observation-pmid-42432542-2026-07-10-5adc8b896313-r2))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42432542-2026-07-10-5adc8b896313-r2`](#source-pubmed-observation-pmid-42432542-2026-07-10-5adc8b896313-r2))

### Sources

<a id="source-pubmed-observation-pmid-42432542-2026-07-10-5adc8b896313-r2"></a>
- **Partially reversible bilateral non-arteritic anterior ischemic optic neuropathy and branch retinal artery occlusion following semaglutide use. a case report. · retained source version 1:2026-10-09:current:6a817979b50bb89081ffe037839f067ae54384fc5c1170093e9150aee26cd381** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42432542/) (`pubmed-observation-pmid-42432542-2026-07-10-5adc8b896313-r2`)

### Correction lineage

updated on 2026-11-16: PubMed revised the bibliographic metadata of PMID 42432542, with a metadata revision date of 2026-10-09. This version reports that observation; the earlier retained observation remains available as version 1.
- Supersedes version: 1
- Correction sources: [`pubmed-observation-pmid-42432542-2026-07-10-5adc8b896313-r2`](#source-pubmed-observation-pmid-42432542-2026-07-10-5adc8b896313-r2)

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Partially reversible bilateral non-arteritic anterior ischemic optic neuropathy and branch retinal artery occlusion following semaglutide use. a case report." Version 2, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-42432542-semaglutide-v2 SHA-256: 2029fd3e7e307ea4a304be7163db75d817288cb76fadb85573197e42df0c4017.

---

<a id="pubmed-pmid-42436546-semaglutide-v1"></a>

## Semaglutide alters behaviour and nucleus accumbens oscillatory activity in healthy mice.

> PubMed lists PMID 42436546 in Molecular brain as Journal Article, with publication-date metadata of 2026-07-11 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42436546-semaglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-11
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42436546-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-42436546-semaglutide-v1
- Content SHA-256: `9a7b75ca87b8b54297a9a78e54e5289c6565f6165c4a602690c0d161ff3f98c6`

### Claims and source pins

#### Headline

Semaglutide alters behaviour and nucleus accumbens oscillatory activity in healthy mice. ([`pubmed-observation-pmid-42436546-2026-07-11-03a19401f44c`](#source-pubmed-observation-pmid-42436546-2026-07-11-03a19401f44c))

#### Summary

PubMed lists PMID 42436546 in Molecular brain as Journal Article, with publication-date metadata of 2026-07-11 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42436546-2026-07-11-03a19401f44c`](#source-pubmed-observation-pmid-42436546-2026-07-11-03a19401f44c))

#### Paragraph 1

PubMed lists PMID 42436546 in Molecular brain as Journal Article, with publication-date metadata of 2026-07-11 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42436546-2026-07-11-03a19401f44c`](#source-pubmed-observation-pmid-42436546-2026-07-11-03a19401f44c))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42436546-2026-07-11-03a19401f44c`](#source-pubmed-observation-pmid-42436546-2026-07-11-03a19401f44c))

### Sources

<a id="source-pubmed-observation-pmid-42436546-2026-07-11-03a19401f44c"></a>
- **Semaglutide alters behaviour and nucleus accumbens oscillatory activity in healthy mice. · retained source version 1:2026-07-11:current:03a19401f44cfd6338ba59075c0ac32635ab5e2c848d0f4a277dffd88998117e** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42436546/) (`pubmed-observation-pmid-42436546-2026-07-11-03a19401f44c`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Semaglutide alters behaviour and nucleus accumbens oscillatory activity in healthy mice." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-42436546-semaglutide-v1 SHA-256: 9a7b75ca87b8b54297a9a78e54e5289c6565f6165c4a602690c0d161ff3f98c6.

---

<a id="pubmed-pmid-42437874-semaglutide-v1"></a>

## PubMed record PMID 42437874

> PeptideScanner retained PubMed bibliographic metadata for PMID 42437874 at 2026-08-10T10:49:10.764Z. PubMed recorded a metadata revision date of 2026-08-01 and an Entrez history date of 2026-07-12. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-42437874-semaglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-01
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42437874-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-42437874-semaglutide-v1
- Content SHA-256: `9c735989d2d2719703864d0a0d4ce535cb973d5f25be2c28094594b4d799f1cf`

### Claims and source pins

#### Headline

PubMed record PMID 42437874 ([`pubmed-observation-pmid-42437874-2026-08-01-6a2e83b67496`](#source-pubmed-observation-pmid-42437874-2026-08-01-6a2e83b67496))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 42437874 at 2026-08-10T10:49:10.764Z. PubMed recorded a metadata revision date of 2026-08-01 and an Entrez history date of 2026-07-12. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42437874-2026-08-01-6a2e83b67496`](#source-pubmed-observation-pmid-42437874-2026-08-01-6a2e83b67496))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 42437874 at 2026-08-10T10:49:10.764Z. PubMed recorded a metadata revision date of 2026-08-01 and an Entrez history date of 2026-07-12. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42437874-2026-08-01-6a2e83b67496`](#source-pubmed-observation-pmid-42437874-2026-08-01-6a2e83b67496))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42437874-2026-08-01-6a2e83b67496`](#source-pubmed-observation-pmid-42437874-2026-08-01-6a2e83b67496))

### Sources

<a id="source-pubmed-observation-pmid-42437874-2026-08-01-6a2e83b67496"></a>
- **PubMed record PMID 42437874 · retained source version 1:2026-08-01:current:6a2e83b67496c83ec8593b14c623b65c262581f2391a44e7e79ab4c3b75ddf29** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42437874/) (`pubmed-observation-pmid-42437874-2026-08-01-6a2e83b67496`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 42437874." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-42437874-semaglutide-v1 SHA-256: 9c735989d2d2719703864d0a0d4ce535cb973d5f25be2c28094594b4d799f1cf.

---

<a id="pubmed-pmid-42443711-semaglutide-v1"></a>

## PubMed record PMID 42443711

> PeptideScanner retained PubMed bibliographic metadata for PMID 42443711 at 2026-08-10T10:49:10.765Z. PubMed recorded a metadata revision date of 2026-08-09 and an Entrez history date of 2026-07-13. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-42443711-semaglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-09
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-10
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42443711-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-42443711-semaglutide-v1
- Content SHA-256: `5333269cb9b18a551a9502bad36d1cac78d2451c760016a678a48a0b1a34b290`

### Claims and source pins

#### Headline

PubMed record PMID 42443711 ([`pubmed-observation-pmid-42443711-2026-08-09-e0d6709185d6`](#source-pubmed-observation-pmid-42443711-2026-08-09-e0d6709185d6))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 42443711 at 2026-08-10T10:49:10.765Z. PubMed recorded a metadata revision date of 2026-08-09 and an Entrez history date of 2026-07-13. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42443711-2026-08-09-e0d6709185d6`](#source-pubmed-observation-pmid-42443711-2026-08-09-e0d6709185d6))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 42443711 at 2026-08-10T10:49:10.765Z. PubMed recorded a metadata revision date of 2026-08-09 and an Entrez history date of 2026-07-13. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42443711-2026-08-09-e0d6709185d6`](#source-pubmed-observation-pmid-42443711-2026-08-09-e0d6709185d6))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42443711-2026-08-09-e0d6709185d6`](#source-pubmed-observation-pmid-42443711-2026-08-09-e0d6709185d6))

### Sources

<a id="source-pubmed-observation-pmid-42443711-2026-08-09-e0d6709185d6"></a>
- **PubMed record PMID 42443711 · retained source version 1:2026-08-09:current:e0d6709185d6584e2f38865800995e8d8035d7b3ae61c230bfcf1c65bca698b8** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42443711/) (`pubmed-observation-pmid-42443711-2026-08-09-e0d6709185d6`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 42443711." Version 1, published 2026-08-10. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-42443711-semaglutide-v1 SHA-256: 5333269cb9b18a551a9502bad36d1cac78d2451c760016a678a48a0b1a34b290.

---

<a id="pubmed-pmid-42462869-semaglutide-v1"></a>

## The STRIDE Trial and Semaglutide: Implications for Clinical Vascular Practice.

> PubMed lists PMID 42462869 in European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery as Editorial, with publication-date metadata of 2026-07-16 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42462869-semaglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-16
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42462869-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-42462869-semaglutide-v1
- Content SHA-256: `f23607f46e491ec0943a343b7d2e3e8214eb731a11965d7ec5619a80de4e4d2c`

### Claims and source pins

#### Headline

The STRIDE Trial and Semaglutide: Implications for Clinical Vascular Practice. ([`pubmed-observation-pmid-42462869-2026-07-16-aa13c6d06019`](#source-pubmed-observation-pmid-42462869-2026-07-16-aa13c6d06019))

#### Summary

PubMed lists PMID 42462869 in European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery as Editorial, with publication-date metadata of 2026-07-16 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42462869-2026-07-16-aa13c6d06019`](#source-pubmed-observation-pmid-42462869-2026-07-16-aa13c6d06019))

#### Paragraph 1

PubMed lists PMID 42462869 in European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery as Editorial, with publication-date metadata of 2026-07-16 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42462869-2026-07-16-aa13c6d06019`](#source-pubmed-observation-pmid-42462869-2026-07-16-aa13c6d06019))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42462869-2026-07-16-aa13c6d06019`](#source-pubmed-observation-pmid-42462869-2026-07-16-aa13c6d06019))

### Sources

<a id="source-pubmed-observation-pmid-42462869-2026-07-16-aa13c6d06019"></a>
- **The STRIDE Trial and Semaglutide: Implications for Clinical Vascular Practice. · retained source version 1:2026-07-16:current:aa13c6d0601990fe27908ec2190cc891d6785255d9ce72d2a1d602450ec63dc1** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42462869/) (`pubmed-observation-pmid-42462869-2026-07-16-aa13c6d06019`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "The STRIDE Trial and Semaglutide: Implications for Clinical Vascular Practice." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-42462869-semaglutide-v1 SHA-256: f23607f46e491ec0943a343b7d2e3e8214eb731a11965d7ec5619a80de4e4d2c.

---

<a id="pubmed-pmid-42469146-semaglutide-v1"></a>

## Management of patients with cardiovascular disease and overweight/obesity: expert opinion on semaglutide use.

> PubMed lists PMID 42469146 in Nutrition, metabolism, and cardiovascular diseases : NMCD as Journal Article, with publication-date metadata of 2026-07-16 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42469146-semaglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-17
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42469146-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-42469146-semaglutide-v1
- Content SHA-256: `079ae88135b0cbba190bddea1bead7c1646cfc7cefdc0a691adc475b1e81fff9`

### Claims and source pins

#### Headline

Management of patients with cardiovascular disease and overweight/obesity: expert opinion on semaglutide use. ([`pubmed-observation-pmid-42469146-2026-07-17-b145ec90ac55`](#source-pubmed-observation-pmid-42469146-2026-07-17-b145ec90ac55))

#### Summary

PubMed lists PMID 42469146 in Nutrition, metabolism, and cardiovascular diseases : NMCD as Journal Article, with publication-date metadata of 2026-07-16 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42469146-2026-07-17-b145ec90ac55`](#source-pubmed-observation-pmid-42469146-2026-07-17-b145ec90ac55))

#### Paragraph 1

PubMed lists PMID 42469146 in Nutrition, metabolism, and cardiovascular diseases : NMCD as Journal Article, with publication-date metadata of 2026-07-16 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42469146-2026-07-17-b145ec90ac55`](#source-pubmed-observation-pmid-42469146-2026-07-17-b145ec90ac55))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42469146-2026-07-17-b145ec90ac55`](#source-pubmed-observation-pmid-42469146-2026-07-17-b145ec90ac55))

### Sources

<a id="source-pubmed-observation-pmid-42469146-2026-07-17-b145ec90ac55"></a>
- **Management of patients with cardiovascular disease and overweight/obesity: expert opinion on semaglutide use. · retained source version 1:2026-07-17:current:b145ec90ac55ba79f43ae851c58bf98d5c04bfe5469d63514d9612c3a6656dba** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42469146/) (`pubmed-observation-pmid-42469146-2026-07-17-b145ec90ac55`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Management of patients with cardiovascular disease and overweight/obesity: expert opinion on semaglutide use." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-42469146-semaglutide-v1 SHA-256: 079ae88135b0cbba190bddea1bead7c1646cfc7cefdc0a691adc475b1e81fff9.

---

<a id="pubmed-pmid-42469146-semaglutide-v2"></a>

## Management of patients with cardiovascular disease and overweight/obesity: expert opinion on semaglutide use.

> PubMed lists PMID 42469146 in Nutrition, metabolism, and cardiovascular diseases : NMCD as Journal Article, Review, Consensus Statement, with publication-date metadata of 2026-07-16 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42469146-semaglutide:v2`
- Evidence domain: Literature metadata
- Date in source: 2026-11-03
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42469146-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-42469146-semaglutide-v2
- Content SHA-256: `de784381c2ca9bb53fc1263c89f927771c1da4c0b4d34608977859edc6a05d19`

### Claims and source pins

#### Headline

Management of patients with cardiovascular disease and overweight/obesity: expert opinion on semaglutide use. ([`pubmed-observation-pmid-42469146-2026-07-17-b145ec90ac55-r2`](#source-pubmed-observation-pmid-42469146-2026-07-17-b145ec90ac55-r2))

#### Summary

PubMed lists PMID 42469146 in Nutrition, metabolism, and cardiovascular diseases : NMCD as Journal Article, Review, Consensus Statement, with publication-date metadata of 2026-07-16 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42469146-2026-07-17-b145ec90ac55-r2`](#source-pubmed-observation-pmid-42469146-2026-07-17-b145ec90ac55-r2))

#### Paragraph 1

PubMed lists PMID 42469146 in Nutrition, metabolism, and cardiovascular diseases : NMCD as Journal Article, Review, Consensus Statement, with publication-date metadata of 2026-07-16 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42469146-2026-07-17-b145ec90ac55-r2`](#source-pubmed-observation-pmid-42469146-2026-07-17-b145ec90ac55-r2))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42469146-2026-07-17-b145ec90ac55-r2`](#source-pubmed-observation-pmid-42469146-2026-07-17-b145ec90ac55-r2))

### Sources

<a id="source-pubmed-observation-pmid-42469146-2026-07-17-b145ec90ac55-r2"></a>
- **Management of patients with cardiovascular disease and overweight/obesity: expert opinion on semaglutide use. · retained source version 1:2026-11-03:current:e2c7150106c88920904f80cacdf70a9a2afef27c01cfe6787f0f347f4641e09d** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42469146/) (`pubmed-observation-pmid-42469146-2026-07-17-b145ec90ac55-r2`)

### Correction lineage

updated on 2026-11-16: PubMed revised the bibliographic metadata of PMID 42469146, with a metadata revision date of 2026-11-03. This version reports that observation; the earlier retained observation remains available as version 1.
- Supersedes version: 1
- Correction sources: [`pubmed-observation-pmid-42469146-2026-07-17-b145ec90ac55-r2`](#source-pubmed-observation-pmid-42469146-2026-07-17-b145ec90ac55-r2)

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Management of patients with cardiovascular disease and overweight/obesity: expert opinion on semaglutide use." Version 2, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-42469146-semaglutide-v2 SHA-256: de784381c2ca9bb53fc1263c89f927771c1da4c0b4d34608977859edc6a05d19.

---

<a id="pubmed-pmid-42474946-semaglutide-v1"></a>

## Affordable Semaglutide in India: Expanding Access and Unanswered Questions for Children and Special Populations.

> PubMed lists PMID 42474946 in Indian pediatrics as Letter, with publication-date metadata of 2026-07-20 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42474946-semaglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-20
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42474946-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-42474946-semaglutide-v1
- Content SHA-256: `12082ca88c91bec261e87e7d2cd269db75e9622a64f1903f51b4cdb0c23087c7`

### Claims and source pins

#### Headline

Affordable Semaglutide in India: Expanding Access and Unanswered Questions for Children and Special Populations. ([`pubmed-observation-pmid-42474946-2026-07-20-e63a85694fb5`](#source-pubmed-observation-pmid-42474946-2026-07-20-e63a85694fb5))

#### Summary

PubMed lists PMID 42474946 in Indian pediatrics as Letter, with publication-date metadata of 2026-07-20 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42474946-2026-07-20-e63a85694fb5`](#source-pubmed-observation-pmid-42474946-2026-07-20-e63a85694fb5))

#### Paragraph 1

PubMed lists PMID 42474946 in Indian pediatrics as Letter, with publication-date metadata of 2026-07-20 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42474946-2026-07-20-e63a85694fb5`](#source-pubmed-observation-pmid-42474946-2026-07-20-e63a85694fb5))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42474946-2026-07-20-e63a85694fb5`](#source-pubmed-observation-pmid-42474946-2026-07-20-e63a85694fb5))

### Sources

<a id="source-pubmed-observation-pmid-42474946-2026-07-20-e63a85694fb5"></a>
- **Affordable Semaglutide in India: Expanding Access and Unanswered Questions for Children and Special Populations. · retained source version 1:2026-07-20:current:e63a85694fb5e6363b4b7ad35adb80e27ad87a19012f948ee5599e18fc6090e1** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42474946/) (`pubmed-observation-pmid-42474946-2026-07-20-e63a85694fb5`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Affordable Semaglutide in India: Expanding Access and Unanswered Questions for Children and Special Populations." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-42474946-semaglutide-v1 SHA-256: 12082ca88c91bec261e87e7d2cd269db75e9622a64f1903f51b4cdb0c23087c7.

---

<a id="pubmed-pmid-42487380-semaglutide-v1"></a>

## The silent rise of self-prescribed semaglutide use among non-obese young adults in the Middle East.

> PubMed lists PMID 42487380 in Eastern Mediterranean health journal = La revue de sante de la Mediterranee orientale = al-Majallah al-sihhiyah li-sharq al-mutawassit as Letter, with publication-date metadata of 2026-06-28 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42487380-semaglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-23
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42487380-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-42487380-semaglutide-v1
- Content SHA-256: `aab5a8f28abf23228280b2054e975b2cd18da20594dd2637e0a0e4eb541eafd3`

### Claims and source pins

#### Headline

The silent rise of self-prescribed semaglutide use among non-obese young adults in the Middle East. ([`pubmed-observation-pmid-42487380-2026-07-23-23f4664a58be`](#source-pubmed-observation-pmid-42487380-2026-07-23-23f4664a58be))

#### Summary

PubMed lists PMID 42487380 in Eastern Mediterranean health journal = La revue de sante de la Mediterranee orientale = al-Majallah al-sihhiyah li-sharq al-mutawassit as Letter, with publication-date metadata of 2026-06-28 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42487380-2026-07-23-23f4664a58be`](#source-pubmed-observation-pmid-42487380-2026-07-23-23f4664a58be))

#### Paragraph 1

PubMed lists PMID 42487380 in Eastern Mediterranean health journal = La revue de sante de la Mediterranee orientale = al-Majallah al-sihhiyah li-sharq al-mutawassit as Letter, with publication-date metadata of 2026-06-28 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42487380-2026-07-23-23f4664a58be`](#source-pubmed-observation-pmid-42487380-2026-07-23-23f4664a58be))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42487380-2026-07-23-23f4664a58be`](#source-pubmed-observation-pmid-42487380-2026-07-23-23f4664a58be))

### Sources

<a id="source-pubmed-observation-pmid-42487380-2026-07-23-23f4664a58be"></a>
- **The silent rise of self-prescribed semaglutide use among non-obese young adults in the Middle East. · retained source version 1:2026-07-23:current:23f4664a58be15d09ef51e43564a4d2a4ae11e80dfc469ccdb96966ddd06d5a6** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42487380/) (`pubmed-observation-pmid-42487380-2026-07-23-23f4664a58be`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "The silent rise of self-prescribed semaglutide use among non-obese young adults in the Middle East." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-42487380-semaglutide-v1 SHA-256: aab5a8f28abf23228280b2054e975b2cd18da20594dd2637e0a0e4eb541eafd3.

---

<a id="pubmed-pmid-42493207-semaglutide-v1"></a>

## PubMed record PMID 42493207

> PeptideScanner retained PubMed bibliographic metadata for PMID 42493207 at 2026-08-10T18:13:56.730Z. PubMed recorded a metadata revision date of 2026-07-29 and an Entrez history date of 2026-07-23. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-42493207-semaglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-29
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42493207-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-42493207-semaglutide-v1
- Content SHA-256: `44c8b71302ede44e20b2903af3607302dc7f43d2917f6ebc0e308f7ab659fc9e`

### Claims and source pins

#### Headline

PubMed record PMID 42493207 ([`pubmed-observation-pmid-42493207-2026-07-29-c3a8aea4a016`](#source-pubmed-observation-pmid-42493207-2026-07-29-c3a8aea4a016))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 42493207 at 2026-08-10T18:13:56.730Z. PubMed recorded a metadata revision date of 2026-07-29 and an Entrez history date of 2026-07-23. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42493207-2026-07-29-c3a8aea4a016`](#source-pubmed-observation-pmid-42493207-2026-07-29-c3a8aea4a016))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 42493207 at 2026-08-10T18:13:56.730Z. PubMed recorded a metadata revision date of 2026-07-29 and an Entrez history date of 2026-07-23. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42493207-2026-07-29-c3a8aea4a016`](#source-pubmed-observation-pmid-42493207-2026-07-29-c3a8aea4a016))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42493207-2026-07-29-c3a8aea4a016`](#source-pubmed-observation-pmid-42493207-2026-07-29-c3a8aea4a016))

### Sources

<a id="source-pubmed-observation-pmid-42493207-2026-07-29-c3a8aea4a016"></a>
- **PubMed record PMID 42493207 · retained source version 1:2026-07-29:current:c3a8aea4a016d793434a4356f67060cf300c097d7c13101aae3134b5d33834ca** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42493207/) (`pubmed-observation-pmid-42493207-2026-07-29-c3a8aea4a016`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 42493207." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-42493207-semaglutide-v1 SHA-256: 44c8b71302ede44e20b2903af3607302dc7f43d2917f6ebc0e308f7ab659fc9e.

---

<a id="pubmed-pmid-42495930-semaglutide-v1"></a>

## PubMed record PMID 42495930

> PeptideScanner retained PubMed bibliographic metadata for PMID 42495930 at 2026-08-10T10:49:10.785Z. PubMed recorded a metadata revision date of 2026-08-06 and an Entrez history date of 2026-07-24. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-42495930-semaglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-06
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-11
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42495930-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-42495930-semaglutide-v1
- Content SHA-256: `422d1f10ea84c2ef66c5cf8749741f183c1048b0a4d9bb161373cd86f85bf035`

### Claims and source pins

#### Headline

PubMed record PMID 42495930 ([`pubmed-observation-pmid-42495930-2026-08-06-12fbcd51f647`](#source-pubmed-observation-pmid-42495930-2026-08-06-12fbcd51f647))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 42495930 at 2026-08-10T10:49:10.785Z. PubMed recorded a metadata revision date of 2026-08-06 and an Entrez history date of 2026-07-24. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42495930-2026-08-06-12fbcd51f647`](#source-pubmed-observation-pmid-42495930-2026-08-06-12fbcd51f647))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 42495930 at 2026-08-10T10:49:10.785Z. PubMed recorded a metadata revision date of 2026-08-06 and an Entrez history date of 2026-07-24. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42495930-2026-08-06-12fbcd51f647`](#source-pubmed-observation-pmid-42495930-2026-08-06-12fbcd51f647))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42495930-2026-08-06-12fbcd51f647`](#source-pubmed-observation-pmid-42495930-2026-08-06-12fbcd51f647))

### Sources

<a id="source-pubmed-observation-pmid-42495930-2026-08-06-12fbcd51f647"></a>
- **PubMed record PMID 42495930 · retained source version 1:2026-08-06:current:12fbcd51f6478058bafd79bc74a677f4a2fbc87e85002f59afd1dd02c8d139ba** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42495930/) (`pubmed-observation-pmid-42495930-2026-08-06-12fbcd51f647`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 42495930." Version 1, published 2026-08-11. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-42495930-semaglutide-v1 SHA-256: 422d1f10ea84c2ef66c5cf8749741f183c1048b0a4d9bb161373cd86f85bf035.

---

<a id="pubmed-pmid-42503575-semaglutide-v1"></a>

## PubMed record PMID 42503575

> PeptideScanner retained PubMed bibliographic metadata for PMID 42503575 at 2026-08-10T18:13:56.757Z. PubMed recorded a metadata revision date of 2026-07-26 and an Entrez history date of 2026-07-26. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-42503575-semaglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-26
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42503575-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-42503575-semaglutide-v1
- Content SHA-256: `a421c33e2152d11a41d45dabd1676340596d98cc4852c84fd1d3f019585f9440`

### Claims and source pins

#### Headline

PubMed record PMID 42503575 ([`pubmed-observation-pmid-42503575-2026-07-26-722e637e5db9`](#source-pubmed-observation-pmid-42503575-2026-07-26-722e637e5db9))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 42503575 at 2026-08-10T18:13:56.757Z. PubMed recorded a metadata revision date of 2026-07-26 and an Entrez history date of 2026-07-26. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42503575-2026-07-26-722e637e5db9`](#source-pubmed-observation-pmid-42503575-2026-07-26-722e637e5db9))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 42503575 at 2026-08-10T18:13:56.757Z. PubMed recorded a metadata revision date of 2026-07-26 and an Entrez history date of 2026-07-26. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42503575-2026-07-26-722e637e5db9`](#source-pubmed-observation-pmid-42503575-2026-07-26-722e637e5db9))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42503575-2026-07-26-722e637e5db9`](#source-pubmed-observation-pmid-42503575-2026-07-26-722e637e5db9))

### Sources

<a id="source-pubmed-observation-pmid-42503575-2026-07-26-722e637e5db9"></a>
- **PubMed record PMID 42503575 · retained source version 1:2026-07-26:current:722e637e5db987cdece21b55219810aa74f3c71014c43128abcfdc3fe2080f5f** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42503575/) (`pubmed-observation-pmid-42503575-2026-07-26-722e637e5db9`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 42503575." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-42503575-semaglutide-v1 SHA-256: a421c33e2152d11a41d45dabd1676340596d98cc4852c84fd1d3f019585f9440.

---

<a id="pubmed-pmid-42504064-semaglutide-v1"></a>

## PubMed record PMID 42504064

> PeptideScanner retained PubMed bibliographic metadata for PMID 42504064 at 2026-08-10T10:49:10.789Z. PubMed recorded a metadata revision date of 2026-08-05 and an Entrez history date of 2026-07-27. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-42504064-semaglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-05
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-11
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42504064-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-42504064-semaglutide-v1
- Content SHA-256: `9897669f9cf73e01ffc143b55c8fbec37c7233e2f34777daf059e3e1f7203024`

### Claims and source pins

#### Headline

PubMed record PMID 42504064 ([`pubmed-observation-pmid-42504064-2026-08-05-878e8d760e08`](#source-pubmed-observation-pmid-42504064-2026-08-05-878e8d760e08))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 42504064 at 2026-08-10T10:49:10.789Z. PubMed recorded a metadata revision date of 2026-08-05 and an Entrez history date of 2026-07-27. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42504064-2026-08-05-878e8d760e08`](#source-pubmed-observation-pmid-42504064-2026-08-05-878e8d760e08))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 42504064 at 2026-08-10T10:49:10.789Z. PubMed recorded a metadata revision date of 2026-08-05 and an Entrez history date of 2026-07-27. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42504064-2026-08-05-878e8d760e08`](#source-pubmed-observation-pmid-42504064-2026-08-05-878e8d760e08))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42504064-2026-08-05-878e8d760e08`](#source-pubmed-observation-pmid-42504064-2026-08-05-878e8d760e08))

### Sources

<a id="source-pubmed-observation-pmid-42504064-2026-08-05-878e8d760e08"></a>
- **PubMed record PMID 42504064 · retained source version 1:2026-08-05:current:878e8d760e08bc60cb7088f527a68aa977580a4b0a199cd345cb7a3bc617b66c** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42504064/) (`pubmed-observation-pmid-42504064-2026-08-05-878e8d760e08`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 42504064." Version 1, published 2026-08-11. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-42504064-semaglutide-v1 SHA-256: 9897669f9cf73e01ffc143b55c8fbec37c7233e2f34777daf059e3e1f7203024.

---

<a id="pubmed-pmid-42513491-semaglutide-v1"></a>

## PubMed record PMID 42513491

> PeptideScanner retained PubMed bibliographic metadata for PMID 42513491 at 2026-08-10T10:49:12.876Z. PubMed recorded a metadata revision date of 2026-07-30 and an Entrez history date of 2026-07-28. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-42513491-semaglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-30
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42513491-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-42513491-semaglutide-v1
- Content SHA-256: `7f723a4baffde2e19d73f46be895e1dc9380d8bcf2170d272469f36ecc9c4229`

### Claims and source pins

#### Headline

PubMed record PMID 42513491 ([`pubmed-observation-pmid-42513491-2026-07-30-d191ee55545c`](#source-pubmed-observation-pmid-42513491-2026-07-30-d191ee55545c))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 42513491 at 2026-08-10T10:49:12.876Z. PubMed recorded a metadata revision date of 2026-07-30 and an Entrez history date of 2026-07-28. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42513491-2026-07-30-d191ee55545c`](#source-pubmed-observation-pmid-42513491-2026-07-30-d191ee55545c))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 42513491 at 2026-08-10T10:49:12.876Z. PubMed recorded a metadata revision date of 2026-07-30 and an Entrez history date of 2026-07-28. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42513491-2026-07-30-d191ee55545c`](#source-pubmed-observation-pmid-42513491-2026-07-30-d191ee55545c))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42513491-2026-07-30-d191ee55545c`](#source-pubmed-observation-pmid-42513491-2026-07-30-d191ee55545c))

### Sources

<a id="source-pubmed-observation-pmid-42513491-2026-07-30-d191ee55545c"></a>
- **PubMed record PMID 42513491 · retained source version 1:2026-07-30:current:d191ee55545c0719a522f006c7f80edf219389a5672b54b49caaa84b08eedb64** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42513491/) (`pubmed-observation-pmid-42513491-2026-07-30-d191ee55545c`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 42513491." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-42513491-semaglutide-v1 SHA-256: 7f723a4baffde2e19d73f46be895e1dc9380d8bcf2170d272469f36ecc9c4229.

---

<a id="pubmed-pmid-42516042-semaglutide-v1"></a>

## PubMed record PMID 42516042

> PeptideScanner retained PubMed bibliographic metadata for PMID 42516042 at 2026-08-10T18:13:56.764Z. PubMed recorded a metadata revision date of 2026-07-28 and an Entrez history date of 2026-07-28. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-42516042-semaglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-28
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42516042-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-42516042-semaglutide-v1
- Content SHA-256: `8fed6bc469a2c4ec915e859133456dfb9b555400a6bd8cf1f4fc6ecf68d913cb`

### Claims and source pins

#### Headline

PubMed record PMID 42516042 ([`pubmed-observation-pmid-42516042-2026-07-28-e103dc60bb7a`](#source-pubmed-observation-pmid-42516042-2026-07-28-e103dc60bb7a))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 42516042 at 2026-08-10T18:13:56.764Z. PubMed recorded a metadata revision date of 2026-07-28 and an Entrez history date of 2026-07-28. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42516042-2026-07-28-e103dc60bb7a`](#source-pubmed-observation-pmid-42516042-2026-07-28-e103dc60bb7a))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 42516042 at 2026-08-10T18:13:56.764Z. PubMed recorded a metadata revision date of 2026-07-28 and an Entrez history date of 2026-07-28. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42516042-2026-07-28-e103dc60bb7a`](#source-pubmed-observation-pmid-42516042-2026-07-28-e103dc60bb7a))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42516042-2026-07-28-e103dc60bb7a`](#source-pubmed-observation-pmid-42516042-2026-07-28-e103dc60bb7a))

### Sources

<a id="source-pubmed-observation-pmid-42516042-2026-07-28-e103dc60bb7a"></a>
- **PubMed record PMID 42516042 · retained source version 1:2026-07-28:current:e103dc60bb7ad39cdc364257d72264a707ec0c1d8adc4f6fc81c6aade90c50eb** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42516042/) (`pubmed-observation-pmid-42516042-2026-07-28-e103dc60bb7a`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 42516042." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-42516042-semaglutide-v1 SHA-256: 8fed6bc469a2c4ec915e859133456dfb9b555400a6bd8cf1f4fc6ecf68d913cb.

---

<a id="pubmed-pmid-42518971-semaglutide-v1"></a>

## PubMed record PMID 42518971

> PeptideScanner retained PubMed bibliographic metadata for PMID 42518971 at 2026-08-10T18:13:56.776Z. PubMed recorded a metadata revision date of 2026-07-29 and an Entrez history date of 2026-07-28. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-42518971-semaglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-29
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42518971-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-42518971-semaglutide-v1
- Content SHA-256: `769481aee90b8b0419181a8fb32f93a3de494921b3d5703f1559806e15525202`

### Claims and source pins

#### Headline

PubMed record PMID 42518971 ([`pubmed-observation-pmid-42518971-2026-07-29-58292640a7bb`](#source-pubmed-observation-pmid-42518971-2026-07-29-58292640a7bb))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 42518971 at 2026-08-10T18:13:56.776Z. PubMed recorded a metadata revision date of 2026-07-29 and an Entrez history date of 2026-07-28. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42518971-2026-07-29-58292640a7bb`](#source-pubmed-observation-pmid-42518971-2026-07-29-58292640a7bb))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 42518971 at 2026-08-10T18:13:56.776Z. PubMed recorded a metadata revision date of 2026-07-29 and an Entrez history date of 2026-07-28. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42518971-2026-07-29-58292640a7bb`](#source-pubmed-observation-pmid-42518971-2026-07-29-58292640a7bb))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42518971-2026-07-29-58292640a7bb`](#source-pubmed-observation-pmid-42518971-2026-07-29-58292640a7bb))

### Sources

<a id="source-pubmed-observation-pmid-42518971-2026-07-29-58292640a7bb"></a>
- **PubMed record PMID 42518971 · retained source version 1:2026-07-29:current:58292640a7bbbe38d98dc525cec8a60486bd81067fa7bf1a5d900c5a2244ac3c** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42518971/) (`pubmed-observation-pmid-42518971-2026-07-29-58292640a7bb`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 42518971." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-42518971-semaglutide-v1 SHA-256: 769481aee90b8b0419181a8fb32f93a3de494921b3d5703f1559806e15525202.

---

<a id="pubmed-pmid-42520650-semaglutide-v1"></a>

## PubMed record PMID 42520650

> PeptideScanner retained PubMed bibliographic metadata for PMID 42520650 at 2026-08-10T18:13:56.780Z. PubMed recorded a metadata revision date of 2026-07-28 and an Entrez history date of 2026-07-28. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-42520650-semaglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-28
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42520650-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-42520650-semaglutide-v1
- Content SHA-256: `58d2a2dce1b6cc0e65b9aafbc8bf158846c3f59e9851f0958a6221f5c3a32c0f`

### Claims and source pins

#### Headline

PubMed record PMID 42520650 ([`pubmed-observation-pmid-42520650-2026-07-28-d7cc87d5cc72`](#source-pubmed-observation-pmid-42520650-2026-07-28-d7cc87d5cc72))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 42520650 at 2026-08-10T18:13:56.780Z. PubMed recorded a metadata revision date of 2026-07-28 and an Entrez history date of 2026-07-28. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42520650-2026-07-28-d7cc87d5cc72`](#source-pubmed-observation-pmid-42520650-2026-07-28-d7cc87d5cc72))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 42520650 at 2026-08-10T18:13:56.780Z. PubMed recorded a metadata revision date of 2026-07-28 and an Entrez history date of 2026-07-28. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42520650-2026-07-28-d7cc87d5cc72`](#source-pubmed-observation-pmid-42520650-2026-07-28-d7cc87d5cc72))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42520650-2026-07-28-d7cc87d5cc72`](#source-pubmed-observation-pmid-42520650-2026-07-28-d7cc87d5cc72))

### Sources

<a id="source-pubmed-observation-pmid-42520650-2026-07-28-d7cc87d5cc72"></a>
- **PubMed record PMID 42520650 · retained source version 1:2026-07-28:current:d7cc87d5cc724b7160bc193cb1725c10ed8189ca2cf201bd1e33d70fd3b4553a** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42520650/) (`pubmed-observation-pmid-42520650-2026-07-28-d7cc87d5cc72`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 42520650." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-42520650-semaglutide-v1 SHA-256: 58d2a2dce1b6cc0e65b9aafbc8bf158846c3f59e9851f0958a6221f5c3a32c0f.

---

<a id="pubmed-pmid-42526426-semaglutide-v1"></a>

## PubMed record PMID 42526426

> PeptideScanner retained PubMed bibliographic metadata for PMID 42526426 at 2026-08-10T18:13:57.051Z. PubMed recorded a metadata revision date of 2026-07-29 and an Entrez history date of 2026-07-29. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-42526426-semaglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-29
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42526426-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-42526426-semaglutide-v1
- Content SHA-256: `0d69d42ddfa178177542f1c1de4a1addf975d6533588fdaf4f1fae92998d33e3`

### Claims and source pins

#### Headline

PubMed record PMID 42526426 ([`pubmed-observation-pmid-42526426-2026-07-29-8359f2d92449`](#source-pubmed-observation-pmid-42526426-2026-07-29-8359f2d92449))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 42526426 at 2026-08-10T18:13:57.051Z. PubMed recorded a metadata revision date of 2026-07-29 and an Entrez history date of 2026-07-29. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42526426-2026-07-29-8359f2d92449`](#source-pubmed-observation-pmid-42526426-2026-07-29-8359f2d92449))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 42526426 at 2026-08-10T18:13:57.051Z. PubMed recorded a metadata revision date of 2026-07-29 and an Entrez history date of 2026-07-29. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42526426-2026-07-29-8359f2d92449`](#source-pubmed-observation-pmid-42526426-2026-07-29-8359f2d92449))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42526426-2026-07-29-8359f2d92449`](#source-pubmed-observation-pmid-42526426-2026-07-29-8359f2d92449))

### Sources

<a id="source-pubmed-observation-pmid-42526426-2026-07-29-8359f2d92449"></a>
- **PubMed record PMID 42526426 · retained source version 1:2026-07-29:current:8359f2d924491416d63dccd95c7e6c6b93d274aec87eb1d624eb1aa66aaf2d03** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42526426/) (`pubmed-observation-pmid-42526426-2026-07-29-8359f2d92449`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 42526426." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-42526426-semaglutide-v1 SHA-256: 0d69d42ddfa178177542f1c1de4a1addf975d6533588fdaf4f1fae92998d33e3.

---

<a id="pubmed-pmid-42535667-semaglutide-v1"></a>

## PubMed record PMID 42535667

> PeptideScanner retained PubMed bibliographic metadata for PMID 42535667 at 2026-08-10T10:49:12.941Z. PubMed recorded a metadata revision date of 2026-08-03 and an Entrez history date of 2026-07-31. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-42535667-semaglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-03
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-11
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42535667-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-42535667-semaglutide-v1
- Content SHA-256: `b458dc71c870ee120e9eb40c7d5be2e35490deb80e3f1309150f05e5693f19d4`

### Claims and source pins

#### Headline

PubMed record PMID 42535667 ([`pubmed-observation-pmid-42535667-2026-08-03-f1bf6858e078`](#source-pubmed-observation-pmid-42535667-2026-08-03-f1bf6858e078))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 42535667 at 2026-08-10T10:49:12.941Z. PubMed recorded a metadata revision date of 2026-08-03 and an Entrez history date of 2026-07-31. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42535667-2026-08-03-f1bf6858e078`](#source-pubmed-observation-pmid-42535667-2026-08-03-f1bf6858e078))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 42535667 at 2026-08-10T10:49:12.941Z. PubMed recorded a metadata revision date of 2026-08-03 and an Entrez history date of 2026-07-31. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42535667-2026-08-03-f1bf6858e078`](#source-pubmed-observation-pmid-42535667-2026-08-03-f1bf6858e078))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42535667-2026-08-03-f1bf6858e078`](#source-pubmed-observation-pmid-42535667-2026-08-03-f1bf6858e078))

### Sources

<a id="source-pubmed-observation-pmid-42535667-2026-08-03-f1bf6858e078"></a>
- **PubMed record PMID 42535667 · retained source version 1:2026-08-03:current:f1bf6858e07811494783a04b8cfe4e860ac31f361922f29ae74cf5fbf77d3385** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42535667/) (`pubmed-observation-pmid-42535667-2026-08-03-f1bf6858e078`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 42535667." Version 1, published 2026-08-11. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-42535667-semaglutide-v1 SHA-256: b458dc71c870ee120e9eb40c7d5be2e35490deb80e3f1309150f05e5693f19d4.

---

<a id="pubmed-pmid-42540132-semaglutide-v1"></a>

## PubMed record PMID 42540132

> PeptideScanner retained PubMed bibliographic metadata for PMID 42540132 at 2026-08-10T10:49:12.959Z. PubMed recorded a metadata revision date of 2026-08-01 and an Entrez history date of 2026-08-01. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-42540132-semaglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-01
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42540132-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-42540132-semaglutide-v1
- Content SHA-256: `2809ac03879af79cb1d272318f9645f9598068cb8a7f200f5e42ef955f5d7536`

### Claims and source pins

#### Headline

PubMed record PMID 42540132 ([`pubmed-observation-pmid-42540132-2026-08-01-93f8379e79bf`](#source-pubmed-observation-pmid-42540132-2026-08-01-93f8379e79bf))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 42540132 at 2026-08-10T10:49:12.959Z. PubMed recorded a metadata revision date of 2026-08-01 and an Entrez history date of 2026-08-01. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42540132-2026-08-01-93f8379e79bf`](#source-pubmed-observation-pmid-42540132-2026-08-01-93f8379e79bf))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 42540132 at 2026-08-10T10:49:12.959Z. PubMed recorded a metadata revision date of 2026-08-01 and an Entrez history date of 2026-08-01. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42540132-2026-08-01-93f8379e79bf`](#source-pubmed-observation-pmid-42540132-2026-08-01-93f8379e79bf))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42540132-2026-08-01-93f8379e79bf`](#source-pubmed-observation-pmid-42540132-2026-08-01-93f8379e79bf))

### Sources

<a id="source-pubmed-observation-pmid-42540132-2026-08-01-93f8379e79bf"></a>
- **PubMed record PMID 42540132 · retained source version 1:2026-08-01:current:93f8379e79bfa658c9b8ee17789518f7f9ec3b4b68edfd80488673d67fb08f9a** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42540132/) (`pubmed-observation-pmid-42540132-2026-08-01-93f8379e79bf`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 42540132." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-42540132-semaglutide-v1 SHA-256: 2809ac03879af79cb1d272318f9645f9598068cb8a7f200f5e42ef955f5d7536.

---

<a id="pubmed-pmid-42541373-semaglutide-v1"></a>

## PubMed record PMID 42541373

> PeptideScanner retained PubMed bibliographic metadata for PMID 42541373 at 2026-08-10T10:49:12.960Z. PubMed recorded a metadata revision date of 2026-08-06 and an Entrez history date of 2026-08-01. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-42541373-semaglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-06
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-11
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42541373-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-42541373-semaglutide-v1
- Content SHA-256: `6fed3c9710defb4ef55e09f9dd305c2ca213ef93038c8bddafd12e4b3cf4d399`

### Claims and source pins

#### Headline

PubMed record PMID 42541373 ([`pubmed-observation-pmid-42541373-2026-08-06-6dbed26f4178`](#source-pubmed-observation-pmid-42541373-2026-08-06-6dbed26f4178))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 42541373 at 2026-08-10T10:49:12.960Z. PubMed recorded a metadata revision date of 2026-08-06 and an Entrez history date of 2026-08-01. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42541373-2026-08-06-6dbed26f4178`](#source-pubmed-observation-pmid-42541373-2026-08-06-6dbed26f4178))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 42541373 at 2026-08-10T10:49:12.960Z. PubMed recorded a metadata revision date of 2026-08-06 and an Entrez history date of 2026-08-01. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42541373-2026-08-06-6dbed26f4178`](#source-pubmed-observation-pmid-42541373-2026-08-06-6dbed26f4178))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42541373-2026-08-06-6dbed26f4178`](#source-pubmed-observation-pmid-42541373-2026-08-06-6dbed26f4178))

### Sources

<a id="source-pubmed-observation-pmid-42541373-2026-08-06-6dbed26f4178"></a>
- **PubMed record PMID 42541373 · retained source version 1:2026-08-06:current:6dbed26f41781729dd27a172594e2057b90dfa9cb1592b929331fdacf34fa4a7** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42541373/) (`pubmed-observation-pmid-42541373-2026-08-06-6dbed26f4178`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 42541373." Version 1, published 2026-08-11. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-42541373-semaglutide-v1 SHA-256: 6fed3c9710defb4ef55e09f9dd305c2ca213ef93038c8bddafd12e4b3cf4d399.

---

<a id="pubmed-pmid-42542232-semaglutide-v1"></a>

## PubMed record PMID 42542232

> PeptideScanner retained PubMed bibliographic metadata for PMID 42542232 at 2026-08-10T10:49:12.963Z. PubMed recorded a metadata revision date of 2026-08-06 and an Entrez history date of 2026-08-01. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-42542232-semaglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-06
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-10
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42542232-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-42542232-semaglutide-v1
- Content SHA-256: `7276a2fed09882a3bc1a8458a1d72b4c5430ae160b576c7448009d3d2bf5ec51`

### Claims and source pins

#### Headline

PubMed record PMID 42542232 ([`pubmed-observation-pmid-42542232-2026-08-06-80fb0ee0507d`](#source-pubmed-observation-pmid-42542232-2026-08-06-80fb0ee0507d))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 42542232 at 2026-08-10T10:49:12.963Z. PubMed recorded a metadata revision date of 2026-08-06 and an Entrez history date of 2026-08-01. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42542232-2026-08-06-80fb0ee0507d`](#source-pubmed-observation-pmid-42542232-2026-08-06-80fb0ee0507d))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 42542232 at 2026-08-10T10:49:12.963Z. PubMed recorded a metadata revision date of 2026-08-06 and an Entrez history date of 2026-08-01. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42542232-2026-08-06-80fb0ee0507d`](#source-pubmed-observation-pmid-42542232-2026-08-06-80fb0ee0507d))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42542232-2026-08-06-80fb0ee0507d`](#source-pubmed-observation-pmid-42542232-2026-08-06-80fb0ee0507d))

### Sources

<a id="source-pubmed-observation-pmid-42542232-2026-08-06-80fb0ee0507d"></a>
- **PubMed record PMID 42542232 · retained source version 1:2026-08-06:current:80fb0ee0507d5b88346f77e9f74e0fa3dd20f7a3dea7a8c3d1c31a5b6ca672d2** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42542232/) (`pubmed-observation-pmid-42542232-2026-08-06-80fb0ee0507d`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 42542232." Version 1, published 2026-08-10. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-42542232-semaglutide-v1 SHA-256: 7276a2fed09882a3bc1a8458a1d72b4c5430ae160b576c7448009d3d2bf5ec51.

---

<a id="pubmed-pmid-42546302-semaglutide-v1"></a>

## PubMed record PMID 42546302

> PeptideScanner retained PubMed bibliographic metadata for PMID 42546302 at 2026-08-10T10:49:12.978Z. PubMed recorded a metadata revision date of 2026-08-03 and an Entrez history date of 2026-08-03. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-42546302-semaglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-03
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-11
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42546302-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-42546302-semaglutide-v1
- Content SHA-256: `a744a8d1ab9aec02dc5728ae20195cbbf8ddcbe5abee973f584f415df0399449`

### Claims and source pins

#### Headline

PubMed record PMID 42546302 ([`pubmed-observation-pmid-42546302-2026-08-03-7bf1d3ce8cac`](#source-pubmed-observation-pmid-42546302-2026-08-03-7bf1d3ce8cac))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 42546302 at 2026-08-10T10:49:12.978Z. PubMed recorded a metadata revision date of 2026-08-03 and an Entrez history date of 2026-08-03. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42546302-2026-08-03-7bf1d3ce8cac`](#source-pubmed-observation-pmid-42546302-2026-08-03-7bf1d3ce8cac))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 42546302 at 2026-08-10T10:49:12.978Z. PubMed recorded a metadata revision date of 2026-08-03 and an Entrez history date of 2026-08-03. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42546302-2026-08-03-7bf1d3ce8cac`](#source-pubmed-observation-pmid-42546302-2026-08-03-7bf1d3ce8cac))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42546302-2026-08-03-7bf1d3ce8cac`](#source-pubmed-observation-pmid-42546302-2026-08-03-7bf1d3ce8cac))

### Sources

<a id="source-pubmed-observation-pmid-42546302-2026-08-03-7bf1d3ce8cac"></a>
- **PubMed record PMID 42546302 · retained source version 1:2026-08-03:current:7bf1d3ce8cac765e6b23fc2e1870d5067aa4ed0d4622446a103167f950afb8b4** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42546302/) (`pubmed-observation-pmid-42546302-2026-08-03-7bf1d3ce8cac`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 42546302." Version 1, published 2026-08-11. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-42546302-semaglutide-v1 SHA-256: a744a8d1ab9aec02dc5728ae20195cbbf8ddcbe5abee973f584f415df0399449.

---

<a id="pubmed-pmid-42547311-semaglutide-v1"></a>

## PubMed record PMID 42547311

> PeptideScanner retained PubMed bibliographic metadata for PMID 42547311 at 2026-08-10T10:49:12.979Z. PubMed recorded a metadata revision date of 2026-08-03 and an Entrez history date of 2026-08-03. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-42547311-semaglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-03
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-11
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42547311-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-42547311-semaglutide-v1
- Content SHA-256: `5403f0895293b5d44536ddcf568de54312134c8178718738b6bccc86cb9e881a`

### Claims and source pins

#### Headline

PubMed record PMID 42547311 ([`pubmed-observation-pmid-42547311-2026-08-03-fdd966b74f86`](#source-pubmed-observation-pmid-42547311-2026-08-03-fdd966b74f86))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 42547311 at 2026-08-10T10:49:12.979Z. PubMed recorded a metadata revision date of 2026-08-03 and an Entrez history date of 2026-08-03. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42547311-2026-08-03-fdd966b74f86`](#source-pubmed-observation-pmid-42547311-2026-08-03-fdd966b74f86))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 42547311 at 2026-08-10T10:49:12.979Z. PubMed recorded a metadata revision date of 2026-08-03 and an Entrez history date of 2026-08-03. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42547311-2026-08-03-fdd966b74f86`](#source-pubmed-observation-pmid-42547311-2026-08-03-fdd966b74f86))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42547311-2026-08-03-fdd966b74f86`](#source-pubmed-observation-pmid-42547311-2026-08-03-fdd966b74f86))

### Sources

<a id="source-pubmed-observation-pmid-42547311-2026-08-03-fdd966b74f86"></a>
- **PubMed record PMID 42547311 · retained source version 1:2026-08-03:current:fdd966b74f8698059242c959e5afd260e6a1dd8b8bb4c877f725db4944f40312** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42547311/) (`pubmed-observation-pmid-42547311-2026-08-03-fdd966b74f86`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 42547311." Version 1, published 2026-08-11. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-42547311-semaglutide-v1 SHA-256: 5403f0895293b5d44536ddcf568de54312134c8178718738b6bccc86cb9e881a.

---

<a id="pubmed-pmid-42549476-semaglutide-v1"></a>

## PubMed record PMID 42549476

> PeptideScanner retained PubMed bibliographic metadata for PMID 42549476 at 2026-08-10T10:49:12.984Z. PubMed recorded a metadata revision date of 2026-08-04 and an Entrez history date of 2026-08-04. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-42549476-semaglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-04
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-11
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42549476-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-42549476-semaglutide-v1
- Content SHA-256: `2cd4c7cbf76abdd44086516785f9cfa4b24e3ffdc7528288bb9eab8801696438`

### Claims and source pins

#### Headline

PubMed record PMID 42549476 ([`pubmed-observation-pmid-42549476-2026-08-04-7a8c79b2c130`](#source-pubmed-observation-pmid-42549476-2026-08-04-7a8c79b2c130))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 42549476 at 2026-08-10T10:49:12.984Z. PubMed recorded a metadata revision date of 2026-08-04 and an Entrez history date of 2026-08-04. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42549476-2026-08-04-7a8c79b2c130`](#source-pubmed-observation-pmid-42549476-2026-08-04-7a8c79b2c130))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 42549476 at 2026-08-10T10:49:12.984Z. PubMed recorded a metadata revision date of 2026-08-04 and an Entrez history date of 2026-08-04. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42549476-2026-08-04-7a8c79b2c130`](#source-pubmed-observation-pmid-42549476-2026-08-04-7a8c79b2c130))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42549476-2026-08-04-7a8c79b2c130`](#source-pubmed-observation-pmid-42549476-2026-08-04-7a8c79b2c130))

### Sources

<a id="source-pubmed-observation-pmid-42549476-2026-08-04-7a8c79b2c130"></a>
- **PubMed record PMID 42549476 · retained source version 1:2026-08-04:current:7a8c79b2c130377457e63439e656fe378a10c934767e56a3710079b8176e4ef6** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42549476/) (`pubmed-observation-pmid-42549476-2026-08-04-7a8c79b2c130`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 42549476." Version 1, published 2026-08-11. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-42549476-semaglutide-v1 SHA-256: 2cd4c7cbf76abdd44086516785f9cfa4b24e3ffdc7528288bb9eab8801696438.

---

<a id="pubmed-pmid-42552573-semaglutide-v1"></a>

## PubMed record PMID 42552573

> PeptideScanner retained PubMed bibliographic metadata for PMID 42552573 at 2026-08-10T10:49:12.986Z. PubMed recorded a metadata revision date of 2026-08-05 and an Entrez history date of 2026-08-05. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-42552573-semaglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-05
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-11
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42552573-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-42552573-semaglutide-v1
- Content SHA-256: `95a42e92eb14df7c0dfb2b9acb089cf2fe30f0ef7a42d3d35b5f94584295a811`

### Claims and source pins

#### Headline

PubMed record PMID 42552573 ([`pubmed-observation-pmid-42552573-2026-08-05-2f9656d8e586`](#source-pubmed-observation-pmid-42552573-2026-08-05-2f9656d8e586))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 42552573 at 2026-08-10T10:49:12.986Z. PubMed recorded a metadata revision date of 2026-08-05 and an Entrez history date of 2026-08-05. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42552573-2026-08-05-2f9656d8e586`](#source-pubmed-observation-pmid-42552573-2026-08-05-2f9656d8e586))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 42552573 at 2026-08-10T10:49:12.986Z. PubMed recorded a metadata revision date of 2026-08-05 and an Entrez history date of 2026-08-05. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42552573-2026-08-05-2f9656d8e586`](#source-pubmed-observation-pmid-42552573-2026-08-05-2f9656d8e586))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42552573-2026-08-05-2f9656d8e586`](#source-pubmed-observation-pmid-42552573-2026-08-05-2f9656d8e586))

### Sources

<a id="source-pubmed-observation-pmid-42552573-2026-08-05-2f9656d8e586"></a>
- **PubMed record PMID 42552573 · retained source version 1:2026-08-05:current:2f9656d8e5862551e6e8e44fad161571d39007cbb8cc7157409fe4458ffb5ee5** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42552573/) (`pubmed-observation-pmid-42552573-2026-08-05-2f9656d8e586`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 42552573." Version 1, published 2026-08-11. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-42552573-semaglutide-v1 SHA-256: 95a42e92eb14df7c0dfb2b9acb089cf2fe30f0ef7a42d3d35b5f94584295a811.

---

<a id="pubmed-pmid-42560442-semaglutide-v1"></a>

## PubMed record PMID 42560442

> PeptideScanner retained PubMed bibliographic metadata for PMID 42560442 at 2026-08-10T10:49:13.020Z. PubMed recorded a metadata revision date of 2026-08-06 and an Entrez history date of 2026-08-06. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-42560442-semaglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-06
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-10
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42560442-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-42560442-semaglutide-v1
- Content SHA-256: `30c50d0829274bb8a82fdeb3c97f94694544bdf8bc52bb0d9631470ae3e20e06`

### Claims and source pins

#### Headline

PubMed record PMID 42560442 ([`pubmed-observation-pmid-42560442-2026-08-06-5a06269afc19`](#source-pubmed-observation-pmid-42560442-2026-08-06-5a06269afc19))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 42560442 at 2026-08-10T10:49:13.020Z. PubMed recorded a metadata revision date of 2026-08-06 and an Entrez history date of 2026-08-06. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42560442-2026-08-06-5a06269afc19`](#source-pubmed-observation-pmid-42560442-2026-08-06-5a06269afc19))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 42560442 at 2026-08-10T10:49:13.020Z. PubMed recorded a metadata revision date of 2026-08-06 and an Entrez history date of 2026-08-06. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42560442-2026-08-06-5a06269afc19`](#source-pubmed-observation-pmid-42560442-2026-08-06-5a06269afc19))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42560442-2026-08-06-5a06269afc19`](#source-pubmed-observation-pmid-42560442-2026-08-06-5a06269afc19))

### Sources

<a id="source-pubmed-observation-pmid-42560442-2026-08-06-5a06269afc19"></a>
- **PubMed record PMID 42560442 · retained source version 1:2026-08-06:current:5a06269afc197bb50ba748a55415c80ba71b056afcd8674a5c2eb41694ad20ed** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42560442/) (`pubmed-observation-pmid-42560442-2026-08-06-5a06269afc19`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 42560442." Version 1, published 2026-08-10. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-42560442-semaglutide-v1 SHA-256: 30c50d0829274bb8a82fdeb3c97f94694544bdf8bc52bb0d9631470ae3e20e06.

---

<a id="pubmed-pmid-42567173-semaglutide-v1"></a>

## PubMed record PMID 42567173

> PeptideScanner retained PubMed bibliographic metadata for PMID 42567173 at 2026-08-10T10:49:13.603Z. PubMed recorded a metadata revision date of 2026-08-07 and an Entrez history date of 2026-08-07. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-42567173-semaglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-07
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-10
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42567173-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-42567173-semaglutide-v1
- Content SHA-256: `d95ce158969fd056e6bcd580fc410fc7e3609c0d668bba328fee9701b34c7723`

### Claims and source pins

#### Headline

PubMed record PMID 42567173 ([`pubmed-observation-pmid-42567173-2026-08-07-7ea898d051f0`](#source-pubmed-observation-pmid-42567173-2026-08-07-7ea898d051f0))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 42567173 at 2026-08-10T10:49:13.603Z. PubMed recorded a metadata revision date of 2026-08-07 and an Entrez history date of 2026-08-07. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42567173-2026-08-07-7ea898d051f0`](#source-pubmed-observation-pmid-42567173-2026-08-07-7ea898d051f0))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 42567173 at 2026-08-10T10:49:13.603Z. PubMed recorded a metadata revision date of 2026-08-07 and an Entrez history date of 2026-08-07. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42567173-2026-08-07-7ea898d051f0`](#source-pubmed-observation-pmid-42567173-2026-08-07-7ea898d051f0))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42567173-2026-08-07-7ea898d051f0`](#source-pubmed-observation-pmid-42567173-2026-08-07-7ea898d051f0))

### Sources

<a id="source-pubmed-observation-pmid-42567173-2026-08-07-7ea898d051f0"></a>
- **PubMed record PMID 42567173 · retained source version 1:2026-08-07:current:7ea898d051f04db6a13d79f3b18f683f9ecd403a711acb9fcaa728f9d6fd209e** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42567173/) (`pubmed-observation-pmid-42567173-2026-08-07-7ea898d051f0`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 42567173." Version 1, published 2026-08-10. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-42567173-semaglutide-v1 SHA-256: d95ce158969fd056e6bcd580fc410fc7e3609c0d668bba328fee9701b34c7723.

---

<a id="pubmed-pmid-42569002-semaglutide-v1"></a>

## PubMed record PMID 42569002

> PeptideScanner retained PubMed bibliographic metadata for PMID 42569002 at 2026-08-10T10:49:13.608Z. PubMed recorded a metadata revision date of 2026-08-08 and an Entrez history date of 2026-08-08. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-42569002-semaglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-08
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-10
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42569002-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-42569002-semaglutide-v1
- Content SHA-256: `8be40d231bcfb8f0c8ea905d42aa94b573d091237aa56af0bcabe9e264d7daf9`

### Claims and source pins

#### Headline

PubMed record PMID 42569002 ([`pubmed-observation-pmid-42569002-2026-08-08-33518c9a4d1f`](#source-pubmed-observation-pmid-42569002-2026-08-08-33518c9a4d1f))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 42569002 at 2026-08-10T10:49:13.608Z. PubMed recorded a metadata revision date of 2026-08-08 and an Entrez history date of 2026-08-08. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42569002-2026-08-08-33518c9a4d1f`](#source-pubmed-observation-pmid-42569002-2026-08-08-33518c9a4d1f))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 42569002 at 2026-08-10T10:49:13.608Z. PubMed recorded a metadata revision date of 2026-08-08 and an Entrez history date of 2026-08-08. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42569002-2026-08-08-33518c9a4d1f`](#source-pubmed-observation-pmid-42569002-2026-08-08-33518c9a4d1f))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42569002-2026-08-08-33518c9a4d1f`](#source-pubmed-observation-pmid-42569002-2026-08-08-33518c9a4d1f))

### Sources

<a id="source-pubmed-observation-pmid-42569002-2026-08-08-33518c9a4d1f"></a>
- **PubMed record PMID 42569002 · retained source version 1:2026-08-08:current:33518c9a4d1f7e8080a6ccc63f77d997a14b0b04f0b39a222887085d48c683a8** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42569002/) (`pubmed-observation-pmid-42569002-2026-08-08-33518c9a4d1f`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 42569002." Version 1, published 2026-08-10. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-42569002-semaglutide-v1 SHA-256: 8be40d231bcfb8f0c8ea905d42aa94b573d091237aa56af0bcabe9e264d7daf9.

---

<a id="pubmed-pmid-42569707-semaglutide-v1"></a>

## PubMed record PMID 42569707

> PeptideScanner retained PubMed bibliographic metadata for PMID 42569707 at 2026-08-10T10:49:13.615Z. PubMed recorded a metadata revision date of 2026-08-08 and an Entrez history date of 2026-08-08. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-42569707-semaglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-08
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-10
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42569707-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-42569707-semaglutide-v1
- Content SHA-256: `cfd7839b0e56cf7d8237bdff814a25025e49691550f13778cf2e0eefac55a2a2`

### Claims and source pins

#### Headline

PubMed record PMID 42569707 ([`pubmed-observation-pmid-42569707-2026-08-08-683f60a11e7e`](#source-pubmed-observation-pmid-42569707-2026-08-08-683f60a11e7e))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 42569707 at 2026-08-10T10:49:13.615Z. PubMed recorded a metadata revision date of 2026-08-08 and an Entrez history date of 2026-08-08. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42569707-2026-08-08-683f60a11e7e`](#source-pubmed-observation-pmid-42569707-2026-08-08-683f60a11e7e))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 42569707 at 2026-08-10T10:49:13.615Z. PubMed recorded a metadata revision date of 2026-08-08 and an Entrez history date of 2026-08-08. PeptideScanner associated this retained record with the identity slug semaglutide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42569707-2026-08-08-683f60a11e7e`](#source-pubmed-observation-pmid-42569707-2026-08-08-683f60a11e7e))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42569707-2026-08-08-683f60a11e7e`](#source-pubmed-observation-pmid-42569707-2026-08-08-683f60a11e7e))

### Sources

<a id="source-pubmed-observation-pmid-42569707-2026-08-08-683f60a11e7e"></a>
- **PubMed record PMID 42569707 · retained source version 1:2026-08-08:current:683f60a11e7ef2718eba45e55ac1c5bccb3377401a06febb1c908458a00c0038** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42569707/) (`pubmed-observation-pmid-42569707-2026-08-08-683f60a11e7e`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 42569707." Version 1, published 2026-08-10. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-42569707-semaglutide-v1 SHA-256: cfd7839b0e56cf7d8237bdff814a25025e49691550f13778cf2e0eefac55a2a2.

---

<a id="pubmed-pmid-42592768-semaglutide-v1"></a>

## Real-world use of oral semaglutide in adults with type 2 diabetes.

> PubMed lists PMID 42592768 in Danish medical journal as Journal Article, Multicenter Study, with publication-date metadata of 2026-06-16 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42592768-semaglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-13
- Source checked: 2026-08-13
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42592768-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-42592768-semaglutide-v1
- Content SHA-256: `db5a40b9a027c492b40d0c4d37d97a6984b4e4c08229924c2142f7ad037cb813`

### Claims and source pins

#### Headline

Real-world use of oral semaglutide in adults with type 2 diabetes. ([`pubmed-observation-pmid-42592768-2026-08-13-05635b809594`](#source-pubmed-observation-pmid-42592768-2026-08-13-05635b809594))

#### Summary

PubMed lists PMID 42592768 in Danish medical journal as Journal Article, Multicenter Study, with publication-date metadata of 2026-06-16 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42592768-2026-08-13-05635b809594`](#source-pubmed-observation-pmid-42592768-2026-08-13-05635b809594))

#### Paragraph 1

PubMed lists PMID 42592768 in Danish medical journal as Journal Article, Multicenter Study, with publication-date metadata of 2026-06-16 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42592768-2026-08-13-05635b809594`](#source-pubmed-observation-pmid-42592768-2026-08-13-05635b809594))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42592768-2026-08-13-05635b809594`](#source-pubmed-observation-pmid-42592768-2026-08-13-05635b809594))

### Sources

<a id="source-pubmed-observation-pmid-42592768-2026-08-13-05635b809594"></a>
- **Real-world use of oral semaglutide in adults with type 2 diabetes. · retained source version 1:2026-08-13:current:05635b809594af79f3aa90a345784c8a1a39f1dd87f9a2500d0629c15bff6c7f** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42592768/) (`pubmed-observation-pmid-42592768-2026-08-13-05635b809594`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Real-world use of oral semaglutide in adults with type 2 diabetes." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-42592768-semaglutide-v1 SHA-256: db5a40b9a027c492b40d0c4d37d97a6984b4e4c08229924c2142f7ad037cb813.

---

<a id="pubmed-pmid-42602345-semaglutide-v1"></a>

## Validation of a Pharmacist-Led Semaglutide Prescribing Algorithm for Type 2 Diabetes and Chronic Kidney Disease: Research Letter.

> PubMed lists PMID 42602345 in Canadian journal of kidney health and disease as Journal Article, with publication-date metadata of 2026-08-13 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42602345-semaglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-15
- Source checked: 2026-08-16
- Published by PeptideScanner: 2026-08-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42602345-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-42602345-semaglutide-v1
- Content SHA-256: `0a41701951808ffde60121faf7117181cdaca720564efc7511860ff7e304d34e`

### Claims and source pins

#### Headline

Validation of a Pharmacist-Led Semaglutide Prescribing Algorithm for Type 2 Diabetes and Chronic Kidney Disease: Research Letter. ([`pubmed-observation-pmid-42602345-2026-08-15-d7b09e1ada6c`](#source-pubmed-observation-pmid-42602345-2026-08-15-d7b09e1ada6c))

#### Summary

PubMed lists PMID 42602345 in Canadian journal of kidney health and disease as Journal Article, with publication-date metadata of 2026-08-13 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42602345-2026-08-15-d7b09e1ada6c`](#source-pubmed-observation-pmid-42602345-2026-08-15-d7b09e1ada6c))

#### Paragraph 1

PubMed lists PMID 42602345 in Canadian journal of kidney health and disease as Journal Article, with publication-date metadata of 2026-08-13 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42602345-2026-08-15-d7b09e1ada6c`](#source-pubmed-observation-pmid-42602345-2026-08-15-d7b09e1ada6c))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42602345-2026-08-15-d7b09e1ada6c`](#source-pubmed-observation-pmid-42602345-2026-08-15-d7b09e1ada6c))

### Sources

<a id="source-pubmed-observation-pmid-42602345-2026-08-15-d7b09e1ada6c"></a>
- **Validation of a Pharmacist-Led Semaglutide Prescribing Algorithm for Type 2 Diabetes and Chronic Kidney Disease: Research Letter. · retained source version 1:2026-08-15:current:d7b09e1ada6ca8247017322a8c94cb5c1f90a19b5a84f84fd35996d27ac02abb** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42602345/) (`pubmed-observation-pmid-42602345-2026-08-15-d7b09e1ada6c`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Validation of a Pharmacist-Led Semaglutide Prescribing Algorithm for Type 2 Diabetes and Chronic Kidney Disease: Research Letter." Version 1, published 2026-08-16. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-42602345-semaglutide-v1 SHA-256: 0a41701951808ffde60121faf7117181cdaca720564efc7511860ff7e304d34e.

---

<a id="pubmed-pmid-42703141-semaglutide-v1"></a>

## Ozempic and thin line between therapy and dependence.

> PubMed lists PMID 42703141 in JPMA. The Journal of the Pakistan Medical Association as Journal Article, with publication-date metadata of 2026-08 (month precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42703141-semaglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-09-07
- Source checked: 2026-09-09
- Published by PeptideScanner: 2026-09-09
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42703141-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-42703141-semaglutide-v1
- Content SHA-256: `7786bbac052144bafe0e4eaec516628a7670774a6f18be2393db13d1ab6b9940`

### Claims and source pins

#### Headline

Ozempic and thin line between therapy and dependence. ([`pubmed-observation-pmid-42703141-2026-09-07-1422a9198254`](#source-pubmed-observation-pmid-42703141-2026-09-07-1422a9198254))

#### Summary

PubMed lists PMID 42703141 in JPMA. The Journal of the Pakistan Medical Association as Journal Article, with publication-date metadata of 2026-08 (month precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42703141-2026-09-07-1422a9198254`](#source-pubmed-observation-pmid-42703141-2026-09-07-1422a9198254))

#### Paragraph 1

PubMed lists PMID 42703141 in JPMA. The Journal of the Pakistan Medical Association as Journal Article, with publication-date metadata of 2026-08 (month precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42703141-2026-09-07-1422a9198254`](#source-pubmed-observation-pmid-42703141-2026-09-07-1422a9198254))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42703141-2026-09-07-1422a9198254`](#source-pubmed-observation-pmid-42703141-2026-09-07-1422a9198254))

### Sources

<a id="source-pubmed-observation-pmid-42703141-2026-09-07-1422a9198254"></a>
- **Ozempic and thin line between therapy and dependence. · retained source version 1:2026-09-07:current:1422a919825417fee86e0dcaad8d4b63eef3b874e4e3044aad64887ff8054667** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42703141/) (`pubmed-observation-pmid-42703141-2026-09-07-1422a9198254`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Ozempic and thin line between therapy and dependence." Version 1, published 2026-09-09. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-42703141-semaglutide-v1 SHA-256: 7786bbac052144bafe0e4eaec516628a7670774a6f18be2393db13d1ab6b9940.

---

<a id="pubmed-pmid-42703150-semaglutide-v1"></a>

## Off-label semaglutide: A call for monitoring protocols in non-obese populations.

> PubMed lists PMID 42703150 in JPMA. The Journal of the Pakistan Medical Association as Journal Article, with publication-date metadata of 2026-08 (month precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42703150-semaglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-09-07
- Source checked: 2026-09-09
- Published by PeptideScanner: 2026-09-09
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42703150-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-42703150-semaglutide-v1
- Content SHA-256: `dd906f36f4d8798d8fba8fc435c24a71eb7586c0d186408b2fe5f584a96f077d`

### Claims and source pins

#### Headline

Off-label semaglutide: A call for monitoring protocols in non-obese populations. ([`pubmed-observation-pmid-42703150-2026-09-07-0980524a08e7`](#source-pubmed-observation-pmid-42703150-2026-09-07-0980524a08e7))

#### Summary

PubMed lists PMID 42703150 in JPMA. The Journal of the Pakistan Medical Association as Journal Article, with publication-date metadata of 2026-08 (month precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42703150-2026-09-07-0980524a08e7`](#source-pubmed-observation-pmid-42703150-2026-09-07-0980524a08e7))

#### Paragraph 1

PubMed lists PMID 42703150 in JPMA. The Journal of the Pakistan Medical Association as Journal Article, with publication-date metadata of 2026-08 (month precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42703150-2026-09-07-0980524a08e7`](#source-pubmed-observation-pmid-42703150-2026-09-07-0980524a08e7))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42703150-2026-09-07-0980524a08e7`](#source-pubmed-observation-pmid-42703150-2026-09-07-0980524a08e7))

### Sources

<a id="source-pubmed-observation-pmid-42703150-2026-09-07-0980524a08e7"></a>
- **Off-label semaglutide: A call for monitoring protocols in non-obese populations. · retained source version 1:2026-09-07:current:0980524a08e7b8526a46aafdaae02e1a06e5a60fb341abe11b3cf13e86254086** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42703150/) (`pubmed-observation-pmid-42703150-2026-09-07-0980524a08e7`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Off-label semaglutide: A call for monitoring protocols in non-obese populations." Version 1, published 2026-09-09. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-42703150-semaglutide-v1 SHA-256: dd906f36f4d8798d8fba8fc435c24a71eb7586c0d186408b2fe5f584a96f077d.

---

<a id="pubmed-pmid-42722400-semaglutide-v1"></a>

## Wegovy: GPs are told not to prescribe GLP semaglutide for heart health without funding guarantee.

> PubMed lists PMID 42722400 in BMJ (Clinical research ed.) as Journal Article, with publication-date metadata of 2026-09-10 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42722400-semaglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-09-10
- Source checked: 2026-11-14
- Published by PeptideScanner: 2026-11-14
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42722400-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-42722400-semaglutide-v1
- Content SHA-256: `2d971fd76abc910b37530faaa8e67820bc938a1f130cb53fe0b5afb87d0b17a7`

### Claims and source pins

#### Headline

Wegovy: GPs are told not to prescribe GLP semaglutide for heart health without funding guarantee. ([`pubmed-observation-pmid-42722400-2026-09-10-fe91a4648774`](#source-pubmed-observation-pmid-42722400-2026-09-10-fe91a4648774))

#### Summary

PubMed lists PMID 42722400 in BMJ (Clinical research ed.) as Journal Article, with publication-date metadata of 2026-09-10 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42722400-2026-09-10-fe91a4648774`](#source-pubmed-observation-pmid-42722400-2026-09-10-fe91a4648774))

#### Paragraph 1

PubMed lists PMID 42722400 in BMJ (Clinical research ed.) as Journal Article, with publication-date metadata of 2026-09-10 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42722400-2026-09-10-fe91a4648774`](#source-pubmed-observation-pmid-42722400-2026-09-10-fe91a4648774))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42722400-2026-09-10-fe91a4648774`](#source-pubmed-observation-pmid-42722400-2026-09-10-fe91a4648774))

### Sources

<a id="source-pubmed-observation-pmid-42722400-2026-09-10-fe91a4648774"></a>
- **Wegovy: GPs are told not to prescribe GLP semaglutide for heart health without funding guarantee. · retained source version 1:2026-09-10:current:fe91a46487749b48b0012c0b190732c2fae71a40426ee2c34450ab6d74c20ba0** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42722400/) (`pubmed-observation-pmid-42722400-2026-09-10-fe91a4648774`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Wegovy: GPs are told not to prescribe GLP semaglutide for heart health without funding guarantee." Version 1, published 2026-11-14. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-42722400-semaglutide-v1 SHA-256: 2d971fd76abc910b37530faaa8e67820bc938a1f130cb53fe0b5afb87d0b17a7.

---

<a id="pubmed-pmid-42754946-semaglutide-v1"></a>

## Semaglutide in Bipolar Disorder: A Differential Finding Needs a Differential Mechanism.

> PubMed lists PMID 42754946 in Acta psychiatrica Scandinavica as Letter, with publication-date metadata of 2026-09-17 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42754946-semaglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-09-18
- Source checked: 2026-11-14
- Published by PeptideScanner: 2026-11-14
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42754946-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-42754946-semaglutide-v1
- Content SHA-256: `a977c6284594b1b85e78f9a80b1408e606b419583701cbee381c14ad83d746b3`

### Claims and source pins

#### Headline

Semaglutide in Bipolar Disorder: A Differential Finding Needs a Differential Mechanism. ([`pubmed-observation-pmid-42754946-2026-09-18-d714d069297d`](#source-pubmed-observation-pmid-42754946-2026-09-18-d714d069297d))

#### Summary

PubMed lists PMID 42754946 in Acta psychiatrica Scandinavica as Letter, with publication-date metadata of 2026-09-17 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42754946-2026-09-18-d714d069297d`](#source-pubmed-observation-pmid-42754946-2026-09-18-d714d069297d))

#### Paragraph 1

PubMed lists PMID 42754946 in Acta psychiatrica Scandinavica as Letter, with publication-date metadata of 2026-09-17 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42754946-2026-09-18-d714d069297d`](#source-pubmed-observation-pmid-42754946-2026-09-18-d714d069297d))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42754946-2026-09-18-d714d069297d`](#source-pubmed-observation-pmid-42754946-2026-09-18-d714d069297d))

### Sources

<a id="source-pubmed-observation-pmid-42754946-2026-09-18-d714d069297d"></a>
- **Semaglutide in Bipolar Disorder: A Differential Finding Needs a Differential Mechanism. · retained source version 1:2026-09-18:current:d714d069297d875260265f2d1afebd9bd494aca9c09708908ae5d14309bc127c** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42754946/) (`pubmed-observation-pmid-42754946-2026-09-18-d714d069297d`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Semaglutide in Bipolar Disorder: A Differential Finding Needs a Differential Mechanism." Version 1, published 2026-11-14. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-42754946-semaglutide-v1 SHA-256: a977c6284594b1b85e78f9a80b1408e606b419583701cbee381c14ad83d746b3.

---

<a id="pubmed-pmid-42769283-semaglutide-v1"></a>

## Original rDNA Semaglutide Versus Synthetic Copies: Differences and Clinical Implications.

> PubMed lists PMID 42769283 in Cureus as Editorial, with publication-date metadata of 2026-08-21 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42769283-semaglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-09-23
- Source checked: 2026-11-14
- Published by PeptideScanner: 2026-11-14
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42769283-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-42769283-semaglutide-v1
- Content SHA-256: `d34b0c48ce6db6df58fb667ec4cc3461f71f0f200931969f59fdaaa625b9c41c`

### Claims and source pins

#### Headline

Original rDNA Semaglutide Versus Synthetic Copies: Differences and Clinical Implications. ([`pubmed-observation-pmid-42769283-2026-09-23-d3abbd23b145`](#source-pubmed-observation-pmid-42769283-2026-09-23-d3abbd23b145))

#### Summary

PubMed lists PMID 42769283 in Cureus as Editorial, with publication-date metadata of 2026-08-21 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42769283-2026-09-23-d3abbd23b145`](#source-pubmed-observation-pmid-42769283-2026-09-23-d3abbd23b145))

#### Paragraph 1

PubMed lists PMID 42769283 in Cureus as Editorial, with publication-date metadata of 2026-08-21 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42769283-2026-09-23-d3abbd23b145`](#source-pubmed-observation-pmid-42769283-2026-09-23-d3abbd23b145))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42769283-2026-09-23-d3abbd23b145`](#source-pubmed-observation-pmid-42769283-2026-09-23-d3abbd23b145))

### Sources

<a id="source-pubmed-observation-pmid-42769283-2026-09-23-d3abbd23b145"></a>
- **Original rDNA Semaglutide Versus Synthetic Copies: Differences and Clinical Implications. · retained source version 1:2026-09-23:current:d3abbd23b1451c91fa2a5c6e76638e2cdd8d21b270e59485b32c72d0fe77d85f** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42769283/) (`pubmed-observation-pmid-42769283-2026-09-23-d3abbd23b145`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Original rDNA Semaglutide Versus Synthetic Copies: Differences and Clinical Implications." Version 1, published 2026-11-14. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-42769283-semaglutide-v1 SHA-256: d34b0c48ce6db6df58fb667ec4cc3461f71f0f200931969f59fdaaa625b9c41c.

---

<a id="pubmed-pmid-42785112-semaglutide-v1"></a>

## Evoke (+) trials of semaglutide for early alzheimer's disease: Innovations, lessons, and implications.

> PubMed lists PMID 42785112 in The journal of prevention of Alzheimer's disease as Journal Article, Review, with publication-date metadata of 2026-09-24 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42785112-semaglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-10-07
- Source checked: 2026-11-14
- Published by PeptideScanner: 2026-11-14
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42785112-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-42785112-semaglutide-v1
- Content SHA-256: `ff3cdb2b845165d2961bbbc11985db77a771dbab593feaf0cc45bc6243d34aad`

### Claims and source pins

#### Headline

Evoke (+) trials of semaglutide for early alzheimer's disease: Innovations, lessons, and implications. ([`pubmed-observation-pmid-42785112-2026-10-07-e496a7300ef8`](#source-pubmed-observation-pmid-42785112-2026-10-07-e496a7300ef8))

#### Summary

PubMed lists PMID 42785112 in The journal of prevention of Alzheimer's disease as Journal Article, Review, with publication-date metadata of 2026-09-24 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42785112-2026-10-07-e496a7300ef8`](#source-pubmed-observation-pmid-42785112-2026-10-07-e496a7300ef8))

#### Paragraph 1

PubMed lists PMID 42785112 in The journal of prevention of Alzheimer's disease as Journal Article, Review, with publication-date metadata of 2026-09-24 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42785112-2026-10-07-e496a7300ef8`](#source-pubmed-observation-pmid-42785112-2026-10-07-e496a7300ef8))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42785112-2026-10-07-e496a7300ef8`](#source-pubmed-observation-pmid-42785112-2026-10-07-e496a7300ef8))

### Sources

<a id="source-pubmed-observation-pmid-42785112-2026-10-07-e496a7300ef8"></a>
- **Evoke (+) trials of semaglutide for early alzheimer's disease: Innovations, lessons, and implications. · retained source version 1:2026-10-07:current:e496a7300ef85c7c2739967ea6ff56cd11513174fe68922e7d5782412964297f** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42785112/) (`pubmed-observation-pmid-42785112-2026-10-07-e496a7300ef8`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Evoke (+) trials of semaglutide for early alzheimer's disease: Innovations, lessons, and implications." Version 1, published 2026-11-14. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-42785112-semaglutide-v1 SHA-256: ff3cdb2b845165d2961bbbc11985db77a771dbab593feaf0cc45bc6243d34aad.

---

<a id="pubmed-pmid-42823892-semaglutide-v1"></a>

## Detection and Excretion Profiling of Semaglutide Use in Human Urine by UHPLC-HRMS for Anti-Doping Purpose.

> PubMed lists PMID 42823892 in Drug testing and analysis as Journal Article, with publication-date metadata of 2026-10-02 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42823892-semaglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-10-02
- Source checked: 2026-11-14
- Published by PeptideScanner: 2026-11-14
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42823892-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-42823892-semaglutide-v1
- Content SHA-256: `7f5517ffe50f596caba94d5b5fc378e8d70103032d208505e8eeaad419237ec4`

### Claims and source pins

#### Headline

Detection and Excretion Profiling of Semaglutide Use in Human Urine by UHPLC-HRMS for Anti-Doping Purpose. ([`pubmed-observation-pmid-42823892-2026-10-02-606a981bdd7b`](#source-pubmed-observation-pmid-42823892-2026-10-02-606a981bdd7b))

#### Summary

PubMed lists PMID 42823892 in Drug testing and analysis as Journal Article, with publication-date metadata of 2026-10-02 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42823892-2026-10-02-606a981bdd7b`](#source-pubmed-observation-pmid-42823892-2026-10-02-606a981bdd7b))

#### Paragraph 1

PubMed lists PMID 42823892 in Drug testing and analysis as Journal Article, with publication-date metadata of 2026-10-02 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42823892-2026-10-02-606a981bdd7b`](#source-pubmed-observation-pmid-42823892-2026-10-02-606a981bdd7b))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42823892-2026-10-02-606a981bdd7b`](#source-pubmed-observation-pmid-42823892-2026-10-02-606a981bdd7b))

### Sources

<a id="source-pubmed-observation-pmid-42823892-2026-10-02-606a981bdd7b"></a>
- **Detection and Excretion Profiling of Semaglutide Use in Human Urine by UHPLC-HRMS for Anti-Doping Purpose. · retained source version 1:2026-10-02:current:606a981bdd7b2280adb5bc7085a3d7836adc8437d9f9de2b84165e9de1f5b30b** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42823892/) (`pubmed-observation-pmid-42823892-2026-10-02-606a981bdd7b`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Detection and Excretion Profiling of Semaglutide Use in Human Urine by UHPLC-HRMS for Anti-Doping Purpose." Version 1, published 2026-11-14. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-42823892-semaglutide-v1 SHA-256: 7f5517ffe50f596caba94d5b5fc378e8d70103032d208505e8eeaad419237ec4.

---

<a id="pubmed-pmid-42862749-semaglutide-v1"></a>

## Semaglutide in Heart Failure with Preserved Ejection Fraction and Obesity: The Gap Between Discussion and Use.

> PubMed lists PMID 42862749 in Cardiology as Journal Article, with publication-date metadata of 2026-10-12 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42862749-semaglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-10-12
- Source checked: 2026-11-14
- Published by PeptideScanner: 2026-11-14
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42862749-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-42862749-semaglutide-v1
- Content SHA-256: `d5cb26f8b5a304ba0cbfc3076db7346c2e96ece896a70ebcef38bb86424b5105`

### Claims and source pins

#### Headline

Semaglutide in Heart Failure with Preserved Ejection Fraction and Obesity: The Gap Between Discussion and Use. ([`pubmed-observation-pmid-42862749-2026-10-12-6f44c0e7d11a`](#source-pubmed-observation-pmid-42862749-2026-10-12-6f44c0e7d11a))

#### Summary

PubMed lists PMID 42862749 in Cardiology as Journal Article, with publication-date metadata of 2026-10-12 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42862749-2026-10-12-6f44c0e7d11a`](#source-pubmed-observation-pmid-42862749-2026-10-12-6f44c0e7d11a))

#### Paragraph 1

PubMed lists PMID 42862749 in Cardiology as Journal Article, with publication-date metadata of 2026-10-12 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42862749-2026-10-12-6f44c0e7d11a`](#source-pubmed-observation-pmid-42862749-2026-10-12-6f44c0e7d11a))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42862749-2026-10-12-6f44c0e7d11a`](#source-pubmed-observation-pmid-42862749-2026-10-12-6f44c0e7d11a))

### Sources

<a id="source-pubmed-observation-pmid-42862749-2026-10-12-6f44c0e7d11a"></a>
- **Semaglutide in Heart Failure with Preserved Ejection Fraction and Obesity: The Gap Between Discussion and Use. · retained source version 1:2026-10-12:current:6f44c0e7d11a72e03ca7083d9e6e483164f3cb1d74d18a5a702c698ba2882c2b** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42862749/) (`pubmed-observation-pmid-42862749-2026-10-12-6f44c0e7d11a`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Semaglutide in Heart Failure with Preserved Ejection Fraction and Obesity: The Gap Between Discussion and Use." Version 1, published 2026-11-14. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-42862749-semaglutide-v1 SHA-256: d5cb26f8b5a304ba0cbfc3076db7346c2e96ece896a70ebcef38bb86424b5105.

---

<a id="pubmed-pmid-42901618-semaglutide-v1"></a>

## GLP-1s and criminality: US trial will test whether semaglutide can fight crime.

> PubMed lists PMID 42901618 in BMJ (Clinical research ed.) as Journal Article, with publication-date metadata of 2026-10-20 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42901618-semaglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-10-20
- Source checked: 2026-11-14
- Published by PeptideScanner: 2026-11-14
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42901618-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-42901618-semaglutide-v1
- Content SHA-256: `134e52837089217cf9c1dea81ba4beaf22b9047d5eb5ea44fd3701c19669fc9c`

### Claims and source pins

#### Headline

GLP-1s and criminality: US trial will test whether semaglutide can fight crime. ([`pubmed-observation-pmid-42901618-2026-10-20-266c1549c0a2`](#source-pubmed-observation-pmid-42901618-2026-10-20-266c1549c0a2))

#### Summary

PubMed lists PMID 42901618 in BMJ (Clinical research ed.) as Journal Article, with publication-date metadata of 2026-10-20 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42901618-2026-10-20-266c1549c0a2`](#source-pubmed-observation-pmid-42901618-2026-10-20-266c1549c0a2))

#### Paragraph 1

PubMed lists PMID 42901618 in BMJ (Clinical research ed.) as Journal Article, with publication-date metadata of 2026-10-20 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42901618-2026-10-20-266c1549c0a2`](#source-pubmed-observation-pmid-42901618-2026-10-20-266c1549c0a2))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42901618-2026-10-20-266c1549c0a2`](#source-pubmed-observation-pmid-42901618-2026-10-20-266c1549c0a2))

### Sources

<a id="source-pubmed-observation-pmid-42901618-2026-10-20-266c1549c0a2"></a>
- **GLP-1s and criminality: US trial will test whether semaglutide can fight crime. · retained source version 1:2026-10-20:current:266c1549c0a234df360d541503fa08dc18f63761c3cba46053ebbea0b9e80a97** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42901618/) (`pubmed-observation-pmid-42901618-2026-10-20-266c1549c0a2`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "GLP-1s and criminality: US trial will test whether semaglutide can fight crime." Version 1, published 2026-11-14. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-42901618-semaglutide-v1 SHA-256: 134e52837089217cf9c1dea81ba4beaf22b9047d5eb5ea44fd3701c19669fc9c.

---

<a id="pubmed-pmid-42946801-semaglutide-v1"></a>

## Semaglutide for MASH in Japanese patients: findings consistent with the overall ESSENCE population.

> PubMed lists PMID 42946801 in Journal of gastroenterology as Editorial, with publication-date metadata of 2026-10-27 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42946801-semaglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-10-28
- Source checked: 2026-11-14
- Published by PeptideScanner: 2026-11-14
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42946801-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-42946801-semaglutide-v1
- Content SHA-256: `bb998000031a6e2adfc6bd2c6346703fc7d950e729e211b9d9eac333c6f6a3ff`

### Claims and source pins

#### Headline

Semaglutide for MASH in Japanese patients: findings consistent with the overall ESSENCE population. ([`pubmed-observation-pmid-42946801-2026-10-28-9e86c5ca2454`](#source-pubmed-observation-pmid-42946801-2026-10-28-9e86c5ca2454))

#### Summary

PubMed lists PMID 42946801 in Journal of gastroenterology as Editorial, with publication-date metadata of 2026-10-27 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42946801-2026-10-28-9e86c5ca2454`](#source-pubmed-observation-pmid-42946801-2026-10-28-9e86c5ca2454))

#### Paragraph 1

PubMed lists PMID 42946801 in Journal of gastroenterology as Editorial, with publication-date metadata of 2026-10-27 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42946801-2026-10-28-9e86c5ca2454`](#source-pubmed-observation-pmid-42946801-2026-10-28-9e86c5ca2454))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42946801-2026-10-28-9e86c5ca2454`](#source-pubmed-observation-pmid-42946801-2026-10-28-9e86c5ca2454))

### Sources

<a id="source-pubmed-observation-pmid-42946801-2026-10-28-9e86c5ca2454"></a>
- **Semaglutide for MASH in Japanese patients: findings consistent with the overall ESSENCE population. · retained source version 1:2026-10-28:current:9e86c5ca2454fdaf310b44749beb054f5d2f03ac36bb39428a9bc6c8dde5d198** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42946801/) (`pubmed-observation-pmid-42946801-2026-10-28-9e86c5ca2454`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Semaglutide for MASH in Japanese patients: findings consistent with the overall ESSENCE population." Version 1, published 2026-11-14. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-42946801-semaglutide-v1 SHA-256: bb998000031a6e2adfc6bd2c6346703fc7d950e729e211b9d9eac333c6f6a3ff.

---

<a id="pubmed-pmid-42977490-semaglutide-v1"></a>

## Recommendations for the use of semaglutide for the management of obesity in children and young people in England: expert consensus statements using a Delphi-like process.

> PubMed lists PMID 42977490 in Archives of disease in childhood as Journal Article, with publication-date metadata of 2026-11-03 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42977490-semaglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-11-03
- Source checked: 2026-11-14
- Published by PeptideScanner: 2026-11-14
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42977490-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-42977490-semaglutide-v1
- Content SHA-256: `6974176c7008071d1a57b3427952b7b716ea6b11fa20b2bedbf8b9f5f1aaaeed`

### Claims and source pins

#### Headline

Recommendations for the use of semaglutide for the management of obesity in children and young people in England: expert consensus statements using a Delphi-like process. ([`pubmed-observation-pmid-42977490-2026-11-03-9d7c54200895`](#source-pubmed-observation-pmid-42977490-2026-11-03-9d7c54200895))

#### Summary

PubMed lists PMID 42977490 in Archives of disease in childhood as Journal Article, with publication-date metadata of 2026-11-03 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42977490-2026-11-03-9d7c54200895`](#source-pubmed-observation-pmid-42977490-2026-11-03-9d7c54200895))

#### Paragraph 1

PubMed lists PMID 42977490 in Archives of disease in childhood as Journal Article, with publication-date metadata of 2026-11-03 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42977490-2026-11-03-9d7c54200895`](#source-pubmed-observation-pmid-42977490-2026-11-03-9d7c54200895))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42977490-2026-11-03-9d7c54200895`](#source-pubmed-observation-pmid-42977490-2026-11-03-9d7c54200895))

### Sources

<a id="source-pubmed-observation-pmid-42977490-2026-11-03-9d7c54200895"></a>
- **Recommendations for the use of semaglutide for the management of obesity in children and young people in England: expert consensus statements using a Delphi-like process. · retained source version 1:2026-11-03:current:9d7c542008957bad0fd8e8d33ece67d01b1fc632e048d408f749efb8ae9188b7** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42977490/) (`pubmed-observation-pmid-42977490-2026-11-03-9d7c54200895`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Recommendations for the use of semaglutide for the management of obesity in children and young people in England: expert consensus statements using a Delphi-like process." Version 1, published 2026-11-14. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-42977490-semaglutide-v1 SHA-256: 6974176c7008071d1a57b3427952b7b716ea6b11fa20b2bedbf8b9f5f1aaaeed.

---

<a id="pubmed-pmid-42999829-semaglutide-v1"></a>

## Boerhaave Syndrome: Case Report on a Rare Complication of Semaglutide Use.

> PubMed lists PMID 42999829 in Cureus as Case Reports, Journal Article, with publication-date metadata of 2026-10-08 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42999829-semaglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-11-09
- Source checked: 2026-11-14
- Published by PeptideScanner: 2026-11-14
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42999829-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-42999829-semaglutide-v1
- Content SHA-256: `d9753f445397186339707f05df2376783836d6b5028af90323b475a9b1bf70c0`

### Claims and source pins

#### Headline

Boerhaave Syndrome: Case Report on a Rare Complication of Semaglutide Use. ([`pubmed-observation-pmid-42999829-2026-11-09-e371c8858168`](#source-pubmed-observation-pmid-42999829-2026-11-09-e371c8858168))

#### Summary

PubMed lists PMID 42999829 in Cureus as Case Reports, Journal Article, with publication-date metadata of 2026-10-08 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42999829-2026-11-09-e371c8858168`](#source-pubmed-observation-pmid-42999829-2026-11-09-e371c8858168))

#### Paragraph 1

PubMed lists PMID 42999829 in Cureus as Case Reports, Journal Article, with publication-date metadata of 2026-10-08 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42999829-2026-11-09-e371c8858168`](#source-pubmed-observation-pmid-42999829-2026-11-09-e371c8858168))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42999829-2026-11-09-e371c8858168`](#source-pubmed-observation-pmid-42999829-2026-11-09-e371c8858168))

### Sources

<a id="source-pubmed-observation-pmid-42999829-2026-11-09-e371c8858168"></a>
- **Boerhaave Syndrome: Case Report on a Rare Complication of Semaglutide Use. · retained source version 1:2026-11-09:current:e371c8858168c324d6ca91b0c8703870fe0ca2b746750f72a69d8ca935be8cfc** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42999829/) (`pubmed-observation-pmid-42999829-2026-11-09-e371c8858168`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Boerhaave Syndrome: Case Report on a Rare Complication of Semaglutide Use." Version 1, published 2026-11-14. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-42999829-semaglutide-v1 SHA-256: d9753f445397186339707f05df2376783836d6b5028af90323b475a9b1bf70c0.

---

<a id="pubmed-pmid-43011941-semaglutide-v1"></a>

## Semaglutide and alcohol use disorder: An evidence gap India must fill.

> PubMed lists PMID 43011941 in Indian journal of psychiatry as Letter, with publication-date metadata of 2026-10-21 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-43011941-semaglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-11-12
- Source checked: 2026-11-14
- Published by PeptideScanner: 2026-11-14
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-43011941-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-43011941-semaglutide-v1
- Content SHA-256: `30248d901523aa3c16d9a2b22bbb3de2ba749f6471639b7a333a134a7d57dc0b`

### Claims and source pins

#### Headline

Semaglutide and alcohol use disorder: An evidence gap India must fill. ([`pubmed-observation-pmid-43011941-2026-11-12-613409fd6beb`](#source-pubmed-observation-pmid-43011941-2026-11-12-613409fd6beb))

#### Summary

PubMed lists PMID 43011941 in Indian journal of psychiatry as Letter, with publication-date metadata of 2026-10-21 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-43011941-2026-11-12-613409fd6beb`](#source-pubmed-observation-pmid-43011941-2026-11-12-613409fd6beb))

#### Paragraph 1

PubMed lists PMID 43011941 in Indian journal of psychiatry as Letter, with publication-date metadata of 2026-10-21 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-43011941-2026-11-12-613409fd6beb`](#source-pubmed-observation-pmid-43011941-2026-11-12-613409fd6beb))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-43011941-2026-11-12-613409fd6beb`](#source-pubmed-observation-pmid-43011941-2026-11-12-613409fd6beb))

### Sources

<a id="source-pubmed-observation-pmid-43011941-2026-11-12-613409fd6beb"></a>
- **Semaglutide and alcohol use disorder: An evidence gap India must fill. · retained source version 1:2026-11-12:current:613409fd6beb4e2b0b882a4eb9203b328d54cd8923d3536f96ae8f4a8e044624** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/43011941/) (`pubmed-observation-pmid-43011941-2026-11-12-613409fd6beb`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Semaglutide and alcohol use disorder: An evidence gap India must fill." Version 1, published 2026-11-14. https://peptidescanner.com/evidence/v1/peptides/semaglutide.json#pubmed-pmid-43011941-semaglutide-v1 SHA-256: 30248d901523aa3c16d9a2b22bbb3de2ba749f6471639b7a333a134a7d57dc0b.

